

**Regenerative Medicine Guidelines****Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP)**

Laxmaiah Manchikanti, MD, Riya Navani, Annu Navani, MD, Mahendra Sanapati, MD, Alan D. Kaye, MD, PhD, Adam M. Kaye, PharmD, Amol Soin, MD, Devi Nampiaparampil, MD, Kenneth D. Candido, MD, Alaa Abd-Elsayed, MD, Theodore T. Sand, PhD, Navneet Boddu, MD, Sairam Atluri, MD, Anss Annie Augustine, BDS, Dajie Wang MD, John Santa Ana, DO, Lady Christine Ong Sio, MD, Vidyasagar Pampati, MSc, Micheal Khadavi, MD, Nebojsa Nick Knezevic, MD, PhD, Robert Farhat, DO, Shivam S. Shah, BS, MD, Shounuck J. Patel, DO, Thomas Nabity Jr., MD, Alexander Bautista, MD, Aaron K. Calodney, MD, Joseph Cabaret, MD, Miles R. Day, MD, Paul J. Christo, MD, Sanjay Bakshi, MD, Shalini Shah, MD, Sheldon Jordan, MD, Sheri L. Albers, DO, Vivek Manocha, MD, and Joshua A. Hirsch, MD

From: American Society of Interventional Pain Physicians

Author Affiliations and any conflicts of interest can be found on pp. S100-S102.

Address Correspondence:  
Laxmaiah Manchikanti, MD  
2831 Lone Oak Road  
Paducah, Kentucky 42003  
E-mail: drlm@thepainmd.com

**Disclaimer:** These guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a "standard of care." These guidelines are meant to provide a basis for the understanding behind the role of biologics in healing, to provide a source of appropriate indications for the use of biologics, to facilitate and help standardize biologic therapy, and to encourage the performance of high-quality studies in an effort to document outcomes and advance this field. There was no external funding in the preparation of this article.

Free full article:  
[www.painphysicianjournal.com](http://www.painphysicianjournal.com)

**Background:** Regenerative medicine is an evolving medical subspecialty dedicated to enhancing the body's natural healing mechanisms to repair or replace damaged tissues. By using autologous or allogeneic biologics, it offers the potential to restore function where conventional therapies have shown limited success. While this field holds great promise and continues to generate enthusiasm among both patients and clinicians, it remains in early stages of clinical validation. Therefore, it must be approached with careful optimism and responsible application, ensuring that its presentation, promotion, and use in clinical settings are grounded in evidence and ethical standards.

**Objective:** To provide updated, evidence-based recommendations for the role of regenerative therapies in managing moderate to severe chronic low back pain.

**Methods:** A multidisciplinary panel of experts, convened by the American Society of Interventional Pain Physicians (ASIPP), systematically reviewed the current evidence and incorporated patient perspectives to develop practical, evidence-informed recommendations. The process included defining key clinical questions, reviewing the literature, formulating evidence-based statements, and reaching consensus through structured discussions and formal voting.

**Results:** A total of 35 authors contributed to the development of these guidelines, with 33 experts participating in the formal consensus process. Altogether, 19 recommendations were generated, with all of them achieving 100% agreement. These recommendations were informed by a comprehensive review of systematic reviews, randomized controlled trials (RCTs), and observational studies encompassing a broad range of regenerative therapies.

Evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to determine certainty levels. Both qualitative and quantitative analyses were applied to synthesize the best available data, resulting in evidence-based recommendations summarized below.

- Intradiscal Injections (PRP):  
Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate
- Intradiscal Injections (BMAC):  
Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate
- Epidural Injections (PRP):

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate**

- Facet Joint Injections (PRP and MSCs):  
**Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Moderate**
- Sacroiliac Joint Injections (PRP):  
**Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Low**
- Functional Spine Unit Injections  
**Evidence Level: Very Low; Consensus-Based Clinical Recommendation: Low**

**Limitations:** The primary limitation of these guidelines is the scarcity of high-quality studies, with much of the available evidence derived from small or heterogeneous trials.

**Precautions:** Regenerative therapies should be considered only after a thorough diagnostic evaluation confirming clinical necessity. Treatment decisions must account for the patient's medical condition, preferences, and expectations. Patients should be fully informed about the nature, potential benefits, risks, and costs of regenerative treatments, most of which are not covered by commercial insurance.

These therapies may be used alone or in conjunction with other evidence-based modalities, such as structured exercise, physical therapy, behavioral therapy, or conventional medical management. Clinicians must follow all applicable U.S. Food and Drug Administration (FDA) regulations and adhere to safety and ethical standards outlined in these guidelines.

**Conclusion:** Based on current evidence, lumbar intradiscal injections of platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) are supported by Level III evidence. Lumbar epidural PRP injections are also supported by Level III evidence, while PRP injections for lumbar facet joints and sacroiliac joints are supported by Level IV evidence. Given the emerging status of biologic therapies and the limited quality of existing studies, the panel provides moderate, consensus-based recommendations for the use of all biologics in the lumbar spine.

**Key words:** Chronic low back pain, discogenic pain, facet joint pain, sacroiliac joint pain, regenerative medicine, platelet-rich plasma, mesenchymal stem cells, stromal vascular fraction, exosomes, bone marrow concentrate, intradiscal injections, facet joint injections, sacroiliac joint injections, epidural injections, Food and Drug Administration, minimal manipulation

*Disclaimer: These guidelines do not constitute inflexible treatment recommendations. Clinicians are expected to establish a plan of care on a case-by-case basis, considering an individual patient's medical condition, personal needs, and preferences, and the physician's experience. Consequently, these guidelines do not represent a "standard of care."*

**Pain Physician 2025: 28:S1-S119**

**SUMMARY OF RECOMMENDATIONS:**

1. What are the available regenerative medicine therapies in the United States?

**Answer:** Available regenerative medicine therapies include PRP and BMC when obtained with FDA-cleared devices.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

2. What are the potential regenerative medicine modalities available in other countries but not the United States?

**Answer:** Multiple therapies are not currently available due to FDA regulations in the United States. In other countries, multiple therapies are available, including adipose stem cells including stromal vascular fraction (SVF), autologous, allogenic, or stored stem cells, stem cells derived from umbilical cord and exosomes. There is no clear guidance on micronized fat and it is used by some in the field.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

3. What are the recognized risks of unapproved stem cell treatments.

**Answer:** There are rare, but significant potential risks associated with unapproved stem cell treatments, including blindness, infections (like human immunodeficiency virus, hepatitis, or bacterial infections), thrombosis, tumor formation, neurological complications, and even death.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: High**

4. Defining Functional Spine Unit.

**Answer:** A functional spinal unit (FSU), also known as spinal motion segment, or articular tide, is the smallest physiological unit of the spine that exhibits the same biomechanical properties of the entire spine. Each FSU is a 3-joint complex and is responsible for coordinated movement protecting neural structures and providing a stable base for the body. A FSU consists of 2 adjacent vertebrae, intervertebral disc, facet joints, ligaments, and muscles. The concept of FSU is crucial for understanding spine health and dysfunction related to degeneration, injury, diagnosis and treatment.

Functional spine unit is utilized in managing back pain in regenerative medicine, in application of therapies in contrast to precision diagnosis and therapy with the single structure, as advocated in interventional pain management.

While this approach appears to be appropriate considering that regenerative medicine therapies are not bound by LCDs and medical policies, functional spine unit may provide better results; however, there is no significant evidence at the present time.

**Evidence Level: Very Low; Consensus-Based Clinical Recommendation: Low**

5. What are the identified risks of regenerative medicine therapies?

**Answer:** Regenerative medicine therapies are similar to interventional techniques with low risk; however, severe complications can occur including infection, specifically, discitis, epidural hematoma, and abscess, superficial infections, allergies, neurological complications, tumor formation and death.

Overall risk of interventional procedures has been considered by some as higher because of the steroid-based injections with chondrotoxicity, tenotoxicity, neurotoxicity, and multiple systematic toxicities. These toxicities are absent with PRP and BMC.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

6. Platelet Rich Plasma (PRP): Quality and Standards

**Answer:** Key issues concerning quality and standards for platelet-rich plasma include a lack of standardized protocols, variations in preparation techniques, and regulatory limitations.

Unlike pharmaceuticals, no universally accepted standard defines the optimal concentration of cells and growth factors. Different conditions may benefit from different formulations (leukocyte-rich versus leukocyte-poor).

Quality assurance practices include process validation, testing and monitoring, traceability, and device selection.

**Evidence Level: Low; Consensus-Based Clinical Recommendation: Moderate**

7. Bone Marrow Aspirate Concentrate (BMAC): Quality and Standards

BMAC devices are expected to produce viable cells with cell viability rates of approximately 90%. The quality of BMAC is heavily dependent on the aspiration technique. Volume and site are important.

There are no established standardized protocols. Consequently, there are variations in preparation technique limited by regulatory standards. Minimum requirements for BMAC include qualifying mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs).

Different processing devices and methods produce different results.

Quality assurance practices include process validation, testing and monitoring, traceability, and device selection

**Evidence Level: Low; Strength of Recommendation: Moderate**

8. Minimum required quality control measures:

Answer: The minimum required quality control measures for clinical purposes include final volume, platelet count, white blood cell (WBC) count, red blood cell (RBC) count, and the concentration factor relative to whole blood. Further, different processing devices and methods produce different results regarding final cell counts, viability, and volume.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: Moderate**

9. Minimum required platelets per injection:

**Answer:** Studies show that a minimum of 4 billion and 10 billion as optimum count of platelets per injection is needed for a significant clinical effect in knee intraarticular injections. Even though limited, literature is available regarding spinal injections, based on other joints, a cumulative dose of around 10 billion platelets into structures of a FSU are recommended. There is literature showing intradiscal injections of PRP with greater than 10 times baseline platelet concentrations resulted in greater improvements in pain scores and functional outcomes at long-term follow-up compared to lower concentration PRP less than five times.

**Evidence Level: Low; Consensus-Based Clinical Recommendation: Moderate**

10. It is essential to understand PRP and BMAC with multiple variations and the effectiveness, technical considerations, and complications with the spinal injections.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

11. Based on the available evidence and all available guidance, patient education is a crucial aspect of the success of regenerative medicine injections.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

12. What is the evidence of effectiveness for PRP and consensus-based clinical recommendations for intradiscal therapy.

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate**

13. The evidence of effectiveness for BMAC and consensus-based clinical recommendations for intradiscal therapy.

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate.**

14. The evidence of effectiveness and consensus-based clinical recommendations for epidural injections with PRP in managing low back and lower extremity pain due to degenerative disc pathology and other conditions.

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate**

15. The evidence of effectiveness and consensus-based clinical recommendations for facet joint intraarticular PRP and MSC injections in managing chronic low back pain.

**Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Moderate**

16. The evidence of effectiveness and consensus-based clinical recommendations for sacroiliac joint PRP injections.

**Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Low**

17. The guidelines for administration of biologics include failure of conservative modalities, understanding of the risks and benefits, willingness to participate in rehabilitation program and appropriate consent with shared decision making.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

18. Risk stratification for regenerative medicine therapies, based on ASIPP guidelines: high risk for intradiscal therapy, moderate risk for epidural injections, low risk for facet joint injections, and low risk for sacroiliac joint injections.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: Moderate**

19. Antiplatelet and anticoagulant therapy guidelines in continuation, discontinuation, and re-establishment are utilized per ASIPP guidelines for low- and high-risk procedures.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: Moderate**

---

## INDEX - REGENERATIVE THERAPIES IN THE MANAGEMENT OF CHRONIC LOW BACK PAIN GUIDELINES 2025

---

◆ <b>1.0 Introduction</b>	<b>S8</b>
◆ <b>2.0 Methods</b>	<b>S10</b>
2.1 Rationale	
2.2 Objective	
2.3 Application	
2.4 Adherence to Trustworthy Standards	
2.4.1 Disclosure of Guideline Funding Source	
2.4.2 Disclosure and Management of Financial Conflicts of Interest	
2.4.3 Composition of Guideline Development Group	
2.5 Evidence Review	
2.5.1 Grading of Evidence	
2.5.2 Assessment Based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) Criteria	
2.5.3 Outcome Measures	
2.5.4 Analysis of Evidence	
2.5.5 Qualitative Analysis	
2.5.6 Quantitative Analysis	
2.5.7 Assessment and Recommendations of Benefits and Harms	
2.5.8 Evidence Summary of Recommendations	
2.5.9 Rating or Grading the Strength of Recommendations	
2.5.10 Specificity of Recommendations	
2.6 Methodologic Quality and Risk of Bias Assessment	
2.6.1 Randomized Controlled Trials (RCTs)	
2.6.1.1 Scoring Cochrane Review Criteria	
2.6.1.2 Scoring IPM-QRB Criteria	
2.6.2 Nonrandomized Studies	
2.6.2.1 Scoring for Risk of Bias in Non-Randomized Studies of Exposure (ROBINS-E)	
2.6.2.2 Scoring For IPM-QRBNR	
2.7 Updating Guidelines	
2.8 Consensus Development of Recommendations	
2.9 Key Questions	
◆ <b>3.0 Impact of Low Back Pain on Health Care</b>	<b>S15</b>
◆ <b>4.0 Prevalence of Usage of Health Care Modalities in Managing Low Back Pain</b>	<b>S16</b>
4.1 Non-Opioid Pharmacologic Therapies	
4.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	
4.1.2 Muscle Relaxants	
4.1.3 Antidepressants	
4.1.4 Anticonvulsants	
4.1.5 Local Anesthetics	
4.2 Non-Pharmacologic and Non-Interventional Techniques in Managing Chronic Pain	
4.2.1 Exercise Programs	
4.2.2 Physical and Occupational Therapy	
4.2.3 Acupuncture	
4.2.4 Massage	
4.2.5 Transcutaneous Electrical Nerve Stimulation (TENS)	
4.2.6 Chiropractic Treatments	
4.2.7 Biofeedback Therapy	
4.2.8 Multidisciplinary Rehabilitation	
4.3 Opioids	
4.4 Interventional Techniques	
4.5 Surgery	
◆ <b>5.0 Functional Spine Unit: Pathophysiologic and Structural Basis of Low Back Pain</b>	<b>S24</b>
5.1 Components of the Functional Spine Unit	
5.1.1 Facet Joint	
5.1.2 Intervertebral Disc	
5.1.3 Vertebral Endplate	
5.1.4 Sacroiliac Joint	
5.1.5 Spinal Muscles and Ligaments	

◆ <b>6.0 Regenerative Medicine</b>	<b>S28</b>
6.1 Platelet-Rich Plasma (PRP)	
6.2 Mesenchymal Stem Cells (MSCs)	
6.2.1 Bone Marrow Aspirate Concentrate (BMAC)	
6.3 Adipose-Derived Stem Cells	
6.3.1 Types of Adipose Tissue Used in Medical Therapies	
6.3.1.1 Biological Activity and Therapeutic Potential	
6.3.1.2 Clinical Applications	
6.3.1.3 Regulatory Considerations and Advantages	
6.3.2 Adipose Tissue-Derived Stromal Vascular Fraction	
6.4 Exosomes	
6.5 Non-Autologous Biologics	
6.6 Other Commercially Available Biologic Preparations	
◆ <b>7.0 Effectiveness of Biologic Therapy in Chronic Low Back Pain</b>	<b>S35</b>
7.1 Intradiscal Injections	
7.2 Epidural Injections	
7.3 Facet Joint Injections	
7.4 Sacroiliac Joint Injections	
7.5 Functional Spine Unit Injections	
7.6 Summary of Evidence	
7.6.1 Intradiscal Injections	
7.6.2 Epidural Injections (PRP)	
7.6.3 Facet Joint Injections (PRP and MSCs)	
7.6.4 Sacroiliac Joint Injections (PRP)	
7.6.5 Functional Spine Unit Injections	
◆ <b>8.0 Current Guidelines for Biologics in Industry and Regulatory Agencies</b>	<b>S76</b>
8.1 FDA/WHO as Regulatory Agency for Biologic Therapies	
8.2 Human Cells, Tissues, & Cellular & Tissue-Based Products (HCT/Ps)	
8.3 Minimal Manipulation	
8.4 Homologous Use	
8.5 Regulatory Scope and Compliance Policy	
8.6 FDA's Comprehensive Framework for Regenerative Medicine	
8.6.1 Expediting the Development of New Therapies	
8.6.2 Implementation of Comprehensive Framework	
◆ <b>9.0 Clinical Guidance</b>	<b>S82</b>
9.1 Safety, Effectiveness, and Informed-Decision Making	
9.2 Office Set-up	
9.3 Contraindications	
9.4 Pre, Intra, and Post Procedural Considerations	
9.4.1 Pre-Procedure	
9.4.2 Intra-Procedure	
9.4.3 Post-Procedure	
9.5 Post-Orthobiologic Rehabilitation	
9.6 Adverse Reactions and Complications	
◆ <b>10.0 Antithrombotic Implications</b>	<b>S86</b>
10.1 Risks in Regenerative Medicine	
10.2 Effects of Antithrombotic Therapy on PRP and Stem Cell Effectiveness	
10.3 Safe and Efficient Administration of Regenerative Medicine in Anticoagulated Patients	
10.4 Determination of Timing of Anticoagulant Interruption	
10.5 Guidelines for Managing Anticoagulant and Antiplatelet Therapy During Interventional Techniques	
◆ <b>11.0 Guidance for Safe and Effective Use of Biologics</b>	<b>S94</b>
◆ <b>12.0 Future Perspective</b>	<b>S95</b>
◆ <b>13.0 Recommendations and Statements</b>	<b>S96</b>
◆ <b>14.0 Conclusion</b>	<b>S99</b>

## 1.0 INTRODUCTION

Regenerative medicine is the science dedicated to the repair, restoration, and regeneration of diseased or injured cells, tissues, or organs to reestablish homeostasis and improve functionality. This multidisciplinary specialty encompasses advanced research that translates from laboratory discovery to clinical applications, spanning from tissue engineering to cellular biology. These efforts have produced a range of injectables, implants, and scaffolds designed to replicate normal tissue structure and function (1-28). Regenerative medicine represents a transformative approach to health care by activating the body's natural repair mechanisms to restore function in tissues and organs previously considered irreparable (23).

Cell biology focuses on the structure, function, and behavior of cells as the fundamental units of all organisms, while tissue engineering combines cells, engineering methods, materials, and biochemical and physicochemical factors to improve or replace biological tissues. Although the term regenerative medicine is sometimes used interchangeably with tissue engineering, the broader field of regenerative medicine incorporates multiple techniques, including prolotherapy, platelet-rich plasma (PRP), and stem cell therapy.

In contemporary practice, the 2 primary components of regenerative medicine in chronic pain management are PRP and stem cell therapy, with exosomes representing an emerging area of application. Many clinicians consider PRP or stem cell injections as effective treatments for degenerative spinal and musculoskeletal conditions (1-22). While these approaches remain under active investigation and debate, enthusiasm for evidence-based regenerative interventions continues to grow. Nonetheless, optimism is tempered by skepticism and concern regarding potential misuse, overuse, and regulatory challenges, which remain frequent topics of professional and public discourse (1-4,12-16,29-37).

The literature often describes the "good," "bad," and "ugly" aspects of regenerative medicine (16). The "good" lies in its potential to repair or replace damaged tissues and organs, offering new hope for previously untreatable conditions. The "bad" involves uncertain long-term outcomes, limited high-quality clinical data, and the significant cost associated with many therapies. The "ugly" encompasses unethical practices, including exploitation of vulnerable patients through unproven stem cell interventions and the risks of tumorigenicity linked to some regenerative products. PRP applications for many conditions are relatively noncontroversial

apart from cost considerations, whereas bone marrow concentrate (BMC) injections, though promising, present greater technical difficulty and expense. Most of the controversy and regulatory scrutiny, however, surrounds stem cell therapies (16).

The U.S. Food and Drug Administration (FDA) continues to issue guidance and warnings regarding the use of stem cells. As of July 2025, enforcement actions remain active against products derived from stromal vascular fraction (SVF), umbilical cord blood, and exosomes. Courts have upheld the FDA's authority to regulate these products as drugs and/or biologics, requiring them to meet established safety and efficacy standards. In parallel, the Federal Trade Commission (FTC) has pursued legal action against clinics engaged in deceptive advertising or marketing of unproven cell-based therapies. The FDA has also increased oversight of clinical trials, halting new studies that involve exporting patients' cells to foreign laboratories for genetic modification and reinfusion, citing concerns about data security and informed consent.

The FDA specifically warns against stem cell tourism due to serious risks associated with unapproved treatments, including blindness, infections such as human immunodeficiency virus or hepatitis, tumor formation, neurological complications, and even death. Approved regenerative treatments remain extremely limited; only a few stem cell products are authorized for specific indications such as certain cancers, blood disorders, and immune deficiencies. Accordingly, stem cell products derived from SVF, umbilical cord blood, and exosomes are not approved for clinical use in treating musculoskeletal conditions.

Although the utilization of regenerative therapies has expanded widely, accurate data on their prevalence and outcomes remain scarce. While numerous guidelines exist for managing spinal pain, including interventional pain management and surgical procedures (38-45), few provide high-quality, evidence-based recommendations specific to regenerative medicine in musculoskeletal disorders (2,4).

The American Society of Interventional Pain Physicians (ASIPP) has been instrumental in developing evidence-based guidelines for interventional pain techniques, opioid management, peripheral nerve stimulation, perioperative anticoagulant and antiplatelet therapy, and regenerative interventions (2,39-42,44,45). This current update continues ASIPP's commitment to advancing safe and effective biologic applications for low back pain management. These

guidelines summarize the available literature on PRP and bone marrow aspirate concentrate (BMAC) injections targeting the lumbar spine, including intervertebral discs, facet joints, sacroiliac joints, paraspinal muscles, ligaments, and tendons, and incorporate

relevant national and international regulatory and bioethical considerations. They also outline the clinical protocols and procedural standards required to deliver these therapies responsibly in a safe, compliant, and professional environment.

## 2.0 METHODS

### 2.1 Rationale

Interventional pain management is defined as "the discipline of medicine devoted to the diagnosis and treatment of pain-related disorders, principally with the application of interventional techniques in managing subacute, chronic, persistent, and intractable pain, independently or in conjunction with other modalities of treatment" (46). Interventional pain management techniques are defined as "minimally invasive procedures including percutaneous precision needle placement, with placement of pharmaceuticals in targeted areas or ablation of targeted nerves; and some surgical techniques such as laser or endoscopic discectomy, placement of intrathecal infusion pumps, and spinal cord stimulators, for the diagnosis and management of chronic, persistent, or intractable pain" (47).

Recent literature has shown a pattern of significant growth, followed by deceleration and eventual decline in the use of several interventional procedures, with the exception of spinal cord stimulation (48-54). Regenerative therapies, however, have become more widely utilized, prompting discussions regarding their evidence base, medical necessity, and appropriate indications. The increase in publications on regenerative medicine in interventional pain management journals, the establishment of dedicated regenerative medicine journals, accredited training programs, and the introduction of board certification, most notably by the American Board of Interventional Pain Physicians (ABIPP), demonstrate the field's growing legitimacy. ABIPP's competency certification in regenerative medicine is recognized in several states as a certifying standard for interventional pain management (2,5-7,17-23,38,55).

Chronic spinal pain is a complex and multifactorial condition, with low back pain being the most prevalent presentation. Its high prevalence, diverse treatment options, and associated social and economic burdens continue to shape medical decision-making. Lumbar intervertebral discs, facet joints, sacroiliac joints, ligaments, fascia, muscles, and nerve root dura are all known pain generators contributing to low back and lower extremity pain (18-21,39,41,56-63). Kirkaldy-Willis et al (64,65) described the degenerative process as involving multiple structures, introducing the "3-joint complex" concept. Building on this foundation, a functional spine unit approach has recently been developed to guide regenerative medicine injections in managing low back pain (65-68).

Traditionally, interventional pain management

has focused on targeting individual pain-generating structures. However, in many regions with limited resources, a more comprehensive, multi-structured approach is used to deliver care that is both practical and accessible. Similarly, regenerative medicine employs a functional unit approach emphasizing the overall function and integration of spinal structures rather than focusing on isolated pathology. Interventional pain physicians, well-versed in image-guided procedures for managing spinal and extremity pain, are ideally suited to integrate regenerative techniques into their practice following appropriate education and training as outlined in these guidelines.

### 2.2 Objective

These guidelines aim to provide a rational and systematic framework for applying regenerative interventions in managing low back pain. They are based on the best available evidence concerning the effectiveness and safety of regenerative therapies for various types of low back pain, including pain attributed to lumbar muscle dysfunction. The literature underscores the importance of evidence-based practice and the need for regular updates to ensure that recommendations align with current clinical standards. Regenerative therapies in this context refer to minimally invasive techniques involving the targeted placement of injectates near structures affected by pain.

### 2.3 Application

These guidelines are intended for use across multiple medical specialties but are specifically designed for interventional pain physicians and other practitioners utilizing regenerative therapies. Their primary purpose is to provide patients, clinicians, regulators, and payers with clear, evidence-based information to determine the medical necessity and appropriateness of regenerative interventions.

### 2.4 Adherence to Trustworthy Standards

In developing these regenerative therapy guidelines, the standards established by the Institute of Medicine (IOM) and the National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) were followed (40,42,44,69-72). The NEATS instrument, created and validated by the Agency for Healthcare Research and Quality (AHRQ) National Guideline Clearinghouse (NGC), serves as a tool to evaluate adherence to best practices in guideline development (70). This process ensures that these regenerative therapy guide-

lines meet the highest standards of reliability, transparency, and evidence-based rigor.

#### **2.4.1 Disclosure of Guideline Funding Source**

These comprehensive, evidence-based guidelines for regenerative therapies in managing chronic low back pain were commissioned, prepared, edited, and endorsed by the American Society of Interventional Pain Physicians (ASIPP) without any external funding.

#### **2.4.2 Disclosure and Management of Financial Conflicts of Interest**

All panel members disclosed potential conflicts of interest covering the previous 5 years. These disclosures extended beyond financial relationships to include professional experience, clinical practice patterns, academic interests, and promotional activities. Members with identified conflicts were recused from any discussions or sections related to their conflicts and agreed not to engage with industry stakeholders regarding any guideline content before data publication.

#### **2.4.3 Composition of Guideline Development Group**

A multidisciplinary panel of experts in chronic pain management and interventional techniques from diverse medical disciplines reviewed the available evidence and developed the recommendations for regenerative therapies. The panel represented both academic and community-based practitioners committed to advancing interventional applications in regenerative medicine.

The group included methodologists such as epidemiologists, statisticians, ethicists, and health services researchers experienced in conducting systematic reviews. Editorial safeguards were implemented to prevent influence from authors with industry funding. The panel was both geographically and professionally diverse, including academicians and practitioners. Of the 35 members participating in guideline preparation, there were 19 anesthesiologists, 1 neurologist, 8 physiatrists, 2 radiologists, 2 scientists/researchers, 2 statisticians, 1 pharmacist, 1 dental surgeon, and 1 graduate student, all actively engaged in clinical care or research related to chronic pain.

### **2.5 Evidence Review**

The evidence-based recommendations for regenerative therapies were developed through a consensus process following a comprehensive review of published

literature addressing the use and safety of regenerative treatments for low back pain. The methodology was based on principles of best evidence synthesis, as outlined by the Cochrane Review, and adapted from multiple ASIPP-modified guidelines (73,74).

#### **2.5.1 Grading of Evidence**

The grading of evidence and recommendations was based on a modified qualitative approach described by ASIPP (73,74), the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework (75,76), and the AHRQ strength of recommendations methodology (71,72). Table 1 outlines the modified qualitative approach to grading evidence described by ASIPP (73), and Table 2 presents the guide for the strength of recommendations developed using the NEATS instrument (70), as modified by the opioid guideline panel (42) and adapted for this guideline.

The grading system for regenerative therapies in low back pain incorporates evidence from randomized controlled trials (RCTs), observational studies, and other clinical reports, as well as systematic reviews and meta-analyses. This approach defines levels of scientific evidence and provides a structured means for grading both the quality of evidence and the strength of corresponding recommendations (70,75,76). Methods consistent with AHRQ's approach to rating the strength of recommendations were also applied (71,72).

#### **2.5.2 Assessment Based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) Criteria**

GRADE is a transparent framework for developing and presenting evidence summaries and provides a systematic approach for making clinical practice recommendations (75,76). It is the most widely adopted tool for grading evidence quality and formulating recommendations. GRADE defines 4 levels of evidence, also referred to as certainty in evidence or quality of evidence: very low, low, moderate, and high, as shown in Table 3. Certainty of evidence is assessed based on risk of bias or methodological quality of the studies, imprecision, inconsistency, indirectness, and publication bias. Considering these factors, confidence in the evidence may be increased or decreased. Reasons for adjusting certainty in evidence, either upward or downward, are provided in Table 4.

#### **2.5.3 Outcome Measures**

An outcome is considered clinically significant if

Table 1. Qualitative modified approach to grading of evidence of therapeutic effectiveness studies.

Level I	Strong	Evidence obtained from multiple relevant high-quality randomized controlled trials
Level II	Moderate	Evidence obtained from at least one relevant high-quality randomized controlled trial or multiple relevant moderate or low-quality randomized controlled trials
Level III	Fair	Evidence obtained from at least one relevant moderate or low-quality randomized trial or Evidence obtained from at least one relevant high-quality non-randomized trial or observational study with multiple moderate or low-quality observational studies
Level IV	Limited	Evidence obtained from multiple moderate or low-quality relevant observational studies
Level V	Consensus based	Opinion or consensus of large group of clinicians and/or scientists

Modified from: Manchikanti L, et al. A modified approach to grading of evidence. *Pain Physician* 2014; 17:E319-E325 (73).

Table 2. Guide for strength of recommendations as modified for ASIPP guidelines.

Rating for Strength of Recommendation	
Strong	<p>There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns about study quality; and/or d) the extent the panelists' agreement. Other compelling considerations (discussed in the guideline's literature review and analyses) may also warrant a strong recommendation.</p> <p>ASIPP Adaptation: Consensus was achieved that there is high certainty that the net benefit is substantial providing strong recommendation.</p> <p>Recommendation: Strong</p>
Moderate	<p>There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few concerns about study quality; and/or d) the extent of panelists' agreement. Other compelling considerations (discussed in the guideline's literature review and analyses) may also warrant a moderate recommendation.</p> <p>ASIPP Adaptation: Consensus was achieved that there is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.</p> <p>Recommendation: Moderate</p>
Weak	<p>There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) limited evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; c) concerns about study quality; and/or d) the extent of panelists' agreement. Other considerations (discussed in the guideline's literature review and analyses) may also warrant a weak recommendation.</p> <p>ASIPP Adaptation: The consensus achieved that there is potential improvement in certain individuals or groups of patients based on individual professional judgement and shared decision making.</p> <p>Recommendation: Weak</p>

Adapted and modified from: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (70).

there is a reduction of at least 2 points on pain scales such as the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS), or at least a 50% reduction in pain with improvement in functional status in at least 50% of the treatment group. A positive study is deemed clinically significant and effective if the primary outcome is statistically significant with a  $P$ -value  $\leq 0.05$ .

#### 2.5.4 Analysis of Evidence

Evidence was analyzed using both qualitative and quantitative evidence synthesis. Quantitative synthesis

was performed when applicable using conventional and single-arm meta-analyses. If a recent quantitative analysis had already been performed, it was used without duplication unless new studies were available.

#### 2.5.5 Qualitative Analysis

Qualitative analysis was based on best-evidence synthesis, modified and collated using multiple criteria, including Cochrane Review and United States Preventive Services Task Force (USPSTF) criteria, as illustrated in Table 1 (73). The analysis utilized 5 levels of evidence,

ranging from strong evidence to opinion- or consensus-based recommendations.

### 2.5.6 Quantitative Analysis

Quantitative analysis was not performed specifically for these guidelines; however, recent publications including quantitative analyses were incorporated into the evidence synthesis.

### 2.5.7 Assessment and Recommendations of Benefits and Harms

These guidelines describe the potential benefits and harms of regenerative therapies for low back pain and explicitly link this information to specific recommendations.

### 2.5.8 Evidence Summary of Recommendations

Supporting documents summarize the relevant evidence for regenerative therapies and link this information to the consensus-based clinical recommendations.

### 2.5.9 Rating or Grading the Strength of Recommendations

For each recommendation related to regenerative therapies, the strength of the recommendation is rated based on benefits and harms, available evidence, and confidence in the underlying evidence, using rating schemes recommended by NEATS (42,70).

### 2.5.10 Specificity of Recommendations

The guideline recommendations are, as much as possible, specific and unambiguous. They are intended to guide actions that should or should not be taken in various clinical settings for regenerative therapies across diverse patient populations.

## 2.6 Methodologic Quality and Risk of Bias Assessment

Key aspects of the guideline methodology included transparency and reproducibility of judgments, separating risk of bias from other constructs such as applicability and precision, and evaluating risk for each outcome.

### 2.6.1 Randomized Controlled Trials (RCTs)

#### 2.6.1.1 Scoring Cochrane Review Criteria

Using Cochrane Review criteria (77), as shown in Appendix Table 1, studies meeting at least 9 of 13 criteria were considered high-quality. Studies meeting 5 to 8 cri-

Table 3. GRADE certainty ratings.

Certainty	What it means
Very low	The true effect is probably markedly different from the estimated effect
Low	The true effect might be markedly different from the estimated effect
Moderate	The authors believe that the true effect is probably close to the estimated effect
High	The authors have a lot of confidence that the true effect is similar to the estimated effect

Source: BMJ Best Practice. Evidence-based medicine (EBM) toolkit. Learn EBM. What is GRADE? Accessed 08/20/2024. <https://bestpractice.bmjjournals.com/info/us/toolkit/learn-ebm/what-is-grade/> (76)

Table 4. Reasons rate certainty in evidence up or down.

Certainty can be rated down for:	Certainty can be rated up for:
<ul style="list-style-type: none"> <li>• Risk of bias</li> <li>• Imprecision</li> <li>• Inconsistency</li> <li>• Indirectness</li> <li>• Publication bias</li> </ul>	<ul style="list-style-type: none"> <li>• Large magnitude of effect</li> <li>• Dose-response gradient</li> <li>• All residual confounding would decrease magnitude of effect (in situations with an effect)</li> </ul>

Source: BMJ Best Practice. Evidence-based medicine (EBM) toolkit. Learn EBM. What is GRADE? Accessed 08/20/2024. <https://bestpractice.bmjjournals.com/info/us/toolkit/learn-ebm/what-is-grade/> (76)

teria were deemed moderate quality, while those scoring less than 5 were considered low-quality and excluded.

#### 2.6.1.2 Scoring IPM-QRB Criteria

Based on the Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment (IPM-QRB) criteria for randomized trials (78), as shown in Appendix Table 2, studies scoring less than 16 were considered low-quality and excluded. Studies scoring 16 to 31 were considered moderate quality, and studies scoring 32 to 48 were considered high-quality.

### 2.6.2 Nonrandomized Studies

#### 2.6.2.1 Scoring for Risk of Bias in Non-Randomized Studies of Exposure (ROBINS-E)

The Risk of Bias in Non-Randomized Studies of Exposure (ROBINS-E) tool (79) was used to assess the risk of bias in estimates from cohort studies evaluating the causal effect of an exposure on an outcome, as shown in Appendix Table 3. Studies that met inclusion criteria and scored 5 or higher were considered high quality. Studies scoring 3 to 4 were classified as moderate quality, while those scoring below 2 were considered low quality and were excluded from the evidence analysis.

### 2.6.2.2 Scoring for IPM-QRBNR

Based on the Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment for Nonrandomized Studies (IPM-QRBNR) criteria (80), as shown in Appendix Table 4, studies meeting inclusion criteria but scoring less than 16 were considered low-quality and excluded. Studies scoring 16 to 31 were regarded as moderate quality, while studies scoring 32 to 48 were considered high quality and included in the evidence synthesis.

### 2.7 Updating Guidelines

These guidelines for regenerative therapies in managing low back pain will be updated within 5 years or sooner if there are significant changes in scientific evidence, public policy, or reported adverse events, with the next update anticipated before January 2030.

### 2.8 Consensus Development of Recommendations

A modified Delphi technique was used to achieve consensus on the guideline statements (81,82). This approach minimizes bias associated with group interactions and allows for anonymity among panelists. Panelists without primary conflicts of interest voted on the approval of specific guideline statements using an online survey. Each panelist could also propose edits to the wording of statements and provide clarifying comments regarding the implementation of the guidelines in clinical practice. For inclusion in the final guidelines, each statement required at least 80% agreement among eligible panel members without primary conflicts of interest. Disagreements occurred in some statements where members differed regarding the strength or direction of the recommendation.

### 2.9 Key Questions

These guidelines focus on the following key questions regarding low back and extremity pain:

1. What is the spinal functional unit describing the pathophysiologic and structural basis of low back pain?
2. What are the available regenerative medicine therapies?
3. Are regenerative medicine therapies effective in treating low back and lower extremity pain?
4. The evidence of effectiveness for the use of intradiscal PRP or bone marrow aspirate concentrate (BMAC) and consensus-based clinical recommendations.
5. The evidence of effectiveness for the use of epidural injections of PRP and derivatives and consensus-based clinical recommendations.
6. The evidence of effectiveness for using intra-articular facet joint injections of PRP and consensus-based clinical recommendations.
7. The evidence of effectiveness for the use of PRP in sacroiliac joint injections and consensus-based clinical recommendations.
8. The evidence of effectiveness for the functional spine unit approach and consensus-based clinical recommendations.
9. What are the current guidelines for biologics?
10. What are the adverse consequences/harms of regenerative therapies?
11. What are the precautions in perioperative management of patients receiving regenerative interventional techniques and antiplatelet and anticoagulant therapy?
12. What are the best preventive and therapeutic strategies to improve outcomes when performing regenerative therapies?

### **3.0 IMPACT OF LOW BACK PAIN ON HEALTH CARE**

Chronic low back pain imposes a substantial socioeconomic burden worldwide (2,39,41,42,83-85). According to a global burden of disease report, low back pain was the leading cause of years lived with disability (YLD) among 395 diseases, injuries, and impairments, accounting for approximately 64 million YLDs, or 7.4% of total YLDs in 2019 (83-85). A 2023 report by the Centers for Disease Control and Prevention (CDC) (85) indicated that 24.3% of U.S. adults experienced chronic pain during the year, with 8.5% reporting high-impact chronic pain. This represents an increase compared to 2021, when chronic pain prevalence was estimated at 21% and high-impact chronic pain at 6.9% (85).

Economic analyses highlight the financial impact of spinal pain management. Dieleman et al (84) reported that U.S. expenditures on personal health care and public health for spinal pain totaled \$134.5 billion in 2016, reflecting a 53.5% increase from \$87.6 billion in 2013. Similarly, costs for managing musculoskeletal disorders rose 43.5%, from \$183.5 billion in 2013 to \$263.3 billion in 2016.

In the United States, national healthcare expenditures are projected to have grown 8.2% in 2024, nearly 3 percentage points faster than the growth in gross domestic product (GDP) at 5.3%, reaching \$5.263 trillion compared to \$4.866 trillion in 2023 and \$4.25 trillion in 2022 (86). This increase occurred despite reductions in service utilization, particularly for interventional procedures (50-52,54), and substantial cuts in physician fee schedules, with payments decreasing by 41% from 2001 to 2025 and projected to reach 45% by 2026 (87-89). These trends may reflect uneven allocation of healthcare funds, with certain sectors and the insurance industry realizing significant profits since the implementation of the Affordable Care Act.

The sustained growth in healthcare spending reflects increased utilization of services, goods, administrative costs, and profit margins (86-88), following a period of muted growth during the COVID-19 pandemic. Consequently, the health share of the economy is expected to rise to 18% in 2024, up from 17.6% in 2023. From 2024 to 2033, as the population ages and healthcare demand grows faster than income, annual national health spending is projected to increase by 5.8%, outpacing the projected GDP growth of 4.3%. By 2033, the health share of the economy is expected to reach 20.3%, highlighting a critical challenge in ensuring sufficient funds for adequate healthcare services.

Pain prevalence varies by spinal region, with the low back being the most affected at 43%, followed by the neck at 32% and the thoracic spine at 13% (90). Annual prevalence of low back and neck pain ranges from 22% to 65%, with lifetime prevalence estimated at 84% for low back pain and 67% for neck pain (2,39,41,42). Chronic spinal pain persists in approximately 60% of patients for over one year, despite conservative or surgical treatments (2,39,41,42).

Chronic spinal conditions are strongly associated with physical disability and mental health disorders, including depression, generalized anxiety disorder, and somatization (2,39,41,42,83-85,91,92). Moreover, chronic spinal pain in parents is linked to an increased risk of similar conditions in their children during adulthood (93).

Although some studies have suggested a decline in low back pain prevalence (94), recent evidence indicates rising prevalence across all chronic pain categories, with low back pain remaining the most common (85). This increase parallels growing economic and societal costs, driven in part by the expansion of treatment modalities, including regenerative medicine therapies (1-22,38-42,44,95-134).

## 4.0 PREVALENCE OF USAGE OF HEALTH CARE MODALITIES IN MANAGING LOW BACK PAIN

The use of various modalities for treating musculoskeletal and spinal pain has grown substantially, including physical therapy, pharmacologic treatments, interventional techniques, and surgical interventions (1-22,38-42,44,98-139).

### 4.1 Non-Opioid Pharmacologic Therapies

Non-opioid pharmacologic therapies play a central role in managing low back pain, particularly as efforts continue to address the opioid crisis. Given the variability and complexity of low back pain, multiple non-opioid pharmacologic treatments have been employed to provide effective and safe pain relief.

#### 4.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs have demonstrated effectiveness in managing acute low back pain by reducing pain and improving function. Evidence suggests that the route of administration can influence efficacy. In a randomized trial, Khankhel et al (127) found that topical diclofenac gel alone was less effective than oral ibuprofen in improving functional impairment. Combining diclofenac gel with oral ibuprofen did not provide additional benefit, indicating that oral NSAIDs remain more effective for acute low back pain in this setting. Furthermore, combining NSAIDs with paracetamol has shown better outcomes than NSAIDs alone, while paracetamol alone has not demonstrated significant clinical benefit in acute low back pain (128).

Although NSAIDs consistently have shown effectiveness in acute low back pain, their efficacy in chronic low back pain is less clear (129,140). Safety concerns persist, with some studies indicating low but notable risk of adverse events. Concomitant use of myorelaxants may increase the likelihood of side effects (129). Cyclooxygenase-2 (COX-2) inhibitors such as Celebrex and Meloxicam are generally considered safer than nonselective NSAIDs due to a lower risk of gastrointestinal complications. Overall, while NSAIDs are integral to managing acute low back pain, their use should be balanced with potential adverse effects.

#### 4.1.2 Muscle Relaxants

Muscle relaxants are often used when muscle spasm contributes to low back pain; however, their effectiveness and safety remain uncertain. Studies evaluating non-benzodiazepine antispasmodics and benzodiazepines

have reported mixed results. A meta-analysis by Cashin et al (130) found that non-benzodiazepine antispasmodics slightly reduced pain intensity at 2 weeks or earlier, but this was not clinically meaningful, and no significant improvement in disability scores was observed. Adverse effects, including nausea, dizziness, and headache, were more frequent with these medications.

Studies assessing the combination of muscle relaxants with NSAIDs also show variable results. Hung et al (131) reported that adding tizanidine to diclofenac did not improve functional outcomes in acute low back pain with sciatica. In contrast, Iliopoulos et al (132) found that a single intramuscular injection of diclofenac combined with Thiocolchicoside led to greater pain reduction and improved mobility compared to diclofenac alone, without increasing adverse effects.

The choice of muscle relaxant may influence outcomes. A randomized trial comparing methocarbamol and diazepam for acute low back pain demonstrated that both agents reduced pain within 60 minutes. Diazepam provided slightly greater pain relief but was associated with a higher incidence of drowsiness (133). Overall, the evidence on muscle relaxants for low back pain remains inconclusive. While some studies indicate short-term benefit, their effect on long-term function is unclear, and further high-quality research is needed to clarify optimal drug selection and dosing.

#### 4.1.3 Antidepressants

Antidepressants have been investigated for analgesic effects in chronic low back pain, particularly when neuropathic mechanisms are implicated. Various classes, including tricyclic antidepressants (TCAs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), have shown mixed effectiveness and safety profiles.

While earlier meta-analyses suggested minimal benefit with higher discontinuation rates, more recent studies have evaluated specific antidepressants and classes. Duloxetine, an SNRI at 60 mg daily, significantly reduced pain intensity and improved quality of life, although higher doses (120 mg) increased adverse events (135). Other antidepressants, such as amitriptyline, eszopiclone, bupropion, imipramine, and desipramine, showed small or inconsistent effects (135). A network meta-analysis by Ma et al (141) ranked TCAs as most effective for pain relief, followed by SNRIs, which also improved functional outcomes. However, both SNRIs and noradrenaline-dopamine reuptake inhibitors were associated with higher risk of adverse effects, including nausea, dizziness, and treatment discontinuation.

Clinicians should carefully weigh risks and benefits before prescribing antidepressants for low back pain, especially in patients without comorbid depression.

#### 4.1.4 Anticonvulsants

Gabapentinoids, including pregabalin and gabapentin, have been widely used for low back pain with neuropathic components, but evidence on their effectiveness is mixed. A meta-analysis of gabapentin and pregabalin for acute sciatica showed limited benefit, with gabapentin improving leg pain but not low back pain or function, and pregabalin showing no significant advantage (142).

Shanthanna et al (143) reported limited evidence of benefit in chronic low back pain, with significant risk of adverse effects, highlighting the need for large, high-quality trials. João et al (144) found gabapentinoids reduced neuropathic pain and sleep interference after spinal cord injury, suggesting a potential minor role for leg pain associated with radiculopathy. Head-to-head comparisons indicated pregabalin may reduce pain more effectively, while gabapentin may provide broader benefits for comorbid symptoms such as anxiety, insomnia, and fatigue (145). Overall, anticonvulsants may provide modest relief in select cases, but their routine use for low back pain is not well supported.

#### 4.1.5 Local Anesthetics

Local anesthetics have been widely used in spinal injections for low back pain (146). Epidural injections combining local anesthetics and steroids have demonstrated efficacy in conditions such as disc herniation, with transforaminal and interlaminar approaches having the strongest evidence, while injections using only local anesthetics or caudal epidurals with or without steroids show moderate evidence (147). Meta-analyses also indicate that lidocaine, with or without steroids, is effective in managing spinal pain from multiple causes (148).

The number of repeat injections required has been examined in several studies. A retrospective study found that transforaminal epidural steroid injections using nonparticulate steroids resulted in a higher proportion of patients not requiring repeat injections within 12 months compared to those receiving particulate steroids (149).

### 4.2 Non-Pharmacologic and Non-Interventional Techniques in Managing Chronic Pain

Many non-invasive or non-interventional tech-

niques for managing chronic pain include exercise programs, physical therapy, acupuncture, massage, transcutaneous electrical nerve stimulation (TENS), biofeedback therapy, and chiropractic treatment.

#### 4.2.1 Exercise Programs

Structured exercise programs are critical in managing chronic pain. All guidelines, local coverage determinations (LCDs), and medical policies mandate some form of physical therapy and structured exercise programs before employing any interventional techniques or opioid therapy. The CDC guidelines (150) provide high-quality evidence supporting exercise therapy for back pain, fibromyalgia, and hip and/or knee osteoarthritis, demonstrating reduced pain and improved function immediately after treatment, with sustained improvements for 2 to 6 months (150-155). Multiple guidelines recommend aerobic, aquatic, and/or resistance exercises for patients with various types of chronic pain, including osteoarthritis of the knee or hip, back pain, and fibromyalgia (140,156-158). Motor control exercise for low back pain has been reported to be more effective for improving function than minimal intervention (159,160).

Exercise therapy has shown moderate effectiveness in treating chronic low back pain, although no single form of exercise has proven superior. A review of 217 RCTs with 20,969 participants with non-specific low back pain lasting more than 12 weeks concluded that Pilates, McKenzie, and functional restoration approaches were more effective than other exercises in reducing pain intensity and functional limitations (161). A systematic review and meta-analysis of 79 RCTs comparing exercise-based interventions to placebo found that exercise training was more effective than active control or standard medical care in reducing chronic musculoskeletal pain (162).

Morkoç et al (136) evaluated the effects of lumbar stabilization and graded activity exercises on biochemical mediators and clinical outcomes in patients with nonspecific chronic low back pain. Lumbar stabilization exercises increased interleukin-6 (IL-6) concentrations while reducing pain, disability, and catastrophizing. Graded activity exercises increased IL-6 concentrations and reduced pain and disability, but lumbar stabilization exercises were more effective in reducing catastrophizing.

Leininger et al (137) studied the cost-effectiveness of spinal manipulation, exercise, and self-management for spinal pain. spinal manipulative therapy (SMT) was

favorable compared to home exercise and advice (HEA) for acute neck pain (ICERs below \$50K/quality-adjusted life year (QALY)) and when added to HEA for chronic back-related leg pain and chronic neck pain in older adults. SMT was likely not cost-effective compared to HEA for chronic back pain in adults or when added to HEA for older adults. SMT compared to exercise therapy in adults with chronic back pain showed favorable outcomes, as did exercise therapy for chronic neck pain in adults and chronic back pain in adolescents (ICERs below \$50K per QALY).

Gonzalez-Gomez et al (163) conducted a systematic review with meta-analysis and meta-regression comparing exercise therapy and manual therapy for chronic low back pain. Six RCTs with 743 patients were included. Meta-analysis showed a small but significant long-term benefit of exercise therapy for disability ( $SMD = -0.25$ , 95% CI  $[-0.43, -0.07]$ ,  $p = 0.007$ ). The GRADE assessment indicated very low certainty across outcomes. Exercise therapy may offer small long-term benefits over manual therapy for disability, influenced by sex, age, and treatment duration. The evidence does not strongly support choosing exercise therapy over manual therapy, or vice versa, as a stand-alone treatment.

#### **4.2.2 Physical and Occupational Therapy**

Physical and occupational therapy have long been considered supportive modalities for treating acute and chronic pain. Their goals are to reduce pain, improve function, prevent disability, facilitate activities of daily living, and enhance quality of life. A systematic review of occupational therapy interventions for chronic pain recommended individualized techniques and education on biomechanics as essential for therapeutic success (164). An evaluation of 83 studies involving 8,816 patients with chronic low back pain found that exercise therapy reduced pain intensity, disability, and improved long-term function compared to non-exercise conventional care. Behavioral therapy was effective in the short-term for reducing pain intensity (165).

Physical therapy is considered a high-cost treatment option. A randomized trial found no difference in pain intensity, frequency, or disability between patients assigned to low-cost group aerobics versus individual physiotherapy or muscle reconditioning sessions (166). Physical therapy can be particularly helpful for patients who are unmotivated, non-drug compliant, lack access to safe exercise facilities, or have not improved with low-intensity exercise (150). A randomized trial (167)

showed that a stepped exercise program combining internet-based exercises, coaching calls, and in-person therapy as needed led to meaningful pain reductions in knee osteoarthritis, with 35% of patients ultimately requiring in-person physical therapy.

The effects of lumbar stabilization and graded activity exercises (136) and the cost-effectiveness of spinal manipulation, exercise, and self-management (137) have been discussed. Insurers often require documentation of recent physical therapy, evidence of adverse effects from therapy, or evidence of a structured exercise program before approving interventional techniques.

#### **4.2.3 Acupuncture**

Acupuncture is increasingly used for chronic pain and is the most popular supplemental alternative therapy (168,169). Studies support its use in non-specific musculoskeletal pain (170), osteoarthritis (171), chronic headache (172), and shoulder pain (173). Acupuncture may reduce opioid use (174). In patients with migraines without aura, true acupuncture is associated with long-term reductions in migraine recurrence compared to sham acupuncture (175). Systematic reviews and meta-analyses demonstrate that acupuncture reduces pain in chronic pelvic pain and chronic prostatitis or chronic pelvic pain syndrome (176,177). Trivedi et al (178) concluded that acupuncture is effective for short-term treatment lasting 3 to 5 months.

Guidelines for low back pain differ in recommendations for acupuncture (179-181), based on systematic reviews that show variable effectiveness. Among 16 systematic reviews, 7 showed greater pain relief and functional improvement than no treatment in short-term follow-up; 5 reviews found that acupuncture added to conventional therapy provided short-term improvements in pain and function (182-185). A meta-analysis of 25 studies with 6,200 patients showed significant, although minor, improvements for acupuncture compared to sham treatments and other analgesics (186).

#### **4.2.4 Massage**

Massage may relieve pain through physical and mental relaxation and increasing pain thresholds via release of endogenous opioids (187). Mechanisms may include stimulation of large nerve fibers, affecting nociceptive primary afferents and immune cells, and modulation of the autonomic nervous system (188,189). Numerous trials, literature reviews, and meta-analyses have evaluated massage efficacy and/or effectiveness (190-192).

Farber et al (190) found low to very low quality evidence due to study bias and imprecision. Massage improved short-term pain for acute, subacute, and chronic low back pain, with some improvement in function at short-term follow-up. Furlan et al (191) noted that massage was superior to inactive treatments in some studies, similar to exercise in others, and generally better than joint mobilization, relaxation therapy, physical therapy, acupuncture, or self-care education. Benefits persisted up to one year in some cases. Thai massage produced similar results to Swedish massage, and combination therapies showed added benefits.

#### **4.2.5 Transcutaneous Electrical Nerve Stimulation (TENS)**

Despite common use, TENS effectiveness is inconclusive. It is not typically covered by insurance and is often restricted to RCT use. Prior assessments found no benefit for chronic pain (193,194). Systematic reviews and meta-analyses (195-198) show little improvement in pain, although some short-term functional benefit may exist. Some evidence suggests TENS reduces pain intensity immediately post-treatment as an adjunct therapy (198,199).

#### **4.2.6 Chiropractic Treatments**

Mobilization and manipulation therapies are widely used for chronic pain, though effectiveness, dosing, and safety are debated. It is important to distinguish types and mechanisms of manipulative treatments in osteopathic and chiropractic practice. SMT effectiveness for chronic low back pain is debated; recommendations are heterogeneous. A systematic review by de Luca et al (200) found moderate evidence supporting manual therapy to reduce pain and disability.

SMT is considered first-line in some systems but second-tier after exercise and behavior therapy in others (201,202). Biomechanical theories suggest SMT reduces mechanical stress; neurophysiological theories suggest it engages primary afferent neurons to modulate pain (203-205). Cochrane review evidence indicates SMT provides slight improvement in function, with small to moderate short-term pain relief compared to non-recommended therapies (206). Most adverse events are mild and transient.

Coulter et al (207) found moderate-quality evidence that manipulation and mobilization reduce pain and improve function in chronic low back pain, with manipulation producing larger effects than mobilization. Similar conclusions were reported for chronic

nonspecific neck pain (208). Multimodal approaches integrating multiple treatment types may provide the greatest benefit.

RAND studies (209) show that chronic low back pain patients receiving chiropractic care report proactive self-care behaviors and positive clinical experiences. Leininger et al (137) demonstrated favorable cost-effectiveness for SMT with ICERs below \$50K per QALY for chronic low back pain.

#### **4.2.7 Biofeedback Therapy**

Biofeedback is a psychological treatment that can be performed alone or as an adjunct to interventional and non-interventional approaches, physical therapy, or cognitive behavioral therapy. Patients receive feedback on physiological processes such as respiratory rate, heart rate, or muscle tension and learn to self-regulate these processes (210). Biofeedback types include electromyographic, heart rate variability, respiratory biofeedback, and neurofeedback, with electromyographic and neurofeedback being most common.

Meta-analyses show biofeedback can be more effective than cognitive behavioral or physical therapy (211-213). Sielski et al (213) found that biofeedback produced small-to-medium reductions in pain lasting up to 8 months, while improving depression, disability, muscle tension, and cognitive coping skills. Longer treatments and higher proportions of biofeedback in overall therapy enhanced outcomes. Biofeedback can be used as standalone or adjunctive therapy to improve pain-related outcomes.

#### **4.2.8 Multidisciplinary Rehabilitation**

Multidisciplinary approaches are effective, efficient, and ethically appropriate given the multidimensional nature of chronic pain. An RCT of 521 patients with chronic low back pain (214) showed that multimodal non-pharmacological interventions including cognitive therapy, mindfulness, and behavior therapy reduced pain and improved physical function, mood, and sleep.

Multidisciplinary rehabilitation involves coordinated care by clinicians, physical and occupational therapists, mental health providers, and specialists as needed (150,215,216). CDC guidelines support multimodal therapies and biopsychosocial rehabilitation to reduce long-term pain and disability compared to usual care or physical treatments alone. Non-pharmacological therapies can also synergize with non-opioid and opioid medications (150,217). Medications should ide-

ally be combined with non-pharmacologic therapies to optimize outcomes (150).

Multimodal therapies are not always available or reimbursed, and iterative use can be time-consuming and costly, with disparities in access (217). Less intense multidisciplinary rehabilitation can be as effective as high-intensity programs (151), and combinations of medications may be considered within multidisciplinary management. Short and intermediate outcomes show clinical effectiveness, but third-party support for multidisciplinary centers largely disappeared by 2010. Evidence for long-term benefits ranges from small to none (140,151,218). Recent reviews report insufficient evidence for multi- or interdisciplinary rehabilitation for lumbar radiculopathy (140,215), and Cochrane reviews indicate similar outcomes for patients treated surgically or with multi- or interdisciplinary rehabilitation at 2 years (218).

### 4.3 Opioids

Opioids are widely used in clinical practice to manage chronic low back pain. As described in ASIPP's opioid guidelines (42), multiple reviews over the years have evaluated opioid use, overuse, abuse, and numerous adverse consequences, including opioid-related deaths. Manchikanti et al (42,219) described a fourth wave of opioid-related deaths, expanding upon the 3 distinct waves previously described by the CDC. This wave began in 2016 and has been steadily increasing


due to multiple factors, including misapplication of 2016 CDC guidelines, increased availability of illicit drugs, spillover effects of the COVID-19 pandemic, and policies that have limited access to interventional procedures for chronic pain treatment (Fig. 1) (42,219-221).

The overall trends at the time of this publication are as follows (221):

- Decline in 2024: Provisional CDC data indicate a 27% one-year drop in overdose deaths in the US in 2024 compared to 2023, following a 4% decline from 2022 to 2023.
- Declines across drug types: Reductions were seen across all major drug categories, including opioids, which have been the primary cause of most overdose deaths over the past decade.
- Fentanyl remains a concern: Synthetic opioids, primarily fentanyl, continue to be the most frequently involved substance in overdose deaths, although deaths involving fentanyl decreased by approximately 37% between 2023 and 2024.
- Long-term perspective: Despite recent improvements, opioid overdose deaths in 2023 were nearly 10 times higher than in 1999. More than 645,000 people have died from opioid overdoses since the epidemic began.

Potential causes for the recent decline include:

- Public health response: Expanded investments in prevention, treatment, and harm reduction programs, including increased availability of naloxone.



- Weaker street fentanyl: Evidence suggests street fentanyl may be weaker in some areas, contributing to fewer overdose deaths.
- Harm reduction strategies: Increased availability and use of naloxone, which can reverse opioid overdoses, is a critical factor.
- Improved treatment access: Better access to evidence-based treatments, such as buprenorphine and methadone, may also contribute to the decline.

The impact on the population includes:

- Geographic variations: Overdose deaths have disproportionately affected different regions and demographic groups over time. Initially impacting white, rural communities, the crisis increasingly affects Black, Hispanic, and American Indian/Alaska Native communities. West Virginia has the highest overdose death rate per capita.
- Premature deaths: Opioid overdose deaths are a leading contributor to premature mortality, with affected individuals losing an average of 38 years of life.
- Impact on children: Children of individuals with addiction are significantly more likely to develop addiction themselves.
- Healthcare burden: Opioid-related hospitalizations and emergency department visits place a substantial burden on healthcare systems.
- Mental health: The COVID-19 pandemic exacerbated the opioid crisis, increasing substance misuse and worsening mental health.

Multiple efforts to address the opioid crisis include:

- Increased naloxone availability: Naloxone is now

available over the counter in most states, with expanded distribution through pharmacies, community programs, and law enforcement.

- Expanded treatment access: Effective treatments for opioid use disorder, such as medication-assisted treatment combining medications with behavioral therapies, are increasingly promoted.
- Prevention and education: Public education about the risks of opioid use and overdose remains essential.
- Addressing health disparities: Targeted interventions are needed to reduce the disproportionate impact on communities of color and other vulnerable populations.

There has been substantial debate regarding the relationship between opioid overdoses and prescription opioid pain relievers, including terminology (42,219,220). Evaluation of the relationship between opioid overdoses, opioid treatment admissions, and prescription opioids in the United States from 2010 to 2019 has been described (220). As shown in Figs. 2 and 3, relationships between total opioid doses, accidental opioid deaths, prescription opioid deaths, opioid treatment admissions, and annual prescription sales (measured in morphine milligram equivalents per capita) are either nonexistent or significantly negative/inverse (222).

#### 4.4 Interventional Techniques

Utilization patterns of interventional techniques have changed substantially over the years, initially showing exponential growth and now showing declines. The COVID-19 pandemic had a lasting impact on




Fig. 2. 2010–2019 update.

AOD = any opioid overdose death; POD = prescription opioid deaths; POS = prescription opioid sales; OTA = opioid treatment admissions; TOD = total overdose deaths; MME = morphine milligram equivalents. The green line represents opioid prescribing (POS, MME/capita); the red lines are opioid deaths (POD, AOD, and TOD); the blue line represents opioid addiction (OTA). Over the past decade, as the green line (prescription opioids) declined by +50%, prescription opioid deaths remained flat while opioid addiction, any opioid and total overdose deaths continued increasing “exponentially” (122).

Source: Aubry L, Carr BT. Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019. *Front Pain Res (Lausanne)* 2022; 3:884674 (121).

interventional pain management practices (223-226). Analyses showed an 18.7% reduction in interventional technique use for chronic pain in the Medicare population in 2020 (227). Even before the pandemic, growth patterns for interventional techniques were changing and sometimes declining in the Medicare population following the implementation of the Affordable Care Act (ACA) (219,228-231).

In a retrospective cohort study, Manchikanti et al (50) found that interventional pain management services per 100,000 Medicare beneficiaries declined cumulatively by 28.9% between 2019 and 2022, with an annual decrease of 10.7%. This contrasts with 2010-2019, which showed a slight yearly decline of 0.4%. The sharp 18.7% reduction occurred between 2019 and 2020, coinciding with the pandemic. From 2020 to 2021, the decline slowed to 1.1%, then accelerated to an 11.5% drop between 2021 and 2022. Contributing factors likely include COVID-19, economic challenges, the ACA, evolving LCD policies, and insurer medical policies. Figure 4 illustrates usage patterns of interventional techniques.

Similarly, Manchikanti et al (49) showed escalating growth followed by rapid decline in facet joint interventions for spinal pain in the Medicare population. Manchikanti et al (48) reported a 24% decline in epidural procedure visits, and Manchikanti et al (51)


showed a 13.5% overall decrease in sacroiliac joint injection procedures post-COVID-19 (2019–2022), averaging a 4.7% annual decline.

#### 4.5 Surgery

Since the first discectomy for disc herniation (mis-identified as a "chondroma") by Mixter, a neurosurgeon, and Barr, an orthopedic surgeon, in 1932 (232), surgical treatments for spinal pain have evolved with multiple techniques and a general trend toward increasing surgical interventions, raising questions about treatment effectiveness (233).

The Spine Patient Outcomes Research Trial (SPORT) collected surgical data prospectively (234), demonstrating increasing national trends in surgical interventions (104,123,125,138,235-246), although most data are from 2015. Best et al (138) reported a 460% increase in intervertebral disc disorder surgeries and a 910% increase in spinal stenosis surgeries from 1994 to 2006. Yoshihara and Yoneoka (125) showed a 2.4-fold population-adjusted increase in surgical intervention for degenerative disc diseases from 2000 to 2009. Bae et al (104) reported a 45% increase in lumbar spinal stenosis surgeries and a 1.9% decrease in lumbar decompressions from 2004 to 2009. Martin et al (236) reported a 62.3% increase in elective fusions, with the largest increase (138.7%) in patients aged 65 or older from

Fig. 3. 2010–2019 regression models: Illustrates the regression of opioid treatment admissions. OTA = opioid treatment admissions; POD = prescription opioid deaths; AOD= any opioid overdose death; TOD = total overdose deaths; POS = prescription opioid sales. Significant, negative relationships were found for OTA, AOD, and TOD. No significant relationship exists between POD and POS. Source: Aubry L, Carr BT. Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010–2019. *Front Pain Res (Lausanne)* 2022; 3:884674 (121).






Fig. 4. Comparative analysis of rate (per 100,000 Medicare recipients) of usage patterns for epidural and adhesiolysis procedures, facet joint interventions and sacroiliac joint blocks, disc procedures and other types of nerve blocks, all interventional techniques (geometric average annual change in rates).

2004 to 2015, and aggregate hospital costs rose 177%, exceeding \$10 billion in 2015.

Lopez et al (235) reported a 24.2% increase in surgical interventions for chronic pain from 2012 to 2017. Re-operation rates for disc herniation and spinal stenosis ranged from 10% to 23% (104), with 40% of post-operative patients developing post-surgery syndrome or failed back surgery syndrome requiring additional treatments (104,240-246). These patients often need multiple modalities, including physical therapy, drug therapy, interventional techniques, complex fusions, and neuromodulation techniques (103,104,113,114,247-261).

Clinicians should ideally exhaust low- to moderate-risk treatments before considering surgery. A retrospective analysis of over 75 million individuals by Kim et al (262) found that nonadherence to clinical guidelines in newly diagnosed low back pain contributed substantially to healthcare costs. Notably, 38.7% of surgical patients did not receive conservative management (physical therapy or epidural steroid injections), accounting for \$265 million in healthcare expenses in the first 12 months after diagnosis (262). This highlights the need for careful consideration of surgical interventions to optimize outcomes efficiently.

## 5.0 FUNCTIONAL SPINE UNIT: PATHOPHYSIOLOGIC AND STRUCTURAL BASIS OF LOW BACK PAIN

### KEY QUESTION 1. *WHAT IS THE SPINAL FUNCTIONAL UNIT DESCRIBING THE PATHOPHYSIOLOGIC AND STRUCTURAL BASIS OF LOW BACK PAIN?*

Multiple structures in the low back have been identified as potential sources of specific pain patterns. However, structures proven to cause pain through precision diagnostic blocks include the intervertebral disc, zygapophyseal (facet) joint, sacroiliac joint, and spinal nerves, while degenerative disc disease is typically diagnosed by imaging. Based on precision diagnostic blocks, Manchikanti et al (57), Schwarzer et al (58,263,264), and DePalma et al (265) have reported the prevalence of internal disc disruption or discogenic pain in 26% to 42% of patients, facet joint pain in 27% to 40% of patients with false positive rates of 27% to 47% using a criterion standard of 80% or greater pain relief (41), and sacroiliac joint pain in 2% to 18% of patients. Despite these findings, not all back pain could be accounted for through precision diagnostic blocks or imaging studies. Consequently, it has been postulated that multiple spinal structures contribute to the degenerative process, as described by Kirkaldy-Willis et al (64,65) in their 3-joint degeneration hypothesis.

Effective management of spinal pain and musculoskeletal disorders depends on accurate diagnosis and the use of evidence-based, cost-effective therapeutic interventions. Traditional interventional pain management has largely followed a narrow "pain generator" model, focusing on limited structural targets for temporary rather than disease-modifying effects (18-21,39,41,56-63). The advent of regenerative injection techniques has broadened this perspective, expanding from isolated pain sources to encompass the entire osteoligamentous complex, referred to as the functional spinal unit (FSU) (7).

Over 5 decades ago, White and Punjabi introduced the concept of the FSU, describing each of the 24 spinal levels in the cervical, thoracic, and lumbar regions as integrated mechanisms providing stable structural support for the body (66). The FSU, or spinal motion segment, represents the smallest unit that reflects the functional characteristics of the spinal column. It consists of 2 vertebrae, the intervertebral disc (IVD), zygapophyseal (facet) joints, and the supporting ligaments, including the ligamentum flavum, supraspinous, interspinous, anterior longitudinal, and posterior lon-

gitudinal ligaments (Fig. 5) (67,263,266). The IVD and paired facet joints form a 3-joint complex that enables motion between adjacent vertebrae while facilitating load transmission (68). This model incorporates multiple tissue types, fascia, muscles, synovial joints, and ligaments, as integral elements of spinal function and treatment.

Segmental instability, often due to ligamentous laxity or degenerative disc height loss, frequently precedes pain and predisposes individuals to progressive injury as stress and inflammation accumulate across related structures (266,267). Spinal ligaments serve as passive stabilizers that link adjacent vertebrae and restrict movement within safe physiological limits to protect neural structures. Composed primarily of collagen with varying levels of elastin, proteoglycans, and water, these ligaments contribute significantly to spinal stability. The paraspinal muscles, including the multifidus, erector spinae, and psoas major, play an equally important dynamic role in lumbar stabilization. Muscle atrophy and fatty degeneration are frequently seen in patients with chronic low back pain, emphasizing the vital function of these stabilizers in the management of degenerative spinal conditions (10).

A solid understanding of spinal biomechanics is fundamental to identifying the pathogenesis of spinal diseases and the contributions of each bony and soft tissue component to overall spinal stability. In a study evaluating the role of posterior elements in the mechanical integrity of the human L4-5 FSU, these components contributed 24-30% of compressive stiffness and 42-54% of torsional stiffness. The apophyseal joints were found to significantly influence both compressive and torsional stiffness of the L4-5 FSU (268). Ligaments stabilize the spine by restricting excessive motion, while facet joints guide motion and limit shear and torsional forces. Ligament stiffness and mechanical responses vary by age, disc level, and degree of degeneration.

Disc degeneration alters vertebral and facet joint geometry, thereby changing segmental motion behavior (269). A study employing finite element and response surface modeling found that variables such as gender, age, weight, and height significantly influence FSU movement. Overweight or obesity was shown to markedly affect FSU biomechanics, with greater impact in males and older individuals, potentially compromising quality of life (270).

The principal functions of the FSU can be summarized as follows:

1. Stability: Provides support for maintaining spinal integrity and body weight distribution.
2. Mobility: Allows flexion, extension, lateral bending, and rotation through coordinated disc and facet joint movement, preventing excessive motion.
3. Load Bearing: Distributes stresses encountered during daily activities, with the IVD absorbing shock and minimizing vertebral stress.
4. Protection of Neural Structures: Shields the spinal cord and nerve roots through a stable vertebral and ligamentous framework.

## 5.1 Components of the Functional Spine Unit

### 5.1.1 Facet Joint

The lumbar facet joints are the only true synovial joints of the spine, formed by articulation between the medially oriented superior articular process of the lower vertebra and the smaller, laterally oriented inferior articular process of the upper vertebra. These diarthrodial joints consist of aneural hyaline cartilage covering the articular surfaces (Fig. 6) (271). The capsular ligament encasing the joint is composed of dense, parallel collagen fibers interwoven with elastic fibers, providing essential resistance to shear and tensile forces during motion (272-275). The subchondral bone, synovium, synovial folds, and joint capsule receive extensive innervation via the medial branch of the dorsal ramus, contributing to both proprioception and nociception (274). Pain from the facet joints may refer to the lower back, lateral hip, posterolateral thigh, groin, or, less commonly, the leg and foot.

Facet joints regulate spinal motion and absorb up to 25% of the load transmitted through the 3-joint complex. Symmetry between joints is essential; asymmetry predisposes to instability and accelerates degeneration of both facets and discs. Under degenerative conditions, facet load bearing can nearly double, leading to progressive deterioration (276). Chronic remodeling and ligamentous weakening are major contributors to degenerative spondyloolisthesis (68). Lumbar facet joints have been implicated in 27% to 40% of low back pain cases, with false positive diag-

nostic rates of 27% to 47% using the 80% pain relief criterion standard (41). Chronic mechanical stress and joint capsule deformation stimulate nociceptors, perpetuating pain (41,57,59,277).

### 5.1.2 Intervertebral Disc

The intervertebral disc (IVD) is an avascular structure




Fig. 5. Functional spinal unit embodies the two vertebra, intervertebral disc, paired facet joints and the adjacent ligaments.

Source: Kushchayev SV, Glushko T, Jarraya M, et al. ABCs of the degenerative spine. *Insights Imaging* 2018; 9:253-274 (266).




Fig. 6. Lateral view of the lumbar spine showing vertebral bodies, intervertebral disc and facet joints. A closer look (top right) at the facet joint anatomy displaying the joint cavity along with the joint capsule, hyaline cartilage and synovial membrane.

Source: Nisolle ML, Ghoundiwal D, Engelma E, et al. Comparison of the effectiveness of ultrasound-guided versus fluoroscopy-guided medial lumbar bundle branch block on pain related to lumbar facet joints: a multicenter randomized controlled non-inferiority study. *BMC Anesthesiol* 2023; 23:76 (271).

composed of a central nucleus pulposus surrounded by concentric lamellae of the annulus fibrosus (Fig. 7) (60,61,277-281). Sandwiched between cartilaginous endplates that facilitate metabolic exchange, the IVD functions in a hypoxic and acidic microenvironment (282-286). Disc homeostasis relies on a delicate equilibrium between anabolic and catabolic activities. Anabolic factors include TGF- $\alpha$ , BMP, GDF5, and IGF, whereas catabolic processes involve enzymes and inflammatory mediators such as IL-1 and TNF- $\alpha$  (284). Degenerative disc disease is characterized by loss of proteoglycans, hydration, and disc height, with resultant redistribution of mechanical load to vertebral bodies and facet joints.

Degenerated discs exhibit reduced compressive height, lessening ligamentum flavum tension but shifting stress to posterior elements. Multilevel degeneration further increases stress on ligaments and pedicles, while non-contiguous degeneration lessens localized stress. These biomechanical variations explain differences between symptomatic and asymptomatic degenerative findings (285).

### 5.1.3 Vertebral Endplate

The vertebral endplate is a critical structure me-

diating nutrient transport and biomechanical stability between the vertebrae and IVD (287). Its porosity supports nutrient diffusion, while its rigidity maintains structural integrity. Degeneration and calcification impair nutrient delivery, leading to progressive disc degeneration. Age-related reductions in proteoglycan and collagen content cause thinning and calcification of the endplate cartilage. A strong correlation exists between Modic changes on MRI and discography-confirmed discogenic pain, reinforcing the endplate's role in chronic low back pain.

### 5.1.4 Sacroiliac Joint

The sacroiliac joint, the largest axial joint in the body, connects the sacrum and ilium, transmitting forces between the spine and lower extremities. It comprises an anterior synovial component and a posterior syndesmosis reinforced by interosseous and posterior ligaments (Fig. 8) (288). The sacrotuberous ligament extends from the sacrum to the ischial tuberosity, while the sacrospinous ligament attaches from the sacrum and coccyx to the ischial spine (289). The joint surfaces, hyaline cartilage on the sacrum and fibrocartilage on the ilium, form an L-shaped articulation allowing minimal multidirectional




Fig. 7. Graphical representation of a motion segment; sagittal view. ALL and PLL refer to the anterior and posterior longitudinal ligaments, respectively. The capsular ligament encloses the zygapophysial joint.

Source: Newell N, Little JP, Christou A, Adams MA, Adam CJ, Masouros SD. Biomechanics of the human intervertebral disc: A review of testing techniques and results. *J Mech Behav Biomed Mater* 2017; 69:420-434 (281).




Fig. 8. Posterior view of the ligaments surrounding the sacroiliac joint.

Source: Bock CE. In: *Hand-Atlas der Anatomie Des Menschen*. Berline, Verlag, 1860 (288).

motion, approximately 2 degrees across flexion-extension, rotation, and translation planes (290,291).

### 5.1.5 Spinal Muscles and Ligaments

Spinal stability depends on the integrated action of IVDs, ligaments, and muscles (Fig. 9) (292). While discs and ligaments provide intrinsic stability, muscles supply dynamic support. The principal ligamentous groups include:

1. The anterior and posterior longitudinal ligaments, preventing hyperextension and hyperflexion, respectively.
2. The interspinous and supraspinous ligaments, connecting adjacent spinous processes.
3. The intertransverse ligaments, linking transverse processes to maintain lateral stability.

4. The ligamenta flava, connecting laminae of adjacent vertebrae to preserve spinal flexibility and alignment.

The iliolumbar ligaments anchor the L5 transverse process to the sacrum (293), while the sacrotuberous and sacrospinous ligaments reinforce the sacroiliac joints (289). Paravertebral muscle atrophy, confirmed in both animal and human MRI studies, has been causally linked to chronic low back pain and discogenic changes (294,295). Fatty infiltration and muscular degeneration compromise spinal stability, heighten stress on the facets and discs, and perpetuate a cycle of pain and structural degeneration.




Fig. 9. Anterior view (left) and lateral view (right) of the vertebral ligaments stabilizing the lumbar spine.  
Source: Marieb EN. In: *Human anatomy & physiology*. United Kingdom, Pearson Education, Limited, 2003 (292).

## 6.0 REGENERATIVE MEDICINE

### KEY QUESTION 2. WHAT ARE THE AVAILABLE REGENERATIVE MEDICINE THERAPIES?

Biological therapies promote the healing of damaged tissues either acutely or chronically, including ligaments, menisci, articular cartilage, tendons, intervertebral discs, and joints. Among the various biologicals used in regenerative therapy for the spine and other musculoskeletal disorders, PRP and multipotent mesenchymal stem cells (MSCs) currently serve as the mainstays of regenerative medicine treatment.

Of all the recent innovations in medicine, none have generated as much attention as regenerative medicine. Since their discovery approximately 50 years ago, MSCs have been extensively researched, resulting in over 55,000 published scientific papers and nearly 1,000 completed clinical trials (1,296). Furthermore, more than 5,000 registered clinical trials on [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (297) emphasize the growing exploration of MSCs in therapeutic applications. Controlled clinical trials have treated over 10,000 patients (296-300), reporting minimal complications associated with these therapies. It is further estimated that between 10,000 and 70,000 patients have received MSC-based treatments in commercial clinics (2,4,22,23,298,301,302). MSCs are widely recognized for their transformative potential in medicine, particularly in clinical areas with limited therapeutic options. Consequently, the European Medicines Agency (EMA) classifies them as Advanced Therapeutic Medicinal Products (ATMPs), underscoring their importance in modern therapeutic strategies.

The most common use of regenerative medicine today lies in musculoskeletal disorders, particularly with autologous PRP and bone marrow concentrate (BMC) for the treatment of spinal and joint pain. Unlike allogeneic or culture-expanded stem cells, these autologous therapies are permitted by the FDA, enabling clinical application. Numerous clinical trials, especially those involving the knee, have demonstrated the safety and effectiveness of these biologic interventions (302).

### 6.1 Platelet-Rich Plasma (PRP)

PRP is a concentrate of whole blood that is centrifuged to isolate plasma enriched with platelets and growth factors. In the United States, PRP has FDA approval for use in ligament grafting and bony matrix approximation during reconstructive procedures. The therapeutic benefits arise from an elevated concen-

tration of platelet-derived growth factors released in response to inflammation, such as platelet-derived growth factor (PDGF). These growth factors play an essential role in healing by enhancing fibroblast and osteoblast metabolic activity, reducing cell apoptosis, promoting angiogenesis to improve tissue perfusion, and increasing expression of procollagen genes and collagen-related growth factors, thereby improving the tensile strength of regenerating tissue (18-24,303-312).

PRP contains platelets, leukocytes, and red blood cells, with platelets serving as the central mediators of anabolic effects through the release of growth factors stored in their alpha granules (308). Notable platelet-derived growth factors essential to tissue repair are shown in Table 5 (313-316). Proteins that promote cell proliferation include endothelial growth factor, PDGF, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (b-FGF). Inhibitory proteins such as b-FGF2 are equally important in preventing over-proliferation (310), although the optimal balance between these proteins remains uncertain. Since each individual produces unique relative concentrations of these proteins, the effectiveness of concentrating autologous platelets for personalized therapy is still being studied.

Therapeutic PRP is recommended to have a platelet concentration at least 2.5 times greater than that of peripheral plasma. Lower concentrations are likely sub-therapeutic, whereas excessively high concentrations may suppress osteoclastic activity (304). PRP formulations vary significantly (309). A meta-analysis identified 14 different treatment indications and 9 unique preparation systems used across clinical studies (317). Consequently, several classification systems have been proposed to categorize PRP based on platelet, leukocyte, and fibrin content, as well as the use of exogenous activators.

Dohan Ehrenfest et al (318) developed a classification system based on leukocyte concentration and fibrin structure. In a comprehensive 2025 review, Zhang et al (298) summarized the active ingredients of PRP and provided a similar classification, outlined below:

- Pure PRP (PPRP) lacks leukocytes and has a low-density fibrin network.
- Leukocyte-rich PRP (L-PRP) has high white blood cell and platelet concentrations with a low-density fibrin network.
- Pure platelet-rich fibrin (P-PRF) is leukocyte-free but has a high-density fibrin network.
- Leukocyte- and platelet-rich fibrin (L-PRF) contains

abundant leukocytes and a high-density fibrin network.

Preparations with a low-density fibrin network (PRP and L-PRP) are injectable and commonly used for musculoskeletal applications, whereas those with a high-density fibrin network (P-PRF and L-PRF) form a clot containing growth factors within the fibrin matrix (318).

DeLong et al (319) introduced the PAW (Platelets, Activation, White Blood Cells) classification, which organizes PRP formulations based on platelet count, presence of activators, and leukocyte concentration. Although PRP terminology remains inconsistent and no universal classification is accepted, clinicians should be aware of the specific components in any PRP preparation.

tion being administered. The American Academy of Orthopaedic Surgeons (AAOS) (320) identified key obstacles limiting PRP advancement and issued consensus recommendations for future research, summarized in Table 6 (320). Factors influencing PRP growth factor composition, related to donor variability, preparation methods, and delivery, are listed in Table 7.

The DEPA (Dose of injected platelets, Efficiency of production, Purity of PRP, Activation of PRP) classification was introduced to refine PRP characterization. Another system, MARSPILL, proposed by Lana et al (321), includes the following parameters: Method, Activation, Red blood cells, Spin, Platelets, Image guidance, Leukocytes, and Light activation.

The platelet-poor plasma fraction also contains bioactive substances, including fibrinogen, alpha-

Table 5. Function of growth factors stored in platelet-rich plasma.

Growth Factor	Function
PDGF	Stimulates cell proliferation, chemotaxis, and differentiation Stimulates angiogenesis
TGF- $\beta$	Stimulates production of collagen type I and type III, angiogenesis, re-epithelialization, and synthesis of protease inhibitors to inhibit collagen breakdown
VEGF	Stimulates angiogenesis by regulating endothelial cell proliferation and migration
EGF	Influences cell proliferation and cytoprotection Accelerates re-epithelialization Increases tensile strength in wounds Facilitates organization of granulation tissue
bFGF	Stimulates angiogenesis Promotes stem cell differentiation and cell proliferation Promotes collagen production and tissue repair
IGF-1	Regulates cell proliferation and differentiation Influences matrix secretion from osteoblasts and production of proteoglycan, collagen, and other noncollagen proteins

Abbreviations: PDGF = platelet-derived growth factor; TGF- $\beta$  = transforming growth factor- $\beta$ ; VEGF = vascular endothelial growth factor; EGF = epidermal growth factor; bFGF = basic fibroblast growth factor; IGF-1 = insulin-like growth factor-1.

Adapted and modified from: Refs. (313-316)

Table 6. Consensus statements on platelet-rich plasma.

1	Nomenclature and classification system that encompasses autologous blood-plasma products and categorizes preparations in a sufficient detail to facilitate comparison across studies is not available. <ul style="list-style-type: none"> <li>• A widespread system must be developed with involvement of academics, clinicians, and industry representatives</li> </ul>
2	Quality assessment with influence of donor variance and processing and delivery factors on the composition of PRP must be established
3	A validated assay of the efficacy of PRP should be established for each clinical application. <ul style="list-style-type: none"> <li>• Specific formulation of PRP should be matched with specific pathologic indications.</li> <li>• Methods for establishing proof of safety and efficacy of PRP should be determined. This process may require evidence of phenotype stability or viability for each indication.</li> </ul>
4	The relationship between PRP composition and efficacy may be established. <ul style="list-style-type: none"> <li>• Minimum standards of reporting for all studies (preclinical and clinical) evaluating PRP must be established to facilitate communication and the interpretation and synthesis of scientific investigations. These standards must include measured characteristics of the PRP, factors relating to the donor, processing, and delivery of the PRP and outcome parameters.</li> </ul>

PRP = platelet-rich plasma

Adapted from: LaPrade RF, Dragoo JL, Koh JL, et al. AAOS Research Symposium Updates and Consensus: Biologic Treatment of Orthopaedic Injuries. *J Am Acad Orthop Surg* 2016; 24:e62-e78 (320).

Table 7. *Variables that may influence the growth factor profile of platelet-rich plasma.*

<ul style="list-style-type: none"> <li>• Donor           <ul style="list-style-type: none"> <li>• Age</li> <li>• Gender</li> <li>• Comorbidities</li> <li>• Concurrent medications (including anti-inflammatories)</li> <li>• Nutritional status</li> </ul> </li> </ul>
<ul style="list-style-type: none"> <li>• Processing           <ul style="list-style-type: none"> <li>• Blood collection and storage conditions</li> <li>• Spin protocol (speed, time)</li> <li>• Activation protocol (agent, concentration, timing)</li> <li>• Storage</li> </ul> </li> </ul>
<ul style="list-style-type: none"> <li>• Delivery           <ul style="list-style-type: none"> <li>• Form of delivery (gel, solution)</li> <li>• Timing of delivery in relation to isolation</li> <li>• Timing of delivery in relation to activation</li> <li>• Host factors (similar to donor factors)</li> <li>• Injury chronicity</li> </ul> </li> </ul>

Adapted from: LaPrade RF, Dragoo JL, Koh JL, et al. AAOS Research Symposium Updates and Consensus: Biologic Treatment of Orthopaedic Injuries. *J Am Acad Orthop Surg* 2016; 24:e62-e78 (320).

2-macroglobulin, and exosomes, which have regenerative potential but are beyond the scope of this discussion.

Berrigan et al (312), in a systematic review and meta-analysis, evaluated the effect of platelet dose on outcomes following PRP injections for musculoskeletal conditions. Their findings suggested a potential dose-response relationship, identifying an optimal threshold of greater than 10 billion platelets for favorable results in knee osteoarthritis. This dose appeared to have a stronger effect on functional outcomes than on pain relief. Most studies have focused on intraarticular knee injections, examining PRP dosage, frequency, type, and use of activators (322). Multiple studies support multiple PRP injections rather than a single treatment (323,324) and favor leukocyte-poor over leukocyte-rich PRP (325).

The injection volume also influences outcomes. Typical intraarticular doses range around 4 mL, as most PRP systems yield 3–5 mL (322). However, Kon et al (326) and Patel et al (327) used 8 mL in their studies, and Dhillon et al (328) referred to this as “superdose PRP,” recommending it for knee osteoarthritis. Hahn et al (329) demonstrated a positive, dose-dependent effect of PRP on human chondrocytes, while another study confirmed similar dose-dependence on human MSCs (330). Bansal et al (331) found that an absolute platelet count of 10 billion was critical for sustained therapeutic efficacy. Patel et al (322) compared conventional versus “superdose” PRP (8 mL) in early knee osteoarthritis and found significantly greater improvements with the

higher dose, though the study was criticized for methodological limitations and lack of imaging. Bennell et al (332) in a 2017 RCT concluded that methodological heterogeneity prevents definitive conclusions about PRP effectiveness in osteoarthritis and called for further high-quality trials.

In a 2025 publication, Rath et al (333) provided a comprehensive review on PRP isolation, activation, and clinical application, presenting a unified framework for optimizing PRP in musculoskeletal repair. They emphasized the urgent need for standardized protocols to improve reproducibility and clinical outcomes. Banu and Sharun (334) proposed minimum reporting requirements for PRP research, including platelet, white blood cell, and red blood cell concentrations. However, outcomes in degenerative spinal conditions remain challenging to interpret (18-21).

The process of PRP preparation introduces inherent variability, as factors such as blood draw volume, centrifugation time, and number of spins affect composition. Even the definition of PRP is debated, while the FDA defines it as containing at least 250,000 platelets per microliter, others suggest a minimum between 1 and 1.5 million platelets per microliter (335). This variability contributes to differences in platelet, leukocyte, and growth factor content among preparations. The 2017 Minimum Information for Biologics in Orthopedics (MIBO) guidelines established standardized parameters for reporting biologics in orthopedic research, including platelet concentration, leukocyte differential, and injection volume (336). Despite these efforts, no uniform injection regimen has yet been defined.

Prior studies have highlighted substantial heterogeneity in PRP research regarding composition, preparation methods, dosage, injection protocols, and rehabilitation strategies (337-340). Platelet dosage, defined as the total number of platelets delivered, calculated by multiplying platelet count, injection volume, and total number of injections, is one key variable affecting outcomes. Everts et al (341) underscored the role of platelet dose in promoting angiogenesis and tissue repair through microvascular regeneration, although few studies have directly examined how platelet dosing influences PRP efficacy across pathologies.

## 6.2 Mesenchymal Stem Cells (MSCs)

Stem cells represent the foundational versions of cells, capable of differentiating into one or more specialized cell types. Embryonic stem cells possess both pluripotency, the ability to differentiate into any cell

type, and self-renewal capacity. Adult stem cells are found throughout mature tissues and are predisposed to generate the specific cell types of that tissue in response to environmental cues (2,342-349). Adult stem cells, initially described by Caplan (343) as "mesenchymal stem cells," have been renamed medicinal signaling cells (MSCs) and are widely recognized as important therapeutic agents in regenerative medicine (343-349), particularly in musculoskeletal and spinal applications. While adult MSCs have a more limited differentiation potential than embryonic stem cells, it is sufficient for many current and emerging therapies in musculoskeletal and spinal medicine.

A key advantage of MSCs is their relative lack of major histocompatibility complex (MHC) class II surface proteins, allowing them to adopt multiple cell fates and reducing the risk of immune rejection during allogeneic transfer (319,350). MSCs residing in the perivascular space as pericytes can migrate to injury sites and differentiate into required cell types, such as osteoblasts, contributing directly to tissue remodeling (319,350).

An important mechanism of MSC action is their "paracrine influence," which can modulate the differentiation of surrounding cells. High concentrations of catabolic cytokines from acute inflammation favor osteoclastic activity, so a shift toward a less inflammatory environment is necessary for MSCs to exert anabolic effects. Evidence supporting this includes: 1) artificially concentrating MSCs to promote osteoblastic activity has been successfully used to prevent graft-versus-host disease, and 2) MSCs are most effective in degenerative conditions with minimal active inflammation (351).

Efforts to standardize MSC nomenclature have been challenging due to variability in isolation, culture, and assay methods, often resulting in complex and inconsistent terminology (2,342). The International Society for Cellular Therapy (ISCT) issued a position statement in 2006 outlining minimum criteria for defining MSCs (352).

Bone marrow-derived MSCs, first described from bone marrow, remain the most commonly utilized adult stem cells and have FDA approval and recommendations for clinical use (2,342). MSCs have since been isolated from multiple tissues, each with distinct advantages and limitations. MSCs from different anatomical sources of the same tissue may vary in yield, immunophenotype, secreted cytokine profile, and proteomic characteristics (320,353-355). For example, cloned MSCs from adipose tissue tend to default to adipogenic differentiation,

whereas bone marrow MSCs preferentially differentiate toward osteogenesis, highlighting the importance of tissue origin in therapeutic outcomes (353). Key regenerative pathways mediated by MSCs include osteogenesis, adipogenesis, chondrogenesis (354-357), and fibrinogenesis (358,359), with varying potentials depending on cell source.

Adipose-derived MSCs (adMSCs) exhibit pro-angiogenic properties, making them promising for ischemic or avascular tissues, such as the avascular zone of the knee meniscus. Bone marrow-derived MSCs (bmMSCs) share similar progenitor potential but also possess homing abilities to injury sites via chemoattractants, integrating into host marrow, bone, and cartilage (351).

Adult stem cells are generally scarce, slow-growing, and require appropriate cytokine stimulation to differentiate effectively. Selecting optimal sources, such as red marrow-rich regions of the iliac crest, can yield 95–100% viable cells (319). Laboratory culture can expand MSC populations (360), but no cultured MSC products have received FDA approval to date (2,27,342,361,362). Accordingly, chemically manipulated adipose tissue-derived SVF or cultured SVF products are not FDA-approved. The AAOS (320) provides a consensus statement on stem cell therapy, summarized in Table 8.

Although MSC numbers in BMC are low, growth factors released during bone marrow aspiration enhance therapeutic potential. It is also important to recognize that adult stem cells may carry host-derived genetic mutations, which can persist in differentiated progeny (319). Gene therapy is under investigation to ensure MSC safety and efficacy.

### 6.2.1 Bone Marrow Aspirate Concentrate (BMAC)

Autologous BMAC is a potent biologic therapy widely used in musculoskeletal medicine in the United States. BMAC contains platelets, erythrocytes, leukocytes, endothelial progenitor cells, and MSCs, with MSCs representing only 0.001–0.01% of the aspirate but contributing critically to therapeutic effects. BMAC also contains regenerative factors, including VEGF, IGF-1, FGF-1, TGF- $\beta$ 1, IL-1 receptor antagonist protein (IRAP), and alpha-2-macroglobulin (A2M) (363). The combination of MSCs and growth factors confers anti-inflammatory, immunomodulatory, anti-apoptotic, angiogenic, anti-microbial, anti-fibrotic, and regenerative properties.

BMAC offers practical advantages: ease of extraction, minimal manipulation, and immediate clinical

Table 8. *Consensus statements on stem cell therapy.*

1	It is essential to identify the factors contributing to tissue development, regeneration, and healing in each specific tissue. <ul style="list-style-type: none"> <li>The mechanisms regulating these contributions must be characterized.</li> </ul>
2	The optimum preparation of stem cells for each indication must be established in a systematic fashion. <ul style="list-style-type: none"> <li>Considerations should include cell number, concomitant use of growth factors, predifferentiation, and vehicle.</li> <li>Mesenchymal stem cells isolated from different tissues must be compared to identify the most appropriate cell source for each specific indication</li> </ul>
3	The mechanism responsible for therapeutic effects observed in applications and appropriate outcome parameters must be established. <ul style="list-style-type: none"> <li>A standardized assay of stem cell efficacy is needed.</li> <li>Methods for establishing proof of safety of stem cell therapy should be determined in collaboration with industry and regulatory agencies. This process may require evidence of phenotype stability or viability.</li> <li>The most appropriate control for clinical studies evaluating stem cell therapy in each indication must be identified.</li> <li>The most appropriate, replicable outcomes must be established.</li> </ul>

Adapted from: LaPrade RF, Dragoo JL, Koh JL, et al. AAOS Research Symposium Updates and Consensus: Biologic Treatment of Orthopaedic Injuries. *J Am Acad Orthop Surg* 2016; 24:e62-e78 (320).

use, aligning with the FDA “same surgical procedure” exception (21 CFR 1271.15(b)). The posterior iliac spine provides the highest concentration of MSCs, and optimized aspiration techniques, multiple puncture sites, low volume, rapid aspiration, improve MSC yield (7,364,365). Patient outcomes correlate with MSC quantity, and image guidance via fluoroscopy or ultrasound enhances procedural safety and accuracy. MSC numbers decline with age, particularly in epiphyseal regions, but remaining MSCs generally suffice for therapeutic efficacy.

Clinical studies have demonstrated BMAC effectiveness in lumbar intervertebral disc degeneration (7,364), joint arthritis, avascular necrosis, non-union fractures, and rotator cuff tears. Long-term follow-up indicates that intraosseous BMAC injections for knee osteoarthritis may provide therapeutic benefits lasting up to 15 years (366). Importantly, autologous BMAC has not been shown to promote cancer (367). Standardized protocols, image guidance, and adherence to FDA regulations are essential for safe and effective BMAC therapy.

### 6.3 Adipose-Derived Stem Cells

Adipose tissue is an abundant source of multipotent stem cells, known as adipose-derived mesenchymal stem cells (adMSCs), first identified in 2001 (368). Adipose tissue contains a heterogeneous cell population: approximately 70% adipocytes, with the remainder comprising endothelial cells, mural cells, fibroblasts, immune cells, preadipocytes, and blood cells (369,370). Tissue from the inner and outer thighs contains higher adMSC concentrations than tissue from the abdomen, waist, or inner knee, and deeper adipose layers yield higher stem cell counts with less fibrous tissue (371).

#### 6.3.1 Types of Adipose Tissue Used in Medical Therapies

Adipose tissue preparations for regenerative therapy include macrofat, microfat, nanofat (372), and SVF, each with distinct structural and cellular properties.

Macrfat consists of adipose globules greater than 2 mm, retaining tissue architecture, vascular structures, and a complete cellular population. Microfat is obtained via small-perforation liposuction cannulas or mechanical fragmentation using a 1.2 mm micronizer, largely preserving connective tissue, vascular elements, adipocytes, and cellular microenvironment. Nanofat is derived from microfat through mechanical emulsification (400–600 micron), retaining a regenerative microenvironment with adMSCs, preadipocytes, endothelial cells, pericytes, macrophages, lymphocytes, and smooth muscle cells within a collagen scaffold. SVF (373) is obtained via enzymatic digestion of adipose extracellular matrix, yielding a heterogeneous single-cell population including adMSCs, endothelial progenitor cells, pericytes, macrophages, and other immune and stromal cells.

Adipose tissue contains significantly higher progenitor cell concentrations than bone marrow, with approximately 5–10% adMSCs (374) versus 0.001–0.01% bmMSCs (375). The abundant availability, ease of extraction, higher stem cell concentration, low senescence, and potent regenerative potential make adipose tissue an advantageous source for regenerative therapies.

##### 6.3.1.1 Biological Activity and Therapeutic Potential

Processed adipose tissue exhibits a rich secretome including proliferative, angiogenic, anti-apoptotic, and differentiation-promoting factors such as PDGF, VEGF, IGF, and HGF. Anti-inflammatory and immunomodula-

tory proteins are also present, including TGF- $\beta$ 1, IL-4, IL-6, IL-10, IL-1RA, prostaglandin E2, NO, SDF-1, IDO, and extracellular vesicles/exosomes (370,376,377).

### 6.3.1.2 Clinical Applications

Microfat and nanofat have expanded clinical utility in regenerative medicine, demonstrating positive outcomes in wound healing (378) and musculoskeletal disorders, including osteoarthritis (379,380), tendon injuries (381), and ligament damage. Usuelli et al (381) reported nanofat injection for Achilles tendinopathy was safe and more effective than PRP, leading to faster and superior tissue repair. Multiple studies confirm the safety and efficacy of autologous microfat and nanofat in knee osteoarthritis, with meta-analyses supporting their therapeutic potential (382). AdMSCs also show promise for femoral head osteonecrosis (383,384), with mechanisms involving chondrocyte proliferation, inflammation modulation, and angiogenesis.

### 6.3.1.3 Regulatory Considerations and Advantages

Microfat and nanofat therapies are autologous, minimally manipulated through mechanical processes, and suitable for immediate point-of-care application, consistent with the FDA "same surgical procedure" exception (21 CFR 1271.15(b)) (36).

## 6.3.2 Adipose Tissue-Derived Stromal Vascular Fraction

Autologous SVF for musculoskeletal applications is obtained via enzymatic digestion of lipoaspirated adipose tissue (385). Mechanical isolation methods have been reviewed (386), but enzymatic digestion remains more common due to higher cell yield (387,388). SVF has been primarily applied in knee osteoarthritis (9 studies) with limited use in wound care (2 studies), discogenic low back pain (1 study), femoral head avascular necrosis (1 study), and jaw reconstruction (1 study) (389). No serious adverse events were reported, with minor harvest site discomfort, edema, soreness, or ecchymosis resolving spontaneously (390). Higher SVF cell counts correlated with improved outcomes in knee osteoarthritis (391,392), with greater benefits in KL Grade III versus Grade IV knees (393).

## 6.4 Exosomes

Exosomes, or small extracellular vesicles (sEVs), mediate intercellular communication (394,395), are secreted by nearly all cell types, and are present in most body fluids. They exhibit low immunogenicity and are

considered a "cell-free" regenerative therapy. Exosomes carry proteins, lipids, DNA, and RNA reflective of the source cell (396). MSC-derived exosomes replicate the paracrine effects of their parent MSCs, including immunomodulation, angiogenesis, tissue proliferation, and antimicrobial activity (360,397). Exosomes present in PRP, SVF, and BMC contribute to their therapeutic effects. Purified exosome preparations have been studied in vitro and in animal models for intervertebral disc degeneration (398) and peripheral nerve regeneration (399,400). Few clinical trials on ClinicalTrials.gov currently investigate MSC-derived exosomes for musculoskeletal pathologies (395). Challenges remain in scaling cGMP exosome production and defining optimal dosing and treatment intervals.

## 6.5 Non-Autologous Biologics

Non-autologous biologics (NABs) used in regenerative therapy include placental tissues, amniotic fluid, cord blood/tissue, cadaveric-derived tissue, and cultured cells (401). NABs containing viable cells or substantially altered tissues require FDA approval (401). Products not requiring approval include dehydrated human amniotic/chorionic membrane (dHACM) sheets, which have shown accelerated wound healing in diabetic ulcers (402) and pediatric burns compared to split-thickness skin grafts (403). Recently approved NABs include cultured human cells on scaffolds for deep partial-thickness burns, achieving 83% wound closure by month 3 (401,404). Most commercially available injectable NABs derived from amniotic fluid, amniotic tissue, or cord blood/tissue remain unapproved by the FDA (401).

## 6.6 Other Commercially Available Biologic Preparations

While a variety of regenerative products exist, including autologous and allogeneic culture-expanded MSCs, exosomes, amniotic fluid, amniotic membrane, and umbilical cord tissue, only autologous PRP and BMC are currently FDA-compliant for clinical use in spinal and joint conditions. Although non-approved donor-derived products may have regenerative potential, limited evidence supports their safety and efficacy.

FDA restrictions have not prevented companies from marketing non-approved regenerative products, often failing to meet manufacturing standards and causing serious infectious complications. The FDA has issued warning letters and consumer alerts regarding these practices (405). Widespread use of unapproved products by illegitimate stem cell clinics has raised

significant safety and legal concerns (406), with consequences including lawsuits, regulatory action, warning letters, settlements, medical board sanctions, and, in some cases, criminal penalties.

Preliminary data suggest some non-approved

products may provide benefits in musculoskeletal pain management (407); however, use of these therapies is not recommended until further research is conducted and FDA approval is obtained, ensuring patient safety and treatment efficacy.

## **7.0 EFFECTIVENESS OF BIOLOGIC THERAPY IN CHRONIC LOW BACK PAIN**

### **KEY QUESTION 3. ARE REGENERATIVE MEDICINE THERAPIES EFFECTIVE IN TREATING LOW BACK AND LOWER EXTREMITY PAIN?**

The components of the 3-joint theory of spinal degeneration include intervertebral disc degeneration and facet joint loading and degeneration, which may result in spinal deformity, nerve root compression, and potentially central canal and/or foraminal stenoses (2,64). Regenerative treatments for low back pain have emerged due to the suboptimal outcomes of conventional therapies and growing interest in disease-modifying approaches. Platelet-rich plasma (PRP) and stem cells represent 2 promising regenerative therapies currently applied in the management of low back pain, with or without radiculopathy.

Diagnostic studies have identified the intervertebral discs, zygapophysial (facet) joints, and sacroiliac joints as the most common sources of low back pain (2,18-21,39,41,56-63). Discogenic pathology, with or without internal disc derangement, is estimated to account for 16.9% to 39% of chronic low back pain cases without radiculopathy. Lumbar disc disorders may manifest as disc prolapse, protrusion, extrusion, or herniation (60). Symptomatic lumbar disc herniation occurs in approximately 1% to 3% of the population, while lumbar radiculopathy and sciatica are estimated at 0.98% (2,18-21,39,41,56-64). The lumbosacral facet joints are also recognized contributors to chronic low back and referred lower extremity pain. Controlled studies indicate that facet joints generate low back pain that is neither radicular nor discogenic in 16% to 41% of cases (41,277). Similarly, studies using controlled diagnostic blocks have implicated the sacroiliac joints in 10% to 25% of low back pain cases without disc herniation, discogenic pain, or radiculitis (408).

Pain arising from disc degeneration, disc herniation, or facet and sacroiliac joint pathology may resolve spontaneously in some patients. However, a significant proportion develop chronic pain requiring more advanced treatment approaches. Many clinical decisions in the management of these disorders are not supported by randomized controlled trials or high-quality observational studies (409).

Consequently, alongside traditional management strategies, there has been a paradigm shift toward a functional spinal unit (FSU) approach for regenerative medicine injections in low back pain, rather than relying solely on precision diagnostic and therapeutic

techniques (28). Regenerative medicine represents a shift from conventional interventional pain management, which predominantly uses precision diagnostic blocks to identify specific pain generators and targets a limited set of structures as temporary measures, toward a disease-modifying approach (8,10,28).

Several cell-based therapies have been proposed, including injections of MSCs or PRP. Evidence supporting these therapies has been developed in basic science research and translated into clinical studies through controlled trials.

The current literature includes systematic reviews, randomized controlled trials, and numerous observational studies. Evidence is strongest for intradiscal biologic treatments but is emerging for facet joint injections, epidural injections, and sacroiliac joint injections. Additional evaluations have been conducted using a spine FSU approach, considering treatments targeting multiple structures, as well as literature regarding injections into ligaments and muscles.

### **7.1 Intradiscal Injections**

#### **KEY QUESTION 4. THE EVIDENCE OF EFFECTIVENESS FOR THE USE OF INTRADISCAL PRP OR BONE MARROW ASPIRATE CONCENTRATE (BMAC) AND CONSENSUS-BASED CLINICAL RECOMMENDATIONS.**

Intervertebral disc degeneration, a primary contributor to discogenic pain, is driven by neuroinflammation-induced nociceptive fiber innervation within the disc (60,61). The intervertebral disc consists of the nucleus pulposus, annulus fibrosus, and cartilaginous endplate, providing structural support and shock absorption. Degenerative changes disrupt these functions, resulting in lumbar spine instability.

Conventional treatments do not halt the degenerative cascade or promote regeneration (60,61,111,279). Mechanisms implicated in disc degeneration include the loss of stem and progenitor markers, extracellular matrix imbalance, increased inflammation, sensory hyperinnervation, vascularization, and dysregulated signaling pathways. In response, regenerative therapies such as MSC and PRP injections have emerged as promising options (2,6,17,95,107-111,279-283,400).

Preclinical and clinical studies increasingly support the efficacy of MSCs and PRP for discogenic low back pain. These findings have been evaluated through controlled trials and systematic reviews (10,410-420).

A search for intradiscal regenerative medicine in-

jections, including PRP, BMC, or BMAC, was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (421), consistent with the search methodology of Manchikanti et al (18). This search identified 2 additional studies included in a 2024 systematic review (18). Two randomized controlled trials (RCTs) assessing intradiscal stem cell injections were identified.

Levi et al (422) performed a double-blind, randomized, sham-controlled trial with BMC in 63 patients (48 receiving BMC, 15 receiving sham). The sham procedure involved simulation of intradiscal injection using a 22-gauge needle tapping at the corresponding transverse process and a rapid intramuscular injection of 3 mL of contrast agent. The study concluded that intradiscal BMC was equivalent to the sham procedure for chronic discogenic low back pain, with both groups demonstrating high but statistically comparable success rates. The authors acknowledged significant limitations, including lack of quality cell analysis, which restricted conclusions regarding BMC effectiveness.

Vadalà et al (423) treated 52 patients with chronic low back pain using BM-MSCs or a sham procedure. Although autologous BM-MSC intradiscal injections demonstrated regenerative effects, including significant increases in disc height and other parameters at 3 and 6 months, no differences in clinical outcomes were observed. Accordingly, the systematic review conducted in 2024, incorporating all available studies and reviews, was utilized for further analysis.

More than 10 systematic reviews have evaluated management of discogenic pain with or without disc herniation, including intradiscal injections (18). Sanapati et al (17) reviewed the literature at that time, including 2 clinical reviews on intradiscal biologics (109,110), preclinical studies (107), and spinal conditions such as spinal cord injury, intervertebral disc repair, and spinal fusion (108). Basso et al (109) focused on 7 clinical studies encompassing 104 patients.

Manchikanti et al (18) performed a systematic review and meta-analysis following PRISMA guidelines (421), incorporating methodological approaches from previous reviews and guidelines to enhance rigor (38,39,41,42,44,74,77,98-102). Their analysis included 8 RCTs (11,424-430), 4 evaluating PRP (11,425,427,428), 5 evaluating MSCs (11,424,426,429,430), and 8 observational studies (7,431-437), 4 assessing PRP (431,432,434,435) and 4 assessing MSCs (7,433,436,437). Study characteristics are summarized in Tables 9 and 10. Methodological quality and risk of bias were assessed using standardized

measures (Appendix Tables 1, 2, and 4). Dual-arm and single-arm meta-analyses are shown in Figures 10-16.

This review incorporated recent studies on PRP, allogenic MSCs, and homologous BMC. Study quality was high according to Cochrane and Newcastle-Ottawa criteria, and moderate to high using IPM-QRB and IPM-QRBNR. No additional studies were available for inclusion; thus, data from this systematic review were used. Methodological quality, GRADE, and overall certainty were re-evaluated and adjusted. Conventional meta-analysis demonstrated significant pain relief at 24 months and functional improvement at 3, 6, and 12 months. Single-arm meta-analysis showed substantial improvements from baseline at all time points between 1 and 24 months.

Qualitative analysis of intradiscal PRP included 4 RCTs (11,425,427,428), 3 of which were positive trials with moderate certainty. Non-randomized and observational studies were also considered in single-arm analyses, with all 4 studies showing positive outcomes (431,432,434,435). GRADE assessment of RCTs is presented in Table 11. Evidence quality was rated as fair, Level III, with low to moderate certainty and moderate recommendation strength based on qualitative and quantitative analysis.

For MSCs, qualitative RCT evidence showed that 4 of 5 trials were positive (11,424,426,430), with 3 positive trials demonstrating moderate certainty (11,424,430). Two recent studies not included in the systematic review (422,423) were both negative. Among 4 nonrandomized or observational studies, all were positive (7,433,436,437); however, Atluri et al (7) used a functional spine unit model with injections into multiple structures. Conventional meta-analysis including this study showed no significant difference at 3 and 6 months for pain compared to control, but at 12 months the response favored MSCs, which continued through 24 months. Functional status favored MSCs at 3, 6, and 12 months. Single-arm meta-analysis demonstrated favorable responses for MSCs for pain at 3 and 6 months and for function at 3, 6, 12, and 24 months. GRADE assessment using all RCTs is shown in Table 1.

Overall, based on qualitative and quantitative evidence, MSC therapy was deemed Level III, fair, with low to moderate certainty and moderate recommendation strength.

Wu et al (110), in a systematic review and single-arm meta-analysis of 6 studies on cell-based therapies for lumbar discogenic pain, concluded that these therapies were associated with improvements in pain

Table 9. Study characteristics of randomized controlled trials assessing intradiscal biologics.

Study Characteristic	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
PLATELET-RICH PLASMA								
Trakki-Wosornu et al, 2016 (425) RA, PC, DB Single center Quality Scores: Cochrane = 12/13 IPM-QRB = 37/48	n = 47 Lumbar discogenic pain Selection Criteria: Clinical Evaluation: Imaging and provocation discography Biologic Used: PRP	n = 29 patients in the treatment group Injection of disc levels that elicited concordant pain with evidence of incompetent annular disruption with less than 2 mL were injected with 1-2 mL of PRP	n = 18 Injection of disc levels that elicited concordant pain with evidence of incompetent annular disruption with less than 2 mL were injected with 1-2 mL of PRP	FRI & NRS for pain, pain and physical function domains of the SF-36 and the modified NASS Outcome Questionnaire 1, 4, & 8 weeks, 6 months, 1 year NRS worst pain 2.12-point change ( $P < 0.01$ ) Significant improvement in FRI scores was maintained through one-year from baseline	Follow-up rate: 92% 8-week follow up: Significant improvement in pain ( $P = 0.02$ , function $P = 0.3$ ) Patient satisfaction ( $P = 0.01$ ) Worst pain decreased from baseline of 7.98 to 5.82. Comparator: 7.72 at baseline and 6.83 One-year follow-up: Significant improvements from baseline to one-year were observed NRS worst pain 2.12-point change ( $P < 0.01$ ) Significant improvement in FRI scores was maintained through one-year from baseline	Well designed, randomized, double-blind control design with a rigorous participation process and high follow-up rate and long-term data of at least one-year in the majority of the treatment group Data collection in the control group was performed only up to 8 weeks	The relief patterns were significant; however, authors have not calculated 50% or greater proportion of patients with the 50% or greater pain relief with maintained improvement compared to controls at 1-year follow-up	Positive trial of PRP Intradiscal injections of PRP x 1 showed significant improvement at 8-week follow-up with maintained improvement compared to controls at 1-year follow-up
PLATELET-RICH PLASMA								
Navani et al, 2024 (11) RA, PC, DB Multicenter Quality Scores: Cochrane = 12/13 IPM-QRB = 38/48	43 patients were randomized into 3 groups: Placebo = 12 PRP = 15 BMC = 16 Selection Criteria: Imaging, clinical assessment Biologic Used: Intradiscal PRP Intradiscal BMC	Intradiscal PRP injection, 1-2 mL, into the painful disc(s) until resistance to further injection was felt by the operator in the PRP group (n = 15) In the BMC group, 1-2 mL of BMC was injected intradiscally until resistance to further injection was felt by the operator (N = 16)	Patients in the placebo group receive deep trigger point injections with normal saline into the muscle (n = 12)	NRS, patient satisfaction, ODI 1, 3, 6, and 12 months	Significant improvement was seen in PRP and BMC groups at 6- and 12-month follow-up compared to baseline There was no significant difference between PRP and BMC over a 12-month period ( $P = 0.094$ ). ODI was significantly reduced ( $P = 0.001$ ) for both biologic groups Changes in pain scores over 12 months were significant ( $P = 0.0043$ ) ODI scores significantly improved in the crossover group also ( $P = 0.0137$ )	Multicenter, randomized, controlled trials with crossover design Overall, good results compared to overall appropriate results compared to placebo There were no differences between PRP and BMC group	Positive trial of PRP Comparative analysis of intradiscal PRP and BMC compared to intramuscular injection of muscle saline injection into the muscle showed significant improvement in biologic treatment groups There was no difference in PRP or BMC	Positive trial of PRP Comparative analysis of intradiscal PRP and BMC compared to intramuscular injection of muscle saline injection into the muscle showed significant improvement in biologic treatment groups There was no difference in PRP or BMC

Table 9 cont. Study characteristics of randomized controlled trials assessing intradiscal biologics.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions	
Goyal et al, 2022 (427) RA, AC Quality Scores: Cochrane = 12/13 IPM-QRB = 37/48	n = 48 patients Selection Criteria: Clinical assessment, imaging, and positive provocation discography Biologic Used: PRP or intradiscal radiofrequency ablation	PIRF ablation was carried out at 70°C for 4 minutes (n = 24)	NIRS, ODI 3 months and 6 months Proportion of patients with > 50% reduction in NIRS	At 3 months, NIRS score was significantly less in radiofrequency group compared to PRP group ( $P = 0.001$ ) At 6 months, there was no significant difference between NIRS and ODI of both groups Both NIRS and ODI decreased significantly over 6 months within each group 11 patients in both groups had > 50% improvement in NRS	A prospective, active, controlled trial comparing radiofrequency vs. PRP	Active controlled trial	Negative trial for PRP The response to intradiscal injection of PRP showed 11 of 25 patients responding at 6 months with $\geq$ 50% relief	Negative trial for PRP	
Akeda et al, 2022 (428) RA, AC, DB Quality Scores: Cochrane = 13/13 IPM-QRB = 38/48	n = 16 Disc degeneration at L3/4-L5/S1 Selection Criteria: Confirmed using standardized provocative discography Biologic Used: PRP	n = 8 Intradiscal injection of 2 mg in 2 mL saline of betamethasone sodium Phosphate	VAS, quality of life, ODI, RMDQ, IOA back pain evaluation questionnaire	VAS scores of both PRP- and corticosteroid group groups decreased significantly ( $P = 0.01$ ) There were no differences between the groups At week 60, success rate was 87.5% in the PRP group and 40% in the corticosteroid group. Even then, it was not statistically significant	Randomized, double-blind, active controlled trial	Small sample size. Active control trial	Significant improvement at 60 weeks in PRP-group compared to baseline data; however, even though it was different, it did not reach statistical significance in comparison with the steroid group	Positive PRP trial	
MESENCHYMAL STEM CELLS									
Pers et al, 2024 (429) RA, PC, DB Multicenter	Randomized patients = 114 BM-MSC group (n = 58) Sham placebo group (n = 56) Quality Scores: Cochrane = 10/13 IPM-QRB = 44/48	Intradiscal injection of 2 mL of 20 million BM-MSCs in injectable-grade Plasma-lyte using a 22G spinal needle	Sham injection without intradiscal puncture consisted of subcutaneous injection in the back of the patient of 2 mL of sterile saline in similar conditions in the surgical theatre	Primary endpoint: Rate of responders defined by improvement of VAS for pain of at least 20% and 20 mm, or improvement of ODI of 20% between baseline and month 12 The secondary structural co-primary endpoint: Change in the disc fluid content measured by quantitative T2 MRI	At 12-month follow-up, the study did not demonstrate clinical and imaging benefits and co-primary endpoint was not reached. However, at 12-months, the percentage of responders was 74% of patients in the experimental group vs. 68.8% in the placebo group The change in disc fluid content suggestive of disc regeneration between baseline and month 12 was an average of 41.7% in the placebo group vs. 37.9% in the treatment group VAS improved at all points in both groups The proportion of patients reaching MCID in VAS pain score with 30% improvement between baseline and 1, 3, 6, 12 and 24 months were slightly elevated in BM-MSC group but not statistically significant The same result was seen in the proportion of patients reaching the MCID in ODI scores with 10-point improvement No serious adverse effects related to the intervention occurred	The first of its nature DB, RA, multicenter PC trial of allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain showed that the procedure is safe. However, at 12 months, the study did not demonstrate clinical and imaging benefits as study endpoints did not reach significance There were non-significant improvements in endpoints, VAS, and ODI	Negative trial of stem cells Comparative analysis of allogenic bone marrow-derived mesenchymal stromal cell-based therapy	Negative trial of stem cells Comparative analysis of allogenic bone marrow-derived mesenchymal stromal cell-based therapy	

Table 9 cont. *Study characteristics of randomized controlled trials assessing intradiscal biologics.*

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Navari et al, 2024 (11) RA, PC, DB Multicenter Quality Scores: Cochrane = 12/13 IPM-QRB = 38/48	43 patients were randomized into 3 groups: Placebo = 12 PRP = 15 BMC = 16 Selection Criteria: Imaging, clinical assessment Biologic Used: Intradiscal PRP Intradiscal BMC	Intradiscal PRP injection, 1-2 mL into the painful disc(s) until resistance to further injection was felt by the operator in the PRP group (n = 15) In the BMC group, 1-2 mL of BMC was injected intradiscally until resistance to further injection was felt by the operator (n = 16)	Patients in the placebo group receive deep trigger point injections with normal saline into the muscle (n = 12)	NRS, patient satisfaction, ODI 1, 3, 6, and 12 months	Significant improvement was seen in PRP and BMC groups at 6- and 12-month follow-up compared to baseline There was no significant difference between PRP and BMC over a 12-month period (P = 0.094) The ODI was significantly reduced (P = 0.001) for both biologic groups The changes in pain scores over 12 months were significant (P = 0.0043) The ODI scores significantly improved in the crossover group also (P = 0.0137)	Multicenter, randomized, controlled trials with crossover design. Overall, good results compared to overall appropriate results compared to placebo Placebo group was intramuscular injection with short-term follow-up, randomization blinding There were no differences between PRP and BMC group There was no difference in PRP or BMC	Positive trial of stem cells Comparative analysis of intradiscal PRP and BMC compared to intramuscular injection of muscle saline muscle showed significant improvement in biologic treatment groups	Positive trial of stem cells 40% of patients with perfect results 28% improvement in all patients Degeneration improved in MSC treated patients and worsened in the controls. Feasibility and safety were confirmed in this preliminary study
Noriega et al, 2017 (426) RA, PC, DB Quality Scores: Cochrane = 11/13 IPM-QRB = 32/48	24 patients with chronic low back pain with lumbar disc degeneration and unresponsive to conservative treatments.	The intervention group received allogeneic bone marrow MSCs by intradiscal injection of 25 x 10 <sup>6</sup> cells per segment under local anesthesia	A sham infiltration of paravertebral musculature with anesthetic	VAS, ODI, MRI, SF-12 Follow-up = 12 months	MSC-treated patients displayed a quick and significant improvement in all agofunctional indices versus the controls Both lumbar pain and disability were significantly reduced at 3 months and improvement was maintained at 6 and 12 months. Overall, there was an average 28% improvement in pain and disability 1 year after the intervention Only 5 of the 12 outcomes in patients (40%) receiving MSCs were described as perfect treatment with 100% improvement	Well performed RCT with multiple parameters. 100% improvement was seen in 40% of the patients Average improvement was only 28% in pain and disability one year after the intervention	Positive trial of stem cells 40% of patients with perfect results 28% improvement in all patients Overall improvement was on average 28% for pain and disability one year after the intervention	Positive trial of stem cells 40% of patients with perfect results 28% improvement in all patients Degeneration improved in MSC treated patients and worsened in the controls. Feasibility and safety were confirmed in this preliminary study

Table 9 cont. Study characteristics of randomized controlled trials assessing intradiscal biologics.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Amirdelfan et al, 2021 (424) RA, PC, DB Multicenter Quality Scores: Cochrane = 13/13 IPM-QRB = 36/48	100 participants with chronic low back pain were divided into 3:3:2:2 ratio Selection Criteria: Clinical and imaging assessment Biologic Used: Allogeneic, MPCs from bone marrow from a healthy donor	Allogeneic expanded STRO-3+ MPCs from iliac crest, 2cc per injection 2 groups: 18 million mesenchymal precursor cells + hyaluronic acid (n = 30) 6 million mesenchymal precursor cells + hyaluronic acid (n = 30) hyaluronic acid control (n = 20), or Saline control (n = 20)	2 Groups: Injection of 2cc hyaluronic acid (n = 20) Injection of saline (n = 20)	VAS, ODI, SF-36	There were significant differences between the control and MPC groups for improvement in VAS and ODI. All study groups showed improvements from baseline at all time points 6 million & 18 million MPC groups showed significant mean VAS score improvement compared with saline at 12, 24, and 36 months and was significant compared with hyaluronic acid at 3 and 6 months for 6 million MPC and at 3 months with 18 million MPC. Both MPC groups, were superior at 12, 24, and 36 months to saline	Multicenter, randomized, placebo-controlled, long-term safety and efficacy study	Positive results with safety and efficacy in a randomized, multi-site trial with multiple variables; however, there were no significant radiographic improvements in any of the groups	Positive trial of stem cells
Gornet et al, 2024 (430) RA, PC, DB Multicenter Quality Scores: Cochrane = 11/13 IPM-QRB = 34/48	n = 60 Selection Criteria: Clinical evaluation, imaging Biologic Used: Allogeneic disc progenitor cells	Intradiscal biologics Low dose cells High dose cells Single intradiscal injection of 1 mL into a single symptomatic lumbar intervertebral disc	Vehicle alone (n = 10) Placebo (n = 10) Single intradiscal injection of 1 mL into a single symptomatic lumbar intervertebral disc	VAS pain improvement > 30% at 12 weeks, ODI, EQ-5D Health Index	At week 52: High dose group had a mean VAS percentage decrease from baseline (62.8%, p = 0.0005), achieving the endpoint of back pain improvement greater than 30%. At week 104: The clinical improvement was maintained in the high dose group. The vehicle group had a smaller significant decrease in VAS (-52.8, p = 0.044). Low dose and placebo group showed non-significant improvements. Overall, only the high dose group had a significant change in disc volume at 52 and 104 weeks	Positive allogeneic disc progenitor cells trial Small number of patients even though sample size calculations were performed. Further, significant adverse events surprisingly in vehicle or placebo groups.	Significant effectiveness of high-dose allogeneic disc progenitor cells with clinically meaningful improvement in back pain and disc volume at one-year and 2 years	Positive allogeneic disc progenitor cells trial

AC = active controlled; BM-MSC = bone marrow mesenchymal stromal cell; DB = double-blind; EQ-5D-5L = EuroQol 5 Dimension; FRI = Functional Rating Index; IPM-QRB = Interventional Pain Management techniques – Quality Appraisal of reliability and Risk of Bias Assessment; JOA = Japanese Orthopedic Association; MCID = minimal clinically important difference; MPC = mesenchymal precursor cells; MRI = magnetic resonance imaging; MSCs = mesenchymal stem cells; NASS = North American Spine Society; NRS = Numeric Rating Scale; ODI = Oswestry Disability Index; P = prospective; PC = placebo controlled; PIRF = percutaneous intradiscal radiofrequency; PRP = platelet-rich plasma; PRPr = platelet-rich plasma releasate; RA = randomized; RCT = randomized controlled trial; RMDQ = Roland Morris Disability Questionnaire; SF-12 = 12-Item Short Form Health Survey; SF-36 = 36-item Short Form Health Survey; STRO-3 = stromal precursor antigen-3; VAS = Visual Analog Scale

Table 10. *Study characteristics of non-randomized and observational studies assessing intradiscal biologics.*

Study Characteristic	Study	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
<b>PLATELET-RICH PLASMA</b>									
Jain et al, 2020 (434)	25 patients	Discogenic pain	PRP injection at a single or multiple disc levels	None	NRS, ODI	At 6-month follow up proportion of patients showing > 50% reduction in NRS was 55%, ODI was 65%.	Appropriate selection criteria NRS and ODI scores appear to have been significantly reduced Authors carefully evaluated correlation coefficients between platelet concentration (PRP) and reduction in NRS and ODI at different time periods. Further, they also evaluated proportion of patients with greater than 50% reduction in NRS and ODI scores	65% of the patients reported greater than 50% reduction in pain scores with significant reduction in ODI scores ( $P = 0.0006$ )	Positive study of PRP
<b>KIRCHNER &amp; ANITUA, 2016 (432)</b>									
O, R, pilot study	n = 86	Lumbar disc degeneration	One intradiscal, one intraarticular facet, and one transforaminal epidural injection	None	VAS over time 1 month, 3 months, 6 months	Pain reduction after PRGF- Endoret injections showed statistically significant drop from $8.4 \pm 1.1$ before the treatment to $0.8 \pm 1.7$ at 6-month follow-up	Only a 6 month follow up	Positive study of PRP Fluoroscopy-guided infiltrations of intervertebral discs and facet joints with PRGF in patients with chronic LBP resulted in significant pain reduction assessed by VAS	
Quality Scores: Newcastle-Ottawa = 6/8		Selection Criteria: Clinical evaluation, imaging					The injection was into the disc plus intraarticular and transforaminal epidural injections. Consequently, specificity may have been lost	The results showed reduction of the VAS over time. The study ended at 6 months with 91% of the patients showing an excellent score, 8.1% showing moderate improvement, and 1.2% were inefficient score group	The results showed an excellent score, 8.1% showing moderate improvement, and 1.2% showing lack of response
IPM-QRBNR = 27/48		Biologic Used: PRGF-Endoret							

Table 10 cont. Study characteristics of non-randomized and observational studies assessing intradiscal biologics.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Machado et al, 2022 (435) P, case series Quality Scores: Newcastle-Ottawa = 6/8 IPM-QRBNR = 25/48	n = 46 Chronic low back pain	1 mL of PRP into each disc. In addition, majority of the patients also received 2 mL for transforaminal injection per site, 5 mL for caudal injection, 2 mL for each facet joint and capsule, and 2 mL for each site of paravertebral muscles	None	VAS, RMDQ	Significant lower scores of RMDQ and pain VAS at weeks 12, 26, 52 in comparison to baseline ( $P = 0.001$ ) Mean VAS pain scores decreased by approximately 35%, RMDQ decreased by 40% at 52 weeks. Opioid consumption was significantly reduced at 52 weeks	There is no specific structure causing the pain; it was multitargeted and multiple injections with no definitive diagnostic process	Positive study of PRP Significant improvement in pain, function, and opioid consumption	
Monfett et al, 2016 (431) P Single center Quality Scores: Newcastle-Ottawa = 6/8 IPM-QRBNR = 23/48	n = 29 Lumbar discogenic pain, lumbar disc degeneration	Injection of PRP	None	Pain relief, functional status 2 years	Statistically and clinically significant improvements in pain and function through 2 years of follow-up	None	A small retrospective evaluation	Positive study of PRP Intradiscal PRP injections show continued safety and improvements in pain and function at 2 years post-procedure
<b>MESENCHYMAL STEM CELLS</b>								
Pettine et al, 2015 (433) P, open-label, NR, 2-arm study Quality Scores: Newcastle-Ottawa = 6/8 IPM-QRBNR = 30/48	26 patients	Selection Criteria: Symptomatic moderate to severe discogenic low back pain	Autologous bone marrow concentration (nonexpanded)	ODI, VAS, and MRI	The average ODI and VAS scores were reduced to 22.8 and 24.4 at 3 months After 36 months, 6 patients proceeded to surgery. • After 36 months, 20 of the 26 patients reported average ODI and VAS improvement to 17.5 ± 32 and 21.9 ± 4.4 respectively One year MRI indicated 40% of patients improved one modified Pfirrmann Grade and no patient worsened radiographically	A first prospective evaluation assessing the effectiveness of intradiscal bone marrow publishing long-term follow-up of 36 months. 20 of 26 patients reported improvement	Nonrandomized prospective evaluation without comparative groups Weak data at 3-month follow-up	Positive study of autologous bone marrow At 36-month follow-up, 6 of 26 patients progressed to surgery. The remaining 20 patients (77%) reported significant ODI and VAS improvements Authors concluded that there were no adverse effects, and the study provided evidence of safety and feasibility of intradiscal BMC therapy

Table 10 cont. *Study characteristics of non-randomized and observational studies assessing intradiscal biologics.*

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Haines et al, 2022 (436) P, cohort study Single center Quality Scores: Newcastle-Ottawa = 6/8 IPM-QRBNR = 28/48	32 patients	Intradiscal injection with 1-6 mL BMAC per disc based on acceptance of the volume by the disc	None	VAS back pain, VAS leg pain, ODI, EQ-5D-5L	32 patients were treated with 92 levels VAS back pain decreased by 2.4 points ( $P = < 0.001$ ) from 3 to one-year post procedure VAS leg pain scores decreased by 1.5 points ( $P = < 0.005$ ) ODI scores decreased by 12.4 points ( $P = < 0.001$ ) MCID: VAS back pain 59.4% VAS leg pain 43.8% ODI 56.3% No complications were reported. Three patients went on to have fusion surgery.	Strict selection criteria and methodology with appropriate statistical analysis	Non-randomized, prospective evaluation without control groups.	Positive study of BMAC Improvement was seen in established MCID values, with 59.4% improvement in VAS back pain scores, 43.8% in VAS leg pain scores, and 56.3% in ODI scores Authors concluded that intradiscal injection of autologous BMAC significantly improved low back pain, disability, and quality of life at one-year
Atluri et al, 2022 (7) Open label, P, NR, 2-arm exploratory study Single center Quality Scores: Newcastle-Ottawa = 8/8 IPM-QRBNR = 36/48	n = 80	Intradiscal injection of BMC 2 mL, epidural space 2 mL, facet joints 0.5 mL, and sacroiliac joint 1 mL	Conservative management	NRS, ODI, EQ-5D-5L, PROMIS global physical and mental health	Significant improvement at 12-month follow-up with 67% of patients in the study group achieving MCID utilizing ODI.	Even though it was an observational, open-label study, it was a prospective controlled study with multiple parameters and outcomes criteria with one-year follow up	All the patients were self-pay thus, only the patients who could afford the treatment were included	Positive study of BMC Positive study with significant improvement shown overall at 12 months in 67% of the patients Injection was not specifically intradiscal, it was intradiscal, intra- facet, epidural, and sacroiliac joint

Table 10 cont. *Study characteristics of non-randomized and observational studies assessing intradiscal biologics.*


Study Characteristic	Study Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Lewandrowski et al, 2023 (437) R, O, cohort study Single center Quality Scores: Newcastle-Ottawa = 6/8 IPM-QRBNR = 31/48	n = 33 Degenerative disc disease diagnosed by imaging Selection Criteria: Clinical evaluation, imaging Biologic Used: Biologic allogeneic polyclonal MSC	Intradiscal injection of approximately 5 million allogeneic polyclonal MSCs and 1% hyaluronic acid derived from immunoselected umbilical cord stem cells	None	VAS, ODI, modified Macnab criteria	2-year follow-up, the average VAS low back pain reduction and ODI reductions were significant Macnab outcomes were excellent in 11 patients (33.3%), good in 19 (57.6%), and fair in 39.1% Imaging - Pfirrmann grading was 4.00 ± 0.72 and improved to 3.65 ± 0.81 at final follow-up	Observational study with long-term follow-up Overall, VAS score reduction at 2-year follow-up was 6.565 ± 1.619 ( $P < 0.001$ ). ODI reduction at 2-year follow-up was 38.333 ± 14.865 ( $P < 0.001$ )	Observational study with a small sample size Favorable outcomes at 2-year follow up	Positive study MSCs	

BMC = bone marrow concentrate; BMAC = bone marrow aspirate concentrate; EQ-5D-5L = EuroQol 5 Dimension; IPM-QRBNR = Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment for Nonrandomized Studies; LBP = low back pain; MCID = Minimal Clinically Important Difference; MRI = magnetic resonance imaging; NR = nonrandomized; NRS = Numeric Rating Scale; O = observational; ODI = Oswestry Disability Index; P = prospective; PROMIS = Patient Reported Outcomes Measurement and Information System; PRP = platelet-rich plasma; PRGF = plasma rich in growth factor; R = retrospective; RMDQ = Roland-Morris Disability Questionnaire; VAS = Visual Analog Scale

and disability scores. Later, Sanapati et al (17), in a 2018 publication, identified 6 studies, one RCT and 5 observational studies, of which 2 RCTs (425,426) and 2 observational studies (431,432) were included in the present analysis. A single-arm meta-analysis demonstrated significant improvement at 6 months, with high heterogeneity across studies, and a reduction in pain scores from baseline of  $40.631 \pm 14$  points (95% CI: -68.07 to -13.19,  $P < 0.0001$ ,  $I^2 = 97.8$ ). At 12 months, significant improvements were also observed in a pooled sample of 57 patients. Sanapati et al (17) identified 9 publications on cell-based therapies for lumbar discogenic low back pain; among these, one RCT (426) and 3 reports of a single study (364,433,438) were excluded from the present analysis due to small sample size. A single-arm analysis of the 6 available studies, including one RCT and a pooled sample size of 71, demonstrated a reduction in pain scores from baseline to 12 months of 36.943 points (95% CI: -49.855 to -24.030,  $P < 0.001$ ), with high heterogeneity ( $I^2 = 86\%$ ). Functional status also improved significantly at 12 months, with a 26.342-point decrease in disability scores (95% CI: -32.359 to -20.325,  $P < 0.001$ ), with moderate heterogeneity ( $I^2 = 55\%$ ).

Yolcu et al (411), in a 2020 systematic review on MSCs and BMC, included 6 studies with 93 patients. Pain improvement was reported in 38.8% of patients at 3 months, 40.8% at 6 months, and 44.1% at 12 months. Average improvement in Oswestry Disability Index (ODI) scores was 24, 26.5, and 25.7 at 3, 6, and 12 months, respectively. The authors concluded that cell-based therapy may have a potential positive impact. However, the systematic review was limited by small sample sizes, non-randomized study designs, and lack of quality assessment or meta-analysis. They also noted that a 50% success rate for pain improvement was not achieved, although disability scores improved significantly.

Her et al (412), in a 2022 systematic review on intradiscal injections of BMAC and culture-expanded BM-MSCs for discogenic pain, included 16 studies with 607 participants in a qualitative synthesis without data



pooling. The studies comprised 3 RCTs, 9 prospective cohorts, 3 case series, and one retrospective study. Studies with fewer than 25 patients or follow-up under 6 months were excluded, leaving 3 studies (426,433,434)

for the present review. Her et al (412) reported that intradiscal autologous or allogeneic BMAC and BM-MSCs generally improved discogenic pain and physical function, with some positive anatomical changes on




Fig. 11A. 3 Months ODI BM/MSC vs. control.




Fig. 11B. 6 Months ODI BM/MSC vs. control.




Fig. 11C. 12 Months ODI BM/MSC vs. control.

Fig. 11. Conventional analysis of functionality with intradiscal MSC administration.

MRI, though findings were inconsistent. The overall GRADE score was very low due to heterogeneity and poor generalizability.


Soufi et al (416), without performing a meta-analysis, conducted a systematic review on stem cell therapy for degenerative disc disease and low back pain. They identified 11 clinical studies, including one RCT with 119 patients, and concluded there was no evidence to support the use of stem cell therapy in humans for these conditions.

Schneider et al (414), in a 2022 systematic review on intradiscal biologic treatments, including PRP and MSCs, included 12 studies and concluded that evidence quality was very low. One RCT evaluating PRP reported positive outcomes but had significant methodological flaws, while a single MSC trial showed negative results. Success rates for PRP injections were 54.8% and for MSCs

53.5% at 6 months, decreasing to 40.7% in a worst-case analysis. Functional improvement greater than 30% was achieved in 74.3% at 6 months, decreasing to 44.1% under worst-case assumptions. The authors concluded that limited observational data support intradiscal biologics for discogenic low back pain, but the evidence for MSCs and PRP was very low quality per GRADE criteria.

Kawabata et al (417) published a 2023 systematic review on advances in PRP for spinal diseases, highlighting promising regenerative potential from basic research and demonstrating safety and efficacy in clinical studies for degenerative disc disease.

Machado et al (10), in a 2023 systematic review on PRP for low back pain, included 13 RCTs and 27 non-randomized studies or case reports. Eleven of 13 RCTs showed favorable outcomes for pain and disability, one




showed no superiority, and one was discontinued due to lack of therapeutic effect at 8 weeks. Injections included epidural, facet joint, and sacroiliac applications. Overall, PRP was found to be generally safe and effective, with a small number of adverse events. Evidence quality was rated as Level II, though the review lacked methodological and GRADE assessments.

Zhang et al (419), in 2024, evaluated PRP injection therapy for chronic low back pain through a network meta-analysis including 4 studies with 154 patients; only 2 studies focused on intradiscal injections. Corticosteroids provided better short-term pain improvement

at 4 weeks, whereas PRP and radiofrequency ablation were similar. At 6 months, PRP demonstrated greater improvements in disability indices.

Peng et al (420), in a 2023 single-arm meta-analysis on intradiscal PRP for discogenic low back pain, included 6 trials (3 RCTs and 3 prospective single-arm trials), of which 2 studies (425,434) were part of this analysis. The meta-analysis showed 51.9% of patients achieved a 50% reduction in pain scores at 6 months, with a significant mean decrease of 1.42 points ( $P = 0.0008$ ) and no significant adverse events reported.


Yum et al (95), in a 2024 review, emphasized the



need for full transparency in PRP preparation and injection protocols and recommended future double-blind RCTs to evaluate platelet concentration, dose, and timelines for expected clinical improvement. This publication was not a systematic review or meta-analysis.

Akeda et al (439), in a 2019 critical review, high-


lighted PRP's potential in stimulating cell proliferation and enhancing intervertebral cell metabolic activity in vitro and in vivo. Animal studies demonstrated that PRP injections improved disc height and matrix integrity, supporting PRP as a promising intradiscal therapy for degenerative disc disease.



Lorio et al (418), in 2024, provided a perspective on intradiscal therapies for lumbar discogenic pain, identifying MSCs, PRP, nucleus pulposus structural allograft, and other cell-based compositions as viable candidates. The review emphasized repairing, supplementing, and restoring damaged discs while

preventing further degeneration, discussed FDA guidance on minimal manipulation and homologous use, and highlighted key evidence gaps and emerging technologies.


Bhujel et al (286), in 2022, reviewed MSC-derived exosomes in intervertebral disc regeneration, high-



lighting their paracrine-mediated effects, including promoting cell proliferation, tissue regeneration, modulating inflammation, and reducing apoptosis. Similarly, Akeda et al (439) confirmed PRP's potential to stimulate intervertebral cell activity and restore structural disc changes.

Overall, multiple systematic reviews and meta-

analyses indicate that intradiscal MSCs and PRP have potential benefits for discogenic low back pain. Existing evidence from RCTs and observational studies suggests effectiveness in pain reduction and functional improvement, but additional high-quality studies are required to further clarify their role in mediating and modulating treatment outcomes.



## 7.2 Epidural Injections

### **KEY QUESTION 5. THE EVIDENCE OF EFFECTIVENESS FOR THE USE OF EPIDURAL INJECTIONS OF PRP AND DERIVATIVES AND CONSENSUS-BASED CLINICAL RECOMMENDATIONS.**

Since intervertebral discs are the body's largest avascular structures with limited regenerative capacity

(60), they depend on nutrient diffusion from capillaries at the vertebral body margins through the cartilaginous endplates. This nutritional limitation has prompted therapeutic strategies aimed at enhancing disc nutrition and regeneration. Regenerative approaches, including PRP and MSCs, are being investigated for their potential to promote disc healing (440-449). PRP contains multiple cytokines and growth factors, such as

Table 11. *Evidence profile using randomized controlled trials of interventions for the same outcome and similar certainty of evidence.*

CERTAINTY ASSESSMENT						Number of Patients	Impact	Certainty
Study	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias		
<b>PLATELET-RICH PLASMA</b>								
Thakli-Wosornu et al, 2016 (425)	RA, PC, DB	Low	NS	NS	NS	Low	47 PRP = 29 Comparator = 18	Positive trial Intradiscal injections of PRP x 1 showed significant improvement at 8-week follow-up with maintained improvement compared to controls at 1-year follow-up.
Navani et al, 2024 (11)	RA, PC, DB	Low/ Moderate	NS	NS	NS	Low	43 Placebo = 12 PRP = 15 BMC = 16	Positive trial Comparative analysis of intradiscal PRP and BMC compared to intramuscular injection of muscle saline injection into the muscle showed significant improvement in biologic treatment groups
Goyal et al, 2022 (427)	RA, AC	Low/ Moderate	NS	NS	NS	Low	48 PRP = 24 PIRF = 24	Negative trial for PRP The response to intradiscal injection of PRP showed poor response with 4 of 26 patients responding at 3 months and 11 of 26 patients responding at 6 months
Akeda et al, 2022 (428)	RA, AC, DB	Low	NS	NS	NS	Low	16 PRPr = 8 Comparator = 8	Positive PRP trial Significant improvement at 60 weeks in PRP group compared to baseline data; however, even though it was different, it did not reach statistical significance in comparison with the steroid group
<b>MESENCHYMAL STEM CELLS</b>								
Pers et al, 2024 (429)	RA, PC, DB	Low	NS	NS	NS	Low	114 BM-MSC = 58 Sham placebo group = 56	Negative trial A large multicenter, RA, PC, trial in degenerative disc disease using a single intradiscal injection of allogenic MSCs, showed no clinical and imaging benefits at 12-month follow-up There were only non-significant improvements in various parameters including disc fluid content, VAS, ODI, with BM-MSC scoring better

Table 11 cont. *Evidence profile using randomized controlled trials of interventions for the same outcome and similar certainty of evidence.*

CERTAINTY ASSESSMENT							Certainty
Study	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Impact
Navani et al, 2024 (11)	RA, PC, DB	Low/ Moderate	NS	NS	NS	Low	Positive trial Comparative analysis of intradiscal PRP and BMC compared to intramuscular injection of muscle saline injection into the muscle showed significant improvement in biologic treatment groups There was no difference in PRP or BMC
Noriega et al, 2017 (426)	RA, PC, DB	Low/ Moderate	NS	NS	NS	Low	Positive trial 40% of patients with perfect results 28% improvement in all patients Degeneration improved in MSC treated patients and worsened in the controls. Feasibility and safety were confirmed in this preliminary trial
Amirclelfan et al, 2021 (424)	RA, PC, DB	Low/ Moderate	NS	NS	NS	Low	Positive trial Allogeneic expanded STRO-3+ MPCs from iliac crest, 2cc per injection Positive results with safety and efficacy in a randomized, multi-site trial with multiple variables; however, there were no significant radiographic improvements in any of the groups
Gornet et al, 2024 (430)	RA, PC, DB, AC	Low	NS	NS	NS	Low	Intradiscal biologics Low dose cells (n = 20) High dose cells (n = 20) Vehicle alone (n = 10) Placebo n = 10 Positive allogeneic disc progenitor cells trial Significant effectiveness of high-dose allogeneic disc progenitor cells with clinically meaningful improvement in back pain and disc volume at one-year and 2 years.

AC = active controlled; BMC = bone marrow concentrate; BM-MSC = bone marrow mesenchymal stromal cell; DB = double-blind; MSC = mesenchymal stem cells; NS = Not serious; PC = placebo controlled; PRP = platelet-rich plasma; PIRF = percutaneous intradiscal radiofrequency; PRPr = platelet-rich plasma release; RA = randomized; STRO-3 = stromal precursor antigen-3

IL-1RA, TGF- $\beta$ 1, platelet-derived growth factor (PDGF), and insulin-like growth factor-1 (IGF-1) (440). Its autologous and antimicrobial properties provide a favorable safety profile, reducing the risk of immunogenic reactions, adverse effects, and infections (441).

Although some disc-related pain and radiculopathy resolve spontaneously, many cases progress to chronic pain requiring more intensive interventions. Management strategies range from conservative therapies, including physical therapy and medications, to interventional procedures and surgeries such as spinal fusion or disc replacement (38,98,99,101,102,105). Interventional techniques, including epidural injections and regenerative therapies, are increasingly employed for chronic spinal pain (10,17,20,21,38,39,42,85,95,98,99,101,102,105,107,110,111,283,413, 415-417,419, 439,450-453).

Disc degeneration is a major contributor to discogenic pain, primarily through inflammation-induced nociceptive innervation within the disc (11,60). The intervertebral disc architecture, consisting of the nucleus pulposus, annulus fibrosus, and cartilaginous endplates, supports structural integrity and shock absorption. Degeneration impairs these functions, resulting in lumbar spine instability (454,455). Conventional treatments fail to halt or reverse the degenerative process (10,17,18,111,284,413,415-417,419,439). Key mechanisms implicated in disc degeneration include loss of stem and progenitor cells, extracellular matrix degradation, inflammation, aberrant sensory innervation, neovascularization, and disrupted signaling pathways. Regenerative interventions using MSCs and PRP are emerging as potential solutions (10,17,18,95,107,110,111,280-283,410-420,439,453,456,457).

Yum et al (95), in a 2024 review, highlighted critical gaps in PRP application for lumbar spine conditions. They emphasized the need for complete transparency in PRP preparation and injection protocols in clinical studies and recommended future double-blind, randomized trials to assess platelet concentration, dosage, and treatment timelines. This publication was not a systematic review or meta-analysis.

Sanapati et al (17) reviewed 9 publications on epidural cell-based therapies for lumbar discogenic low back pain, including one RCT and 3 single-study reports. Due to small sample sizes and other limitations, these studies were excluded from the present analysis. A single-arm analysis of 6 studies (including one RCT,  $n = 71$ ) demonstrated a significant reduction in pain scores at 12 months by 36.943 points (95% CI: -49.855

to -24.030,  $P < 0.001$ ;  $I^2 = 86\%$ ) and a 26.342-point improvement in disability scores (95% CI: -32.359 to -20.325,  $P < 0.001$ ;  $I^2 = 55\%$ ). The authors concluded that MSCs and PRP may be effective for discogenic low back pain, radicular pain, facet joint pain, and sacroiliac joint pain, although the level of evidence varied.

Muthu et al (458) conducted a meta-analysis of 5 RCTs involving 310 patients (PRP: 153; Steroids: 157) to evaluate the safety and efficacy of epidural PRP versus steroid injections for radiculopathy due to lumbar disc disease. Outcomes were assessed at multiple timepoints up to 48 weeks. PRP provided comparable results for pain relief, functional status, and overall health without increased adverse events. The authors concluded that epidural PRP offers similar benefits and safety to steroid injections.

Manchikanti et al (20) performed a systematic review and meta-analysis following PRISMA guidelines (421), including 9 RCTs (456,457,459-465) on epidural biologics for chronic spinal pain. No additional studies were identified. Evidence quality was rated as fair (Level III), with moderate effect size and recommendation strength based on qualitative synthesis and GRADE methodology. Study characteristics are shown in Table 12. Methodologic quality and risk of bias were assessed using standardized metrics (Appendix Tables 1 and 2). Conventional meta-analysis results are presented in Figs. 17 and 18, and all RCTs were included in certainty assessment using GRADE criteria (Table 13).

For qualitative analysis, 7 RCTs used PRP (456,457,460-464) and 2 used autologous conditioned serum (459,465), with 8 positive studies (456,457,459,460,462-465) and one neutral trial (461). All studies were randomized, with no observational studies included. Meta-analysis showed slight favorability for PRP in pain relief at 3 and 6-months, with no differences in functional status at these time points. Evidence quality was rated fair (Level III), with low to moderate certainty and moderate recommendation strength based on qualitative and quantitative assessment.

### 7.3 Facet Joint Injections

#### ***KEY QUESTION 6. THE EVIDENCE OF EFFECTIVENESS FOR USING INTRA-ARTICULAR FACET JOINT INJECTIONS OF PRP AND CONSENSUS-BASED CLINICAL RECOMMENDATIONS.***

Current literature identifies multiple potential sources of spinal and extremity pain, established

Table 12. Study characteristics of randomized controlled trials assessing epidural injections of PRP and derivatives.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Gupta et al, 2024 (456) RCT, AC Quality Scores: Cochrane = 13/13 IPM-QRB = 32/48	46 patients  Lumbar intervertebral disc prolapse with radiculopathy	n = 23  Epidural injection of PRP 3 mL. PRP was prepared from 30 mL of whole blood, resulting in 3-5 mL of PRP	n = 23  Epidural injection of PRP 3 mL. PRP was prepared from 30 mL of whole blood, resulting in 3-5 mL of PRP	75% pain relief as success criteria compared with pre- procedural pain VAS ODI SF-12 scores  Multiple injections of steroids were provided in steroid group, as well as PRP group  Multiple injections of PRP were provided	At one-year follow-up, 26% of the patients in the steroid group and 30% of the patients in PRP group demonstrated significant improvement in all outcome measures. In the PRP group, 7 patients received repeat lumbar transforaminal injections and 9 underwent surgery. Further, in the PRP group, 7 patients received repeat injection of steroids. In the steroid group, 9 patients received more transforaminal injections, and 8 patients underwent surgery at one-year follow-up.	At the 6-month follow-up, 39% of the patients in the steroid group and 56% of the patients in PRP group continued to demonstrate improvement.	Active control trial Relatively small sample size 3-5 mL of PRP obtained from 30 mL of whole blood which is considered as inadequate The data was not clear enough at 3 months	Positive PRP trial Significant improvement in pain relief (> 75%) and improvement in function at 6 months in PRP group compared to corticosteroid group
Jayaasoorya et al, 2024 (462) RCT, AC Quality Scores: Cochrane = 9/13 IPM-QRB = 23/48	64 patients  Low back pain of discogenic origin	n = 32  Epidural injection of PRP 3 mL. PRP was prepared from 20 mL of whole blood, resulting in 2-4 mL of PRP	n = 32  Epidural injection of methylprednisolone 1.5 mL, 1.5 mL of 2% lidocaine, and 0.5 mL of sodium chloride solution	VAS MODQ SLRT  3 months	In terms of VAS ratings, MODQ scores, and SLRT, study subjects who received autologous PRP injections via lumbar epidural demonstrated a greater improvement in the symptoms with pain relief, disability and SLRT. At 3 months, the methylprednisolone group with a baseline VAS of $7.06 \pm 0.09$ reduced to $5.2 \pm 0.65$ , whereas in the PRP group baseline VAS was $7.21 \pm 1.31$ , which reduced to $3.26 \pm 0.79$ with statistically significant difference ( $P = < 0.05$ )	Active control trial Small sample size Poor description of technique and patient management and blinding 2-4 mL of PRP was obtained from 20 mL of whole blood which is considered as inadequate	Positive PRP trial Significant improvement in pain relief at 3 months in PRP group compared to corticosteroid group There were also clinically significant differences with ODI questionnaire and SLRT scores	

Table 12 cont. Study characteristics of randomized controlled trials assessing epidural injections of PRP and derivatives.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Wonggarupong et al, 2023 (464) RCT, AC Quality Scores: Cochrane = 13/13 IPM-QRB = 32/48	30 patients n = 15	Transforaminal epidural injection under fluoroscopic guidance with injection of 2 mL of PRP was injected n = 15 PRP Group n = 15 Triamcinolone Group n = 15	Transformaminal epidural steroid injection under fluoroscopic guidance with a total of 2 mL of 1% lidocaine with 40 mg of triamcinolone PRP was prepared from 26 mL of whole blood with resultant PRP of 3 mL	n = 15 Leg VAS Back VAS ODI 2, 6, 12, and 24 week follow-up	Leg VAS was significantly reduced ( $P = 0.002$ ) from baseline of $65.27 \pm 15.32$ for PRP to $15.33 \pm 9.9$ , compared to $59.67 \pm 19.68$ to $30 \pm 7.45$ with triamcinolone. ODI reduced for PRP from $44.73 \pm 10.71$ to $15.07 \pm 7.79$ , compared to for triamcinolone of baseline $43.13 \pm 10.81$ to $21.3 \pm 5.21$ . This was statistically not significant; however, clinically significant with higher mean difference between groups and also >50% reduction from baseline in both groups. Back VAS for PRP reduced from baseline of $64.27$ to $17.53$ to at 24 weeks $17.8 \pm 11.33$ , compared to baseline of $73 \pm 13.86$ to $28.5 \pm 10.29$ for triamcinolone. There was no statistically significant difference; however, the differences were clinically relevant in both groups, specifically in PRP with a reduction of over 60%.	Randomized controlled trial Active control trial Small number of patients PRP was suboptimal with 26 mL of whole blood with resultant PRP of 3 mL	Positive trial of PRP compared to epidural steroids The results showed significant improvement with leg VAS. Results also showed clinically relevant reductions in Back VAS and ODI, even though it did not reach statistically significant difference	
Godek et al, 2023 (465) RCT, AC Quality Scores: Cochrane = 11/13 IPM-QRB = 23/48	100 patients Lumbar degenerative disc disease Biologic Used: ACS (Orthokine)	Group A: Epidural with interlaminar approach with ultrasound- guided injections utilizing ACS (Orthokine) n = 50 Group B: Perineural (perifascicular) approach – 2 ultrasound guided injections as experimental interventions each containing 2 doses of ACS (Orthokine), 8 mL	n = 50 NRS ODI RMDQ EQ-5D-5L VAS LSS	Both perineural and interlaminar epidural injections showed similar results at 24-week follow-up with significant improvement in ODI scores, RMDQ scores, EQ-5D-5L mobility scores, EQ-5D-5L self-care scores, and EQ-5D-5L usual activities. There was no significant difference among the groups. The effect size of perineural group was superior with a statistically significant superiority in favor of the perineural group for EQ-5D-5L mobility ( $P = 0.0432$ ) and index ( $P = 0.0359$ ) at week 12	Randomized controlled trial Active control trial A comparison of 2 techniques High volume of ACS (Orthokine) 2 injections at 7-day intervals for both interlaminar and transforaminal epidural injections The needle position was not confirmed under fluoroscopy Same volumes were considered very high for transforaminal group	Positive trial of ACS (Orthokine) in lumbar degenerative disc disease There was no significant difference with either approach. This was a technical comparison. There were 2 injections 7 days apart The volumes of injections were similar for interlaminar and transforaminal group which is considered as very high		

Table 12 cont. Study characteristics of randomized controlled trials assessing epidural injections of PRP and derivatives.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Singh et al, 2023 (463) RCT, AC Quality Scores: Cochrane = 10/13 IPM-QRB = 27/48	45 patients  Prolapsed lumbar intervertebral disc  n = 23	  Under fluoroscopic guidance, peri- discal injection of steroid (triamcinolone 40 mg, 1 mL) with local anesthetic (bupivacaine 0.25%, 2 mL)	  Peri-discal injection of steroid (triamcinolone 40 mg, 1 mL) with local anesthetic (bupivacaine 0.25%, 2 mL)	NRS GPE  Up to 6 months	  Intervention Group: 3 mL of PRP was derived from 30 mL of whole blood. Concentration of platelets in the prepared PRP was ensured to be at least 3 to 5 times higher than that in whole blood (i.e., 450,000 to 17,500,000 per $\mu$ L range. At initial follow-up of one- month, epidural steroids were superior.  6-month follow-up: PRP group showed reduction of NRS from 6.91 $\pm$ 0.94 to 1.43 $\pm$ 0.75 compared to steroid group where from baseline of 7.38 $\pm$ 1.16 to 5.43 $\pm$ 0.75 with statistically significant difference ( $P < 0.001$ ). GPE scores also showed significant difference of ( $P < 0.001$ ).	  Randomized controlled trial  Amount of whole blood extracted was 30 mL, even though this is lower than recommended 60 mL, but better than other studies using only 20 mL	  Small number of patients Active control trial  30 mL of whole blood rather than 60 mL extracted	  Positive trial of PRP compared to epidural steroids  At 6-month follow-up superior results were demonstrated with PRP with pain rating, as well as GPE scores.
Saraf et al, 2023 (457) P, RCT, DB Quality Scores: Cochrane = 12/13 IPM-QRB = 26/48	60 patients  Discogenic lumbar radiculopathy  n = 31	  Biologic Used: PRP  n = 29	  Single transforaminal injection of steroid with 2 mL of methylprednisolone acetate (40 mg/ mL) with 1 mL 1% lignocaine  Single transforaminal injection of PRP n = 29	VAS MODI SLRT  1 month, 3 months, and 6 months	  There was significant statistical improvement of VAS and MODI in both groups at follow-up ( $P < 0.05$ ). In PRP group, minimal clinically important change ( $> 2$ cm difference of mean for VAS and $> 10$ -point change in MODI) for both outcome scores was achieved at all follow-up intervals of 3 and 6 months. In the steroid group, improvement was seen only at 3 months for both VAS and MODI. In comparison of both groups, better results were seen with PRP at 6 months ( $P < 0.001$ for both VAS and MODI), however, there was no significant difference at 3 months.  SLRT was negative in 90% in PRP group and 62% in steroid group at 6 months.	  Randomized controlled trial  Both VAS and MODI improvement was seen only at 3 months.  In comparison of both groups, better results were seen with PRP at 6 months ( $P < 0.001$ for both VAS and MODI), however, there was no significant difference at 3 months.  SLRT was negative in 90% in PRP group and 62% in steroid group at 6 months.	  Active control trial Relatively small sample	  Positive PRP trial  PRP showed significantly better outcomes at 3 and 6 months in reference to pain, function, and SLRT

Table 12 cont. Study characteristics of randomized controlled trials assessing epidural injections of PRP and derivatives.

Study Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Xu et al, 2021 (461) RCT, AC Quality Scores: Cochrane = 11/13 IPM-QRB = 33/48	124 patients  Lumbar disc herniation	n = 61  Transformaminal epidural under ultrasound guidance	n = 63  Epidural injection of local anesthetic and steroids with 2 mL of betamethasone + 0.5 mL of 0.9% sterile saline + 0.5 mL of 2% lidocaine	VAS PPT ODI Physical function SF-36 Latency of F-wave	Similar results for both epidural injection and PRP VAS improved from baseline of 6 to 2.0 at end of one-year in PRP group as well as steroid group ODI improved from baseline of 35 to 19 in PRP group and to 20 in ODI group There was significant improvement in both groups compared to baseline	Procedure was performed with high volume injection of PRP and steroid solutions with spread may have extended to multiple segments	Neutral trial of PRP and steroid injections Both groups showed significant improvements in VAS and ODI, as well as other parameters compared to baseline; however, there was no difference between the groups	
Ruiz-Lopez & Tsai, 2020 (460) RCT, AC Quality Scores: Cochrane = 13/13 IPM-QRB = 30/48	50 patients  Complex degenerative spinal pain	LR-PRP  n = 25  Caudal epidural injection under fluoroscopic guidance with injection of 20 mL of LR-PRP mixture with 16.5 mL of LR-PRP and 3.5 mL of non-ionic iohexol contrast medium.	Caudal epidural steroid injection with local anesthetic n = 25  Caudal epidural under fluoroscopic guidance with a total of 20 mL corticosteroid mixture (60 mg triamcinolone with local anesthetic and 3.5 mL of contrast medium)	VAS SF-36	Significantly lower VAS scores were reported in patients who received LR- PRP injections. In reference to SF-36 measurements only patients receiving LR-PRP had a significant improvement in domains which included physical functioning, role- physical, general health, and physical component summary.	Active control trial Small sample size Preparation of PRP was inadequate compared to the standardization protocols with 60 mL of blood deriving a total of 16.5 mL of PRP which may explain the suboptimal results.		


Table 12 cont. Study characteristics of randomized controlled trials assessing epidural injections of PRP and derivatives.

Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Becker et al, 2007 (459) RCT, AC Quality Scores: Cochrane = 11/13 IPM-QRB = 32/48	84 patients Lumbar radicular pain Biologic Used: ACS (Orthokine) Epidural perineural injection with ACS (Orthokine) n = 32 Epidural perineural triamicinolone 10 mg n = 25 Epidural perineural triamicinolone 5 mg n = 27	Transforminal or perineural injection of ACS (Orthokine) once per week for 3 consecutive weeks.	Second Group (n = 25): Triamcinolone 10 mg with 1 mL of local anesthetic approaching the nerve root through oblique interlaminar approach with a 29-gauge spinal needle	At week 12 patients receiving ACS (Orthokine) showed a consistent pattern of superiority over both triamicinolone groups with regard to the primary outcome measure of VAS. Statistically significant difference was observed at 22 weeks in direct comparison to the treatment of 5 mg group. There was no statistically significant difference between all groups with respect to ODI. Pairwise comparisons of treatment groups and VAS at end of observation showed with a mean difference of -13.5 with 5 mg triamcinolone and -9.3 with 10 mg triamcinolone	Randomized controlled trial with comparison of ACS (Orthokine) and triamcinolone in 2 separate doses	Positive trial of ACS (Orthokine) compared to triamcinolone ACS (Orthokine) was superior to triamcinolone at 26 weeks The results of epidurals are as expected to deteriorate after several weeks after 22 weeks.	Active control trial. There was no significant difference with ODI. Multiple injections	

AC = active controlled; ACS = autologous conditioned serum; DB = double-blind; EQ-5D-5L = EuroQol 5 Dimension; GPE = Global Perceived Effect; IPM-QRB = Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment; LSS = level sum score; LR-PRP = leucocyte-rich platelet-rich plasma; MODQ = Modified Oswestry Disability Questionnaire; NRS = Numeric Rating Scale; ODI = Oswestry Disability Index; P = prospective; PPT = pressure pain thresholds; PRP = platelet-rich plasma; RCT = randomized controlled trial; RMDQ = Roland Morris Disability Questionnaire; SF-12 = 12-Item Short Form Health Survey; SF-36 = 36-item Short Form Health Survey; VAS = Visual Analog Scale

through controlled diagnostic blocks, including the intervertebral discs, facet joints, nerve root dura, and sacroiliac joints (41). For axial spinal pain of facet joint origin, 3 primary interventional modalities are commonly employed: therapeutic facet joint nerve blocks, radiofrequency neurotomy of lumbar medial branch nerves, and intra-articular injections (41). Despite their widespread use, the economic and societal burden of chronic spinal pain continues to rise due to the increasing application of diverse treatment modalities (2,6,17,38,41,100,102-105,110,219,466-469). Among these, regenerative medicine approaches, particularly PRP and stem cell injections, have gained attention for use in various spinal structures, including facet joints (6,17,95,108-110,470-472).

Several systematic reviews have evaluated regenerative therapies for chronic spinal pain. Ambrosio et al (470) conducted a systematic review of minimally invasive interventional treatments for chronic low back pain caused by lumbar facet joint syndrome, including intraarticular PRP. They found that intraarticular PRP resulted in long-term improvements in pain, disability, and patient satisfaction compared to corticosteroid injections. One




RCT by Wu et al (473), included in the review, provided supporting evidence for the efficacy of intraarticular PRP.

Sanapati et al (17) performed a comprehensive literature review on lumbar facet intra-articular injections, incorporating a single-arm meta-analysis. Their review included 3 studies evaluating PRP in lumbar facet joint injections (432,473,474), concluding that the qualitative evidence for PRP was limited, rated as Level IV.

Machado et al (10), in a systematic review of PRP for low back pain, identified PRP as a promising alternative for patients with lumbar facet syndrome. They reported that intra-articular PRP injections demonstrated both safety and effectiveness, with no complications compared to local anesthetics or corticosteroids.

Zhang et al (419) conducted a network meta-analysis of RCTs comparing PRP injections to various control groups. Their findings indicated that PRP was



more effective than corticosteroids and comparable to radiofrequency neurotomy at six-month follow-up.

Manchikanti et al (19) conducted a systematic review of regenerative medicine therapies for axial spinal pain of facet joint origin with meta-analysis following PRISMA guidelines (421). Qualitative analysis included 4 RCTs (473,475-477) and 6 observational studies (7,432,435,478-481).

Among the RCTs, all evaluated PRP; one cervical facet joint injection trial (476) was negative, while all lumbar facet joint single-injection studies were positive (473,475,477). In the observational studies, one involved adipose tissue (481), 4 used PRP (432,435,478-480), and 2 used MSCs (7,481). One cervical facet PRP study was included (478,479). Many studies utilized a functional spine unit approach, complicating isolated evaluation of facet joint injections. For example, Kirchner and Anitua (432) combined intradiscal, facet, and transforami-

nal epidural injections; Machado et al (435) injected facet joints, discs, epidural space, and paravertebral muscles; Barbieri et al (480) injected discs, epidural space, facet joints, and sacroiliac joints. Among MSC studies, Rothoerl et al (481) injected only facet joints, whereas Atluri et al (7) used bone marrow concentrate in discs, facets, spinal nerves, and sacroiliac joints. Three PRP studies were positive (432,435,478,479) and one was negative (480). Study characteristics are shown in Tables 14 and 15, with methodologic quality and risk of bias assessed using standardized metrics (Appendix Tables 1-4). All RCTs were included in GRADE certainty assessment (Table 16).

A search for facet joint interventions with regenerative therapies identified a single prospective study by Baltzer et al (482), including 78 patients with chronic facet joint syndrome treated with either PRP or bupivacaine. Multiple weekly injections were administered.

Table 13. Evidence profile using randomized controlled trials of interventions for the same outcome and similar certainty of evidence assessing epidural injections of PRP and derivatives.

CERTAINTY ASSESSMENT						Impact	Certainty
Study	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Number of Patients
Gupta et al, 2024 (456)	RCT, AC	Low	NS	NS	NS	Low	46 patients Epidural injection of PRP n = 23 Epidural injection utilizing Corticosteroids n = 23
Jayasoorya et al, 2024 (462)	RCT, AC	Low	NS	NS	NS	Low	64 patients Epidural injection of PRP n = 32 Epidural injection utilizing Corticosteroids n = 32
Wongjarupong et al, 2023 (464)	RCT, AC	Low	NS	NS	NS	Low	30 patients PRP Group n = 15 Triamcinolone Group n = 15
Godek et al, 2023 (465)	RCT, AC	Low	NS	NS	NS	Low	100 patients Group A: Epidural interlaminar approach with ultrasound-guided injections utilizing ACS (Orthokine) n = 50 Group B: Perineural injection with ultrasound guided injections utilizing ACS (Orthokine) n = 50

Table 13 cont. Evidence profile using randomized controlled trials of interventions for the same outcome and similar certainty of evidence assessing epidural injections of PRP and derivatives.

CERTAINTY ASSESSMENT <sup>a</sup>							Impact	Certainty
Study	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Number of Patients	
Singh et al, 2023 (463)	RCT, AC	Low	NS	NS	NS	Low	45 patients Group 1: PRP n = 23 Group 2: Steroid with local anesthetic n = 22	Moderate • At 6-month follow-up superior results were demonstrated with PRP with pain rating, as well as GPE scores. Suboptimal PRP Positive trial of PRP
Saraf et al, 2023 (457)	P, RCT, DB	Low	NS	NS	NS	Low	60 patients Single transformaminal injection of PRP n = 29	Moderate • PRP showed significantly better outcomes at 3 and 6 months in reference to pain, function, and SIRT Positive PRP trial
Xu et al, 2021 (461)	RCT, AC	Low	NS	NS	NS	Low	124 patients Ultrasound guided transformaminal injection n = 61	Moderate • Both groups showed significant improvements in VAS and ODI, as well as other parameters compared to baseline; however, there was no difference between the groups Low
Ruiz-Lopez & Tsai, 2020 (460)	RCT, AC	Low	NS	NS	NS	Low	124 patients Ultrasound guided epidural steroid injection n = 63	Moderate • Imaging with ultrasound Neutral trial of PRP
Becker et al, 2007 (459)	RCT, AC	Very Low	NS	NS	NS	Low	50 patients Caudal epidural injections of LR-PRP or corticosteroid administered under fluoroscopic guidance n = 25	Low • Positive trial of PRP of caudal epidural compared to corticosteroids Suboptimal PRP
							84 patients Epidural perineural injection with ACS (Orthokine) n = 32	Low • ACS (Orthokine) was superior to triamcinolone at 26 weeks • The results of epidurals are as expected to deteriorate after several weeks after 22 weeks.

AC = active controlled; ACS = autologous conditioned serum; DB = double-blind; GPE = Global Perceived Effect; NS = Not serious; ODI = Oswestry Disability Index; PRP = platelet-rich plasma; P = prospective; RA = randomized; SIRT = straight leg raising test; VAS = Visual Analog Scale

Table 14. Study characteristics of randomized controlled trials assessing intraarticular facet joint injections of PRP.

Study Characteristic	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
<b>PLATELET-RICH PLASMA</b>								
Wu et al, 2017 (473) RA, AC Quality Scores: Cochrane = 13/13 IPM-QRB = 37/48	n = 46 Lumbar facet joint syndrome Biologic Used: PRP Group A = PRP Group B = LA with steroids Selection Criteria: Clinical assessment Single intraarticular injections Radiographic evidence	Group A: Intraarticular injection with PRP	Group B: Intraarticular injection with local anesthetic/ corticosteroid	VAS at rest and during flexion RMDQ ODI Modified MacNab criteria for pain relief and applications of post-treatment drugs	There were significant differences between the 2 groups in VAS, ODI ( $P < 0.05$ ) For group A, subjective satisfaction was progressive over time with significant long- term improvement There were no treatment-related complications in either group during follow-up	This is the first randomized control, blinded, trial with diagnosis confirmed by the single intraarticular diagnostic block Outcomes with PRP are superior to corticosteroid injections Patient satisfaction also increased gradually for PRP group, whereas it decreased for steroid group	This is an active control trial with no placebo group A single diagnostic block was performed with intraarticular local anesthetic injection, which is not ideal to achieve appropriate diagnosis	Positive for PRP Autologous PRP is a superior treatment option with longer duration efficacy compared to intraarticular steroid injections Both autologous PRP and local anesthetic/ corticosteroid for intra-articular injection are effective
Koib et al, 2022 (475) P, RA, comparative, single blinded study, AC Quality Scores: Cochrane = 11/13 IPM-QRB = 32/48	n = 30 Lumbar facet joint disease Biologic Used: PRP Group I – PRP injection Group II – Intraarticular injection with steroid Selection Criteria: Clinical evaluation MRI findings of lumbar facet joint synovitis No diagnostic blocks			Low back pain VAS RMDQ ODI Intraarticular injection of corticosteroids Intraarticular injection of autologous PRP	Both groups showed a significant improvement in all parameters at follow- up after 3 months PRP injections promoted better performance in terms of MRI synovitis grade in all lumbar facet joint levels compared to corticosteroid injections	Randomized controlled trial, first of its nature to study the role of PRP versus corticosteroids in the treatment of synovitis Multiple outcome parameters were utilized	A single blind study, with no placebo group There were no diagnostic blocks performed to accurately predict the diagnosis of facet joint pain Short-term follow-up	The results show significant improvement compared to corticosteroids with PRP intraarticular injections The study results provide hypothetical improvement requiring additional studies to confirm the results

Table 14 cont. *Study characteristics of randomized controlled trials assessing intraarticular facet joint injections of PRP.*

Study Characteristic	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Allison et al, 2024 (476)	n = 40	Cervical facetogenic pain	Intraarticular injection of PRP	NRS PSEQ NDI	1-, 3-, & 6 months post intervention	The first randomized controlled trial evaluating intraarticular PRP in the cervical spine. Further, selection criteria was rigorous with dual medial branch blocks	Despite excellent design and rigorous methodology, the study does not show significant difference between corticosteroids and PRP	Negative for PRP

Table 14 cont. *Study characteristics of randomized controlled trials assessing intraarticular facet joint injections of PRP*

Study Characteristic	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Methodological Quality Scoring								

AC = active controlled; DB = double blind; C = controlled; IPM-QRB = Interventional Pain Management techniques – Quality Appraisal of reliability and Risk of Bias Assessment; LA = local anesthetic; MCID = minimal clinically important difference; MRI = magnetic resonance imaging; NDI = Neck Disability Index; NRS = Numeric Rating Scale; ODI = Oswestry Disability Index; P = prospective; PRP = platelet-rich plasma; PSEQ = Pain Self-Efficacy Questionnaire; RA = randomized; RMDQ = Roland Morris Disability Questionnaire; SF-36 = Short Form survey 36; VAS = Visual Analog Scale

Table 15. *Study characteristics of non-randomized and observational studies assessing intraarticular facet joint injections of MSCs and PRP*

Study Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
<b>PLATELET-RICH PLASMA</b>								
Kirchner & Anitaua, 2016 (432)	n = 86  Lumbar disc degeneration	One intradiscal, one intraarticular facet, and one transforaminal epidural injection	None	VAS over time  1-, 3-, & 6-months	Pain reduction after PRGF-Endoret injections showed statistically significant drop from 8.4 ± 1.1 before the treatment to 0.8 ± 1.7 at 6-month follow-up  At the end of 6 months, 91% of patients showed an excellent score, with 8.1% showing moderate improvement and 1.2% were inefficient score group	Only a 6 month follow up  The injection was into the disc plus intraarticular and transforaminal epidural injections. Consequently, specificity has been lost	The results of PRGF injection into discs and facet joints showed reduction of the VAS over time  The study ended at 6 months with 91% of the patients showing an excellent score, 8.1% showing moderate improvement, and 1.2% showing lack of response	Positive PRGF study
O, R, pilot study  Quality Scores: ROBINS-E = 4/7 IPM-QRBNR = 27/48	Biologic Used: PRGF-Endoret  Selection Criteria: Clinical assessment Imaging No diagnostic blocks							
Smith et al, 2022, P, O  Quality Scores: ROBINS-E = 7/7 IPM-QRBNR = 27/48	n = 44  Chronic whiplash-associated disorders and cervical facet joint mediated pain  Biologic Used: PRP  Forty-four people (82% female, mean age ¼ 45.2 (range: 25–71) years) underwent cervical facet joint PRP. Nine people received repeat PRP interventions. Thirty-five people provided 12-month data.  Selection Criteria: Clinical evaluation Imaging Single medial branch blocks with criterion standard of 80% pain relief or greater than 50% relief of pain with significant improvement in activities of daily living in the 6-hour post procedure.	Cervical facet joint PRP injection	None	NPRS NDI  3-, 6-, & 12- months	There was a significant improvement in pain and disability following PRP (and possibly adjunct physiotherapy) received during this time period  At 12-months, 53% of people exceeded MCID for pain, reporting a mean improvement of 66% (95%CI: 55–77%) on the NPRS  For NDI scores, 69% of people exceeded MCID, reporting a mean improvement of 48% (95%CI: 38–58%)  37% of people reported greater than 50% relief of pain 12-months post-cervical facet joint PRP	One of the early studies evaluating cervical facet joint pain  A prospective case series  Diagnosis was confirmed by a single medial branch even though not the most optimal, in conjunction with clinical examination and imaging  Reasonably long term follow-up.  Methodologically excellent study	Positive PRP study  In people with chronic whiplash associated disorders and facet-mediated pain, our long-term data suggests that PRP (and possibly adjunct physiotherapy) is effective  A controlled study is warranted to evaluate the efficacy of PRP	

Table 15 cont. Study characteristics of non-randomized and observational studies assessing intraarticular facet joint injections of MSCs and PRP.

Study Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Machado et al, 2022 (335) P, case series Quality Scores: ROBINS-E = 4/7 IPM-QRBNR = 24/48	n = 46 Chronic low back pain	PRP into the facet joints, intervertebral discs, epidural space and/or paravertebral muscles	None	VAS RMDQ	Mean VAS was reduced from 8.48 to 5.17 and mean RMDQ from 18.0 to 10.98 at 12 weeks (p < 0.001)	Prospective case series with relatively long-term follow of one-year. Well-designed following the standard protocol items, recommendations for interventional trials SPIRIT checklist. The study also shows that patients who received injections of 3 structures have shown better improvement.	Non-randomized design Multiple structures injected at the same time confounding the diagnosis and treatment	Positive PRP study PRP approach demonstrated clinically favorable results and may be a promising treatment for chronic low back pain
Barbieri et al, 2022 (480) P, case series Quality Scores: ROBINS-E = 4/7 IPM-QRBNR = 23/48	n = 32 Chronic low back pain	PRGF was injected into the intervertebral disc, epidural space and/or facet and sacroiliac joints	None	VAS ODI PGIC	Overall, the patients did not ameliorate after PRGF treatment, although 8 patients showed an algo-functional improvement. They were mainly males treated at 2 sites who were younger, less sedentary and with fewer musculoskeletal co-morbidities than the nonresponders	This study does not possess any strengths other than being another publication with a prospective case series	Prospective case series without a comparator Negative PRGF study	Overall, the patients did not ameliorate after PRGF treatment, even though 8 of 32 patients showed an algo-functional improvement
<b>MESENCHYMAL STEM CELLS</b>								
Rothoerl et al, 2023 (481) O	n = 37 Facet joint syndrome	Adipose derived autologous stem cells were injected into facet joints	None	VAS ODI 1 week, 1 year, & 5 years	Every patient reported improved VAS pain at any follow-up (1 week, 1 year, & 5 years) with ADRC compared to the baseline	Stem cell usage from adipose has not been described in facet joint pain in the past	Non-randomized design This is the first publication with a long-term follow-up	Positive study of stem cells Data indicates that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experienced improved quality of life in the long term

Table 15 cont. *Study characteristics of non-randomized and observational studies assessing intraarticular facet joint injections of MSCs and PRP.*

Study Study Characteristic Methodological Quality Scoring	Number of Patients and Interventions	Intervention Group	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions	
Alturi et al, 2022 (7)	n = 80	Low back pain Biologic Used: Autologous bone marrow mesenchymal stem cells	Conventional treatment with nonsteroid anti- inflammatory drugs, over-the- counter drugs, structured exercise programs, physical therapy, spinal injections and opioids, etc., as indicated	ODI NRS EQ-5D-3L GMH GPH	Significant improvement was achieved in functional status measured by ODI, pain relief measured by NRS-11, and other parameters	This is a large prospective, open-label, non- randomized, parallel-controlled, 2-arm comparative study	The results showed significant improvements at 12-month follow- up with 67% of the patients in the study group achieving MCID utilizing ODI when compared to 8% in the control group	Non-randomized design Multiple structures were injected at the same time This is the first study evaluating bone marrow concentrate	The results of this study showed significant improvement in function and pain relief in 67% of the study group, and achieved MCID for ODI at 12 months, when compared to only 8% in the control group

ADRC = adipose tissue-derived regenerative cells; EQ-5D-5L = EuroQol 5 Dimension; GMH = Global Mental Health; GPH = Global Physical Health; IPM-QRBNR = Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment for Nonrandomized Studies; MCID = Minimal Clinically Important Difference; NDI = Neck Disability Index; NPRS = Numerical pain rating scale; NR = nonrandomized; NRS = Numeric Rating Scale; O = observational; ODI = Oswestry Disability Index; P = prospective; PGIC = Patient Global Impression of Change; PRGF = plasma rich in growth factor; PRP = platelet-rich plasma; R = retrospective; RMDQ = Roland-Morris Disability Questionnaire; ROBINS-E = Risk of Bias in Non-Randomized Studies of Exposure; SPIRT = Standard Protocol Items: Recommendations for Interventional Trials; VAS = Visual Analog Scale

PRP infiltrations significantly reduced pain scores compared to baseline up to one year ( $P = 0.001$ ). Oswestry Disability Index scores improved by approximately 50% at 6 months ( $P = 0.001$ ) and were significantly better at one year ( $P < 0.01$ ). The authors concluded that CT-guided leukocyte-poor PRP injections provided substantially better outcomes than intra-articular bupivacaine.

Meta-analysis was not available. Based on qualitative and quantitative evidence, including GRADE certainty assessment, the evidence was deemed Level III, or fair, with a clinical recommendation of moderate certainty.

## 7.4 Sacroiliac Joint Injections

### KEY QUESTION 7. THE EVIDENCE OF EFFECTIVENESS FOR THE USE OF PRP IN SACROILIAC JOINT INJECTIONS AND CONSENSUS- BASED CLINICAL RECOMMENDATIONS.

The sacroiliac joint is the largest axial joint in the human body, playing a critical role in stability and in transmitting forces from the upper trunk to the lower extremities (483). Degenerative changes such as osteoarthritis represent progressive disorders of synovial joints caused by an imbalance between joint damage and repair, resulting in pain (484). Inflam-

Table 16. Evidence profile utilizing GRADE criteria with inclusion of randomized controlled trials for facet joint injections of PRP for the same outcome and similar certainty of evidence.

CERTAINTY ASSESSMENT							Certainty
Study	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	
Wu et al, 2017 (473)	RA, AC	Low	NS	NS	Low	Total = 46 Group A (randomized) intraarticular injection with PRP = 23 Group B (randomized) intraarticular injection with local anesthetic and corticosteroid = 23	Randomized controlled trial with active control design, compared injection of PRP with injection of local anesthetic and corticosteroid. Reasonably well designed. Applicable to clinical practice. Single diagnostic block Positive for PRP
Kotb et al, 2022 (475)	RA, SB, AC	Low	NS	NS	Low	Total = 30 Group I PRP injection = 15 Group II Intraarticular injection with steroid = 15	This is a small randomized, single-blinded study with active control design with patients receiving either intraarticular injection of PRP or injection of local anesthetics with corticosteroids providing positive results applicable to clinical practice. No diagnostic block Positive for PRP
Allison et al, 2024 (476)	RA, PC, DB	Low	NS	NS	Low	Total = 40 Group I cervical intraarticular injection of PRP = 21 Group II cervical intraarticular injection with corticosteroid = 19	This is a randomized, double blind controlled trial. Very well designed comparing cervical intraarticular facet joint injection of PRP with intraarticular corticosteroid injections showing negative results. Negative for PRP
Cauchon et al, 2024 (477)	RA, AC, TB	Low	NS	NS	Low	Total = 50 Group I lumbar intraarticular injection of PRP = 25 Group II lumbar intraarticular injection with corticosteroid = 25	This is a randomized, triple blind, active control trial, extremely well designed comparing lumbar intraarticular facet joint injection of PRP with intraarticular corticosteroid injection showing positive results with very well performed study with significantly superior results. Positive for PRP

AC = active controlled; DB = double-blind; NS = Not serious; PC = placebo controlled; PRP = platelet-rich plasma; RA = randomized; SB = single-blind; TB = triple blind

matory sacroiliac joint pain arises from dysregulated inflammatory responses, involving complex cellular and chemotactic profiles with both inflammatory and catabolic mediators contributing to joint degeneration (483). Additionally, joint hypermobility, a biomechanical dysfunction caused by pelvic ligament laxity or mechanical stress, compromises the sacroiliac joint's capacity to bear axial loads, placing strain on adjacent tissues (485).

The sacroiliac joint is a recognized source of low back and lower extremity pain, alongside the intervertebral discs, nerve roots, and facet joints (38,52,54,62,102,486). However, diagnostic accuracy remains controversial, particularly regarding the utility of intra-articular injections (38,102). Controlled diagnostic block studies implicate the sacroiliac joints in 10% to 25% of low back pain cases unrelated to disc herniation, discogenic pain, or radiculitis (38,41,57,62,102,486).

Management of chronic lumbosacral pain includes conservative approaches such as physical therapy and pharmacological treatments, as well as interventional procedures (2,38-42,44,48-54,85,99-102,219,450,451,469,487-499). Regenerative medicine therapies, including PRP and MSCs, have gained interest for treating spinal disorders, including sacroiliac joint pain, intervertebral disc degeneration, and facet joint dysfunction (10,17,18,95,283,410,413,415-419,439,472,483-485,500-512).

Sanapati et al (17) conducted a systematic review and meta-analysis of regenerative medicine injections for low back pain, including sacroiliac joint injections. They identified one high-quality RCT (510), one moderate-quality observational study (511), and one low-quality case report (512), concluding that the qualitative evidence was Level IV (on a scale of I to V based on a modified evidence grading system). Meta-analysis was not feasible.

Goodwin et al (503), in a qualitative systematic review with pooled analysis, examined 4 clinical trials and 2 case studies. They concluded that although PRP injections appeared beneficial, the evidence did not support their use over the current steroid standard of care.

Burnham et al (504) reviewed PRP for sacroiliac joint pain and identified 3 eligible studies, including one randomized comparative trial and 2 case series. Using the GRADE system, they rated the quality of evidence supporting PRP effectiveness as very low.

Ruffilli et al (506), in a systematic review and meta-analysis of injectable treatments for sacroiliac joint pain, analyzed 43 studies, with 16% involving PRP injections. They reported a failure rate of 26% for

steroid injections versus 14% for PRP injections. While early data on PRP appeared promising, the authors concluded that current literature limitations prevent determination of the optimal injectable approach.

Rothenberg et al (483), in a descriptive review, found the evidence for sacroiliac joint PRP to be inconsistent and insufficient to make definitive recommendations.

Although PRP and MSC therapies have a long history in orthopedic injuries, few studies specifically address sacroiliac joint dysfunction. Most research focuses on degenerative intervertebral discs. PRP, first described in the early 1990s as a biological glue, is defined as a platelet concentration above baseline. Platelets deliver growth factors and bioactive molecules essential for proliferation, vessel remodeling, angiogenesis, inflammation modulation, coagulation, and cell differentiation, all contributing to tissue repair and healing (512).

Despite growing evidence supporting PRP and BMC therapies for other axial skeleton applications, including intradiscal and intra-articular injections, significant gaps remain regarding their therapeutic value for sacroiliac joint dysfunction.

Manchikanti et al (21) conducted a systematic review of sacroiliac joint PRP and stem cell injections with meta-analysis following PRISMA guidelines (421). This review included 2 RCTs (291,510) and 3 observational studies (513-515). Using the GRADE framework and qualitative synthesis, the evidence was determined to be Level IV (limited) with a weak recommendation. Study characteristics are shown in Tables 17 and 18, with methodologic quality and risk of bias assessed using standardized metrics (Appendix Tables 1-4). All RCTs were included in GRADE certainty assessment (Table 19).

PRISMA-guided search criteria for sacroiliac joint regenerative injections identified no additional studies beyond those included in the 2025 systematic review by Manchikanti et al (21). Qualitative and quantitative analysis included the 2 RCTs (291,510), with one active-control trial positive and the other negative. Among the observational studies, 2 PRP injection studies were positive (514,515) and one was negative (513). GRADE assessment indicated one study with moderate positive impact and 2 with low positive impact. Consequently, the evidence level was IV (limited), with a clinical recommendation of low.

Burnham et al (504) is particularly notable among previously published systematic reviews. They defined the primary outcome as >50% pain improvement and

Table 17. Study characteristics of randomized controlled trials assessing the role of PRP injections of sacroiliac joints.

Study Characteristic	Number of Patients & Selection Criteria	Sacroiliac Joint PRP Injection	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Singla et al, 2017 (510) RA, Single-blinded, C Quality Scores: Cochrane = 11/13 IPM-QRB = 32/48	40 patients allocated into 2 groups Group P = PRP group (n = 20) Group S = Steroid group (n = 20) Selection Criteria: Clinical examination • Positive provocative test • Imaging	20 patients received 3 mL of leukocyte-free PRP with 0.5 mL of calcium chloride, with a total volume of 3.5 mL, with ultrasound-guided intraarticular sacroiliac joint injection	20 patients received 1.5 mL of methylprednisolone, 40 mg per mL, and 1.5 mL of 2% lidocaine with 0.5 mL of saline, with a total volume of 3.5 mL, with ultrasound- guided intraarticular sacroiliac joint injection	• VAS scores • MODQ scores • SF-12 health survey scores • Complications assessment at 2, 4, & 6 weeks & 3 months • Proportion of Pain relief > 50%	PRP injections provided significantly lower VAS with better pain relief at 3 months as compared to steroid injections Effectiveness of steroid injection was reduced to only 25% at 3 months in Group S, while it was 90% in Group P A strong association was observed in patients receiving PRP and showing a reduction of VAS > 50% from baseline when other factors were controlled No adverse events noted	Randomized controlled trial Active controlled trial with no placebo group Small sample size Short-term follow-up	Positive trial for PRP Results show significantly better improvement with PRP injection compared to steroid injection	Positive trial for PRP Active controlled trial with no placebo group Small sample size Short-term follow-up
Chen et al, 2022 (291) RA, DB, C Quality Scores: Cochrane = 11/13 IPM-QRB = 35/48	26 patients with a positive response of 80% or greater to a single diagnostic block with a fluoroscopically guided intraarticular injection Randomization into 2 groups, either steroid or PRP	Intraarticular sacroiliac joint injection of 0.5 to 1 mL of contrast medium used to confirm in the placement of the needle Following this, the steroid group received a single injection consisting of a combination of 1 mL of betamethasone sodium phosphate and acetate suspension, 6 mg per mL and 1 mL of 2% lidocaine PRP	Intraarticular sacroiliac joint injection of 0.5 to 1 mL of contrast medium used to confirm in the placement of the needle Following this, the steroid group received a single injection consisting of a combination of 1 mL of betamethasone sodium phosphate and acetate suspension, 6 mg per mL and 1 mL of 2% lidocaine PRP	• Level of pain ODI • Proportion of pain relief > 50% 1, 3, & 6 months At 6 months, neither group showed significant improvement No adverse events noted	Both groups improved at all time periods – 1, 3, & 6 months At 3 months, 70% of the steroid group patients and 21.4% of PRP group patients showed significant improvement At 6 months, neither group showed significant improvement No adverse events noted	• Randomized, double blind, clinical trial available • Well performed study with appropriate outcome parameters Small sample size Active controlled trial	Negative for PRP Even though PRP patients and steroid patients both showed significant improvement, both showed improvement from baseline At 3 months, a significantly higher proportion of patients in steroid group showed better results	Negative for PRP Even though PRP patients and steroid patients both showed significant improvement, both showed improvement from baseline At 3 months, a significantly higher proportion of patients in steroid group showed better results

C = controlled; DB = double-blind; IPM-QRB = Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment; MODQ = Modified Oswestry Disability Index; ODI = Oswestry Disability Index; PRP = platelet-rich plasma; RA = randomized; SF-12 = 12-Item Short Form Survey; VAS = Visual Analog Scale

Table 18. Study characteristics of non-randomized and observational studies assessing the role of PRP injections of sacroiliac joints.

Study Characteristic Methodological Quality Scoring	Number of Patients & Selection Criteria	Sacroiliac Joint PRP Injection	Comparator	Outcome Measures and Time of Measurement	Results	Strengths	Weaknesses	Conclusions
Mohi Eldin et al, 2019 (5/3) P, NR, C Quality Scores: ROBINS-E = 7/7 IPM-QRBNR = 36/48	Total number of patients = 186 124 patients in PRF group 62 patients in PRP group Selection Criteria: • Clinical evaluation with at least 3 positive provocation tests • Diagnostic nerve blocks	A single injection of PRP under fluoroscopic guidance	A single injection of PRF under fluoroscopic guidance	VAS 6-month follow-up	82 of 124 patients were considered as negative in PRF group, whereas 41 of 62 patients were considered negative in PRP patients Overall result appears to be both PRF & PRP were negative No adverse events noted	Nonrandomized comparative evaluation with a relatively large sample size	Nonrandomized study Outcomes criteria not well described	Negative for PRP Only a small proportion of patients showed improvement in both PRF & PRP groups
Wallace et al, 2020 (5/4) P, NR Quality Scores: ROBINS-E = 5/7 IPM-QRBNR = 25/48	50 patients Selection Criteria: • Clinical signs • Imaging • Clinical evaluation with 3 positive provocative tests No diagnostic blocks were performed	50 received PRP injection with 3 mL of PRP under ultrasound guidance	None	Pain relief with ODI 2 & 4 weeks, 3 & 6 months	The mean reduction in ODI and pain scales was significant at 6 months after injection compared with baseline values No adverse events noted	Performed in a clinical setting with 6-month follow-up	Prospective study performed in a clinical setting Nonrandomized study with relatively small sample	Positive PRP study
Saunders et al, 2018 (5/15) NR, O Quality Scores: ROBINS-E = 4/7 IPM-QRBNR = 18/48	45 patients compared to the control group receiving hypertonic glucose injections Selection Criteria: • Clinical examination	PRP injection was performed under ultrasound guidance	• VAS RMDQ • Quebec Back Pain Inventory • Clinical tests of sacroiliac joint incompetence	Prolotherapy injections performed under ultrasound guidance	The outcome measures of change in pain scores, improvement in function between the groups was superior for the PRP group All PRP patients experiencing significant improvement in pain score & function The number of injections required was less for the PRP group with mean of 1.6 than the controls with mean of 3.0 No adverse events noted	Prospective, nonrandomized comparative evaluation	Positive PRP study PRP was described as a viable alternative to hypertonic dextrose injection with significantly better relief at 12-month follow-up	Lack of placebo group in a nonrandomized study which may have induced multiple confounding factors

C = controlled; IPM-QRBNR = Interventional Pain Management Techniques – Quality Appraisal of Reliability and Risk of Bias Assessment for Nonrandomized Studies; NR = nonrandomized; O = observational; ODI = Oswestry Disability Index; P = prospective; PRF = platelet-rich plasma; PRP = platelet-rich fibrin; RMDQ = Roland-Morris Disability Questionnaire; ROBINS-E = Risk of Bias in Non-Randomized Studies of Exposure; VAS = visual analog scale

the secondary outcome as functional improvement of > 30% at 3 or more months post-intervention, consistent with the criteria used in this assessment and those applied by Sanapati et al (17). Unlike the present review, their selection criteria did not impose a minimum patient number. They initially identified 151 publications, with only 3 meeting inclusion criteria, including one randomized comparative trial in which the PRP group had a significantly higher likelihood of achieving > 50% pain improvement at 3 months (510). Pooled pain outcomes from 2 additional studies indicated that approximately 93% of patients achieved > 50% pain improvement; however, both studies included only 14 patients and lacked a comparative group.

In contrast, the current systematic review incorporated 2 RCTs (291,510) and 3 observational studies (513-515), with only one study overlapping with Burnham et al's review (504). The conclusions of Burnham et al (504) align with our findings, indicating that the evidence supporting PRP for sacroiliac joint pain is of very low quality according to the GRADE system. Similarly, Ruffilli et al (506), in a systematic review and meta-analysis, concluded that while PRP data appear promising, the limitations of the current literature prevent a clear determination of the most appropriate injectable approach.

## 7.5 Functional Spine Unit Injections

### ***KEY QUESTION 8. THE EVIDENCE OF EFFECTIVENESS FOR THE FUNCTIONAL SPINE UNIT APPROACH AND CONSENSUS-BASED CLINICAL RECOMMENDATIONS.***

While most studies focused on single-structure injections, several investigated multiple injection targets.

In a retrospective pilot study of 86 patients with low back pain, Kirchner and Anitua (432) administered plasma rich in growth factor (PRGF) into multiple lumbar spine structures. Each patient received intradiscal, intra-articular facet joint, and transforaminal epidural injections under fluoroscopic guidance, resulting in statistically significant pain reduction up to 6 months. Atluri et al (7) conducted a prospective nonrandomized trial assessing autologous bone marrow-MSCs for chronic low back pain associated with lumbar spinal degeneration involving multiple anatomical structures. Forty patients in the treatment group received autologous BMC injections into discs, facet joints, sacroiliac joints, and around spinal nerves, tailored to the primary pain source. At 12 months, 67% of patients demonstrated significant improvements in pain and functional outcomes, along with reduced opioid use. This study was the first to demonstrate the benefits of administering bone marrow-MSC injections across multiple structures in a single session for chronic spinal degeneration.

In another prospective case series, 46 patients with chronic low back pain received PRP injections into facet joints, intervertebral discs, epidural space, and/or paravertebral muscles. Across the cohort, mean VAS scores decreased by approximately 35%, and disability scores improved by about 40% at one-year follow-up. Over 80% of participants had radiographic evidence of more than one abnormality on MRI, including facet joint arthropathy, spinal canal stenosis, intervertebral disc disease, and paravertebral muscle atrophy. This study highlighted the utility of multitarget PRP injections in addressing multiple pain generators (435).

Table 19. Evidence profile using randomized controlled trials and nonrandomized or observational studies for sacroiliac injections of PRP for the same outcome and similar certainty of evidence.

Study	Study Design	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Number of Patients	Impact	Certainty
Singla et al, 2017 (510)	RA, single blinded, C	Moderate	NS	NS	NS	Low	40	Positive	Moderately positive
Chen et al, 2022 (291)	RA, DB, C	Moderate	NS	NS	NS	Low	26	Negative	Moderately negative
Mohi Eldin et al, 2019 (513)	P, NR, C	High	NS	S	S	Very low	186	Negative	Moderately negative
Wallace et al, 2020 (514)	P, NR	Very high	S	S	S	Very low	50	Positive	Low positive impact
Saunders et al, 2018 (515)	NR, O	Very high	S	S	S	Very low	45	Positive	Low positive impact

C = controlled; DB = double-blind; MSC = mesenchymal stem cells; NR = nonrandomized; NS = nonrandomized; O = observational; P = prospective; RA = randomized; S = serious

Most published studies on spinal orthobiologics primarily focus on degenerative disc disease. Understanding the spine's biomechanical dynamics and the distribution of load across various structures clarifies that most patients with chronic low back pain have multiple pain generators rather than a single source. Consequently, a comprehensive treatment strategy that simultaneously targets these pain generators and addresses the functional spine unit (FSU) is essential for optimizing patient outcomes.

Williams et al (516) reported a case series demonstrating the safety and efficacy of autologous concentrated platelet product injections and prolotherapy in 14 patients with neck pain using an FSU-based treatment protocol. Patients with axial neck pain, with or without radiculopathy, received multiple injections targeting the cervical facet joint, including the cervical facet capsule, supraspinous and interspinous ligaments, and cervical epidural space. The results showed clinically significant improvements in pain and functional outcomes at 24 months, supporting the FSU treatment paradigm and its potential application in managing spinal pain by addressing ligamentous laxity, intra-articular facet arthritis, and nerve root irritation.

## 7.6 Summary of Evidence

The evidence for intradiscal injections, epidural injections, facet joint injections, sacroiliac joint injections,

and multitarget injections using an FSU approach is summarized here. Evidence is derived from randomized and nonrandomized studies and synthesized based on study quality, risk of bias, qualitative and quantitative analyses when available, and the GRADE framework.

### 7.6.1 *Intradiscal Injections*

PRP: Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate

BMAC: Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate

### 7.6.2 *Epidural Injections (PRP)*

Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate

### 7.6.3 *Facet Joint Injections (PRP and MSCs)*

Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Moderate

### 7.6.4 *Sacroiliac Joint Injections (PRP)*

Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Low

### 7.6.5 *Functional Spine Unit Injections*

Evidence Level: Very Low; Consensus-Based Clinical Recommendation: Low

## **8.0 CURRENT GUIDELINES FOR BIOLOGICS IN INDUSTRY AND REGULATORY AGENCIES**

### **KEY QUESTION 9. WHAT ARE THE CURRENT GUIDELINES FOR BIOLOGICS?**

#### **8.1 FDA/WHO as Regulatory Agency for Biologic Therapies**

Biologics are more complex than chemically synthesized drugs due to their structural heterogeneity and interactions with biological systems. Each biologic's development and production processes vary because they are derived from living organisms. As new therapies emerge and evolve, maintaining regulatory oversight is essential to ensure the safety, efficacy, and quality of these biologics. The FDA and World Health Organization (WHO) play critical roles in regulating biologic therapies. Currently, biologics are used in pain management for conditions such as osteoarthritis, neuropathic pain, and chronic pain syndromes.

The FDA provides a Biologics Licensing and Approval Process (BLA), which requires a Biologics License Application to approve biologics. A BLA can be submitted by any legal person or entity involved in the manufacture of the biologic or an applicant who assumes responsibility for ensuring that the product and establishment comply with required standards. The BLA process includes clinical testing and a thorough regulatory review to demonstrate the biologic's safety, efficacy, and quality. Once these criteria are met, the FDA grants approval. After approval, the FDA continues to monitor biologics through post-market surveillance programs to identify any adverse effects or long-term safety concerns related to their use (517).

The FDA regularly publishes guidance documents outlining regulatory expectations for the development and approval of biologics. In 2018, the FDA introduced the Biosimilars Action Plan (BAP) to promote innovation and competition in the biological product market, streamline the development and approval of biologics, and enhance understanding of biologics among patients, clinicians, and payers. The FDA's Patient-Focused Drug Development (PFDD) initiative also encourages incorporating patient perspectives into the drug development process. The FDA provides additional guidance for preclinical testing, clinical trial designs, and long-term patient monitoring for cell and gene therapies that fall under Human Cells, Tissues, & Cellular & Tissue-Based Products (HCT/Ps). The FDA enacted the Regenerative Medicine Advanced Therapy (RMAT) Designation in 2017 to expedite the develop-

ment of pathways for regenerative therapies that show potential in early trials.

The WHO is responsible for the global regulation of biologic therapies, including those used for pain management, by developing guidelines and standards for its member states. Its key responsibilities include establishing international standards for biologics' production and quality control, assisting countries to strengthen regulatory oversight to ensure that biologics meet safety and efficacy standards, and evaluating and listing biologic products that meet WHO standards to facilitate access. The WHO has developed quality assurance guidelines for producing biologics, ensuring that those used in clinical practice meet quality and safety standards, which are crucial for patient safety. The WHO's Prequalification Program assesses the quality and safety of medicines, including biologics, allowing manufacturers to gain recognition for their products (518,519).

In addition, the FDA and WHO collaborate on various regulatory initiatives concerning standards for biologics. This collaboration includes participation in forums such as the International Conference on Harmonization (ICH), which addresses the regulatory oversight of biologics. Their joint efforts are significant in harmonizing regulatory standards, guideline development, and global health initiatives.

#### **8.2 Human Cells, Tissues, & Cellular & Tissue-Based Products (HCT/Ps)**

The FDA regulates HCT/Ps under 21 CFR Part 1271 with a risk-based approach to ensure they are safe for patient use. The guidelines have 2 sections: Section 361 HCT/Ps (minimally regulated) and Section 351 HCT/Ps (subject to more stringent regulation) (362).

Products regulated under Section 361 of the Public Health Service (PHS) Act are subject to less stringent oversight because they are considered minimally manipulated. Examples include skin grafts, bone grafts, and corneal transplants. These products are used in a homologous manner to their natural function. Minimal manipulation means the processing does not alter the original characteristics of the cells or tissues. No pre-market approval is needed for these products, but they must meet Good Tissue Practices (GTP), which ensure the safe handling, testing, and storage of HCT/Ps.

Products regulated under Section 351 of the PHS Act require a Biologics License Application (BLA). These include cell therapies where stem cells are expanded or differentiated in culture, gene therapies, and some

tissue-engineered products. These products must undergo pre-market approval and clinical trial phases. cGMP applies, and these products require stringent controls over the manufacturing, packaging, and distribution of HCT/Ps. They are evaluated for safety, efficacy, and quality, and manufacturers must comply with extensive post-market surveillance to monitor long-term outcomes and adverse events.

The FDA mandates that HCT/Ps be used for their homologous function, meaning the product must serve a purpose in the body consistent with its natural role. For example, cartilage tissue should be used to repair cartilage, not for treating other tissues or organs. For cell and gene therapies categorized under HCT/Ps, the FDA provides additional guidance on preclinical testing, clinical trial design, and long-term patient monitoring. In 2017, the FDA introduced the RMAT Designation to expedite development pathways for regenerative therapies that demonstrate potential in early clinical trials.

MSCs are widely used for their regenerative potential in conditions such as osteoarthritis, degenerative disc disease, and tendon injuries. They are considered minimally regulated by the FDA. PRP therapy is used for joint pain, tendon injuries, and discogenic back pain and is considered a Section 361 HCT/P when used homologously. Amniotic tissue-derived products treat chronic wounds, joint injuries, and orthopedic conditions. These are typically considered minimally manipulated under FDA Section 361 as long as they are used homologously. BMAC, which contains a mixture of stem cells, growth factors, and other regenerative cells from bone marrow, has been employed for intradiscal injections to treat low back pain and knee osteoarthritis. Due to its more than minimal manipulation, stringent FDA guidelines under Section 361 apply to BMAC's use in regenerative therapies.

### 8.3 Minimal Manipulation

Section 1271.10(a)(1) (21 CFR 1271.10(a)(1)) provides that one of the criteria for an HCT/P to be regulated solely under Section 361 of the PHS Act and the regulations in Part 1271 is that the HCT/P is minimally manipulated (13,362). As defined in 21 CFR 1271.3(f), minimal manipulation means:

1. For structural tissue, processing that does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement.
2. For cells or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells or tissues.

The FDA noted that if information does not exist to show that the processing meets the definition of "minimal manipulation," the FDA considers the processing of an HCT/P to be "more than minimal manipulation" and therefore ineligible for regulation solely under Section 361 of the PHS Act and 21 CFR Part 1271 (13,362).

Section 1271.3(f) provides 2 definitions of "minimal manipulation," one for structural tissues and one for cells or nonstructural tissues. For structural tissue, minimal manipulation means that the processing of the HCT/P does not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement (21 CFR 1271.3(f)(1)). For cells or nonstructural tissues, minimal manipulation means that the processing of the HCT/P does not alter the relevant biological characteristics of cells or tissues (21 CFR 1271.3(f)(2)).

Original relevant characteristics of structural tissues generally include properties of that tissue in the donor that contribute to the tissue's function or functions. Similarly, relevant biological characteristics of cells or nonstructural tissues generally include properties of the cells or nonstructural tissues within the donor that contribute to the cells' or tissue's function(s). Processing that alters the original characteristics of the HCT/P raises increased safety and effectiveness concerns because there is less basis to predict the product's function after transplantation (362). Thus, the determination of whether an HCT/P is minimally manipulated is based on the effect manufacturing has on the original relevant characteristics of the HCT/P as it exists within the donor, not on its intended use in the recipient.

Processing is defined as any activity performed on an HCT/P other than recovery, donor screening, donor testing, storage, labeling, packaging, or distribution, such as testing for microorganisms, preparation, sterilization, steps to inactivate or remove adventitious agents, preservation for storage, and removal from storage (21 CFR 1271.3(ff)). Processing also includes cutting, grinding, shaping, culturing, enzymatic digestion, and decellularization (362).

Tissues that physically support or serve as a barrier or conduit, connect, cover, or cushion in the donor are generally considered structural tissues for determining the applicable regulatory definition (e.g., bone, skin).

Adipose tissue is a structural tissue that can be applied to the HCT/P regulatory framework. Adipose tissue is typically defined as a connective tissue composed of clusters of cells (adipocytes) surrounded by a reticular fiber network and interspersed with small blood ves-

sels, divided into lobes and lobules by connective tissue septa (362). Additionally, adipose tissue contains other cells, including preadipocytes, fibroblasts, vascular endothelial cells, and macrophages (362). Adipose tissue provides cushioning and support for different tissues, including the skin and internal organs, stores energy in the form of lipids, and insulates the body, among other functions. While adipose tissue has multiple functions, because it predominantly comprises adipocytes and surrounding connective tissues that provide cushioning and support to the body, the FDA considers adipose tissue a structural tissue for applying the HCT/P regulatory framework.

To evaluate whether the processing of adipose tissue meets the regulatory definition of minimal manipulation, one should consider whether the processing alters the original relevant characteristics of the adipose tissue relating to its utility to provide cushioning and support (Fig. 19). An opposing view may consider the presence of stem cells within adipose tissue as an indication that this tissue also functions as a repository for regenerative factors.

#### 8.4 Homologous Use

Section 1271.10(a)(2) (21 CFR 1271.10(a)(2)) provides that one of the criteria for an HCT/P to be regulated solely under Section 361 of the PHS Act and the regulations in Part 1271 is that the "HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent."

As defined in 21 CFR 1271.3(c), homologous use means the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic functions in the recipient as in the donor. This criterion reflects the FDA's conclusion that there would be increased safety and effectiveness concerns for HCT/Ps intended for a non-homologous use, because there is less basis for predicting the product's behavior. In contrast, HCT/Ps for homologous use can reasonably be expected to function appropriately (assuming all other criteria are also met) (13,362).

In applying the homologous use criterion, the FDA determines the intended use of the HCT/P as reflected by the labeling, advertising, and other indications of a manufacturer's objective intent, and then applies the homologous use definition.

Homologous use means the repair, reconstruction, replacement, or supplementation of a recipient's cells

or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor (21 CFR 1271.3(c)), including when such cells or tissues are for autologous use. Recipient cells or tissues that are identical (e.g., skin for skin) to the donor cells or tissues perform one or more of the same basic functions in the recipient as they did in the donor. Recipient cells or tissues that may not be identical to the donor's cells or tissues can also meet the homologous use criterion if they perform one or more of the same basic functions in the recipient as in the donor (13,362).

For the purpose of applying the HCT/P regulatory framework, the same basic function or functions of HCT/Ps are considered those basic functions that the HCT/P performs in the donor's body, which, when transplanted, implanted, infused, or transferred, the HCT/P would be expected to perform in the recipient. The HCT/P in the recipient does not need to perform all of the basic functions it performed in the donor to meet the definition of homologous use. However, to meet the definition, any of the basic tasks that the HCT/P is expected to perform in the recipient must be a basic function that the HCT/P performed in the donor.

Using an HCT/P from adipose tissue for the repair, reconstruction, replacement, or supplementation of adipose tissue would be considered a homologous use. In such situations, the FDA considers the HCT/P from adipose tissue to be performing the same basic function in the recipient as in the donor. In contrast, using an HCT/P from adipose tissue to treat a degenerative, inflammatory, or demyelinating disorder would generally be considered a non-homologous use. Figure 19 illustrates how manufacturers and healthcare providers should apply the criteria outlined in 21 CFR 1271.15(b) and 1271.10(a) for HCT/Ps (362).

#### 8.5 Regulatory Scope and Compliance Policy

This guidance applies only to products and establishments subject to the FDA's regulations in 21 CFR Part 1271. Establishments that meet the same surgical procedure exception in 21 CFR 1271.15(b) are not subject to the FDA's regulations in 21 CFR Part 1271.

This guidance also does not apply to products that fall outside the definition of HCT/P in 21 CFR 1271.3(d). For example, PRP (blood taken from an individual and given back to the same individual as PRP) is not an HCT/P under Part 1271 because it is a blood product. Accordingly, the FDA does not apply the criteria in 21 CFR 1271.10(a) to PRP, and PRP is outside the scope of this guidance.

## 8.6 FDA's Comprehensive Framework for Regenerative Medicine

As described by Marks and Gottlieb (13), the FDA recognizes the time and effort required to create regulatory submissions and the impact that working through the regulatory process can have on the timelines for developing innovative products. Consequently, in November 2017, building on existing policy and emerging scientific opportunities, the FDA released a comprehensive framework for the oversight of regen-

erative medicine to help the field advance. This regulatory framework is articulated in 2 final and 2 draft guidance documents, as shown in Table 20 (13).

The FDA's new policy framework more clearly describes the distinctions for regenerative medicine developers between therapies that require premarket authorization and those that do not. It provides clear criteria for minimal manipulation and homologous use, as well as a risk-based compliance and enforcement policy as part of the overall regulatory framework.




Table 20. *Four guidance documents describing the regenerative medicine framework.\**

Document	Summary	Example
Same Surgical Procedure Exception under 21 CFR 12.71.15(b): Questions and Answers Regarding the Scope of the Exception -- Final	Addresses the criteria required for the exception, the types of procedures generally considered to be the same surgical procedure, and what processing steps can be undertaken to still meet the exception. In essence, this guidance clarifies how the regulations apply in order to facilitate the optimal care of patients undergoing surgical procedures.	A situation in which this guidance would apply is when a piece of the skull is removed for decompression after traumatic head injury. The bone may be minimally processed, stored, and then returned to the patient a few weeks later when the acute event is over, without the need for regulatory interaction with FDA.
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use – Final	Provides FDA's interpretation of the existing regulatory definitions of minimal manipulation and homologous use. The guidance clarifies that these are distinct concepts and notes how to determine whether an HCT/P has been minimally manipulated or is intended for homologous use. The guidance also describes the compliance and enforcement policy that the FDA will use for HCT/Ps. For the first 36 months after issuance of the final guidance in November 2017, the FDA intends to exercise enforcement discretion for certain products that pose a low risk to public health so that sponsors will be able to have a dialogue with the agency and file the appropriate regulatory documentation.	Adipose tissue is considered to be a structural tissue for the purpose of the regulatory framework. This is relevant to determining the appropriate regulatory pathway for stem cells derived from adipose tissue, which in many applications will be regulated under both Sections 351 and 361 of the Public Health Service Act.
Evaluation of Devices Used with Regenerative Medicine Advanced Therapies – Draft	Provides a comprehensive resource to developers of devices used with RMATs. Topics covered include how the FDA will simplify and streamline its application of regulatory requirements for devices and cell-tissue combination products.	Under certain circumstances, a device that is used with an RMAT might be classified as a class III device or be limited to a specific intended use with only one type of cell.
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions -- Draft	Provides information about the expedited programs available to RMATs, including fast-track and breakthrough-therapy designations, and describes the FDA's considerations in implementing the new expedited program for RMATs. The guidance also describes an innovative program using cooperative development open to regenerative medicine products.	Multiple sites that manufacture a product using a common process may collaborate on clinical trials as part of a development program, which ultimately results in biologics licenses for each of the individual sites.

\*The listed guidance documents can be accessed at:

[www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm58218.htm](http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm58218.htm)

RMAT denotes regenerative medicine advanced therapy

Source: Marks P, Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine. *N Engl J Med* 2018;378:954-959 (13).

### 8.6.1 *Expediting the Development of New Therapies*

The FDA has developed a process to expedite the development of new therapies. While the FDA has traditionally focused on ensuring the quality, safety, and efficacy of medical products, its mandate has expanded to include a role in accelerating the development of new therapies, particularly those aimed at treating serious or life-threatening conditions. Consequently, the expedited programs include fast track designation, priority review, accelerated approval, and designation as a breakthrough therapy.

The FDA reports that these programs have successfully expedited the development of new therapies. Additionally, the agency has emphasized its role in facilitating innovation while maintaining its approval standards, particularly in areas of unmet medical need and with emerging technologies, as outlined in the legislative initiative contained in the 21st Century Cures Act, enacted on December 13, 2016 (520).

To further advance therapeutic innovation in stem cell therapies and other HCT/Ps, the 21st Century Cures Act introduced an additional expedited program known as the Regenerative Medicine Advanced Therapy (RMAT) designation. This designation provides sponsors of qualified regenerative medicine products intended to treat serious or life-threatening conditions with benefits similar to those granted under the breakthrough therapy designation, provided that preliminary clinical evidence suggests the therapy addresses unmet medical needs.

The key distinction between RMAT and breakthrough therapy designation is that RMAT requires preliminary clinical proof of efficacy, whereas breakthrough designation requires preliminary evidence of a substantial improvement over existing therapy. Additionally, RMAT-designated products that receive accelerated approval may use a broader range of options to fulfill post-approval commitments, such as conducting traditional studies, maintaining patient

registries, or submitting other forms of objective real-world evidence. Multiple requests have been submitted for RMAT designation, with the FDA approving at least one-third of them.

### ***8.6.2 Implementation of Comprehensive Framework***

The FDA stated that it aims to apply a modernized approach to existing regulations and statutes, balancing the goal of promoting rapid development of innovative products for patients with medical needs while ensuring that such therapies remain both safe and effective. As part of this regulatory framework, the FDA articulated a risk-based compliance and enforcement policy. This policy allows developers of lower-risk products up to 36 months from November 16, 2017, to determine whether they need to submit an application for an investigational new drug or a marketing application in light of the newly published guidance docu-

ments. If such an application is required, developers are provided with time to prepare and submit it. However, the FDA intends to take enforcement actions in cases where it believes that unproven products may place patients at risk.

Working within the current regulatory framework, the FDA will use all available regulatory pathways and adopt new principles designed to make pre-market evaluation of stem cell-based therapies more efficient. On a broader scale, the FDA will integrate new strategies to help small investigators and firms meet product approval standards through efficient and expedited pathways. To achieve this objective, the FDA will provide tools to encourage individual physicians or small groups of physicians to collaborate in the development of stem cell or other regenerative medicine products, ultimately enabling each participating physician or group to obtain a biologics license (Fig. 19).

## **9.0 CLINICAL GUIDANCE**

### **KEY QUESTION 10. WHAT ARE THE ADVERSE CONSEQUENCES/HARMS OF REGENERATIVE THERAPIES?**

### **KEY QUESTION 11. WHAT ARE THE PRECAUTIONS IN PERIOPERATIVE MANAGEMENT OF PATIENTS RECEIVING REGENERATIVE INTERVENTIONAL TECHNIQUES AND ANTIPLATELET AND ANTICOAGULANT THERAPY?**

### **KEY QUESTION 12. WHAT ARE THE BEST PREVENTIVE AND THERAPEUTIC STRATEGIES TO IMPROVE OUTCOMES WHEN PERFORMING REGENERATIVE THERAPIES?**

#### **9.1 Safety, Effectiveness, and Informed-Decision Making**

Regenerative medicine remains a developing field that is not currently covered by medical insurance. At the time of this writing, there are no standardized protocols or treatments governed by the Centers for Medicare and Medicaid Services (CMS). Because of this, the physician–patient partnership must be emphasized more strongly than in most other procedures. Understanding the safety and effectiveness of treatments is essential to making informed decisions that best serve patients while advancing the field.

At its foundation, autologous sources of orthobiologics are inherently safe, as the injectate is obtained from and re-injected into the same patient. Autologous sources carry a very low risk of rejection, allergic reaction, or infection. Standard hygiene and sterilization protocols must always be followed when handling blood products. Most commercially available kits are closed systems, which further minimize the risk of contamination. Proper training in the handling of biologics (blood, bone marrow, adipose) is essential, as is ongoing protocol review. Physicians performing these procedures are expected to adhere to the same practice standards used for any injection procedure involving the joints or spine, maintaining sterile technique and image guidance. The most commonly reported adverse effects are mild and typically include injection-site pain, swelling, or stiffness that resolve over time and require only conservative management.

Numerous published studies discuss the effectiveness of orthobiologics. The 3 key variables influencing outcomes are dose, severity of the treated structure, and injection technique. These procedures must be performed by well-trained physicians under image

guidance (fluoroscopy or ultrasound). Dosing and disease severity then become the primary determinants of efficacy. A review of the literature indicates that orthobiologic treatments show the greatest benefit for mild to moderate degeneration, tendinosis, and partial tears of ligaments and tendons. Quantitative analysis of the injectate is essential, as studies have demonstrated that therapeutic effectiveness depends on appropriate dosing. Generally, PRP concentrations exceeding 5 billion platelets and BMACs with more than 100 million total nucleated cells are recommended.

Interventional physicians presenting these treatment options to patients must be prepared to discuss the realistic potential of these procedures and manage patient expectations accordingly. Because these treatments remain an expensive, out-of-pocket expense for most patients, understanding their safety, effectiveness, and limitations is critical. A standard consent form for interventional procedures can serve as a foundation for informed consent. In our practice, additional language is included to explain the experimental nature of these treatments, as they are not FDA-approved for orthopedic conditions of the joints or spine. All treatment options are reviewed, and patient questions and concerns are fully addressed prior to proceeding with any orthobiologic procedure.

#### **9.2 Office Set-up**

When setting up an office for regenerative medicine, always prioritize decisions that optimize patient outcomes.

- **Location:** An ideal location is within a medical community near other practices, close to major freeways, and easily accessible for patients traveling from a distance. However, location is not critical, patients will travel for excellent care. For new practices, subleasing from an existing medical office can help reduce start-up costs. For existing practices adding regenerative medicine, utilize current office space but designate specific rooms, and ideally a separate waiting area, for regenerative medicine patients.
- **Staffing:** Dedicate one receptionist and one medical assistant to regenerative medicine. If adding regenerative medicine to an existing practice, obtain a separate phone number, create a Doing Business As (DBA), and use a distinct name for marketing. In the initial stages, the most important staff member is the receptionist. Invest in their training by having them observe consultations and procedures to

fully understand the process and accurately answer patient questions. How leads are handled is critical for converting inquiries into visits and procedures.

- **Equipment and Supplies:** A quantitative laboratory capable of providing cell counts for PRP and BMC samples is essential and often overlooked. Without knowing cell counts, dosing accuracy cannot be confirmed, and inadequate dosing can compromise outcomes.
- **Ultrasound:** Use ultrasound for both diagnostics and needle guidance. Proper training is crucial to develop proficiency. Ultrasound should become an extension of the physical exam for evaluating visible structures and ensuring accurate needle placement during procedures. Inaccurate delivery of regenerative products can lead to suboptimal results.
- **Fluoroscopy:** Use fluoroscopy for guidance during interosseous or intradiscal spine procedures. If a fluoroscope or lead-lined OR is not available in the office, partner with a local ambulatory surgery center and pay a facility fee per case. This arrangement is also suitable for procedures requiring anesthesia if in-office anesthesia is not feasible.
- **Patient Registry:** Maintain a patient registry to track treatment outcomes and share data with patients. Multiple regenerative registries are available; select one and use it consistently for all patients.
- **Supplies:** Supplies for regenerative medicine are similar to those used in pain management procedures and include local anesthetics, needles, syringes, ultrasound probe covers, and sterile prep materials. In addition to local anesthesia, nitrous gas is a suitable in-office option that avoids the requirements associated with intravenous (IV) anesthesia. Proper preoperative screening and intraoperative monitoring are essential for safe IV anesthesia administration.
- **Electronic Medical Records:** The choice of EMR depends on whether the practice is entirely out-of-pocket or mixed insurance and cash-based. If offering both, ensure proper advanced beneficiary notices and consent forms are used to confirm patient understanding that insurance will not be billed.
- **Client Experience:** Regenerative medicine differs from traditional pain management or “sick care.” Patients seeking regenerative treatments are often proactive and have already decided to pursue these therapies, they are choosing whom to trust. Take the approach of a plastic surgery practice: be kind, take time during consultations, and clearly explain the rationale for each recommended procedure. Edu-

cate rather than sell. Avoid promotional tactics such as “book today and get \$500 off”; instead, build trust through professionalism and transparency.

### 9.3 Contraindications

**Absolute Contraindications** – Regenerative medicine procedures, like conventional pain-relieving procedures, are elective. Injections should not be performed if any of the following conditions are present:

- Active Cancer
- Active infection
- Hemodynamically unstable or other disorder meeting hospitalization criteria
- Abnormally high numbers on baseline cell analysis could represent an undiagnosed cancer or active infection and need further work-up before reinjection.

**Relative Contraindications** – The risk versus benefit of treatment should be carefully considered in the following situations:

- Low baseline platelet counts (50-100k platelets/uL)
- Antiplatelet therapy, including NSAIDs
- Immunotherapy disease-modifying antirheumatic drugs (DMARDs)
- Low PRP or BMC numbers on post-processing cell analysis, as injecting a suboptimal dose is less likely to be effective.
- Advanced conditions have a lower probability of efficacy due to a lower baseline substrate.
- Bony growths, such as osteophytes, are sources of pain/tear.
- Significant loss of range of motion, causing significant functional limitations, as range of motion tends not to improve with treatment.
- Unhealthy patients with poor protoplasm, such as those with metabolic syndrome, organ failure, or home oxygen use, have reduced regenerative capacity.
- Inability to participate in a proper rehabilitation program post-procedure.

### 9.4 Pre, Intra, and Post Procedural Considerations

#### 9.4.1 Pre-Procedure

Orthobiologic treatment protocols continue to evolve. As with any intervention, identifying appropriate candidates and target diagnoses is essential. Maximizing the benefit of orthobiologics requires accurate

identification of the anatomical structures responsible for symptoms. Patients with multiple systemic or autoimmune disorders may not be suitable candidates. Studies have shown that PRP is beneficial for soft tissue injuries and mild degenerative conditions, while BMAC is more effective for advanced cases. Once the treatment plan is established, target structures and concentration volumes should be determined in advance.

Active infection or cancer, thrombocytopenia, NSAID or immunotherapy use, prior surgery at the treatment site, and imaging findings should be reviewed as relative contraindications. A complete blood count is recommended for patients with a history of cancer, infection, or thrombocytopenia before treatment. Discontinuation of NSAIDs and immunotherapy 7–10 days prior to and for 2 weeks following the procedure is advised to optimize results. Adequate hydration for 2–3 days before the procedure is recommended. Supplements may also be considered before and after the procedure to support recovery.

#### **9.4.2 Intra-Procedure**

For PRP, venous blood should be drawn using a large-bore needle (18–20 G) to minimize cellular damage. Double centrifugation producing over 10 billion platelets yields optimal results. Bone marrow aspiration is typically performed at the posterior superior iliac spine (PSIS). After concentration, a total nucleated cell count above 1.5 billion is the goal.

The needle approach should be carefully planned, accounting for anatomical variations and nearby neurovascular structures. Image guidance (ultrasound or fluoroscopy) is required for precise placement of the orthobiologic material. IV conscious sedation or inhaled nitrous oxide may be used for comfort. The treatment area should be prepared and draped in a sterile manner. IV antibiotics are recommended for intradiscal and intraosseous procedures. Vital signs must be continuously monitored according to American Society of Anesthesiologists (ASA) guidelines during the procedure to ensure patient safety.

#### **9.4.3 Post-Procedure**

Post-procedural care includes monitoring for bleeding or infection and maintaining hydration. Acceptable post-injection medications include gabapentinoids, acetaminophen, muscle relaxants, and opioids as alternatives to NSAIDs. Cryotherapy can be applied to the treatment site for the first 24 hours, followed by heat therapy thereafter. Cryotherapy may also be

continued at the bone marrow aspiration site. Patients should avoid overuse of the treated area.

Symptoms often intensify during the first 7–10 days after injection due to the inflammatory healing response but typically return to baseline within a few weeks. Range of motion and daily activities are encouraged until the 4-week follow-up. From weeks 4–6, patients should begin a home exercise program at approximately 50% of normal intensity using isometric exercises, increasing activity gradually based on tolerance and avoiding prolonged soreness. After 6 weeks, most activity restrictions are lifted if symptoms remain controlled. Noticeable improvement typically occurs between weeks 4–6, with continued progress for several months. Follow-up evaluation is generally performed at 3 months post-injection.

### **9.5 Post-Orthobiologic Rehabilitation**

Tissue healing follows a predictable cascade initiated by an external trigger, either an injury or an orthobiologic treatment. Although there is considerable variability in published rehabilitation protocols (339), the standard approach aligns with the 4 overlapping phases of tissue healing (521):

- Stage 1: Hemostasis
- Stage 2: Acute inflammatory phase
- Stage 3: Proliferative or repair phase
- Stage 4: Remodeling phase

During rehabilitation, it is important to recognize that optimal loading can improve a tissue's mechanical properties by enhancing fiber alignment through progressive, therapeutic stress (522). Because the rate and strength of healing are tissue-specific, so too is optimal loading. Insufficient loading may weaken tissue and impair mobility, while excessive loading may damage newly formed tissue; moderate loading, in contrast, supports the repair process.

The physiologic timeframe for tissue loading and protection is outlined in Table 21 (521). During the hemostatic and inflammatory stages, limited or protected weight-bearing facilitates cross-link formation, while gentle motion prevents stiffness. Pain typically decreases as healing progresses to the proliferative phase (weeks 3–6), during which light concentric and later eccentric loading can aid recovery. Adjunctive techniques, including soft tissue mobilization and extracorporeal shock-wave therapy, may be beneficial. From weeks 6–12, the remodeling phase features increased tensile strength as type 3 collagen is replaced by a more organized matrix.

Table 21. *Tissue-specific loading and healing time.*

Tissue	Healing Capacity Vacularity	Force to Facilitate Healing	Tissue Healing Time	Loading Protection
Muscle	Good, abundant	Contractile Loading Isometric-> Concentric-> Eccentric muscle	6-8 wk	ROM parameters, SubMax Isometrics-> Max Isometrics-> Concentrics-> Eccentrics-> Ballistic progressions
Tendon	Fair, less	Contractile Loading Isometric-> Concentric-> Eccentric	8-12 wk	ROM parameters, SubMax Isometrics-> Max Isometrics-> Concentrics-> Eccentrics-> Ballistic progressions
Ligament	Less, Diminished	Tension Controlled fiber Tension in line of stress	7-14 wk	Bracing with protected ROM parameters
Cartilage Labrum Intervertebral Disc	Limited/absent	Cyclical Compression, Decompression & Shear Imbibing pumping effect; controlled	6-12 wk	Bracing, Unloading, progressing weight bearing, Aquatics, Stationary Bike, weight bearing loading and controlled torsional stress
Subchondral Bone/Bone		Controlled Weight Bearing	8-12 wk	Weight Bearing Status, Unloading

Used with permission, Eric Honbo

Toward the end of this stage, functional exercises and gradual return to full activity may occur (521). However, individual variations of 4–8 weeks are common, depending on pathology, comorbidities, biomechanics, activity level, and tissue quality.

## 9.6 Adverse Reactions and Complications

Orthobiologic injections are among the safest orthopedic procedures due to their typically autologous nature, minimally invasive technique, and lack of systemic adverse effects. Nonetheless, patients should be informed about possible risks, benefits, and indications.

The most common adverse effect is transient post-procedural pain (523), resulting from the localized inflammatory response that drives the therapeutic effect. A 2024 review of adverse events associated with PRP primarily identified isolated case reports of local infection following musculoskeletal PRP injection. Additional reports included one allergic reaction to calcium citrate and 2 cases of persistent synovitis (524).

Because intervertebral discs are avascular, intradiscal injections carry a higher risk of infection. Discitis has been reported following intradiscal bone marrow concentrate, adipose, and leukocyte-poor PRP injections (525). A meta-analysis by Peng et al (420) evaluating intradiscal PRP injections for discogenic low back pain found no significant adverse events across 6 studies, including 3 randomized controlled trials and 3 prospective single-arm trials.

To reduce the risk of discitis, recommendations include using leukocyte-rich PRP, administering intradiscal antibiotics (525), applying a double-needle technique, and sterilizing the field twice with chlorhexidine (526).

Although theoretical concerns exist regarding neoplasm formation, a multicenter study of over 2,300 patients treated with MSCs derived from bone marrow and adipose tissue for musculoskeletal disorders showed a lower incidence of neoplasms compared to the general population (523).

## 10.0 ANTITHROMBOTIC IMPLICATIONS

### 10.1 Risks in Regenerative Medicine

Bone marrow aspirations and intra-articular or soft tissue injections are associated with low bleeding risk, whereas central nervous system or meningeal-related injections carry a higher bleeding risk. ASIPP conducted a comprehensive review with a literature search (44,45) to analyze multiple guidelines and produce recommendations specific to interventional techniques and associated bleeding risks. These recommendations are influenced by factors including patient-specific risk profiles and the judgment of the managing physician (44,45,527–532). Thromboembolic events must also be considered, as any interventional procedure carries some bleeding risk. Clinical correlation with the patient's medical history, social history, and individual risk factors is essential.

### 10.2 Effects of Antithrombotic Therapy on PRP and Stem Cell Effectiveness

The coagulation cascade is critical to platelet function, and disruption of platelet surfaces or premature activation may reduce clinical efficacy (532). With the increasing use of MSC technology in regenerative medicine, cell viability must also be considered in the context of antithrombotic therapy. Studies show that even low-dose heparin can negatively affect ex vivo MSC growth and differentiation potential, highlighting the importance of evaluating bone marrow in patients receiving heparin, particularly when ex vivo expansion of human mesenchymal stem cells (hMSCs) is planned (533).

PRP use is rising due to its potential to promote ligament and tendon healing and serve as a non-surgical alternative. Many candidates for PRP therapy, however, are on anticoagulants or antiplatelet drugs. While anticoagulants are necessary during PRP processing to prevent premature activation, systemic antithrombotic agents influence platelet stability and likely reduce PRP efficacy, necessitating discontinuation prior to injection therapy (534). PRP enhances cell proliferation, collagen synthesis, angiogenesis, and revascularization, supporting tissue regeneration. Sutherland et al (534) demonstrated the effectiveness of autologous MSCs in regenerative medicine using sheep models for tissue-engineered heart valve reconstruction.

The regenerative effect of PRP relies on localized release of bioactive factors such as cytokines and growth factors, which are activated and aggregated at the injury site. Platelet characteristics, particularly their activation and aggregation potential, are therefore critical (535). NSAIDs inhibit platelet activation, reduce alpha granule

storage, and impair aggregation. This results in lower-quality autologous PRP and may negatively affect healing outcomes. Studies have shown that NSAID exposure significantly inhibits platelet function, regardless of the drug type, duration, or blood processing method used for PRP preparation (535). Cyclooxygenase inhibition by NSAIDs impedes platelet activation and release of growth factors, including TGF- $\alpha$  and platelet factor 4, confirming that PRP produced after NSAID use may be suboptimal.

While NSAIDs remain important for pain control post-injury, their effect on bone healing is debated. Animal studies demonstrate mixed outcomes, and clinicians are cautioned that the absence of definitive evidence does not indicate safety, emphasizing that NSAIDs should be avoided in high-risk patients (536).

Ramsook and Danesh (532) discussed PRP use in the context of antithrombotic therapy, emphasizing that disruption of the coagulation cascade may result in prematurely activated platelets and reduced efficacy. They recommend discontinuing antithrombotic agents within an appropriate timeframe prior to injection therapy. Overall, principles regarding antithrombotic and anticoagulant management are consistent with those used in other interventional techniques.

There remains limited literature regarding the safety, efficacy, and timing of PRP injections in patients on antithrombotic therapy. The integrity of platelet membranes is essential for proper release of growth factors and bio-proteins, which underpins PRP efficacy. Antithrombotic agents that destabilize platelets reduce PRP effectiveness, highlighting the need for proper discontinuation protocols. Future research may provide clearer guidance for PRP and stem cell therapy in these patients.

### 10.3 Safe and Efficient Administration of Regenerative Medicine in Anticoagulated Patients

The use of regenerative medicine interventions in patients receiving anticoagulant and antiplatelet therapy is increasing (44). This trend necessitates a multidisciplinary approach to balance the importance of anticoagulation with the requirements of interventional procedures, including timing, discontinuation, or temporary interruption of therapy (44). Anticoagulants and antiplatelet agents are commonly prescribed to reduce thromboembolic risk in patients with conditions such as angina, atherosclerosis, atrial fibrillation, cerebrovascular accidents, ischemic heart disease, myocardial infarction, pulmonary embolism, and peripheral vascular disease. Treatment strategies may include continuation of oral anticoagu-

lants, switching to alternate agents, adding antiplatelet therapy, performing left atrial appendage closure, or combining these approaches (537).

The 2024 ASIPP updated guidelines provide consensus-based recommendations on perioperative management of antiplatelet and anticoagulant therapy in patients undergoing interventional procedures. These guidelines are based on best evidence synthesis, review of bleeding risks, practice patterns, and perioperative management strategies (44). Risk stratification of interventional procedures incorporates: anatomic factors, procedural factors, bleeding risk factors, anticoagulant/antiplatelet-related risks, and medical or physiological risk factors. Table 22 summarizes factors associated with increased bleeding risk (538).

#### 10.4 Determination of Timing of Anticoagulant Interruption

The timing of anticoagulant use and its interruption is a critical consideration and varies among specialties and authors. Table 23 presents sample recommended preoperative withholding times for oral antiplatelet and anticoagulant drugs as reported in the literature (539). Figure 20 illustrates an algorithm for anticoagulant and antiplatelet discontinuation in patients undergoing interventional procedures.

Figure 21 depicts recommended perioperative withholding times for antiplatelet or anticoagulant drugs,

reflecting recommendations from various authorities. For high-risk procedures, aspirin, clopidogrel (Plavix), and prasugrel (Effient) are discontinued 6 days before the procedure and can be resumed the following day. Ticagrelor (Brilinta) is stopped 5 days before and resumed the day after the procedure. For intermediate or moderate-risk procedures, aspirin is discontinued 3 days prior, clopidogrel (Plavix) 5 days, prasugrel (Effient) 5 days, and ticagrelor (Brilinta) 3 days. Recommendations for low-risk procedures are variable; drugs may either be continued or withheld based on clinical judgment and procedural risk.

Table 22. Factors associated with increased bleeding risk.

Need for oral anticoagulation in addition to dual antiplatelet therapy
Advanced age (older than 75 years)
Frailty
Anemia with hemoglobin < 110 g/L
Chronic renal failure (creatinine clearance < 40 mL/min)
Low body weight (<60 kg)
Hospitalization for bleeding within past year
Previous stroke/intracranial bleed
Regular need for NSAIDs or prednisone

NSAIDs: nonsteroidal anti-inflammatory drugs

Source: Mehta SR, Bainey KR, Cantor WJ et al; members of the Secondary Panel. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. *Can J Cardiol* 2018; 34:214-233 (538).

Table 23. Recommended preoperative withholding times of oral antiplatelet and anticoagulant drugs.

Drug	Half-life	Time to withhold prior to		Time to restart after	
		Minor surgery	Major surgery	Minor surgery	Major surgery
Warfarin (Coumadin)	20–60 h	3–5 days*	3–5 days	24 h, overlapping therapy with heparin	48–72 h; overlapping therapy with heparin
Apixaban (Eliquis)	8–15 h	24 h**	48 h**	24 h	24–48 h
Rivaroxaban (Xarelto)	5–9 h (Elderly: 11–13 h)	24 h**	48 h**	24 h	24–48 h
Edoxaban (Savaysa, Lixiana)	10–14 h	24 h**	48 h**	24 h	24–48 h
Betrixaban (Bevyxxa)	19–27 h	≥ 4 days	≥ 4 days	24 h	24–48 h
Dabigatran (Pradaxa)	12–17 h	CrCl > 50 mL: 24 h CrCl < 50 mL: 72 h	CrCl > 50 mL: 72 h CrCl < 50 mL: 120 h	24 h	24–48 h
Aspirin	7–10 days	usually continued	usually continued	usually continued	usually continued
Clopidogrel (Plavix)	7–10 days	5–7 days	5–7 days	24 h	24–48 h
Prasugrel (Effient)	7–10 days	5–7 days	5–7 days	24 h	24–48 h
Ticagrelor (Brilinta)	5–7 days	3–5 days	3–5 days	24 h	24–48 h

\*In some cases, continued drug administration is feasible

\*\*In case of impaired renal function, withholding interval should be prolonged and/or drug level should be evaluated by laboratory tests

CrCl: creatinine clearance

Adapted and modified: Moster M, Bolliger D. Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update. *Curr Anesth Rep* 2022; 12:286–296 (372).




Fig. 20. An algorithm for anticoagulant and antiplatelet discontinuation in individuals undergoing interventional procedures.

### \* *Anticoagulants:*

- *Anticoagulants.*
  - Vitamin K antagonists include warfarin (*Coumadin*)
  - Direct oral anticoagulants (*DOACs*) include dabigatran (*Pradaxa*), apixaban (*Eliquis*), rivaroxaban (*Xarelto*), and edoxaban (*Savaysa, Lixiana*)
  - Platelet inhibitors include aspirin
  - Platelet aggregation inhibitors include clopidogrel (*Plavix*), Prasugrel (*Effient*), and Ticagrelor (*Brilinta*)




Fig. 21. Perioperative management of antiplatelet or anticoagulant drugs for interventional procedures.




Fig. 22. Perioperative management of interventional techniques in patients on direct oral anticoagulants (DOACs).

Figure 22 presents perioperative management of patients receiving direct oral anticoagulants during interventional procedures. For high-risk patients, direct oral anticoagulants are interrupted 2 days before, on the day of, and one day following the procedure, totaling 4 days, except in patients with creatinine clearance  $\leq 50$  mL/min. In such cases, dabigatran (Pradaxa) is stopped for 4 days and resumed on day two, totaling 6 days of cessation. For intermediate or moderate-risk patients, preprocedural cessation is 2 days, including the day before and the day of the procedure, with resumption the next day. Dabigatran in this category is interrupted for 2 days with resumption on the first day post-procedure, totaling 3 days. For low-risk patients, cessation is generally unnecessary, but adjustments may be made depending on individual variables, following the intermediate-risk recommendations if indicated.

Regarding warfarin (Coumadin), Douketis et al (540,541) recommend continuation for minimal bleeding risk. For low to moderate bleeding risk, warfarin is withheld for 5 days with bridging, though the guidance notes limited benefit of bridging. For interventional procedures, a 1–3 day interruption is recommended to achieve an optimal INR  $\leq 3.0$  for low-risk procedures, 2–3 days with INR  $\leq 2.0$  for intermediate-risk procedures, and 3–5 days with INR  $\leq 1.5$  for high-risk procedures. Low molecular weight heparin bridging may be considered for high-risk procedures such as SCS and intrathecal implantable device placement. Bridging may be managed by a cardiologist or, if recommended, by the interventional pain physician.

Based on these considerations, ASIPP guidance has developed an algorithmic approach for interventional procedures in patients on anticoagulant or antiplatelet therapy, as shown in Figure 20.

Table 24. ASIPP guidelines for antithrombotic medication management and interventional techniques.

MEDICATION	Time to Wait After Last Dose of Medication Before Interventional Techniques Are Performed		Timing of Therapy Restoration or Restarting
	LOW RISK PROCEDURES	MODERATE OR INTERMEDIATE RISK PROCEDURES	
	<ul style="list-style-type: none"> <li>Trigger point and intramuscular injections</li> <li>Peripheral nerve blocks</li> <li>Sacroiliac joint injections</li> <li>All facet joint interventions (intra-articular injections, medial branch and L5 dorsal ramus nerve blocks and radiofrequency neurotomy)</li> <li>Intraarticular injections of extremities</li> <li>Pocket revision and implantable pulse generator/intrathecal pump replacement</li> <li>Peripheral nerve stimulation trial and implantation of extremities and other superficial nerves</li> <li>Lumbar transforaminal epidural injections at L3, L4, L5, and S1</li> <li>Ganglion impar blocks</li> <li>Sacroiliac joint nerve radiofrequency</li> <li>Trigeminal branch nerve blocks (mandibular, maxillary, and other branches)</li> </ul>	<ul style="list-style-type: none"> <li>Caudal epidural injections</li> <li>Caudal epidural adhesiolysis</li> <li>Lumbar interlaminar epidural at L5, S1</li> <li>Cervical, thoracic, and lumbar transforaminal at L1 and L2</li> <li>Peripheral nerve stimulation trial and implantation of lumbar medial branches</li> <li>Perioperative nerve blocks (stellate ganglion, thoracic sympathetic, splanchnic, celiac plexus, lumbar sympathetic, hypogastric plexus)</li> <li>Trigeminal adhesiolysis with interlaminar or transforaminal approach (cervical, thoracic, and lumbar)</li> <li>Intervertebral spinous prosthesis including lateral fusion</li> <li>SI joint fusion</li> <li>Intracept procedure</li> </ul>	<ul style="list-style-type: none"> <li>Cervical, thoracic, and lumbar (above L5) interlaminar epidurals</li> <li>Peripheral nerve stimulation trial and implantation of thoracic and cervical medial branches</li> <li>Trigeminal ganglion, ophthalmic division, and sphenopalatine ganglion blocks</li> <li>Discography and intradiscal procedures</li> <li>Dorsal column and dorsal root ganglion stimulator trial and implantation</li> <li>Intrathecal catheter and pump implant</li> <li>Vertebral augmentation</li> <li>Perioperative and endoscopic disc decompression procedures</li> <li>Minimally invasive lumbar decompression (MILD)</li> <li>Trigeminal and cranial nerve blocks and stimulation</li> <li>Sympathetic blocks (stellate ganglion, thoracic sympathetic, splanchnic, celiac plexus, lumbar sympathetic, hypogastric plexus)</li> <li>Perioperative adhesiolysis with interlaminar or transforaminal approach (cervical, thoracic, and lumbar)</li> <li>Intervertebral spinous prosthesis including lateral fusion</li> <li>SI joint fusion</li> <li>Intracept procedure</li> </ul>

Table 24 cont. ASIPP guidelines for antithrombotic medication management and intervention techniques.

MEDICATION	Time to Wait After Last Dose of Medication Before Interventional Techniques Are Performed			Timing of Therapy Restoration or Restarting
	LOW RISK PROCEDURES	MODERATE OR INTERMEDIATE RISK PROCEDURES	HIGH-RISK PROCEDURES	
Trigger point and intramuscular injections	• Caudal epidural injections	• Cervical, thoracic, and lumbar (above L5) interlaminar epidurals	• Peripheral nerve stimulation trial and implantation of thoracic and cervical medial branches	
Peripheral nerve blocks	• Caudal epidural adhesiolysis	• Lumbar interlaminar epidural at L5, S1	• Trigeminal ganglion, ophthalmic division, and sphenopalatine ganglion blocks	
Sacroiliac joint injections	• All facet/joint interventions (intra-articular injections, medial branch and L5/dorsal ramus nerve blocks and radiofrequency neurotomy)	• Cervical, thoracic, and lumbar transforaminal at L1 and L2	• Discography and intradiscal procedures	
All facet/joint interventions (intra-articular injections, medial branch and L5/dorsal ramus nerve blocks and radiofrequency neurotomy)	• Peripheral nerve stimulation trial and implantation of lumbar medial branches	• Peripheral nerve stimulation trial and implantation	• Dorsal column and dorsal root ganglion stimulator trial and implantation	
Intraarticular injections of extremities	• Pocket revision and implantable pulse generator/intrathecal pump replacement	• Intrathecal catheter and pump implant	• Vertebral augmentation	
Peripheral nerve stimulation trial and implantation of extremities and other superficial nerves	• Peripheral nerve stimulation trial and implantation of other superficial nerves	• Percutaneous and endoscopic disc decompression procedures	• Percutaneous and endoscopic disc decompression procedures	
Lumbar transforaminal epidural injections at L3, L4, L5, and S1	• Ganglion impar blocks	• Minimally invasive lumbar decompression (MILD)	• Minimally invasive lumbar decompression (MILD)	
Ganglion impar blocks	• Sacroiliac joint nerve radiofrequency	• Trigeminal and cranial nerve blocks and stimulation	• Trigeminal and cranial nerve blocks and stimulation	
Sacroiliac joint nerve blocks (mandibular, maxillary, and other branches)	• Trigeminal branch nerve blocks (mandibular, maxillary, and other branches)	• Sympathetic blocks (stellate ganglion, thoracic sympathetic, splanchnic, celiac plexus, lumbar sympathetic, hypogastric plexus)	• Sympathetic blocks (stellate ganglion, thoracic sympathetic, splanchnic, celiac plexus, lumbar sympathetic, hypogastric plexus)	
		• Percutaneous adhesiolysis with interlaminar or transforaminal approach (cervical, thoracic, and lumbar)	• Percutaneous adhesiolysis with interlaminar or transforaminal approach (cervical, thoracic, and lumbar)	
		• Intervertebral spinous prosthesis including lateral fusion	• Intervertebral spinous prosthesis including lateral fusion	
		• SI joint fusion	• SI joint fusion	
		• Intrafacet procedure	• Intrafacet procedure	
NSAIDs (COX 1) (COX 2)	May continue or stop 1-10 days due to lack of protective effect	May continue or stop 1-10 days due to lack of protective effect	May continue or stop 1-10 days due to lack of protective effect	24 hours
THC/CBD	May continue or stop 1-10 days	May continue or stop 1-10 days	Stop for 5 days	24 hours
Galic	Continue or may stop for 3 days	Continue or may stop for 3 days	Stop for 6 days	24 hours
Vitamin E	Continue or may stop for 3 days	Continue or may stop for 3 days	Stop for 6 days	24 hours
Fish Oil	Continue or may stop for 3 days	Continue or may stop for 3 days	Stop for 6 days	24 hours
Aspirin				
Low-Dose Aspirin	Continue or may stop for 3 days	Continue or may stop for 3 days	Stop for 6 days	24 hours
High Dose Aspirin	Continue or may stop for 3 days	Continue or may stop for 3 days	Stop for 6 days	24 hours
Antiplatelet Agents (Phosphodiesterase Inhibitors)				
Dipyridamole (Persantine)	May continue	May continue	May continue or stop for 2 days	12 hours
Cilostazol (Pletal)	May continue	May continue	May continue or stop for 2 days	12 hours
Aggrenox (dipyridamole plus aspirin)	May continue	May continue	Stop for 6 days	24 hours
Platelet Aggregation Inhibitors				

Table 24 cont. ASIPP guidelines for antithrombotic medication management and interventional techniques.

MEDICATION	Time to Wait After Last Dose of Medication Before Interventional Techniques Are Performed			Timing of Therapy Restoration or Restarting
	LOW RISK PROCEDURES	MODERATE OR INTERMEDIATE RISK PROCEDURES	HIGH-RISK PROCEDURES	
Clopidogrel (Plavix)	May continue	May continue or stop for 5 days	Stop for 6 days	12 hours
Prasugrel (Effient)	May continue	May continue or stop for 5 days	Stop for 6 days	24 hours
Ticagrelor (Brilinta)	May continue	May continue or stop for 3 days	Stop for 5 days	24 hours
Vitamin K Antagonists				
Warfarin	May continue or stop for 1-2 days INR $\leq$ 3.0	May continue or stop for 2-3 days INR $\leq$ 2.0	Stop for 3-5 days INR $\leq$ 1.5	12-24 hours
Direct Oral Anticoagulants (DOACs)				
Dabigatran (Pradaxa)	May continue or stop for 1 day	Stop for 2 days	Stop for 2 days	24 hours
Dabigatran (Pradaxa) (CrCl $\leq$ 50 mL/min)	May continue or stop for 1 day	Stop for 3-4 days	Stop for 3-4 days	24 hours
Apixaban (Eliquis)	May continue or stop for 1 day	Stop for 1 day	Stop for 2 days	24 hours
Rivaroxaban (Xarelto)	May continue or stop for 1 day	Stop for 1 day	Stop for 2 days	24 hours
Edoxaban (Savaysa, Lixiana)	May continue or stop for 1 day	Stop for 1 day	Stop for 2 days	24 hours
Heparins				
Heparin (treatment) - IV	Discontinue for 4 hours	Discontinue for 4 hours	Discontinue for 4 hours	24 hours
Heparin (treatment) - SC	Discontinue for 6 hours	Discontinue for 6 hours	Discontinue for 24 hours	24 hours
Low Molecular Weight Heparin	Discontinue for 24 hours	Discontinue for 24 hours	Discontinue for 24 hours	24 hours

Adapted and modified from: Manchikanti L, Sanapati MR, Nampiaparampil D, et al. Perioperative management of antiplatelet and anticoagulant therapy in patients undergoing interventional techniques: 2024 updated guidelines from the American Society of Interventional Pain Physicians (ASIPP). *Pain Physician* 2024;27:S1-S94 (369).

## 10.5 Guidelines for Managing Anticoagulant and Antiplatelet Therapy During Interventional Techniques

ASIPP guidelines and recommendations are based on a comprehensive literature review of thromboembolic risk, bleeding risk, anatomical considerations, procedural factors, and medical or physiological status. Prior guidelines for interventional pain management, general surgery, endoscopy, and ophthalmic surgery from multiple organizations were also reviewed. Table 24 presents recommended management of antiplatelet and anticoagulant medications for interventional procedures (44), while Table 25 provides a procedural checklist for managing anticoagulant and antiplatelet therapy during interventional techniques.

Table 25. *Procedural checklist for managing anticoagulant and antiplatelet therapy during interventional techniques.*

<b>PROCEDURE:</b>
1.0 Patient evaluation and Identification of Risk Factors <ul style="list-style-type: none"> <li><input type="checkbox"/> 1.1 Age</li> <li><input type="checkbox"/> 1.2 Diabetes</li> <li><input type="checkbox"/> 1.3 Bleeding disorders</li> <li><input type="checkbox"/> 1.4 Hypertension</li> <li><input type="checkbox"/> 1.5 Obesity</li> <li><input type="checkbox"/> 1.6 Low body weight</li> <li><input type="checkbox"/> 1.7 Renal disease</li> <li><input type="checkbox"/> 1.8 Low creatinine clearance</li> </ul>
2.0 Identification of Anticoagulant or Antithrombotic Medication <ul style="list-style-type: none"> <li><input type="checkbox"/> 2.1 Aspirin Use: <ul style="list-style-type: none"> <li>• Primary Prophylaxis: Absence of established cardiovascular disease or risk factor</li> <li>• Secondary Prophylaxis: Presence of cardiovascular or cerebrovascular disease</li> </ul> </li> <li><input type="checkbox"/> 2.2 Antiplatelets <ul style="list-style-type: none"> <li>• Clopidogrel (Plavix)</li> <li>• Prasugrel (Effient)</li> <li>• Ticagrelor (Brilinta)</li> </ul> </li> <li><input type="checkbox"/> 2.3 Direct oral anticoagulants (DOACs) <ul style="list-style-type: none"> <li>• Dabigatran (Pradaxa)</li> <li>• Apixaban (Eliquis)</li> <li>• Rivaroxaban (Xarelto)</li> <li>• Edoxaban (Savaysa, Lixiana)</li> </ul> </li> <li><input type="checkbox"/> 2.4 Warfarin (Coumadin)</li> <li><input type="checkbox"/> 2.5 Identification of over-the-counter drugs influencing thrombolysis: <ul style="list-style-type: none"> <li>• Garlic</li> <li>• Vitamin E</li> </ul> </li> <li><input type="checkbox"/> 2.6 Fish Oil <ul style="list-style-type: none"> <li>• Primary Prophylaxis: Absence of established cardiovascular disease or risk factor</li> <li>• Secondary Prophylaxis: Presence of cardiovascular or cerebrovascular disease</li> </ul> </li> <li><input type="checkbox"/> 2.7 SSRIs <ul style="list-style-type: none"> <li>• Citalopram (Celexa)</li> <li>• Fluoxetine (Prozac)</li> <li>• Escitalopram (Lexapro)</li> <li>• Paroxetine (Paxil)</li> <li>• Sertraline (Zoloft)</li> </ul> </li> <li><input type="checkbox"/> 2.8 NSAIDs</li> </ul>
<input type="checkbox"/> 3.0 Risk Stratification and Recommendations <ul style="list-style-type: none"> <li>• Low risk</li> <li>• Moderate or intermediate risk</li> <li>• High risk</li> </ul>
<input type="checkbox"/> 4.0 Informed Decision Making
<input type="checkbox"/> 5.0 Restarting of Drugs
<input type="checkbox"/> 6.0 Postoperative Monitoring

## **11.0 GUIDANCE FOR SAFE AND EFFECTIVE USE OF BIOLOGICS**

The current body of evidence on the use of orthobiologics for the spine remains limited. Variations in the extent and duration of pathology, types of biologic products, procedural techniques, and outcome measures make it challenging to draw definitive recommendations from the literature. The lack of standardization in methodology and analysis hinders the ability to reproduce study models or make firm conclusions. As factors influencing healing and regeneration remain incompletely understood, clinicians continue to experiment with new combinations, further contributing to heterogeneity in composition, techniques, and outcomes (25,416,542).

In general, clinical studies indicate that orthobiologic therapies for low back pain are well-tolerated,

with few reported side effects. Evidence suggests that orthobiologic injections may offer meaningful pain relief and improved function for patients with degenerative disc disease and related spinal conditions. However, the predictability of structural repair remains inconsistent across studies.

The high cost of orthobiologic injections and lack of insurance coverage continue to be significant barriers to widespread access and adoption, limiting availability for many patients. This situation may change as more robust data on the safety and long-term effectiveness of biologics, compared with corticosteroids, become available. Large-scale randomized controlled trials are essential to determine whether orthobiologic therapies provide consistent, durable results for low back pain and to identify the conditions under which they are most effective.

## 12.0 FUTURE PERSPECTIVE

Over the past decade, the field of orthobiologics has experienced substantial growth, and its future holds significant potential for expansion in both evidence-based applications and clinical utilization (1-34,543-546). Continued progress is expected to refine treatment indications and contraindications, optimize cellular dosing, and facilitate the development of combination therapies that integrate orthobiologics with other interventional techniques. Advancements in bioengineering and tissue engineering are anticipated to enhance product lines and drive innovation throughout the field.

Clinical data generally demonstrate higher efficacy in treating vascularized structures such as bone, tendon, and ligament. One of the greatest long-term challenges, however, lies in addressing less vascularized tissues such as fibrocartilage and intervertebral discs. Future success will rely on a comprehensive understanding of the genetic, anatomical, biomechanical, environ-

mental, and lifestyle factors that influence treatment outcomes. This insight will support more deliberate and personalized application of orthobiologics, ultimately improving patient outcomes.

Collaboration among key professional societies will be essential for advancing the field. Such partnerships are expected to play a pivotal role in developing standards of care, best practice guidelines, compliance policies, and certification programs that ensure high-quality treatment at the point of care.

Biologic therapies hold significant potential to relieve pain, enhance patients' quality of life, and regenerate damaged tissues, potentially reversing age-related degeneration or spinal injuries. While challenges remain in ensuring long-term safety, efficacy, and accessibility, addressing these hurdles could enable orthobiologics to transform spine care, offering minimally invasive regenerative solutions that reduce the need for surgical interventions and provide durable patient benefit.

## **13.0 RECOMMENDATIONS AND STATEMENTS**

1. What are the available regenerative medicine therapies in the United States?

**Answer:** Available regenerative medicine therapies include PRP and BMC when obtained with FDA-cleared devices.

**Evidence Level:** High; **Consensus-Based Clinical Recommendation:** High

2. What are the potential regenerative medicine modalities available in other countries but not the United States?

**Answer:** Multiple therapies are not currently available due to FDA regulations in the United States. In other countries, multiple therapies are available, including adipose stem cells including stromal vascular fraction (SVF), autologous, allogenic, or stored stem cells, stem cells derived from umbilical cord and exosomes. There is no clear guidance on micronized fat and it is used by some in the field.

**Evidence Level:** High; **Consensus-Based Clinical Recommendation:** High

3. What are the recognized risks of unapproved stem cell treatments.

**Answer:** There are rare, but significant potential risks associated with unapproved stem cell treatments, including blindness, infections (like human immunodeficiency virus, hepatitis, or bacterial infections), thrombosis, tumor formation, neurological complications, and even death.

**Evidence Level:** Moderate; **Consensus-Based Clinical Recommendation:** High

4. Defining Functional Spine Unit.

**Answer:** A functional spinal unit (FSU), also known as spinal motion segment, or articular tide, is the smallest physiological unit of the spine that exhibits the same biomechanical properties of the entire spine. Each FSU is a 3-joint complex and is responsible for coordinated movement protecting neural structures and providing a stable base for the body. A FSU consists of 2 adjacent vertebrae, intervertebral disc, facet joints, ligaments, and muscles. The concept of FSU is crucial for understanding spine health and dysfunction related to

degeneration, injury, diagnosis and treatment.

Functional spine unit is utilized in managing back pain in regenerative medicine, in application of therapies in contrast to precision diagnosis and therapy with the single structure, as advocated in interventional pain management.

While this approach appears to be appropriate considering that regenerative medicine therapies are not bound by LCDs and medical policies, functional spine unit may provide better results; however, there is no significant evidence at the present time.

**Evidence Level:** Very Low; **Consensus-Based Clinical Recommendation:** Low

5. What are the identified risks of regenerative medicine therapies?

**Answer:** Regenerative medicine therapies are similar to interventional techniques with low risk; however, severe complications can occur including infection, specifically, discitis, epidural hematoma, and abscess, superficial infections, allergies, neurological complications, tumor formation and death. Overall risk of interventional procedures has been considered by some as higher because of the steroid-based injections with chondrotoxicity, tenotoxicity, neurotoxicity, and multiple systematic toxicities. These toxicities are absent with PRP and BMC.

**Evidence Level:** High; **Consensus-Based Clinical Recommendation:** High

6. Platelet Rich Plasma (PRP): Quality and Standards

**Answer:** Key issues concerning quality and standards for platelet-rich plasma include a lack of standardized protocols, variations in preparation techniques, and regulatory limitations.

Unlike pharmaceuticals, no universally accepted standard defines the optimal concentration of cells and growth factors. Different conditions may benefit from different formulations (leukocyte-rich versus leukocyte-poor).

Quality assurance practices include process validation, testing and monitoring, traceability, and device selection.

**Evidence Level:** Low; **Consensus-Based Clinical Recommendation:** Moderate

7. Bone Marrow Aspirate Concentrate (BMAC): Quality and Standards

**Answer:** BMAC devices are expected to produce viable cells with cell viability rates of approximately 90%. The quality of BMAC is heavily dependent on the aspiration technique. Volume and site are important.

There are no established standardized protocols. Consequently, there are variations in preparation technique limited by regulatory standards. Minimum requirements for BMAC include qualifying mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs).

Different processing devices and methods produce different results.

Quality assurance practices include process validation, testing and monitoring, traceability, and device selection

**Evidence Level: Low; Strength of Recommendation: Moderate**

8. Minimum required quality control measures:

**Answer:** The minimum required quality control measures for clinical purposes include final volume, platelet count, white blood cell (WBC) count, red blood cell (RBC) count, and the concentration factor relative to whole blood. Further, different processing devices and methods produce different results regarding final cell counts, viability, and volume.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: Moderate**

9. Minimum required platelets per injection:

**Answer:** Studies show that a minimum of 4 billion and 10 billion as optimum count of platelets per injection is needed for a significant clinical effect in knee intraarticular injections. Even though limited, literature is available regarding spinal injections, based on other joints, a cumulative dose of around 10 billion platelets into structures of a FSU are recommended. There is literature showing intradiscal injections of PRP with greater than 10 times baseline platelet concentrations resulted in greater improvements in pain scores and functional outcomes at long-term follow-up compared to lower concentration PRP less than five times.

**Evidence Level: Low; Consensus-Based Clinical Recommendation: Moderate**

10. It is essential to understand PRP and BMAC with multiple variations and the effectiveness, technical considerations, and complications with the spinal injections.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

11. Based on the available evidence and all available guidance, patient education is a crucial aspect of the success of regenerative medicine injections.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

12. What is the evidence of effectiveness for PRP and consensus-based clinical recommendations for intradiscal therapy.

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate**

13. The evidence of effectiveness for BMAC and consensus-based clinical recommendations for intradiscal therapy.

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate.**

14. The evidence of effectiveness and consensus-based clinical recommendations for epidural injections with PRP in managing low back and lower extremity pain due to degenerative disc pathology and other conditions.

**Evidence Level: III, Fair; Consensus-Based Clinical Recommendation: Moderate**

15. The evidence of effectiveness and consensus-based clinical recommendations for facet joint intraarticular PRP and MSC injections in managing chronic low back pain.

**Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Moderate**

16. The evidence of effectiveness and consensus-based

clinical recommendations for sacroiliac joint PRP injections.

**Evidence Level: IV, Limited; Consensus-Based Clinical Recommendation: Low**

17. The guidelines for administration of biologics include failure of conservative modalities, understanding of the risks and benefits, willingness to participate in rehabilitation program and appropriate consent with shared decision making.

**Evidence Level: High; Consensus-Based Clinical Recommendation: High**

18. Risk stratification for regenerative medicine

therapies, based on ASIPP guidelines: high risk for intradiscal therapy, moderate risk for epidural injections, low risk for facet joint injections, and low risk for sacroiliac joint injections.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: Moderate**

19. Antiplatelet and anticoagulant therapy guidelines in continuation, discontinuation, and re-establishment are utilized per ASIPP guidelines for low- and high-risk procedures.

**Evidence Level: Moderate; Consensus-Based Clinical Recommendation: Moderate**

## 14.0 CONCLUSION

Both PRP and MSCs are used autologously to support and enhance the healing process. Their natural properties, including functional strengths and limitations, continue to be investigated. The guidelines presented have reviewed studies that both support and challenge the current clinical applications of these biologics. PRP is a concentration of inflammatory mediators and growth factors that complement tissue repair in injured areas. Biologics are increasingly viewed as a cost-effective and accelerated approach to healing and are becoming a reasonable alternative for patients who have not responded to standard-of-care treatments. Based on current literature, treatments targeting lumbar intervertebral discs, facets, and sacroiliac joints are typically performed only after a definitive diagnosis and following failure of conservative therapy. Published studies report outcomes of single-injection biologics for chronic pathology, demonstrating primarily short-term relief, with PRP being the most commonly used biologic in the lumbar spine.

Recent advancements, particularly in regenerative injection techniques, have shifted the focus toward a comprehensive treatment model addressing the entire

FSU, offering a disease-modifying approach. The FSU, the smallest functional unit of the spine, consists of 2 vertebrae, an intervertebral disc, facet joints, and supporting ligaments. It plays a critical role in maintaining spinal stability, mobility, load distribution, and neural protection. The FSU absorbs shock, distributes mechanical loads, and protects the spinal cord and nerve roots. This publication aims to explore the concept of the FSU and evaluate the potential role of orthobiologics, such as PRP and MSCs, in managing back pain associated with various spinal conditions.

Emerging literature demonstrates the use of multiple-structure injections, which reflects an increasingly common clinical practice.

The continued clinical success of biologics will depend on standardizing their use, achieving consistent outcomes, and demonstrating overall reductions in healthcare costs. This can be accomplished through the publication of high-quality studies, which will enhance the predictability of biologic therapy. Advancing the science and application of regenerative medicine will require dedicated efforts from all stakeholders to further develop and optimize biologic therapies for the benefit of patients.

## Acknowledgments

The authors wish to thank Tonie M. Hatton and Diane E. Neihoff, transcriptionists, for their assistance in preparation of this article. We would like to thank the editorial board of Pain Physician for review and criticism in improving the article.

## Disclosures

**Funding:** There was no external funding in the preparation of the guidelines. Internal funding provided by the American Society of Interventional Pain Physicians (ASIPP) was limited to preparation of the publication.

## Authors Affiliations

Laxmaiah Manchikanti, MD

Dr. Manchikanti is Director, Pain Management Centers of America, Paducah, KY, Clinical Professor, Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY, and Professor of Anesthesiology-Research, Department of Anesthesiology, School of Medicine, LSU Health Sciences Center, Shreveport, LA, USA  
drlm@thepainmd.com

Riya Navani

Ms. Navani is a Undergraduate Student, Biology, Department: Neurosciences, Stanford University, Stanford, CA, USA  
rnnavani@stanford.edu

Annu Navani, MD

Dr. Navani is Founder and Chief Medical Officer, Le Reve Regenerative Wellness, San Jose, CA and Chief Medical Officer, Boomerang Healthcare, Walnut Creek, CA, USA  
annu@navani.net

Mahendra Sanapati, MD

Dr. Sanapati is Assistant Professor (Gratis) of Anesthesiology and Research, Department of Anesthesiology and Perioperative Medicine, University of Louisville School of Medicine, Louisville, KY, and Voluntary Faculty, Indiana University School of Medicine, Evansville, IN, USA  
msanapati@gmail.com

Alan D. Kaye, MD, PhD

Dr. Kaye is Professor, Interventional Pain Fellowship Director, Vice Chair of Research, Department of Anesthesiology; Professor, Department of Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA; Professor, Department of Anesthesiology, Tulane School of Medicine, and Professor, Department of Anesthesiology and Pharmacology, LSU School of Medicine, New Orleans, LA, USA  
alan.kaye@lsuhs.edu

ment of Anesthesiology, Tulane School of Medicine, and Professor, Department of Anesthesiology and Pharmacology, LSU School of Medicine, New Orleans, LA, USA  
alan.kaye@lsuhs.edu

Adam M. Kaye, PharmD

Dr. A.M. Kaye is Clinical Professor of Pharmacy, Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, USA  
akaye@pacific.edu

Amol Soin, MD

Dr. Soin is Medical Director, Ohio Pain Clinic, and Clinical Assistant Professor of Surgery at Wright State University, Dayton, OH, USA  
drsoin@gmail.com

Devi Nampiaparampil, MD

Dr. Nampiaparampil is Medical Director, Metropolis Pain Medicine PLLC, and Clinical Associate Professor, Department of Rehabilitation Medicine, NYU Grossman School of Medicine, New York, NY, USA  
devichechi@gmail.com

Kenneth D. Candido, MD

Dr. Candido is Chief, Division of Pain Medicine, Thorek Memorial Hospital, Clinical Professor of Surgery and Anesthesia, University of Illinois College of Medicine-Chicago, Chicago, IL, and Professor of Surgery, Ponce School of Medicine, Ponce, PR, USA  
kdcandido1@gmail.com; kdcandido2@gmail.com

Alaa Abd-Elsayed, MD

Dr. Abd-Elsayed is Medical Director, UW Health Pain Services, and Professor of Anesthesiology, at the University of Wisconsin, Madison, WI, USA  
alaawny@hotmail.com; abdelsayed@wisc.edu

Theodore T. Sand, PhD

Dr. Sand is Senior Consultant at Sand Consulting, Poway, CA, USA  
docsand@hotmail.com

Navneet Boddu, MD

Dr. Boddu is Medical Director, Advanced Pain & Regenerative Specialists, Oceanside CA, USA  
sr4md@yahoo.com

Sairam Atluri, MD

Dr. Atluri is Medical Director, Tri-State Spine Care Institute, Cincinnati, OH, USA, and Director, Department of Pain and Regenerative Medicine, Arete Hospitals, Hyderabad, TN India  
saiatluri@gmail.com

Anss Annie Augustine, BDS

Ms. Augustine, Metropolis Pain Medicine PLLC,  
New York, NY, USA  
Annsannie.p7@gmail.com

Dajie Wang, MD

Dr. Wang is Director, Jefferson Pain Center, Dept. of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia PA, USA  
dajie.wang@jefferson.edu

John Santa Ana, DO

Dr. Santa Ana is regenerative medicine specialist, Michigan Center for Regenerative Medicine, Rochester, MI  
dr.santaana@mcfm.com

Lady Christine Ong Sio, MD

Dr. Ong Sio is Clinical Faculty Gratis, Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY, USA  
ladychristine.ongsio@uoflhealth.org

Vidyasagar Pampati, MSc

Vidyasagar Pampati is a Statistician, Pain Management Centers of America, Paducah, KY, USA  
sagar@thepainmd.com

Micheal Khadavi, MD

Dr. Khadavi, Sports Medicine Physician, Kansas City Orthopedic Alliance, Overland Park, KS and Physical Medicine & Rehabilitation Department, University of Missouri, Columbia, MO, USA  
mjkhadavi@gmail.com

Nebojsa Nick Knezevic, MD, PhD

Dr. Knezevic is Vice Chair for Research, Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, and Clinical Professor, Department of Anesthesiology and Department of Surgery, College of Medicine, University of Illinois, Chicago, IL, USA  
nick.knezevic@gmail.com

Robert Farhat, DO

Dr. Farhat is a Regenerative Medicine Specialist, Michigan Center for Regenerative Medicine, Rochester Hills, MI, USA  
dr.farhat@mcfm.com

Shivam S. Shah, BS, MD

Dr. Shah, School of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA  
sss002@lsuhs.edu

Shounuck J. Patel, DO

Dr. Patel is the owner/physician, The Patel Center for Functional Regeneration, Newport Beach, CA, and Clinical Professor, Western University College of Osteopathic Medicine of the Pacific, Pomona,

CA, and Clinical Professor, Touro University College of Osteopathic Medicine, Vallejo, CA, USA  
business@dr-patel.com

Tom Nabity, MD

Dr. Nabity is Associate Professor, Oakland University William Beaumont School of Medicine, Rochester, MI, USA  
dr.nabity@mcfm.com

Alexander Bautista, MD

Dr. Bautista is Professor of Anesthesiology, Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY, USA  
alexander.bautista@louisville.edu

Aaron K. Calodney, MD

Dr. Calodney is Director of Clinical Research, Precision Spine Care, and Clinical Associate Professor, Department of Anesthesiology & Perioperative Medicine, University of Texas, School of Medicine, Tyler, TX, USA  
aaroncalodney@icloud.com

Joseph Cabaret, MD

Dr. Cabaret is founder & CEO, Genesis Pain Specialists, Camarillo, CA, USA  
jcab@mac.com  
joecabaret@gmail.com; jcab@mac.com

Miles R. Day, MD

Dr. Day is Director, Grace Health System - Pain Management Center and Pain Medicine Fellowship Program Director and Tenured Professor, Department of Anesthesiology, Texas Tech University HSC, Lubbock, TX USA  
miles.day@ttuhsc.edu

Paul J. Christo, MD

Dr. Christo is Chief, Division of Pain Medicine, Associate Professor, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA  
pchristo@jhmi.edu

Sanjay Bakshi, MD

Dr. Bakshi is CEO, PRC Associates, Daytona Beach, FL, USA  
drbakshi58@gmail.com

Shalini Shah, MD

Dr. Shah is Vice-Chair & Professor, Department of Anesthesiology & Perioperative Care, University of California Irvine Health, Orange, CA, USA  
shahshalini@gmail.com

Sheldon Jordan, MD

Dr. Jordan is CEO at The Regenesis Project and Neurological Associates, the Interventional Group,

Santa Monica, CA, USA  
kennedy@theneuroassociates.com; sjordan@theneuroassociates.com

Sheri L. Albers, DO  
Dr. Albers, VA Healthcare System, University of Kentucky, Lexington, KY, USA  
Sla2oz@aol.com

Vivek Manocha, MD  
Dr. Manocha is Clinical Assistant Professor, Department of Surgery, Wright State University School of Medicine, Dayton, OH, and Interventional Pain Physician, Beacon Orthopedics & Sports Medicine, Cincinnati, OH, USA  
vmanocha@beaconortho.com

Joshua A. Hirsch, MD  
Dr. Hirsch is the Director of Interventional Neuroradiology, Chief Interventional Spine at the Massachusetts General Hospital and Professor at Harvard Medical School, Boston, MA, USA  
jahirsch@mgh.harvard.edu

**Conflict of Interest**  
Dr. Soin has several patents in non-opioid pain pharmaceuticals and neuromodulation (SCS and PNS) and artificial intelligence, has stock options with Neuros Medical, has received equipment, materials, drugs, medical writing, gifts or other services from Avanos for research, and has other financial or nonfinancial interests with Alyea Therapeutics, Neuros Medical, Neuronoff, and Avanos.

Dr. Abd-Elsayed is a consultant for Medtronic, Curonix, Avanos, and Averitas.

Dr. Boddu is a Member of Scientific Advisory Board Apex Biologix and SAB TSOI, Bio Cuetics.

Dr. Khadavi is a paid consultant for medical education and product development for Arthrex, receives support for attending meetings, and is President and board member of TOBI.

Dr. Shah receives a "Train New Trainers Education Grant" State of California, made to institution, is a consultant for SPR Therapeutics & Vertex Pharma and is President, Orange County Medical Association.

Dr. Shounuck Patel receives payment or honoraria from Interventional Orthobiologics Foundation and Expert Education Institute and support for attending meetings.

Dr. Nabity is a share and stockholder with Greyledge BioTech, share and stockholder and CMO of Forever Labs, and receives payment or honoraria for IOF, Injection Trainer.

Dr. Calodney receives consulting fees from Medtronic, Nevro, Stryker, Saluda and PainTEQ.

Dr. Jordan has patents pending and issued for exosome delivery to brain.

Dr. Hirsch receives grants or contracts from the Neiman Health Policy Institute, is a Medtronic, Relevant, and Sanofi consultant, and is the Chair of CSMB of neurovascular studies for Balt: Rapid Medical.

## REFERENCES

1. Manchikanti L, Navani A, Sanapati M. Evolution of regenerative medicine in managing musculoskeletal and spinal disorders. In: Manchikanti L, Navani A, Atluri S, Sanapati M (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*, 2nd ed. Springer Nature Switzerland, 2024, pp 3-34.
2. Navani A, Manchikanti L, Albers SL, et al. Responsible, safe, and effective use of biologics in the management of low back pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. *Pain Physician* 2019; 22:S1-S74.
3. Manchikanti L, Centeno CJ, Atluri S, et al. Bone marrow concentrate (BMC) therapy in musculoskeletal disorders: Evidence-based policy position statement of American Society of Interventional Pain Physicians (ASIPP). *Pain Physician* 2020; 23:E85-E131.
4. Lattermann C, Leite CBG, Frisbie DD, et al. Orthobiologics in orthopedic applications: A report from the TMI Havemeyer meeting on orthobiologics. *J Cart Joint Preser* 2022; 2:100055.
5. Navani A, Jeyaraman M, Jeyaraman N, et al. Precision medicine in orthobiologics: A paradigm shift in regenerative therapies. *Bioengineering (Basel)* 2025; 12:908.
6. Navani A, Ambach MA, Wei JJ, Gupta D. Biologic therapies for intervertebral degenerative disc disease: A review of novel applications. *J Stem Cells Res, Rev & Rep* 2017; 4:1023.
7. Atluri S, Murphy MB, Dragella R, et al. Evaluation of the effectiveness of autologous bone marrow mesenchymal stem cells in the treatment of chronic low back pain due to severe lumbar spinal degeneration: A 12-month, open-label, prospective controlled trial. *Pain Physician* 2022; 25:193-207.
8. de Oliveira CAA, Oliveira BS, Theodoro R, et al. Orthobiologic management options for degenerative disc disease. *Bioengineering (Basel)* 2024; 11:591.
9. Lana JF, Purita J, Jeyaraman M, et al. Innovative approaches in knee osteoarthritis treatment: A comprehensive review of bone marrow-derived products. *Biomedicines* 2024; 12:2812.
10. Machado ES, Soares FP, Vianna de Abreu E, et al. Systematic review of platelet-rich plasma for low back pain. *Biomedicines* 2023; 11:2404.
11. Navani A, Ambach M, Calodney A, et al. The safety and effectiveness of orthobiologic injections for discogenic chronic low back pain: A multicenter prospective, crossover, randomized controlled trial with 12 months follow-up. *Pain Physician* 2024; 27:E65-E77.
12. Marks PW, Witten CM, Calif RM. Clarifying stem-cell therapy's benefits and risks. *N Engl J Med* 2017; 376:1007-1009.
13. Marks P, Gottlieb S. Balancing safety and innovation for cell-based regenerative medicine. *N Engl J Med* 2018; 378:954-959.
14. Trounson A. Potential pitfall of pluripotent stem cells. *N Engl J Med* 2017; 377:490-491.
15. Akkas F, Turner L, Richardson E. Adverse events related to unapproved stem cell products and other regenerative interventions: Recommendations for more robust regulation of the direct-to-consumer marketplace. *Regen Med* 2022; 17:63-68.
16. Vitro Biopharma. Stem cell therapy: The good, the bad, & the ugly. September 29, 2020. Accessed 7/23/2025. [www.vitrobiopharma.com/blogs/white-papers/stem-cell-therapy-the-good-the-bad-the-ugly](http://www.vitrobiopharma.com/blogs/white-papers/stem-cell-therapy-the-good-the-bad-the-ugly)
17. Sanapati J, Manchikanti L, Atluri S, et al. Do regenerative medicine therapies provide long-term relief in chronic low back pain: A systematic review and metaanalysis. *Pain Physician* 2018; 21:515-540.
18. Manchikanti L, Knezevic E, Knezevic NN, et al. Effectiveness of intradiscal regenerative medicine therapies for long-term relief of chronic low back pain: A systematic review and meta-analysis. *Pain Physician* 2024; 27:E995-E1032.
19. Manchikanti L, Abd-Elsayed A, Kaye AD, et al. A systematic review of regenerative medicine therapies for axial spine pain of facet joint origin. *Curr Pain Headache Rep* 2025; 29:61.
20. Manchikanti L, Abd-Elsayed A, Jin MY, et al. A systematic review and meta-analysis of randomized controlled trials of epidural regenerative medicine therapies in managing spinal pain. *Curr Pain Headache Rep* 2025; in press.
21. Manchikanti L, Kaye AD, Abd-Elsayed A, et al. A systematic review of sacroiliac joint injections of platelet-rich plasma (PRP) and stem cells. *Curr Pain Headache Rep* 2025; 29:63.
22. Capparelli C, Gallicchio VS. Regenerative medicine in spine care: Clinical potential of mesenchymal stem cells for chronic low back pain. *J Stem Cell Res* 2025; 6:72.
23. Poliwoda S, Noor N, Downs E, et al. Stem cells: A comprehensive review of origins and emerging clinical roles in medical practice. *Orthop Rev (Pavia)* 2022; 14:37498.
24. Stokes DJ, Felan NA, McQuivey KS, McGinley BM, Frank RM. Biologics approaches – when, why, and how? *Operative Tech Sports Med* 2024; 32:151082.
25. Chakravarthy K, Chen Y, He C, et al. Stem cell therapy for chronic pain management: Review of uses, advances, and adverse effects. *Pain Physician* 2017; 20:293-305.
26. Corbett MS, Webster A, Hawkins R, et al. Innovative regenerative medicines in the EU: A better future in evidence? *BMC Med* 2017; 15:49.
27. Charo A, Sipp D. Rejuvenating regenerative medicine regulation. *N Engl J Med* 2018; 378:504-505.
28. Navani A, Vardhan S, Aggarwal A, Navani R, Lana JF, Diwan SA. Functional spinal unit approach for orthobiologic injections for low back pain. *Pain Physician* 2025; 28:S145-S156.
29. Daley GQ. Polar extremes in the clinical use of stem cells. *N Engl J Med* 2017; 376:1075-1077.
30. U.S. Food and Drug Administration. FDA News Release. FDA acts to remove unproven, potentially harmful treatment used in 'stem cell' centers targeting vulnerable patients. *Vaccinia Virus Vaccine (Live)* seized after being used inappropriately in vulnerable cancer patients. PR Newswire, August 28, 2017. Accessed 7/15/2025. [www.prnewswire.com/news-releases/fda-acts-to-remove-unproven-potentially-harmful-treatment-used-in-stem-cell-centers-targeting-vulnerable-patients-300510096.html](http://www.prnewswire.com/news-releases/fda-acts-to-remove-unproven-potentially-harmful-treatment-used-in-stem-cell-centers-targeting-vulnerable-patients-300510096.html)
31. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. June 3, 2021. Accessed 7/23/2025. [www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies](http://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies)
32. Federal Trade Commission. Stem Cell Institute co-founders and companies banned from marketing stem cell treatments and ordered to pay more

than \$5.1 million for refunds and civil penalties. January 8, 2025. Accessed 7/23/2025.  
[www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51](http://www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51)

33. Ibarra A. Some California stem cell clinics use unproven therapies. A new court ruling cracks down. Cal Matters, October 4, 2024. Accessed 7/23/2025.  
<https://calmatters.org/health/2024/10/stem-cell-therapy-fda/>

34. Lee B, Brookes N, Levin AS. Litigation of unlicensed US stem cell products. *Cell Stem Cell* 2025; 32:684-688.

35. Regulatory considerations for human cell, tissues, and cellular and tissue-based products: Minimal manipulation and homologous use. Guidance for industry and food and drug administration staff. July 2020. Accessed 5/15/2025.  
[www.fda.gov/ownloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf](http://www.fda.gov/ownloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf)

36. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. Same surgical procedure exception under 21 CFR 1271.15(b): Questions and answers regarding the scope of the exception. Guidance for industry. November 17, 2017. Accessed 5/15/2025.  
[www.fda.gov/media/89920/download](http://www.fda.gov/media/89920/download)

37. Federation of State Medical Boards. Regenerative and stem cell therapy practices. Report and Recommendations of the Workgroup to Study Regenerative and Stem Cell Therapy Practices. April 2018. Accessed 7/23/2025.  
[www.fsmb.org/siteassets/advocacy/policies/fsmb-stem-cell-workgroup-report.pdf](http://www.fsmb.org/siteassets/advocacy/policies/fsmb-stem-cell-workgroup-report.pdf)

38. Janapala RN, Knezevic E, Knezevic NN, et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation of the sacroiliac joint. *Curr Pain Headache Rep* 2024; 28:335-372.

39. Manchikanti L, Knezevic NN, Navani A, et al. Epidural interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) comprehensive evidence-based guidelines. *Pain Physician* 2021; 24:S27-S208.

40. Manchikanti L, Sanapati MR, Soin A, et al. Comprehensive evidence-based guidelines for implantable peripheral nerve stimulation (PNS) in the management of chronic pain: From the American Society of Interventional Pain Physicians (ASIPP). *Pain Physician* 2024; 27:S115-S191.

41. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive evidence-based guidelines for facet joint interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. *Pain Physician* 2020; 23:S1-S127.

42. Manchikanti L, Kaye AM, Knezevic NN, et al. Comprehensive, evidence-based, consensus guidelines for prescription of opioids for chronic non-cancer pain from the American Society of Interventional Pain Physicians (ASIPP). *Pain Physician* 2023; 26:S7-S126.

43. American Academy of Orthopedic Surgeons. Platelet-rich plasma (PRP) for knee osteoarthritis technology overview. Accessed 7/22/2025.  
[www.aaos.org/globalassets/quality-and-practice-resources/biologics/technology-overview\\_prp-for-knee-oa.pdf](http://www.aaos.org/globalassets/quality-and-practice-resources/biologics/technology-overview_prp-for-knee-oa.pdf)

44. Manchikanti L, Sanapati MR, Nampiappampil D, et al. Perioperative management of antiplatelet and anticoagulant therapy in patients undergoing interventional techniques: 2024 updated guidelines from the American Society of Interventional Pain Physicians (ASIPP). *Pain Physician* 2024; 27:S1-S94.

45. Manchikanti L, Kaye AD, Nampiappampil DE, Sanapati MR, Abd-Elsayed A, Hirsch JA. Perioperative management of patients receiving interventional techniques and antiplatelet and anticoagulant therapy: A balancing act. *Curr Pain Headache Rep* 2025; 29:107.

46. The National Uniform Claims Committee. Specialty Designation for Interventional Pain Management-09. Accessed 05/23/2024.  
[www.cms.hhs.gov/transmittals/Downloads/r1779b3.pdf](http://www.cms.hhs.gov/transmittals/Downloads/r1779b3.pdf)

47. Medicare Payment Advisory Commission. Report to the Congress: Paying for interventional pain services in ambulatory settings. Washington, DC: MedPAC. December 2001. Accessed 5/23/2024.  
<https://permanent.fdlp.gov/lps21261/dec2001PainManagement.pdf>

48. Manchikanti L, Sanapati MR, Pampati V, et al. A 24% decline in the utilization of epidural procedure visits for chronic spinal pain management in the Medicare population from 2019 to 2022: Updated analysis of the effect of multiple factors. *Pain Physician* 2024; 27:E983-E994.

49. Manchikanti L, Abd-Elsayed A, Kaye AD, et al. Escalating growth to rapid decline of utilization patterns of facet joint interventions in managing spinal pain in the Medicare population: Updated analysis of the effect of multiple factors from 2000 to 2022. *Pain Physician* 2024; 27:E979-E982.

50. Manchikanti L, Pampati V, Sanapati MR, et al. Exponential decline of 28.9% in utilization of interventional pain management techniques among Medicare beneficiaries from 2019 to 2022: Updated analysis on the ongoing effects of COVID-19, economic decline, the Affordable Care Act (ACA), and medical policies. *Pain Physician* 2024; 27:455-467.

51. Manchikanti L, Pampati V, Knezevic NN, et al. The influence of COVID-19 on utilization of epidural procedures in managing chronic spinal pain in the Medicare population. *Spine (Phila Pa 1976)* 2023; 48:950-961.

52. Manchikanti L, Kaye AD, Latchaw RE, et al. Impact of COVID-19 pandemic on utilization patterns of facet joint interventions in managing spinal pain in Medicare population. *Pain Ther* 2023; 12:505-527.

53. Manchikanti L, Pampati V, Vangala BP, et al. Spinal cord stimulation trends of utilization and expenditures in fee-for-service (FFS) Medicare population from 2009 to 2018. *Pain Physician* 2021; 24:293-308.

54. Manchikanti L, Pampati V, Kaye AD, et al. An updated review of utilization patterns of sacroiliac joint interventions in the fee-for-service (FFS) Medicare population from 2000-2022. *Curr Pain Headache Rep* 2025; in press.

55. American Board of Interventional Pain Physicians. Accessed 7/23/2025.  
<https://abipp.org/>

56. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques of chronic spinal pain: Part II: Guidance and recommendations. *Pain Physician* 2013; 16:S49-S283.

57. Manchikanti L, Singh V, Pampati V, et al. Evaluation of the relative contributions of various structures in chronic low back pain. *Pain Physician* 2001; 4:308-316.

58. Schwarzer AC, April CN, Derby R, Fortin J, Kine G, Bogduk N. The prevalence and clinical features of internal disc disruption in patients with chronic low

back pain. *Spine (Phila Pa 1976)* 1995; 20:1878-1883.

59. Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. The relative contributions of the disc and zygapophyseal joint in chronic low back pain. *Spine (Phila Pa 1976)* 1994; 19:801-806.

60. Manchikanti L, Soin A, Benyamin RM, et al. An update of the systematic appraisal of the accuracy and utility of discography in chronic spinal pain. *Pain Physician* 2018; 21:91-110.

61. Bogduk N, Aprill C, Derby R. Lumbar discogenic pain: State-of-the-art review. *Pain Med* 2013; 14:813-836.

62. Hancock MJ, Maher CG, Latimer J, et al. Systematic review of tests to identify the disc, SIJ or facet joint as the source of low back pain. *Eur Spine J* 2007; 16:1539-1550.

63. Savettieri G, Salemi G, Rocca WA, et al. Prevalence of lumbosacral radiculopathy in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. *Acta Neurol Scand* 1996; 93:464-469.

64. Kirkaldy-Willis WH, Wedge JH, Yong-Hing K, Tchang S, de Korompay V, Shannon R. Lumbar spinal nerve lateral entrapment. *Clin Orthop Relat Res* 1982; 169:171-178.

65. Kirkaldy-Willis WH, Farfan HF. Instability of the lumbar spine. *Clin Orthop Relat Res* 1982; 165:110-123.

66. Miele VJ, Panjabi MM, Benzel EC. Anatomy and biomechanics of the spinal column and cord. *Handb Clin Neurol* 2012; 109:31-43.

67. Physiopedia. Functional Spinal Unit. Accessed 09/04/2025.  
www.physio-pedia.com/Functional\_Spinal\_Unit

68. Iorio JA, Jakoi AM, Singla A. Biomechanics of degenerative spinal disorders. *Asian Spine J* 2016; 10:377-384.

69. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. *BMJ* 2001; 323:334-336.

70. Jue JJ, Cunningham S, Lohr K, et al. Developing and testing the agency for healthcare research and quality's National Guideline Clearinghouse Extent of Adherence to Trustworthy Standards (NEATS) instrument. *Ann Intern Med* 2019; 170:480-487.

71. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E (eds); Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Institute of Medicine. Clinical Practice Guidelines We Can Trust. The National Academies Press, Washington, DC, 2011.

72. Harris RP, Helfand M, Woolf SH, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force. *Am J Prevent Med* 2001; 20:21-35.

73. Manchikanti L, Falco FJE, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. *Pain Physician* 2014; 17:E319-E325.

74. Manchikanti L, Atluri S, Boswell MV, et al. Methodology for evidence synthesis and development of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. *Pain Physician* 2021; 24:S1-S26.

75. Cuello-Garcia CA, Santesso N, Morgan RL, et al. GRADE guidance 24 optimizing the integration of randomized and nonrandomized studies of interventions in evidence syntheses and health guidelines. *J Clin Epidemiol* 2022; 142:200-208.

76. BMJ Best Practice. Evidence-based medicine (EBM) toolkit. Learn EBM. What is GRADE? Accessed 08/20/2024.  
<https://bestpractice.bmjjournals.com/info/us/toolkit/learn-ebm/what-is-grade/>

77. Furlan AD, Malmivaara A, Chou R, et al. 2015 Updated method guideline for systematic reviews in the Cochrane Back and Neck Group. *Spine (Phila Pa 1976)* 2015; 40:1660-1673.

78. Manchikanti L, Hirsch JA, Cohen SP, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. *Pain Physician* 2014; 17:E263-E290.

79. Higgins JPT, Morgan RL, Rooney AA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). *Environ Int* 2024; 186:108602.

80. Manchikanti L, Hirsch JA, Heavner JE, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques. *Pain Physician* 2014; 17:E291-E317.

81. Centeno CJ, Jerome MA, Pastoriza SM, et al. Use of bone marrow concentrate to treat pain and musculoskeletal disorders: An academic Delphi investigation. *Pain Physician* 2021; 24:263-273.

82. King C, Arnold R, Dao E, et al. Consensus-based approach to managing opioids, including opioid misuse and opioid use disorder, in patients with serious illness: Protocol for a modified Delphi process. *BMJ Open* 2021; 11:e045402.

83. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396:1204-1222.

84. Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996-2016. *JAMA* 2020; 323:863-884.

85. Lucas JW, Sohi I. Chronic pain and high-impact chronic pain in U.S. adults, 2023. NCHS Data Brief, no. 518. Hyattsville, MD: National Center for Health Statistics. November 2024. Accessed 12/4/2024.  
[www.cdc.gov/nchs/data/databriefs/db518.pdf](http://www.cdc.gov/nchs/data/databriefs/db518.pdf)

86. Keehan SP, Madison AJ, Poisal JA, et al. National health expenditure projections, 2024-33: Despite insurance coverage declines, health to grow as share of GDP. *Health Aff (Millwood)* 2025; 44:776-787.

87. Manchikanti L, Sanapati R, Pampati V, et al. Physician payment reform in interventional pain management: Balancing cost, quality, access, and survival of independent practices. *Pain Physician* 2025; 28:377-396.

88. Manchikanti L, Hubbell III PJ, Pasupuleti R, Conn A, Sanapati M. Non-partisan proposal for reforming physician payment system and preserving telehealth services. *Pain Physician* 2025; 28:E329-E335.

89. Manchikanti L, Sanapati R, Hubbell III PJ, et al. Escalating growth of spending on Medicare Advantage (MA) plans: Save Medicare from insolvency and balance the budget. *Pain Physician* 2025; 28:359-376.

90. Leboeuf-Yde C, Nielsen J, Kyvik KO, Fejer R, Hartvigsen J. Pain in the lumbar, thoracic or cervical regions: Do age or gender matter? A population-based study of 34,902 Danish twins 20-71 years of age. *BMC Musculoskelet Disord* 2009; 10:39.

91. Guez M, Hildingsson C, Nasic S, Toolanen G. Chronic low back pain in individuals with chronic neck pain of traumatic and non-traumatic origin: A population-based study. *Acta Orthop* 2006; 77:132-137.

92. Ge L, Pereira MJ, Yap CW, Heng BH. Chronic low back pain and its impact

on physical function, mental health, and health-related quality of life: A cross sectional study in Singapore. *Sci Rep* 2022; 12:20040.

93. Lier R, Nilsen TI, Vasseljen O, Mork PJ. Neck/upper back and low back pain in parents and their adult offspring: Family linkage data from the Norwegian HUNT Study. *Eur J Pain* 2015; 19:762-771.

94. Ferreira ML, de Luca K, Haile LM, et al; GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. *Lancet Rheumatol* 2023; 5:e316-e329.

95. Yum JL, De Luigi AJ, Umphrey GL, Ganter BK, Yoo M. Platelet-rich plasma treatment for the lumbar spine: A review and discussion of existing gaps. *Pain Physician* 2024; 27:283-302.

96. Manchikanti L, Helm S 2nd, Benyamin RM, Hirsch JA. A critical analysis of Obamacare: Affordable care or insurance for many and coverage for few? *Pain Physician* 2017; 20:111-138.

97. Manchikanti L, Hirsch JA. Repeal and replace of affordable care: A complex, but not an impossible task. *Pain Physician* 2016; 19:E1109-E1113.

98. Manchikanti L, Knezevic E, Latchaw RE, et al. Comparative systematic review and meta-analysis of Cochrane review of epidural injections for lumbar radiculopathy or sciatica. *Pain Physician* 2022; 25:E889-E916.

99. Manchikanti L, Knezevic E, Knezevic NN, et al. Effectiveness of facet joint nerve blocks in managing chronic axial spinal pain of facet joint origin: A systematic review and meta-analysis. *Pain Physician* 2024; 27:E169-E206.

100. Manchikanti L, Knezevic NN, Knezevic E, et al. A systematic review and meta-analysis of the effectiveness of radiofrequency neurotomy in managing chronic neck pain. *Pain Ther* 2023; 12:19-66.

101. Manchikanti L, Knezevic E, Knezevic NN, et al. The effectiveness of medial branch blocks and radiofrequency neurotomy in managing chronic thoracic pain: A systematic review and meta-analysis. *Pain Physician* 2023; 26:413-435.

102. Janapala RN, Knezevic E, Knezevic NN, et al. Systematic review and metaanalysis of effectiveness of therapeutic sacroiliac joint injections. *Pain Physician* 2023; 26:E413-E435.

103. Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion in the United States: Analysis of trends from 1998 to 2008. *Spine (Phila Pa 1976)* 2012; 37:67-76.

104. Bae HW, Rajaee SS, Kanim LE. Nationwide trends in the surgical management of lumbar spinal stenosis. *Spine (Phila Pa 1976)* 2013; 38:916-926.

105. Kim CH, Chung CK, Park CS, Choi B, Kim MJ, Park BJ. Reoperation rate after surgery for lumbar herniated intervertebral disc disease: Nationwide cohort study. *Spine (Phila Pa 1976)* 2013; 38:581-590.

106. Chou R, Hashimoto R, Friedly JL, et al. Pain Management Injection Therapies for Low Back Pain. Technology Assessment Report ESIBo813. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. HHSA 290-2012-00014-I.) Rockville, MD: Agency for Healthcare Research and Quality; Original Publication: March 20, 2015; Revised Publication: July 10, 2015. Accessed 08/13/2024. [www.cms.gov/medicare/coverage/determinationprocess/downloads/id98ta.pdf](http://www.cms.gov/medicare/coverage/determinationprocess/downloads/id98ta.pdf)

107. Wang Z, Perez-Terzic CM, Smith J, et al. Efficacy of intervertebral disc regeneration with stem cells—A systematic review and meta-analysis of animal controlled trials. *Gene* 2015; 564:1-8.

108. Khan S, Mafi P, Mafi R, Khan W. A systematic review of mesenchymal stem cells in spinal cord injury, intervertebral disc repair and spinal fusion. *Curr Stem Cell Res Ther* 2018; 13:316-323.

109. Basso M, Cavagnaro L, Zanirato A, et al. What is the clinical evidence on regenerative medicine in intervertebral disc degeneration? *Musculoskelet Surg* 2017; 101:93-104.

110. Wu T, Song HX, Dong Y, Li JH. Cell based therapies for lumbar discogenic low back pain: Systematic review and single-arm meta-analysis. *Spine (Phila Pa 1976)* 2018; 43:49-57.

111. Ufondu W, Robinson CL, Hussain N, et al. Intradiscal autologous biologics for the treatment of chronic discogenic low back pain. *Curr Pain Headache Rep* 2024; 28:1079-1095.

112. Deyo RA, Mirza SK, Turner JA, Martin BI. Overtreating chronic back pain: Time to back off? *J Am Board Fam Med* 2009; 22:62-68.

113. Lad SP, Babu R, Ugiliweneza B, Patil CG, Boakye M. Surgery for spinal stenosis: Long-term reoperation rates, health care cost, and impact of instrumentation. *Spine (Phila Pa 1976)* 2014; 39:978-987.

114. Rajaee SS, Kanim LE, Bae HW. National trends in revision spinal fusion in the USA: Patient characteristics and complications. *Bone Joint J* 2014; 96-B:807-816.

115. O'Gara T, Kemper KJ, Birkedal J, Curl W, Miller N, Abadie B. Survey of conventional and complementary and alternative therapy in patients with low back pain. *J Surg Orthop Adv* 2016; 25:27-33.

116. Karvelas DA, Rundell SD, Friedly JL, et al. Subsequent health-care utilization associated with early physical therapy for new episodes of low back pain in older adults. *Spine J* 2017; 17:380-389.

117. Chou R, Fu R, Dana T, Pappas M, Hart E, Mauer KM. Interventional Treatments for Acute and Chronic Pain: Systematic Review. Comparative Effectiveness Review No. 247. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 75Q80120D0006.) AHRQ Publication No. 21-EHCo30. Rockville, MD: Agency for Healthcare Research and Quality; September 2021. Accessed 7/23/2025. [https://effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-247-interventional-treatments-acute-chronic-pain\\_o.pdf](https://effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-247-interventional-treatments-acute-chronic-pain_o.pdf)

118. Sclafani JA, Constantin A, Ho PS, Akuthota V, Chan L. Descriptive analysis of spinal neuroaxial injections, surgical interventions, and physical therapy utilization for degenerative lumbar spondylolisthesis within Medicare beneficiaries from 2000 to 2011. *Spine (Phila Pa 1976)* 2017; 42:240-246.

119. Amirdelfan K, Webster L, Poree L, Sukul V, McRoberts P. Treatment options for failed back surgery syndrome patients with refractory chronic pain: An evidence based approach. *Spine (Phila Pa 1976)* 2017; 42:S41-S52.

120. Ritzwoller DP, Crounse L, Shetterly S, Rublee D. The association of comorbidities, utilization and costs for patients identified with low back pain. *BMC Musculoskelet Disord* 2006; 7:72.

121. Leavitt SB. NSAID dangers may limit pain-relief options. *Pain-Topics News/Research UPDATES*, March 14, 2010.

122. Moore A, Wiffen P, Kalso E. Antiepileptic drugs for neuropathic pain and fibromyalgia. *JAMA* 2014; 312:182-183.

123. Pannell WC, Savin DD, Scott TP, Wang JC, Daubs MD. Trends in the surgical treatment of lumbar spine disease in the

United States. *Spine J* 2015; 15:1719-1727.

124. Gaudin D, Krafci BM, Mansour TR, Alnemari A. Considerations in spinal fusion surgery for chronic lumbar pain: Psychosocial factors, rating scales, and perioperative patient education-A review of the literature. *World Neurosurg* 2017; 98:21-27.

125. Yoshihara H, Yoneoka D. National trends in the surgical treatment for lumbar degenerative disc disease: United States, 2000 to 2009. *Spine J* 2015; 15:265-271.

126. Graves JM, Fulton-Kehoe D, Jarvik JG, Franklin GM. Health care utilization and costs associated with adherence to clinical practice guidelines for early magnetic resonance imaging among workers with acute occupational low back pain. *Health Serv Res* 2014; 49:645-665.

127. Khankhel N, Friedman BW, Baer J, et al. Topical diclofenac versus oral ibuprofen versus diclofenac + ibuprofen for emergency department patients with acute low back pain: A randomized study. *Ann Emerg Med* 2024 Jun; 83:542-551.

128. Baroncini A, Maffulli N, Al-Zyoud H, Bell A, Sevic A, Migliorini F. Nonopioid pharmacological management of acute low back pain: A level I of evidence systematic review. *J Orthop Res* 2023; 41:1781-1791.

129. Cashin AG, Wand BM, O'Connell NE, et al. Pharmacological treatments for low back pain in adults: An overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2023;:CD013815.

130. Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: Systematic review and meta-analysis. *BMJ* 2021; 374:n1446.

131. Hung KKC, Lam RPK, Lee HKH, et al. Comparison of diclofenac with tramadol, tizanidine or placebo in the treatment of acute low back pain and sciatica: Multi-center randomized controlled trial. *Postgrad Med J* 2024; 100:741-750.

132. Iliopoulos K, Koufaki P, Tsilikas S, et al. A randomized controlled trial evaluating the short-term efficacy of a single-administration intramuscular injection with the fixed combination of thiocolchicoside-diclofenac versus diclofenac monotherapy in patients with acute moderate-to-severe low back pain. *BMC Musculoskelet Disord* 2023; 24:476.

133. Sharifi M, Abdorazzaghnejad A, Yazdchi M, Bahreini M. Methocarbamol versus diazepam in acute low back pain in the emergency department: A randomised double-blind clinical trial. *Emerg Med J* 2023; 40:493-498.

134. Ferraro MC, Bagg MK, Wewege MA, et al. Efficacy, acceptability, and safety of antidepressants for low back pain: A systematic review and meta-analysis. *Syst Rev* 2021; 10:62.

135. Leão Nunes Filho MJ, Barreto ESR, Antunes Júnior CR, et al. Efficacy of antidepressants in the treatment of chronic nonspecific low back pain: A systematic review and meta-analysis. *Pain Manag* 2024; 14:437-451.

136. Morkoç B, Aktan O, Sönmez G, et al. Effects of lumbar stabilization exercises on serum biomarker levels and clinical outcomes in lumbar disc herniation: A subgroup analysis of a randomized controlled trial. *Turk J Med Sci* 2025; 55:572-584.

137. Leininger BD, Kuntz KM, Hodges JS, et al. Cost-effectiveness of spinal manipulation, exercise, and self-management for spinal pain. *Chiropr Man Therap* 2025; 33:36.

138. Best MJ, Buller LT, Eismont FJ. National trends in ambulatory surgery for intervertebral disc disorders and spinal stenosis: A 12-year analysis of the national surveys of ambulatory surgery. *Spine (Phila Pa 1976)* 2015; 40:1703-1711.

139. Ragab A, Deshaze RD. Management of back pain in patients with previous back surgery. *Am J Med* 2008; 121:272-278.

140. Qaseem A, Wilt TJ, McLean RM, Forciea MA, for the Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2017; 166:514-530.

141. Ma T, Qi H, Mao Y, Wang Y, Duan B, Ma K. Comparative efficacy and safety of antidepressants for patients with chronic back pain: A network meta-analysis. *J Clin Pharmacol* 2024; 64:205-214.

142. Giménez-Campos MS, Pimenta-Ferreiro-Ramos P, Díaz-Cambrónero JI, Carbonell-Sánchez R, López-Briz E, Ruiz-García V. A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain. *Aten Primaria* 2022; 54:102144.

143. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2017; 14: e1002369.

144. João RB, Tagore Chan JO, Huang ES, et al. Gabapentinoids for neuropathic pain after spinal cord injury: An updated meta-analysis of randomized controlled trials. *Pain Pract* 2025; 25:e70060.

145. Gammoh O, Al-Smadi A, Shawagfeh MQ, et al. The clinical difference between gabapentin and pregabalin: Data from a pilot comparative trial. *Rev Recent Clin Trials* 2021; 16:279-287.

146. Kepes ER, Duncalf D. Treatment of backache with spinal injections of local anesthetics, spinal and systemic steroids. A review. *Pain* 1985; 22:33.

147. Manchikanti L, Knezevic E, Knezevic NN, et al. A comparative systematic review and meta-analysis of 3 routes of administration of epidural injections in lumbar disc herniation. *Pain Physician* 2021; 24:425-440.

148. Knezevic N, Manchikanti L, Urits I, et al. Lack of superiority of epidural injections with lidocaine with steroids compared to without steroids in spinal pain: A systematic review and meta-analysis. *Pain Physician* 2020; 23:S239-S270.

149. Moreira AM, Diaz L, Presley J, et al. Comparing the effectiveness and safety of dexamethasone, methylprednisolone and betamethasone in lumbar transforaminal epidural steroid injections. *Pain Physician* 2024; 27:341-348.

150. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. *MMWR Recomm Rep* 2022; 71:1-95.

151. Skelly AC, Chou R, Dettori JR, et al. Noninvasive nonpharmacological treatment for chronic pain: A systematic review update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. Report No.: 20-EHCo09.

152. Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. *Cochrane Database Syst Rev* 2005; 3:CD00335.

153. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. *Cochrane Database Syst Rev* 2015; 1:CD004376.

154. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. *Cochrane Database Syst Rev* 2014; 4:CD007912.

155. Busch AJ, Barber KAR, Overend TJ, Peloso PMJ, Schachter CL. Exercise for treating fibromyalgia syndrome. *Cochrane Database Syst Rev* 2007; 4:CD003786.

156. American College of Occupational and

Environmental Medicine. Chronic pain guideline. Westminster, CO: ReedGroup; 2017.

157. Hochberg MC, Altman RD, April KT, et al.; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 2012; 64:465-474.

158. Macfarlane GJ, Kornisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis* 2017; 76:318-328.

159. Saragiotti BT, Maher CG, Yamato TP, et al. Motor control exercise for chronic non-specific low-back pain. *Cochrane Database Syst Rev* 2016; 1:CD012004.

160. Byström MG, Rasmussen-Barr E, Grootenhuis WJ. Motor control exercises reduces pain and disability in chronic and recurrent low back pain: A meta-analysis. *Spine (Phila Pa 1976)* 2013; 38:E350-E358.

161. Hayden JA, Ellis J, Ogilvie R, et al. Some types of exercise are more effective than others in people with chronic low back pain: A network meta-analysis. *J Physiother* 2021; 67:252-262.

162. Miller CT, Owen PJ, Than CA, et al. Attempting to separate placebo effects from exercise in chronic pain: A systematic review and meta-analysis. *Sports Med* 2022; 52:789-816.

163. González-Gómez L, Moral-Munoz JA, Rosales-Tristáncho A, Cuevas-Moreno A, Cardellat-González M, Rodríguez-Domínguez ÁJ. Exercise therapy versus manual therapy for the management of pain intensity, disability, and physical function in people with chronic low back pain: A systematic review with meta-analysis and meta-regression. *Eur J Pain* 2025; 29:e70090.

164. Hesselstrand M, Samuelsson K, Liedberg G. Occupational therapy interventions in chronic pain--A Systematic review. *Occup Ther Int* 2015; 22:183-194.

165. van Middelkoop M, Rubinstein SM, Kuijpers T, et al. A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. *Eur Spine J* 2011; 20:19-39.

166. Mannion AF, Müntener M, Taimela S, Dvorak J. A randomized clinical trial of three active therapies for chronic low back pain. *Spine (Phila Pa 1976)* 1999; 24:2435-2448.

167. Allen KD, Woolson S, Hoenig HM, et al. Stepped exercise program for patients with knee osteoarthritis: A randomized controlled trial. *Ann Intern Med* 2021; 174:298-307.

168. Huang L, Xu G, Sun M, et al. Recent trends in acupuncture for chronic pain: A bibliometric analysis and review of the literature. *Complement Ther Med* 2023; 72:102915.

169. Nahin RL, Boineau R, Khalsa PS, Stussman BJ, Weber WJ. Evidence-based evaluation of complementary health approaches for pain management in the United States. *Mayo Clin Proc* 2016; 91:1292-1306.

170. McKee MD, Nielsen A, Anderson B, et al. Individual vs. group delivery of acupuncture therapy for chronic musculoskeletal pain in urban primary care – A randomized trial. *J Gen Intern Med* 2020; 35:1227-1237.

171. Li H, Zheng Y, Wang Y, et al. Therapeutic effect of Qinglong tail-wagging acupuncture method in knee osteoarthritis and its influence on inflammatory factors. *Am J Transl Res* 2021; 13:3206-3213.

172. Zheng H, Gao T, Zheng QH, et al. Acupuncture for patients with chronic tension-type headache: A randomized controlled trial. *Neurology* 2022; 99:e1560-e1569.

173. Dyson-Hudson TA, Kadar P, LaFountaine M, et al. Acupuncture for chronic shoulder pain in persons with spinal cord injury: A small-scale clinical trial. *Arch Phys Med Rehabil* 2007; 88:1276-1283.

174. Tedesco D, Gori D, Desai KR, et al. Drug-free interventions to reduce pain or opioid consumption after total knee arthroplasty: A systematic review and meta-analysis. *JAMA Surg* 2017; 152:e172872.

175. Zhao L, Chen J, Li Y, et al. The long-term effect of acupuncture for migraine prophylaxis: A randomized clinical trial. *JAMA Intern Med* 2017; 177:508-515.

176. Lin KY, Chang YC, Lu WC, Kotha P, Chen YH, Tu CH. Analgesic efficacy of acupuncture on chronic pelvic pain: A systematic review and meta-analysis study. *Healthcare (Basel)* 2023; 11:830.

177. Pan J, Jin S, Xie Q, et al. Acupuncture for chronic prostatitis or chronic pelvic pain syndrome: An updated systematic review and meta-analysis. *Pain Res Manag* 2023; 2023:7754876.

178. Trivedi H, Avrit TA, Chan L, Burchette M, Rathore R. The benefits of integrative medicine in the management of chronic pain: A review. *Cureus* 2022; 14:e29963.

179. Airaksinen O, Brox JI, Cedraschi C, et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. *Eur Spine J* 2006; 15:S192-S300.

180. National Collaborating Centre for Primary Care (UK). Low Back Pain: Early Management of Persistent Non-specific Low Back Pain [Internet]. London, Royal College of General Practitioners (UK), May 2009.

181. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med* 2007; 147:478-491.

182. Liu L, Skinner M, McDonough S, Mabire L, Baxter GD. Acupuncture for low back pain: An overview of systematic reviews. *Evid Based Complement Alternat Med* 2015; 2015:328196.

183. Trigkilidas D. Acupuncture therapy for chronic lower back pain: A systematic review. *Ann R Coll Surg Engl* 2010; 92:595-598.

184. Patel M, Urts I, Kaye AD, Viswanath O. The role of acupuncture in the treatment of chronic pain. *Best Pract Res Clin Anaesthesiol* 2020; 34:603-616.

185. Urts I, Schwartz RH, Orhurhu V, et al. A comprehensive review of alternative therapies for the management of chronic pain patients: Acupuncture, tai chi, osteopathic manipulative medicine, and chiropractic care. *Adv Ther* 2021; 38:76-89.

186. Lam M, Galvin R, Curry P. Effectiveness of acupuncture for nonspecific chronic low back pain: A systematic review and meta-analysis. *Spine (Phila Pa 1976)* 2013; 38:2124-2138.

187. Ernst E. Massage therapy for low back pain: A systematic review. *J Pain Symptom Manage* 1999; 17:65-69.

188. Melzack R, Wall PD. *The Challenge of Pain*, 2nd ed. Penguin Books, London, 1996.

189. Moyer CA, Rounds J, Hannum JW. A meta-analysis of massage therapy research. *Psychol Bull* 2004; 130:3-18.

190. Farber K, Wieland LS. *Massage for low-back pain*. Explore (NY) 2016; 12:215-217.

191. Furlan AD, Imamura M, Dryden T, Irvin E. Massage for low back pain: An updated systematic review within the framework of the Cochrane Back Review Group. *Spine (Phila Pa 1976)* 2009; 34:1669-1684.

192. Tsao JC. Effectiveness of massage therapy for chronic, non-malignant pain: A review. *Evidence-based complementary and alternative medicine: eCAM* 2007;

4:165-179.

193. Reeve J, Corabian P. *Transcutaneous Electrical Nerve Stimulation (TENS) and Pain Management*. Ottawa, Ontario, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1995.

194. Dubinsky RM, Miyasaki J. Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2010; 74:173-176.

195. Khadilkar A, Milne S, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. *Cochrane Database Syst Rev* 2005; 3:CD003008.

196. Wu LC, Weng PW, Chen CH, Huang YY, Tsuang YH, Chiang CJ. Literature review and meta-analysis of transcutaneous electrical nerve stimulation in treating chronic back pain. *Reg Anesth Pain Med* 2018; 43:425-433.

197. Gibson W, Wand BM, Meads C, Catley MJ, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for chronic pain - An overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2019; 2:CD011890.

198. Rampazo ÉP, Martignago CCS, de Noronha M, Liebano RE. Transcutaneous electrical stimulation in neck pain: A systematic review and meta-analysis. *Eur J Pain* 2022; 26:18-42.

199. Johnson MI, Paley CA, Jones G, Mulvey MR, Wittkopf PG. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: A systematic review and meta-analysis of 381 studies (the meta-TENS study). *BMJ Open* 2022; 12:e051073.

200. de Luca KE, Fang SH, Ong J, Shin KS, Woods S, Tuchin PJ. The effectiveness and safety of manual therapy on pain and disability in older persons with chronic low back pain: A systematic review. *J Manipulative Physiol Ther* 2017; 40:527-534.

201. Bons SCS, Borg MAJP, Van den Donk M, et al. NHG guideline for a specific low-back pain, 2017. Accessed 4/11/2023. <https://richtlijnen.nhg.org/standaarden/aspecifieke-lagerugpijn#volledige-tекст>

202. Foster NE, Anema JR, Cherkin D, et al; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: Evidence, challenges, and promising directions. *Lancet* 2018; 391:2368-2383.

203. Bialosky JE, Bishop MD, Robinson ME, Zeppieri G Jr, George SZ. Spinal manipulative therapy has an immediate effect on thermal pain sensitivity in people with low back pain: A randomized controlled trial. *Phys Ther* 2009; 89:1292-1303.

204. Xia T, Long CR, Vining RD, et al. Association of lumbar spine stiffness and flexion-relaxation phenomenon with patient-reported outcomes in adults with chronic low back pain - A single-arm clinical trial investigating the effects of thrust spinal manipulation. *BMC Complement Altern Med* 2017; 17:303.

205. Bialosky JE, Bishop MD, Price DD, Robinson ME, George SZ. The mechanisms of manual therapy in the treatment of musculoskeletal pain: A comprehensive model. *Man Ther* 2009; 14:531-538.

206. Rubinstein SM, de Zoete A, van Middelkoop M, Assendelft WJJ, de Boer MR, van Tulder MW. Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: A systematic review and meta-analysis of randomised controlled trials. *BMJ* 2019; 364:l689.

207. Coulter ID, Crawford C, Hurwitz EL, et al. Manipulation and mobilization for treating chronic low back pain: A systematic review and meta-analysis. *Spine J* 2018; 18:866-879.

208. Coulter ID, Crawford C, Vernon H, et al. Manipulation and mobilization for treating chronic nonspecific neck pain: A systematic review and meta-analysis for an appropriateness panel. *Pain Physician* 2019; 22:E55-E70.

209. Sherbourne CD, Ryan GW, Whitley MD, et al. Coping and management techniques used by chronic low back pain patients receiving treatment from chiropractors. *J Manipulative Physiol Ther* 2019; 42:582-593.

210. Hays RD, Sherbourne CD, Spritzer KL, et al. Experiences with chiropractic care for patients with low back or neck pain. *J Patient Exp* 2020; 7:357-364.

211. Flor H, Birbaumer N. Comparison of the efficacy of electromyographic biofeedback, cognitive-behavioural therapy, and conservative medical interventions in the treatment of chronic musculoskeletal pain. *J Consult Clin Psychol* 1993; 61:653-658.

212. Magnusson, Chow DH, Diamandopoulos Z, Pope MH. Motor control learning in chronic low back pain. *Spine (Phila Pa 1976)* 2008; 33:E532-E538.

213. Sielski R, Rief W, Glombiewski JA. Efficacy of biofeedback in chronic back pain: A meta-analysis. *Int J Behav Med* 2017; 24:25-41.

214. Burns JW, Jensen MP, Thorn B, et al. Cognitive therapy, mindfulness-based stress reduction, and behavior therapy for the treatment of chronic pain: Randomized controlled trial. *Pain* 2022; 163:376-389.

215. Flynn DM. Chronic musculoskeletal pain: Nonpharmacologic, noninvasive treatments. *Am Fam Physician* 2020; 102:465-477.

216. Interagency Pain Research Coordinating Committee. National pain strategy: A comprehensive population health-level strategy for pain. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2015. Accessed 9/22/2025. [www.ninds.nih.gov/sites/default/files/documents/NationalPainStrategy\\_508C.pdf](http://www.ninds.nih.gov/sites/default/files/documents/NationalPainStrategy_508C.pdf)

217. U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force. Final Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations. May 9, 2019. Accessed 9/20/2025. [www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf](http://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf)

218. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. *Cochrane Database Syst Rev* 2014; 9:CD000963.

219. Manchikanti L, Singh VM, Staats PS, et al. Fourth wave of opioid (illicit drug) overdose deaths and diminishing access to prescription opioids and interventional techniques: Cause and effect. *Pain Physician* 2022; 25:97-124.

220. Aubry L, Carr BT. Overdose, opioid treatment admissions and prescription opioid pain reliever relationships: United States, 2010-2019. *Front Pain Res (Lausanne)* 2022; 3:884674.

221. Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System. Drug Overdose Deaths. Accessed 7/23/2025. [www.cdc.gov/nchs/nvss/drug-overdose-deaths.htm](http://www.cdc.gov/nchs/nvss/drug-overdose-deaths.htm)

222. Haegerich T. *The opioid overdose epidemic in the United States NCIPC/CDC Research Priorities*. 2018.

223. Manchikanti L, Pampati V, Jha SS, et al. The impact of COVID-19 on

interventional pain management practices is significant and long-lasting: An interventional pain management physician survey. *Pain Physician* 2022; 25:131-144.

224. Godbout-Parent M, Spilak T, Pagé MG, et al. The calm after the storm: A state-of-the-art review about recommendations put forward during the COVID-19 pandemic to improve chronic pain management. *J Clin Med* 2023; 12:7233.

225. Berg S. American Medical Association. The 12 factors that drive up physician burnout. May 28, 2020. Accessed 10/23/2024.  
[www.ama-assn.org/practice-management/physician-health/12-factors-drive-physician-burnout](http://www.ama-assn.org/practice-management/physician-health/12-factors-drive-physician-burnout)

226. Alkhamees AA, Aljohani MS, Kalani S, et al. Physician's burnout during the COVID-19 pandemic: A systematic review and meta-analysis. *Int J Environ Res Public Health* 2023; 20:4598.

227. Manchikanti L, Pampati V, Sanapati MR, et al. COVID-19 pandemic reduced utilization of interventional techniques 18.7% in managing chronic pain in the Medicare population in 2020: Analysis of utilization data from 2000 to 2020. *Pain Physician* 2022; 25:223-238.

228. Manchikanti L, Senapathi SHV, Milburn JM, et al. Utilization and expenditures of vertebral augmentation continue to decline: An analysis in fee-for-service (FFS) Recipients from 2009 to 2018. *Pain Physician* 2021; 24:401-415.

229. Manchikanti L, Soin A, Mann DP, Bakshi S, Pampati V, Hirsch JA. Reversal of growth of utilization of interventional techniques in managing chronic pain in Medicare population post Affordable Care Act. *Pain Physician* 2017; 20:551-567.

230. Manchikanti L, Sanapati MR, Pampati V, Boswell MV, Kaye AD, Hirsch JA. Update on reversal and decline of growth of utilization of interventional techniques in managing chronic pain in the Medicare population from 2000 to 2018. *Pain Physician* 2019; 22:521-536.

231. Manchikanti L, Vanaparty R, Atluri S, Sachdeva H, Kaye AD, Hirsch JA. COVID-19 and the opioid epidemic: Two public health emergencies that intersect with chronic pain. *Pain Ther* 2021; 10:269-286.

232. Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. *N Eng J Med* 1934; 211:210-215.

233. Truumees E. A history of lumbar disc herniation from Hippocrates to the 1990s. *Clin Orthop Relat Res* 2015; 473:1885-1895.

234. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical vs nonoperative treatment for lumbar disk herniation: The Spine Patient Outcomes Research Trial (SPORT): A randomized trial. *JAMA* 2006; 296:2441-2450.

235. Lopez CD, Boddapati V, Lombardi JM, et al. Recent trends in Medicare utilization and reimbursement for anterior cervical discectomy and fusion. *Spine J* 2020; 20:1737-1743.

236. Martin BI, Mirza SK, Spina N, Spiker WR, Lawrence B, Brodke DS. Trends in lumbar fusion procedure rates and associated hospital costs for degenerative spinal diseases in the United States, 2004 to 2015. *Spine (Phila Pa 1976)* 2019; 44:369-376.

237. Al Jammal OM, Delavar A, Maguire KR, et al. National trends in the surgical management of lumbar spinal stenosis in adult spinal deformity patients. *Spine (Phila Pa 1976)* 2019; 44:E1369-E1378.

238. Jain N, Phillips FM, Shimer AL, Khan SN. Surgeon reimbursement relative to hospital payments for spinal fusion: Trends from 10-year Medicare analysis. *Spine (Phila Pa 1976)* 2018; 43:720-731.

239. Kim CH, Chung CK, Choi Y, et al. Direct medical costs after surgical or nonsurgical treatment for degenerative lumbar spinal disease: A nationwide matched cohort study with a 10-year follow-up. *PLoS One* 2021; 16:e0260460.

240. Machado GC, Witzleb AJ, Fritsch C, Maher CG, Ferreira PH, Ferreira ML. Patients with sciatica still experience pain and disability 5 years after surgery: A systematic review with meta-analysis of cohort studies. *Eur J Pain* 2016; 20:1700-1709.

241. Schwartz AM, Farley KX, Guild GN, Bradbury TL Jr. Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2030. *J Arthroplasty* 2020; 35:S79-S85.

242. Beschloss AM, Taghlabi KM, Rodriguez DA, et al. Demographic and economic trends in vertebral fracture surgeries throughout the United States. *N Am Spine Soc J* 2022; 12:100175.

243. Kerezoudis P, Alvi MA, Freedman BA, Nassr A, Bydon M. Utilization trends of recombinant human bone morphogenetic protein in the United States. *Spine (Phila Pa 1976)* 2021; 46:874-881.

244. Deng H, Yue JK, Ordaz A, Suen CG, Sing DC. Elective lumbar fusion in the United States: National trends in inpatient complications and cost from 2002-2014. *J Neurosurg Sci* 2021; 65:503-512.

245. Xu Y, Yen D, Whitehead M, Xu J, Johnson AP. Use of instrumented lumbar spinal surgery for degenerative conditions: Trends and costs over time in Ontario, Canada. *Can J Surg* 2019; 62:393-401.

246. Varshneya K, Medress ZA, Jensen M, et al. Trends in anterior lumbar interbody fusion in the United States: A MarketScan study from 2007 to 2014. *Clin Spine Surg* 2020; 33:E226-E230.

247. Oster BA, Kikanloo SR, Levine NL, Lian J, Cho W. Systematic review of outcomes following 10-year mark of Spine Patient Outcomes Research Trial for intervertebral disc herniation. *Spine (Phila Pa 1976)* 2020; 45:825-831.

248. McGirt MJ, Ambrossi GL, Datoo G, et al. Recurrent disc herniation and long-term back pain after primary lumbar discectomy: Review of outcomes reported for limited versus aggressive disc removal. *Neurosurgery* 2009; 64:338-344; discussion 344-345.

249. Fritsch CG, Ferreira ML, Maher CG, et al. The clinical course of pain and disability following surgery for spinal stenosis: A systematic review and meta-analysis of cohort studies. *Eur Spine J* 2017; 26:324-335.

250. Fritsch EW, Heisel J, Rupp S. The failed back surgery syndrome: Reasons, intraoperative findings, and long-term results: A report of 182 operative treatments. *Spine (Phila Pa 1976)* 1996; 21:626-633.

251. Parker SL, Mendenhall SK, Godil SS, et al. Incidence of low back pain after lumbar discectomy for herniated disc and its effect on patient-reported outcomes. *Clin Orthop Relat Res* 2015; 473:1988-1999.

252. Raad M, Reidler JS, El Dafrawy MH, et al. US regional variations in rates, outcomes, and costs of spinal arthrodesis for lumbar spinal stenosis in working adults aged 40-65 years. *J Neurosurg Spine* 2018; 30:83-90.

253. Machado GC, Maher CG, Ferreira PH, et al. Trends, complications, and costs for hospital admission and surgery for lumbar spinal stenosis. *Spine (Phila Pa 1976)* 2017; 42:1737-1743.

254. Schofferman J, Reynolds J, Herzog R, Covington E, Dreyfuss P, O'Neill C. Failed back surgery: Etiology and diagnostic evaluation. *Spine J* 2003; 3:400-403.

255. Waguespack A, Schofferman J, Slosar P, Reynolds J. Etiology of long-term failures

of lumbar spine surgery. *Pain Med* 2002; 3:18-22.

256. DePalma MJ, Ketchum JM, Saullo TR. Etiology of chronic low back pain in patients having undergone lumbar fusion. *Pain Med* 2011; 12:732-739.

257. DePalma MJ, Ketchum JM, Saullo TR, Laplante BL. Is the history of a surgical discectomy related to the source of chronic low back pain? *Pain Physician* 2012; 15:E1-E6.

258. Helm IL S, Racz GB, Gerdesmeyer L, et al. Percutaneous and endoscopic adhesiolysis in managing low back and lower extremity pain: A systematic review and meta-analysis. *Pain Physician* 2016; 19:E245-E282.

259. Manchikanti L, Knezevic NN, Sanapati SP, Sanapati MR, Kaye AD, Hirsch JA. Is percutaneous adhesiolysis effective in managing chronic low back and lower extremity pain in post-surgery syndrome: A systematic review and meta-analysis. *Curr Pain Headache Rep* 2020; 24:30.

260. Manchikanti L, Knezevic NN, Sanapati MR, Boswell MV, Kaye AD, Hirsch JA. Effectiveness of percutaneous adhesiolysis in managing chronic central lumbar spinal stenosis: A systematic review and meta-analysis. *Pain Physician* 2019; 22:E523-E550.

261. Manchikanti L, Soin A, Boswell MV, Kaye AD, Sanapati M, Hirsch JA. Effectiveness of percutaneous adhesiolysis in post lumbar surgery syndrome: A systematic analysis of findings of systematic reviews. *Pain Physician* 2019; 22:307-322.

262. Kim LH, Vail D, Azad TD, et al. Expenditures and health care utilization among adults with newly diagnosed low back and lower extremity pain. *JAMA Netw Open* 2019; 2:e193676.

263. Schwarzer AC, Aprill C, Derby R, Fortin J, Kine G, Bogduk N. Clinical features of patients with pain stemming from the lumbar zygapophyseal joints. Is the lumbar facet syndrome a clinical entity? *Spine (Phila Pa 1976)* 1994; 10:1132-1137.

264. Schwarzer AC, Wang S, Bogduk N, McNaught PJ, Laurent R. Prevalence and clinical features of lumbar zygapophysial joint pain: A study in an Australian population with chronic low back pain. *Ann Rheum Dis* 1995; 54:100-106.

265. DePalma MJ, Ketchum JM, Saullo T. What is the source of chronic low back pain and does age play a role? *Pain Med* 2011; 12:224-233.

266. Kushchayev SV, Glushko T, Jarraya M, et al. ABCs of the degenerative spine. *Insights Imaging* 2018; 9:253-274.

267. Hooper RA, Frizzell JB, Faris P. Case series on chronic whiplash related neck pain treated with intraarticular zygapophysial joint regeneration injection therapy. *Pain Physician* 2007; 10:313-318.

268. Asano S, Kaneda K, Umehara S, Tadano S. The mechanical properties of the human L4-5 functional spinal unit during cyclic loading. The structural effects of the posterior elements. *Spine (Phila Pa 1976)* 1992; 17:1343-1352.

269. Heuer F, Schmidt H, Klezl Z, Claes L, Wilke HJ. Stepwise reduction of functional spinal structures increase range of motion and change lordosis angle. *J Biomech* 2007; 40:271-280.

270. Somovilla-Gómez F, Lostado-Lorza R, Corral-Bobadilla M, Escribano-García R. Improvement in determining the risk of damage to the human lumbar functional spinal unit considering age, height, weight and sex using a combination of FEM and RSM. *Biomech Model Mechanobiol* 2020; 19:351-387.

271. Nisolle ML, Ghoudiwal D, Engelmann E, et al. Comparison of the effectiveness of ultrasound-guided versus fluoroscopy-guided medial lumbar bundle branch block on pain related to lumbar facet joints: A multicenter randomized controlled non-inferiority study. *BMC Anesthesiol* 2023; 23:76. Erratum in: *BMC Anesthesiol* 2023; 23:157.

272. Inoue N, Orías AAE, Segami K. Biomechanics of the lumbar facet joint. *Spine Surg Relat Res* 2019; 41:7.

273. Yamashita T, Minaki Y, Ozaktay AC, Cavanaugh JM, King AI. A morphological study of the fibrous capsule of the human lumbar facet joint. *Spine (Phila Pa 1976)* 1996; 21:538-543.

274. O'Leary SA, Paschos NK, Link JM, Klineberg EO, Hu JC, Athanasiou KA. Facet joints of the spine: Structure-function relationships, problems and treatments, and the potential for regeneration. *Annu Rev Biomed Eng* 2018; 20:145-170.

275. Kapetanakis S, Gkantsinikoudis N. Anatomy of lumbar facet joint: A comprehensive review. *Folia Morphol (Warsz)* 2021; 80:799-805.

276. Lorenz M, Patwardhan A, Vanderby R Jr. Load-bearing characteristics of lumbar facets in normal and surgically altered spinal segments. *Spine (Phila Pa 1976)* 1983; 8:122-130.

277. Manchikanti L, Kosanovic R, Pampati V, et al. Low back pain and diagnostic lumbar facet joint nerve blocks: Assessment of prevalence, false-positive rates, and a philosophical paradigm shift from an acute to a chronic pain model. *Pain Physician* 2020; 23:519-529.

278. Kirnaz S, Capadona C, Wong T, et al. Fundamentals of intervertebral disc degeneration. *World Neurosurg* 2022; 157:264-273.

279. Mohd Isa IL, Teoh SL, Mohd Nor NH, Mokhtar SA. Discogenic low back pain: Anatomy, pathophysiology and treatments of intervertebral disc degeneration. *Int J Mol Sci* 2022; 24:208.

280. Rudnik-Jansen I, van Kruining Kodele S, Creemers L, Joosten B. Biomolecular therapies for chronic discogenic low back pain: A narrative review. *JOR Spine* 2024; 7:e1345.

281. Newell N, Little JP, Christou A, Adams MA, Adam CJ, Masouros SD. Biomechanics of the human intervertebral disc: A review of testing techniques and results. *J Mech Behav Biomed Mater* 2017; 69:420-434.

282. Miguélez-Rivera L, Pérez-Castrillo S, González-Fernández ML, et al. Immunomodulation of mesenchymal stem cells in discogenic pain. *Spine J* 2018; 18:330-342.

283. Wang F, Cheung CW, Wong SSC. Regenerative medicine for the treatment of chronic low back pain: A narrative review. *J Int Med Res* 2023; 51:3000605231155777.

284. Zeckser J, Wolff M, Tucker J, Goodwin J. Multipotent mesenchymal stem cell treatment for discogenic low back pain and disc degeneration. *Stem Cells Int* 2016; 2016:3908389.

285. Von Forell GA, Stephens TK, Samartzis D, Bowden AE. Low back pain: A biomechanical rationale based on "patterns" of disc degeneration. *Spine (Phila Pa 1976)* 2015; 40:1165-1172.

286. Bhujel B, Shin HE, Choi DJ, Han I. Mesenchymal stem cell-derived exosomes and intervertebral disc regeneration: Review. *Int J Mol Sci* 2022; 23:7306.

287. Lotz JC, Fields AJ, Liebenberg EC. The role of the vertebral end plate in low back pain. *Global Spine J* 2013; 3:153-164.

288. Bock CE. In: *Hand-Atlas der Anatomie Des Menschen*. Berline, Verlag, 1860.

289. Kiapour A, Joukar A, Elgafy H, Erbulut DU, Agarwal AK, Goel VK. Biomechanics of the sacroiliac joint: Anatomy, function, biomechanics, sexual dimorphism, and causes of pain. *Int J Spine Surg* 2020; 14:3-13.

290. Vleeming A, Schuenke MD, Masi AT, Carreiro JE, Danneels L, Willard FH.

The sacroiliac joint: An overview of its anatomy, function and potential clinical implications. *J Anat* 2012; 221:537-567.

291. Chen AS, Solberg J, Smith C, et al. Intra-articular platelet rich plasma vs corticosteroid injections for sacroiliac joint pain: A double-blinded, randomized clinical trial. *Pain Med* 2022; 23:1266-1271.

292. Marieb EN. In: *Human anatomy & physiology*. United Kingdom, Pearson Education, Limited, 2003.

293. Vital JM. The spinal ligaments. In: Vital JM, Cawley D (eds). *Spinal Anatomy: Modern Concepts*. Springer, Switzerland, 2020.

294. Seyedhoseinpoor T, Taghipour M, Dadgoo M, et al. Alteration of lumbar muscle morphology and composition in relation to low back pain: A systematic review and meta-analysis. *Spine J* 2022; 22:660-676.

295. Hedges PW, Danneels L. Changes in structure and function of the back muscles in low back pain: Different time points, observations, and mechanisms. *J Orthop Sports Phys Ther* 2019; 49:464-476.

296. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: Cell biology to clinical progress. *NPJ Regen Med* 2019; 4:22.

297. Petrosyan A, Martins PN, Solez K, Uygun BE, Gorantla VS, Orlando G. Regenerative medicine applications: An overview of clinical trials. *Front Bioeng Biotechnol* 2022; 10:942750.

298. Zhang Z, Liu P, Xue X, et al. The role of platelet-rich plasma in biomedicine: A comprehensive overview. *iScience* 2025; 28:111705.

299. Atluri S, Manocha V, Boddu N, et al. Safety and effectiveness of intravascular mesenchymal stem cells to treat organ failure and possible application in COVID-19 complications. *Pain Physician* 2020; 23:S391-S420.

300. Lalu MM, Sullivan KJ, Mei SH, et al. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. *Elife* 2016; 5:e17850.

301. Caplan AI. Cell-Based Therapies: The Nonresponder. *Stem Cells Transl Med* 2018; 7:762-766.

302. Kyriakidis T, Pitsilos C, Iosifidou M, et al. Stem cells for the treatment of early to moderate osteoarthritis of the knee: A systematic review. *J Exp Orthop* 2023; 10:102.

303. Bodor M, Dregalla R, Uribe Y. Platelet rich plasma. In: Manchikanti L, Navani S, Atluri S (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*. ASIPP Publishing, Paducah, 2019, pp 67-82.

304. Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. *Clin Oral Implants Res* 2006; 17:212-219.

305. Yoshida R, Cheng M, Murray MM. Increasing platelet concentration in platelet-rich plasma inhibits anterior cruciate ligament cell function in three-dimensional culture. *J Orthop Res* 2014; 32:291-295.

306. Wasterlain AS, Braun HJ, Harris AH, Kim HJ, Dragoo JL. The systemic effects of platelet-rich plasma injection. *Am J Sports Med* 2013; 41:186-193.

307. Karli DC. Platelet rich plasma, bone marrow concentrate, and adipose mesenchymal stem cells: Hemo-analysis and quality control: What does it all mean? In: Manchikanti L, Navani A, Atluri S (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*. ASIPP Publishing, Paducah, 2019, pp 173-182.

308. Wu PI, Diaz R, Borg-Stein J. Platelet-rich plasma. *Phys Med Rehabil Clin N Am* 2016; 27:825-853.

309. Lansdown DA, Fortier LA. Platelet-rich plasma: Formulations, preparations, constituents, and their effects. *Oper Tech Sports Med* 2017; 25:7-12.

310. Beitzel K, Allen D, Apostolakos J, et al. US Definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. *J Knee Surg* 2015; 28:29-34.

311. Mascarinas A, Harrison J, Boachie-Adjei K, Lutz G. Regenerative treatments for spinal conditions. *Phys Med Rehabil Clin N Am* 2016; 27:1003-1017.

312. Berrigan W, Tao F, Kopcow J, et al. The effect of platelet dose on outcomes after platelet rich plasma injections for musculoskeletal conditions: A systematic review and meta-analysis. *Curr Rev Musculoskelet Med* 2024; 17:570-588.

313. Malanga GA, Goldin M. PRP: Review of the current evidence for musculoskeletal conditions. *Curr Phys Med Rehabil Rep* 2014; 2:1-5.

314. Davis VL, Abukabda AB, Radio NM, et al. Platelet-rich preparations to improve healing. Part I: Workable options for every size practice. *J Oral Implantol* 2014; 40:500-510.

315. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: A milieu of bioactive factors. *Arthroscopy* 2012; 28:429-439.

316. Blair P, Flaumenhaft R. Platelet alpha-granules: Basic biology and clinical correlates. *Blood Rev* 2009; 23:177-189.

317. Sheth U, Simunovic N, Klein G, et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: A meta-analysis. *J Bone Joint Surg* 2012; 94:298-307.

318. Dohan Ehrenfest DM, Rasmussen L, Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol* 2009; 27:158-167.

319. DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: ThePAW classification system. *Arthroscopy* 2012; 28:998-1009.

320. LaPrade RF, Dragoo JL, Koh JL, Murray IR, Geeslin AG, Chu CR. AAOS Research Symposium updates and consensus: Biologic treatment of orthopaedic injuries. *J Am Acad Orthop Surg* 2016; 24:e62-e78.

321. Lana JF, Purita J, Silva Rava CA, et al. Bone marrow concentrate. In: Manchikanti L, Navani A, Atluri S (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*. ASIPP Publishing, Paducah, KY 2019, pp 83-98.

322. Patel S, Gahlaut S, Thami T, Chouhan DK, Jain A, Dhillon MS. Comparison of conventional dose versus superdose platelet-rich plasma for knee osteoarthritis: A prospective, triple-blind, randomized clinical trial. *Orthop J Sports Med* 2024; 12:23259671241227863.

323. Görmeli G, Görmeli CA, Ataoglu B, Çolak C, Aslantürk O, Ertem K. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: A randomized, double-blind, placebo-controlled trial. *Knee Surg Sports Traumatol Arthrosc* 2017; 25:958-965.

324. Kavadar G, Demircioglu DT, Celik MY, Emre TY. Effectiveness of platelet-rich plasma in the treatment of moderate knee osteoarthritis: A randomized prospective study. *J Phys Ther Sci* 2015; 27:38633867.

325. Filardo G, Kon E, Pereira Ruiz MT, et al. Platelet-rich plasma intraarticular injections for cartilage degeneration and osteoarthritis: Single- versus double-spinning approach. *Knee Surg Sports Traumatol Arthrosc* 2012; 20:2082-2091.

326. Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intraarticular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: From early

degeneration to osteoarthritis. *Arthrosc J* 2011; 27:1490-1501.

327. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, double-blind, randomized trial. *Am J Sports Med* 2013; 41:356-364.

328. Dhillon MS, Patel S, Bansal T. Improvising PRP for use in osteoarthritis knee-upcoming trends and futuristic view. *J Clin Orthop Trauma* 2019; 10:32-35.

329. Hahn O, Kieb M, Jonitz-Heincke A, Bader R, Peters K, Tischer T. Dose-dependent effects of platelet-rich plasma powder on chondrocytes in vitro. *Am J Sports Med* 2020; 48:1727-1734.

330. Wang K, Li Z, Li J, et al. Optimization of the platelet-rich plasma concentration for mesenchymal stem cell applications. *Tissue Engineering* 2018; 25:54.

331. Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. *Sci Rep* 2021; 11:3971.

332. Bennell KL, Hunter DJ, Paterson KL. Platelet-rich plasma for the management of hip and knee osteoarthritis. *Curr Rheumatol Rep* 2017; 19:24.

333. Rath M, Spinnen J, Kuhrt LD, et al. Platelet-rich plasma - A comprehensive review of isolation, activation, and application. *Acta Biomater* 2025; 204:52-75.

334. Banu SA, Sharun K. Minimum reporting requirements for platelet-rich plasma in biomaterial research. *Biomater Adv* 2025; 175:214314.

335. Marx RE. Platelet-rich plasma (PRP): What is PRP and what is not PRP? *Implant Dent* 2001; 10:225-228.

336. Murray IR, Geeslin AG, Goudie EB, Petriglano FA, LaPrade RF. Minimum information for studies evaluating biologics in orthopaedics (MIBO): Platelet-rich plasma and mesenchymal stem cells. *J Bone Joint Surg Am* 2017; 99:809-819.

337. Nelson PA, George T, Bowen E, Sheean AJ, Bedi A. An update on orthobiologics: Cautious optimism. *Am J Sports Med* 2024; 52:242-257.

338. Southworth TM, Naveen NB, Tauro TM, Leong NL, Cole BJ. The use of platelet-rich plasma in symptomatic knee osteoarthritis. *J Knee Surg* 2019; 32:37-45.

339. Townsend C, Von Rickenbach KJ, Bailowitz Z, Gellhorn AC. Post-procedure protocols following platelet-rich plasma injections for tendinopathy: A systematic review. *PM R* 2020; 12:904-915.

340. Everts PA, van Erp A, DeSimone A, Cohen DS, Gardner RD. Platelet rich plasma in orthopedic surgical medicine. *Platelets* 2021; 32:163-174.

341. Everts PA, Lana JF, Onishi K, et al. Angiogenesis and tissue repair depend on platelet dosing and Bioformulation Strategies following Orthobiological platelet-rich plasma procedures: A narrative review. *Biomedicines* 2023; 11:1922.

342. Manchikanti L, Navani A. Evolution of regenerative medicine in managing chronic pain. In: Manchikanti L, Navani A, Atluri S (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*. ASIPP Publishing, Paducah, KY, 2019, pp 1-38.

343. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. *J Cell Physiol* 2007; 213:341-347.

344. Caplan AI. Cell delivery and tissue regeneration. *J Control Release* 1989; 11:157-165.

345. Caplan AI. Mesenchymal stem cells. *J Orthop Res* 1991; 9:641-650.

346. Caplan AI. Review: Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics. *Tissue Eng* 2005; 11:1198-1211.

347. Caplan AI. Mesenchymal stem cells: Time to change the name! *Stem Cells Transl Med* 2017; 6:1445-1451.

348. Sell S. *Stem Cells Handbook*. Springer Science & Business Media, New York, NY, 2013.

349. Kobolak J, Dinnyes A, Memic A, Khademhosseini A, Mobasheri A. Mesenchymal stem cells: Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. *Methods* 2016; 99:62-68.

350. Rigotti G, Marchi A, Sbarbati A. Adipose-derived mesenchymal stem cells: Past, present, and future. *Aesthetic Plast Surg* 2009; 33:271-273.

351. Watson L, Elliman SJ, Coleman CM. From isolation to implantation: A concise review of mesenchymal stem cell therapy in bone fracture repair. *Stem Cell Res Ther* 2014; 5:51.

352. Murray IR, West CC, Hardy WR, et al. Natural history of mesenchymal stem cells, from vessel walls to culture vessels. *Cell Mol Life Sci* 2014; 71:1353-1374.

353. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. *Stem Cells* 2005; 23:412-423.

354. Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotype of human adipose derived cells: Temporal changes in stromal-associated and stem cell associated markers. *Stem Cells* 2006; 24:376-385.

355. Kilroy GE, Foster SJ, Wu X, et al. Cytokine profile of human adipose derived stem cells: Expression of angiogenic, hematopoietic, and proinflammatory factors. *J Cell Physiol* 2007; 212:702-709.

356. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. *Dev Cell* 2005; 8:739-750.

357. Cawthorn WP, Bree AJ, Yao Y, et al. Wnt6, Wnt5a and Wnt5b inhibit adipogenesis and stimulate osteoblastogenesis through a b-catenin-independent mechanism. *Bone* 2012; 50:477-489.

358. Li Y, Foster W, Deasy BM, et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. *Am J Pathol* 2004; 164:1007-1019.

359. Serra R, Johnson M, Filvaroff EH, et al. Expression of a truncated, kinase defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. *J Cell Biol* 1997; 139:541-552.

360. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. *Exp Mol Med* 2013; 45:e54.

361. U.S. Food and Drug Administration. FDA New Release: FDA announces comprehensive regenerative medicine policy framework. November 16, 2017.

362. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal manipulation and Homologous Use. Guidance for Industry and Food and Drug Administration Staff. July 2020. Accessed 9/22/2025. [www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal)

363. Schafer R, Debaun MR, Fleck E, et al

al. Quantitation of progenitor cell populations and growth factors after bone marrow aspirate concentration. *J Transl Med* 2019; 17:115.

364. Pettine K, Suzuki R, Sand T, Murphy M. Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up. *Int Orthop* 2016; 40:135-140.

365. Hernigou P, Homma Y, Flouzat Lachaniette CH, et al. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. *Int Orthop* 2013; 37:2279-2287.

366. Hernigou P, Delambre J, Quienec S, Poignard A. Human bone marrow mesenchymal stem cells injection in subchondral lesions of knee osteoarthritis: A prospective randomized study versus contralateral arthroplasty at a mean fifteen year follow-up. *Int Orthop* 2021; 45:365-373.

367. Hernigou P, Homma Y, Flouzat-Lachaniette CH, Poignard A, Chevallier N, Rouard H. Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate. *J Bone Joint Surg Am* 2013; 95:2215-2221.

368. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue implications for cell-based therapies. *Tissue Eng* 2001; 7:211-228.

369. Eto H, Suga H, Matsumoto D, et al. Characterization of structure and cellular components of aspirated and excised adipose tissue. *Plast Reconstr Surg* 2009; 124:1087-1097.

370. Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose and other tissues: Basic biological properties and clinical applications. *Stem Cells Int* 2012; 2012:461718.

371. Banyard D, Sarantopoulos C, Brovikova A, et al. Phenotypic analysis of stromal vascular fraction after mechanical shear reveals stress-induced progenitor populations. *Plast Reconstr Surg* 2016; 138:237e.

372. Ding P, Lu E, Li G, Sun Y, Yang W, Zhao Z. Research Progress on preparation, mechanism, and clinical application of nanofat. *J Burn Care Res* 2022; 43:1140-1144.

373. Chu DT, Nguyen Thi Phuong T, Tien NLB, et al. Adipose tissue stem cells for therapy: An update on the progress of isolation, culture, storage and clinical application. *J Clinical Med* 2019; 8:917.

374. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: An underappreciated source of stem cells for biotechnology. *Trends Biotechnol* 2006; 24:150-154.

375. Bhat S, Viswanathan P, Chandanala S, Prasanna SJ, Seetharam RN. Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions. *Sci Rep* 2021; 11:3403.

376. Kachgal S, Putnam AJ. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. *Angiogenesis* 2011; 14:47-59.

377. Sharma S, Muthu S, Jeyaraman M, Ranjan R, Jha SK. Translational products of adipose tissue-derived mesenchymal stem cells: Bench to bedside applications. *World J Stem Cells* 2021; 13:1360-1381.

378. Amos PJ, Kapur SK, Stapor PC, et al. Human adipose-derived stromal cells accelerate diabetic wound healing: Impact of cell formulation and delivery. *Tissue Eng Part A* 2010; 16:1595-1606.

379. Hong Z, Chen J, Zhang S, et al. Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: A double-blind randomized self-controlled trial. *Int Orthop* 2019; 43:1123-1134.

380. Yokota N, Yamakawa M, Shirata T, Kimura T, Kaneshima H. Clinical results following intra-articular injection of adipose-derived stromal vascular fraction cells in patients with osteoarthritis of the knee. *Regen Ther* 2017; 6:108-112.

381. Usuelli FG, Grassi M, Maccario C, et al. Intratendinous adipose-derived stromal vascular fraction (SVF) injection provides a safe, efficacious treatment for Achilles tendinopathy: Results of a randomized controlled clinical trial at a 6-month follow-up. *Knee Surg Sports Traumatol Arthrosc* 2018; 26:2000-2010.

382. Agarwal N, Mak C, Bojanic C, To K, Khan W. Meta-analysis of adipose tissue derived cell-based therapy for the treatment of knee osteoarthritis. *Cells* 2021; 10:1365.

383. Wyles CC, Houdek MT, Crespo-Diaz RJ, et al. Adipose-derived mesenchymal stem cells are phenotypically superior for regeneration in the setting of osteonecrosis of the femoral head. *Clin Orthop Relat Res* 2015; 473:3080-3090.

384. Aimaiti A, Saiwulaiti Y, Saiyiti M, Wang YH, Cui L, Yusufu A. Therapeutic effect of osteogenically induced adipose derived stem cells on vascular deprivation-induced osteonecrosis of the femoral head in rabbits. *Chin J Traumatol* 2011; 14:215-220.

385. Sand TT. Adipose Tissue-Derived Stromal Vascular Fraction. In: Manchikanti L, Navani A, Atluri S, and Sanapati M (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*, 2nd ed. Springer Nature Switzerland, 2024, pp 161-170.

386. Goncharov EN, Koval OA, Igorevich, El, et al. Analyzing the clinical potential of stromal vascular fraction: A comprehensive literature review. *Medicina* 2024; 60:221.

387. Tang Q, Zhao XS, Guo A, et al. Therapeutic applications of adipose-derived stromal vascular fractions in osteoarthritis. *World J Stem Cells* 2022; 14:744-755.

388. Condé-Green A, Kotamarti VS, Sherman LS, et al. Shift toward mechanical isolation of adipose-derived stromal vascular fraction: Review of upcoming techniques. *Plast Reconstr Surg Glob Open* 2016; 4:e1017.

389. Ferreira FMY, da Conceição Carvalho Jr J, Ferreira LM. Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF). *Regen Ther* 2023; 24:332e342.

390. Boada-Pladelllorens A, Avellanet M, Pages-Bolíbar E, Veiga A. Stromal vascular fraction therapy for knee osteoarthritis: A systematic review. *Ther Adv Musculoskelet Dis* 2022; 14:1-15.

391. Garza JR, Campbell RE, Tjoumakaris FP. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: A double-blinded prospective randomized controlled clinical trial. *Am J Sports Med* 2020; 48:588-598.

392. Tsubosaka M, Matsumoto T, Sobajima S, Matsushita T, Iwaguro H, Kuroda R. Comparison of clinical and imaging outcomes of different doses of adipose-derived stromal vascular fraction cell treatment for knee osteoarthritis. *Cell Transpl* 2021; 30:1-12.

393. Lapuente JP, Dos-Anjos S, Blázquez-Martínez A. Intra-articular infiltration of adipose-derived stromal vascular fraction cells slows the clinical progression of moderate-severe knee osteoarthritis: Hypothesis on the regulatory role of intra-articular adipose tissue. *J Orthop Surg Res* 2020; 15:137.

394. Jordan S, Haroon J. The Role of Exosomes in Regenerative Medicine. In: Manchikanti L, Navani A, Atluri S, and Sanapati M (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*, 2nd ed. Springer

Nature Switzerland, 2024, pp 195-201.

395. Teo KYW, Tan R, Wong KL, Hey DHW, Hui JHP, Teo WST. Small extracellular vesicles from mesenchymal stromal cells: The next therapeutic paradigm for musculoskeletal disorders. *Cyotherapy* 2023; 25:837-846.

396. Hade MD, Suire CN, Suo Z. Mesenchymal stem cell-derived exosomes: Applications in regenerative medicine. *Cells* 2021; 10:1959.

397. McLaughlin C, Datta P, Singh YP, et al. Mesenchymal stem cell-derived extracellular vesicles for therapeutic use and in bioengineering applications. *Cells* 2022; 11:3366.

398. Krut Z, Pelled G, Gazit D, Gazit Z. Stem cells and exosomes: New therapies for intervertebral disc degeneration. *Cells* 2021; 10:2241.

399. Hermann M, Diederichs S, Melnik S, et al. Extracellular vesicles in musculoskeletal pathologies and regeneration. *Front Bioeng Biotechnol* 2021; 8:624096.

400. Papadopoulos KS, Piperi C, Korkolopoulou P. Clinical applications of adipose-derived stem cell (ADSC) exosomes in tissue regeneration. *Int J Mol Sci* 2024; 25:5916.

401. Sand TT. Non-autologous Biologics. In: Manchikanti L, Navani A, Atluri S, and Sanapati M (eds). *Essentials of Regenerative Medicine in Interventional Pain Management*, 2nd ed. Springer Nature Switzerland, 2024, pp 181-193.

402. Au AS, Leung WY, Stavosky JW. Efficacy of dehydrated human amnion chorion membrane in the treatment of diabetic foot ulcers: A review. *J Am Podiatr Med Assoc* 2021; 111:1-9.

403. Ahuja N, Jin R, Powers C, Billi A, Bass K. Dehydrated human amnion chorion membrane as treatment for pediatric burns. *Adv Wound Care (New Rochelle)* 2020; 9:602-611.

404. Gibson ALF, Holmes JH, Shupp JW, et al. A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraftconstruct in patients with deep partial-thickness thermal burns. *Burns* 2021; 47:1024-1037.

405. U.S. Food and Drug Administration. Consumer alert on regenerative medicine products including stem cells and exosomes. July 22, 2020. Accessed 7/15/2025. [www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes](http://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes)

406. Rubin R. Unproven but profitable: The boom in US stem cell clinics. *JAMA* 2018; 320:1421-1423.

407. Gupta A. Exosomes for the management of low back pain: A review of current clinical evidence. *Cureus* 2024; 16:e57539.

408. Simopoulos TT, Manchikanti L, Gupta S, et al. Systematic review of the diagnostic accuracy and therapeutic effectiveness of sacroiliac joint interventions. *Pain Physician* 2015; 18:E713-E756.

409. Califf RM, Robb MA, Bindman AB, et al. Transforming evidence generation to support health and health care decisions. *N Engl J Med* 2016; 375:2395-2400.

410. Valimahomed AK, Haffey PR, Urman RD, Kaye AD, Yong RJ. Regenerative techniques for neuraxial back pain: A systematic review. *Curr Pain Headache Rep* 2019; 23:20.

411. Yolcu YU, Moinuddin FM, Wahab W, Alvi MA, Qu W, Bydon M. Use of regenerative treatments in treatment of lumbar degenerative disc disease: A systematic review. *Clin Neurol Neurosurg* 2020; 195:105916.

412. Her YF, Kubrova E, Martinez Alvarez GA, D'Souza RS. The analgesic efficacy of intradiscal injection of bone marrow aspirate concentrate and culture-expanded bone marrow mesenchymal stromal cells in discogenic pain: A systematic review. *J Pain Res* 2022; 15:3299-3318.

413. Kubrova E, Martinez Alvarez GA, Her YF, Pagan-Rosado R, Qu W, D'Souza RS. Platelet rich plasma and platelet-related products in the treatment of radiculopathy-A systematic review of the literature. *Biomedicines* 2022; 10:2813.

414. Schneider BJ, Hunt C, Conger A, et al. The effectiveness of intradiscal biologic treatments for discogenic low back pain: A systematic review. *Spine J* 2022; 22:226-237.

415. Singjie LC, Kusuma SA, Saleh I, Kholinne E. The potency of platelet-rich plasma for chronic low back pain: A systematic review and metaanalysis of randomized controlled trial. *Asian Spine J* 2023; 17:782-789.

416. Soufi KH, Castillo JA, Rogdriguez FY, DeMesa CJ, Ebinu JO. Potential role for stem cell regenerative therapy as a treatment for degenerative disc disease and low back pain: A systematic review. *Int J Mol Sci* 2023; 24:8893.

417. Kawabata S, Akeda K, Yamada J, et al. Advances in platelet-rich plasma treatment for spinal diseases: A systematic review. *Int J Mol Sci* 2023; 24:7677.

418. Lorio MP, Tate JL, Myers TJ, Block JE, Beall DP. Perspective on intradiscal therapies for lumbar discogenic pain: State of the science, knowledge gaps, and imperatives for clinical adoption. *J Pain Res* 2024; 17:1171-1182.

419. Zhang X, Zhang A, Guan H, Zhou L, Zhang J, Yin W. The clinical efficacy of platelet-rich plasma injection therapy versus different control groups for chronic low back pain: A network meta-analysis of randomized controlled trials. *J Pain Res* 2024; 17:1077-1089.

420. Peng B, Xu B, Wu W, Du L, Zhang T, Zhang J. Efficacy of intradiscal injection of platelet-rich plasma in the treatment of discogenic low back pain: A single-arm meta-analysis. *Medicine (Baltimore)* 2023; 102:e3312.

421. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021; 372:n71.

422. Levi D, Tyskzo S, Horn S, Pham N, Levin J. Bone marrow concentrate intradiscal injection for chronic discogenic low back pain: A double-blind randomized sham-controlled trial. *Interv Pain Med* 2025; 4:100611.

423. Vadalà G, Russo F, Lavazza C, et al. Intradiscal mesenchymal stromal cell therapy for the treatment of low back pain due to moderate-to-advanced multilevel disc degeneration: A preliminary report of a double-blind, phase IIB randomized clinical trial (DREAM Study). *JOR Spine* 2025; 8:e70086.

424. Amirdelfan K, Bae H, McJunkin T, et al. Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: A prospective randomized, placebo-controlled 36-month study of safety and efficacy. *Spine J* 2021; 21:212-230.

425. Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. Lumbar intradiscal platelet-rich plasma (PRP) injections: A prospective, double-blind, randomized controlled study. *PM R* 2016; 8:1-10.

426. Noriega DC, Adura F, Hernández-Ramajo R, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: A randomized controlled trial. *Transplantation* 2017; 10:1945-1951.

427. Goyal T, Paswan AK, Jain D, Verma N, Dubey RK. Comparative evaluation of efficacy of percutaneous intradiscal radiofrequency ablation and platelet rich plasma injection for discogenic low back pain: A prospective randomized trial. *J*

*Musculosk Res* 2022; 25:2250009.

428. Akeda K, Ohishi K, Takegami N, et al. Platelet-rich plasma releasate versus corticosteroid for the treatment of discogenic low back pain: A double-blind randomized controlled trial. *J Clin Med* 2022; 11:304.

429. Pers YM, Soler-Rich R, Vadalà G, et al; RESPINE consortium. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: A prospective, multicentre, randomised placebo controlled trial (RESPINE study). *Ann Rheum Dis* 2024; 83:1572-1583.

430. Gornet MF, Beall DP, Davis TT, et al. Allogeneic disc progenitor cells safely increase disc volume and improve pain, disability, and quality of life in patients with lumbar disc degeneration—results of an FDA-approved biologic therapy randomized clinical trial. *Int J Spine Surg* 2024; 18:237-248.

431. Monfett M, Harrison J, Boachie-Adjei K, Lutz G. Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: An update. *Int Orthop* 2016; 40:1321-1328.

432. Kirchner F, Anitaua E. Intradiscal and intra-articular facet infiltrations with plasma rich in growth factors reduce pain in patients with chronic low back pain. *J Craniovertebr Junction Spine* 2016; 7:250-256.

433. Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. *Stem Cells* 2015; 33:146-156.

434. Jain D, Goyal T, Verma N, Paswan AK, Dubey RK. Intradiscal platelet-rich plasma injection for discogenic low back pain and correlation with platelet concentration: A prospective clinical trial. *Pain Med* 2020; 21:2719-2725.

435. Machado ES, Ambach MA, Caldas JM, Wei JJ, Bredemeier M. Personalized multitarget biologic injection in the spine: Prospective case series of multitarget platelet-rich plasma for low back pain. *Regen Med* 2022; 17:11-22.

436. Haines CM, Bhatt FR, Orosz LD, et al. Low back pain, disability, and quality of life one year following intradiscal injection of autologous bone marrow aspirate concentrate. *Stem Cells Int* 2022; 2022:9617511.

437. Lewandrowski KU, Dowling A, Vera JC, Leon JFR, Telfeian AE, Lorio MP. Pain relief after allogenic stem cell disc therapy. *Pain Physician* 2023; 26:197-206.

438. Pettine KA, Suzuki RK, Sand TT, Murphy MB. Autologous bone marrow concentrate intradiscal injection for the treatment of degenerative disc disease with three-year follow-up. *Int Orthop* 2017; 41:2097-2103.

439. Akeda K, Yamada J, Linn ET, Sudo A, Masuda K. Platelet-rich plasma in the management of chronic low back pain: A critical review. *J Pain Res* 2019; 12:753-767.

440. Anitaua E, Padilla S. Biologic therapies to enhance intervertebral disc repair. *Regen Med* 2018; 13:55-72.

441. Fabbro MD, Bortolin M, Taschieri S, Ceci C, Weinstein RL. Antimicrobial properties of platelet-rich preparations. A systematic review of the current pre-clinical evidence. *Platelets* 2016; 27:276-285.

442. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. *Autoimmun Rev* 2005; 4:162-170.

443. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. *Inflamm Res* 2003; 52:404-407.

444. Anitaua E, Milani I, Martínez Á, et al. A long-term retrospective observational clinical study evaluating the efficacy of plasma rich in growth factors (PRGF) in the treatment of back pain. *Pain Ther* 2025; 14:675-690.

445. Kirchner F, Milani I, Martínez A, et al. Plasma Rich in Growth Factors (PRGF) in the treatment of cervical and lumbar back pain: A retrospective observational clinical study. *Pain Physician* 2021; 24:E649-E660.

446. Anitaua E, Milani I, Martínez A, et al. Plasma Rich in Growth Factors (PRGF) in the treatment of patients with chronic cervical and lumbar pain: A prospective observational clinical study. *Pain Physician* 2023; 26:E725-E736.

447. Anitaua E, Prado R, Nurden AT, Nurden P. Characterization of plasma rich in growth factors (PRGF): Components and Formulations. In: Anitaua E, Cugat R, Sánchez M, editors. *Platelet-Rich Plasma in Orthopaedics and Sports Medicine*. Cham: Springer International Publishing; 2018, pp. 29-45.

448. Centeno C, Markle J, Dodson E, et al. The use of lumbar epidural injection of platelet lysate for treatment of radicular pain. *J Exp Orthop* 2017; 4:38.

449. Burnouf T, Strunk D, Koh MB, Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? *Biomaterials* 2016; 76:371-387.

450. Manchikanti L, Pasupuleti R, Pampati V, Sanapati MR, Hirsch JA. Assessment of radiation exposure with mandatory two fluoroscopic views for epidural procedures. *Pain Physician* 2023; 23:557-567.

451. Kwak SG, Choo YJ, Kwak S, Chang MC. Effectiveness of transforaminal, interlaminar, and caudal epidural injections in lumbosacral disc herniation: A systematic review and network meta-analysis. *Pain Physician* 2023; 26:113-123.

452. Manchikanti L, Sanapati MR, Pampati V, Soin A, Hirsch JA. Updated assessment of practice patterns of perioperative management of antiplatelet and anticoagulant therapy in interventional pain management. *Pain Physician* 2024; 27:S95-S114.

453. Desai MJ, Mansfield JT, Robinson DM, Miller BC, Borg-Stein J. Regenerative medicine for axial and radicular spine-related pain: A narrative review. *Pain Pract* 2020; 20:437-453.

454. Kirkaldy-Willis WH, Wedge JH, Yong-Hing K, Reilly J. Pathology and pathogenesis of lumbar spondylosis and stenosis. *Spine (Phila Pa 1976)* 1978; 3:319-328.

455. Molinos M, Almeida CR, Caldeira J, Cunha C, Gonçalves RM, Barbosa MA. Inflammation in intervertebral disc degeneration and regeneration. *J R Soc Interface* 2015; 12:20150429.

456. Gupta A, Chhabra HS, Singh V, Nagarjuna D. Lumbar transforaminal injection of steroids versus platelet-rich plasma for prolapse lumbar intervertebral disc with radiculopathy: A randomized double-blind controlled pilot study. *Asian Spine J* 2024; 18:58-65.

457. Saraf A, Hussain A, Sandhu AS, Bishnoi S, Arora V. Transforaminal injections of platelet-rich plasma compared with steroid in lumbar radiculopathy: A prospective, double-blind randomized study. *Indian J Orthop* 2023; 57:1126-1133.

458. Muthu S, Viswanathan VK, Gangadaran P. Is platelet-rich plasma better than steroids as epidural drug of choice in lumbar disc disease with radiculopathy? Meta-analysis of randomized controlled trials. *Exp Biology Med* 2025; 250:10390.

459. Becker C, Heidersdorf S, Drewlo S, de Rodriguez SZ, Krämer J, Willburger RE. Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: An investigator-initiated, prospective, double-blind, reference-controlled

study. *Spine (Phila Pa 1976)* 2007; 32:1803-1808.

460. Ruiz-Lopez R, Tsai YC. A randomized double-blind controlled pilot study comparing leucocyte-rich platelet-rich plasma and corticosteroid in caudal epidural injection for complex chronic degenerative spinal pain. *Pain Pract* 2020; 20:639-646.

461. Xu Z, Wu S, Li X, Liu C, Fan S, Ma C. Ultrasound-guided transforaminal injections of platelet-rich plasma compared with steroid in lumbar disc herniation: A prospective, randomized, controlled study. *Neural Plast* 2021; 2021:5558138.

462. Jayasoorya A, Samal N, Pisulkar G, Salwan A, Kawde K. Revolutionizing back pain management: Is epidural platelet-rich plasma the superior choice over steroids? *Cureus* 2024; 16:e55423.

463. Singh GK, Talawar P, Kumar A, Sharma RS, Purohit G, Bhandari B. Effect of autologous platelet-rich plasma (PRP) on low back pain in patients with prolapsed intervertebral disc: A randomised controlled trial. *Indian J Anaesth* 2023; 67:277-282.

464. Wongjarupong A, Pairuchvej S, Laothapornsvan P, et al. "Platelet-Rich Plasma" epidural injection an emerging strategy in lumbar disc herniation: A randomized controlled trial. *BMC Musculoskelet Disord* 2023; 24:335.

465. Godek P, Szczepanowska-Wolowiec B, Golicki D. Comparison of analgesic efficacy between epidural and perineural administration of autologous conditioned serum in the conservative treatment of low back pain due to lumbar degenerative disc disease: A randomized, open-label, controlled clinical trial. *Brain Sci* 2023; 13:749.

466. Manchikanti L, Pampati V, Kaye AD, Hirsch JA. Therapeutic lumbar facet joint nerve blocks in the treatment of chronic low back pain: Cost utility analysis based on a randomized controlled trial. *Korean J Pain* 2018; 31:27-38.

467. Patel N, Nowak K, Vaidyanathan A, et al. The effect of sedation on diagnostic lumbar medial branch blocks for facetogenic low back pain: An observational study. *Pain Physician* 2024; 27:E407-E418.

468. Sittimart M, Butani D, Poonsiri C, et al. Cost-utility analysis of radiofrequency ablation among facet joint-related chronic low back pain patients in Thailand. *Pain Physician* 2024; 27:E761-E773.

469. Lown Institute Hospital Index.

Unnecessary Back Surgery: Older Americans put at Risk While Billions in Medicare Funds Wasted. November 14, 2024. Accessed 11/25/2024. <https://lownhospitalsindex.org/unnecessary-back-surgery/>

470. Ambrosio L, Vadalà G, Russo F, et al. Interventional minimally invasive treatments for chronic low back pain caused by lumbar facet joint syndrome: A systematic review. *Global Spine J* 2023; 13:1163-1179.

471. Apostolakis S, Kapetanakis S. Platelet-rich plasma for degenerative spine disease: A brief overview. *Spine Surg Relat Res* 2023; 8:10-21.

472. Grossen AA, Lee BJ, Shi HH, Shakir HJ, Cornett EM, Kaye AD. Platelet-rich plasma injections: Pharmacological and clinical considerations in pain management. *Curr Pain Headache Rep* 2022; 26:741-749.

473. Wu J, Zhou J, Liu C, et al. A prospective study comparing platelet-rich plasma and local anesthetic (LA)/corticosteroid in intra-articular injection for the treatment of lumbar facet joint syndrome. *Pain Pract* 2017; 17:914-924.

474. Wu J, Du Z, Lv Y, et al. A new technique for the treatment of lumbar facet joint syndrome using intra-articular injection with autologous platelet rich plasma. *Pain Physician* 2016; 19:617-625.

475. Kotb SY, Sherif NM, Saleh HA, Ahmed SF, Sakr HM, Taeimah MO. The role of intra-articular injection of autologous platelet-rich plasma versus corticosteroids in the treatment of synovitis in lumbar facet joint disease. *Saudi Med J* 2022; 43:1200-1208.

476. Allison DJ, Ebrahimzadeh S, Muise S, et al. Intra-articular corticosteroid injections versus platelet-rich plasma as a treatment for cervical facetogenic pain: A randomized clinical trial. *Reg Anesth Pain Med* 2024 Nov 14; Epub ahead of print.

477. Cauchon AM, Mares C, Fan XY, et al. Comparing the efficacy of intra-articular injection of Platelet Rich Plasma (PRP) with corticosteroids (CS) in patients with chronic zygapophyseal joint low back pain confirmed by double intra-articular diagnostic blocks: A triple-blinded randomized multicentric controlled trial with a 6-month follow-up. *Interv Pain Med* 2024; 3:100525.

478. Smith A, Andruski B, Deng G, Burnham R. Cervical facet joint platelet-rich plasma in people with chronic whiplash-associated disorders: A prospective case series of short-term outcomes. *Interv Pain Med* 2022; 1:100078.

479. Smith A, Andruski B, Deng G, Burnham R. Cervical facet joint platelet-rich plasma in people with chronic whiplash-associated disorders: A prospective case series of longer term 6- and 12-month outcomes. *Interv Pain Med* 2023; 2:100237.

480. Barbieri M, Colombini A, Stogicza A, de Girolamo L. Effectiveness of plasma rich in growth factors in the management of chronic spinal pain: A case series of 32 patients. *Regen Med* 2022; 17:175-184.

481. Rothoerl R, Tomelden J, Alt EU. Safety and efficacy of autologous stem cell treatment for facetogenic chronic back pain. *J Pers Med* 2023; 13:436.

482. Baltzer AW, Enneper J, Baltzer LM, Godde G. Platelet rich plasma for the therapy of the lumbar facet joint syndrome: A prospective study about CT-guided facet joint injections with PRP compared to local anesthetics. *Orthop Rev (Pavia)* 2025; 17:141416.

483. Rothenberg JB, Godha K, Civitarese DM, et al. Pain and functional outcomes of the sacroiliac joint after platelet-rich plasma injection: A descriptive review. *Regen Med* 2021; 16:87-100.

484. Hunter DJ, McDougall JJ, Keefe FJ. The symptoms of osteoarthritis and the genesis of pain. *Med Clin North Am* 2009; 93:83-100.

485. Enix DE, Mayer JM. Sacroiliac joint hypermobility biomechanics and what it means for health care providers and patients. *PM R* 2019; 11 Suppl 1:S32-S39.

486. Schwarzer AC, April CN, Bogduk N. The sacroiliac joint in chronic low back pain. *Spine (Phila Pa 1976)* 1995; 20:31-37.

487. Manchikanti L, Sanapati MR, Pampati V, Hirsch JA. Compliance and documentation for evaluation and management services in interventional pain management practice. *Pain Physician* 2023; 26:503-525.

488. Ezeonu T, Narayanan R, Huang R, et al. Higher socioeconomic status is associated with greater rates of surgical resource utilization prior to spine fusion surgery. *Spine J* 2025; 25:631-639.

489. Oh TK, Song IA. Prevalence and risk factors for persistent spinal pain syndrome Type II following spinal surgery: A nationwide retrospective cohort study. *Pain Physician* 2024; 27:555-563.

490. Albishi W, AbuDujain NM, Dakhil AB, Alzeer M. The utilization of radiofrequency techniques for upper extremity pain management. *Pain*

*Physician* 2023; 26:125-135.

491. Rieger M, Le H, van Kuijk SMJ, et al. Intradiscal glucocorticoid injection in discogenic back pain and influence on modic changes: A systematic review and meta-analysis of RCTs. *Pain Physician* 2023; 26:E449-E465.

492. Huntoon MA, Slavin KV, Hagedorn JM, Crosby ND, Boggs JW. A retrospective review of real-world outcomes following 60-day peripheral nerve stimulation for the treatment of chronic pain. *Pain Physician* 2023; 26:273-281.

493. Lee JH, Lee YJ, Park HS, Lee JH. Clinical effectiveness of posterior annular targeted ablative decompression as an alleviative intervention for lumbosacral discogenic pain: Systematic review and meta-analysis. *Pain Physician* 2023; 26:E437-E447.

494. Vachirakorntong B, Kawana E, Zhitny VP, et al. Radiofrequency ablation's effectiveness for treating abdominal and thoracic chronic pain syndromes: A systematic review of the current literature. *Pain Physician* 2023; 26:E737-E759.

495. Hill-Oliva M, Ampen-Darko KK, Shekane P, et al. The use of telemedicine in outpatient pain management: A scoping review. *Pain Physician* 2023; 26:535-548.

496. Yson SC, Sembrano JN, Polly DW Jr. Sacroiliac joint fusion: Approaches and recent outcomes. *PM R* 2019; 11 Suppl 1:S114-S117.

497. Newman DP, Soto AT. Sacroiliac joint dysfunction: Diagnosis and treatment. *Am Fam Physician* 2022; 105:239-245.

498. Rashbaum RF, Ohnmeiss DD, Lindley EM, Kitchel SH, Patel VV. Sacroiliac joint pain and its treatment. *Clin Spine Surg* 2016; 29:42-48.

499. Chang E, Rains C, Ali R, Wines RC, Kahwati LC. Minimally invasive sacroiliac joint fusion for chronic sacroiliac joint pain: A systematic review. *Spine J* 2022; 22:1240-1253.

500. Beall DP, Davis TT, Amirdelfan K, et al. Nucleus pulposus allograft supplementation in patients with lumbar discogenic pain: Initial 6-month outcomes from a prospective clinical pilot study. *Pain Physician* 2024; 27:E865-E871.

501. Navani A. Biologics in interventional spinal procedure: The past, the present, and the vision. *Pain Physician* 2023; 26:E775-E785.

502. Pauza K, Boachie-Adjei K, Nguyen JT, et al. Long-term investigation of annulargrams and intra-annular fibrin to treat chronic discogenic low back pain and radiculopathy: 1-, 2-, and 3-year outcome comparisons of patients with and without prior surgery. *Pain Physician* 2024; 27:537-553.

503. Goodwin B, Averell N, Al-Shehab U, et al. Efficacy of platelet-rich plasma for sacroiliac joint dysfunction: A qualitative systematic review with pooled analysis. *Regen Med* 2023; 18:505-514.

504. Burnham T, Sampson J, Speckman RA, Conger A, Cushman DM, McCormick ZL. The effectiveness of platelet-rich plasma injection for the treatment of suspected sacroiliac joint complex pain: A systematic review. *Pain Med* 2020; 21:2518-2528.

505. Kaye AD, Edinoff AN, Rosen YE, et al. Regenerative medicine: Pharmacological considerations and clinical role in pain management. *Curr Pain Headache Rep* 2022; 26:751-765.

506. Ruffilli A, Cerasoli T, Barile F, et al. Injectve treatments for sacroiliac joint pain: A systematic review and meta-analysis. *Indian J Orthop* 2024; 58:637-649.

507. Al-Mnayyis A, Obeidat S, Badr A, et al. Radiological insights into sacroiliitis: A narrative review. *Clin Pract* 2024; 14:106-121.

508. Sayed D, Deer TR, Tieppo Francio V, et al. American Society of Pain and Neuroscience Best Practice (ASPN) guideline for the treatment of sacroiliac disorders. *J Pain Res* 2024; 17:1601-1638.

509. Maloney J, Strand N, Wie C, et al. Current review of regenerative medicine therapies for spine-related pain. *Curr Pain Headache Rep* 2024; 28:949-955.

510. Singla V, Batra YK, Bharti N, Goni VG, Marwaha N. Steroid vs. platelet-rich plasma in ultrasound-guided sacroiliac joint injection for chronic low back pain. *Pain Pract* 2017; 17:782-791.

511. Navani A, Gupta D. Role of intra-articular platelet-rich plasma in sacroiliac joint pain. *Tech Reg Anesth Pain Manage* 2015; 19:54-59.

512. Ko GD, Mindra S, Lawson GE, Whitmore S, Arseneau L. Case series of ultrasound-guided platelet-rich plasma injections for sacroiliac joint dysfunction. *J Back Musculoskelet Rehabil* 2017; 30:363-370.

513. Mohi Eldin M, Sorour OO, Hassan ASA, Baraka M, Ahmed MF. Percutaneous injection of autologous platelet-rich fibrin versus platelet-rich plasma in sacroiliac joint dysfunction: An applied comparative study. *J Back Musculoskelet Rehabil* 2019; 32:511-518.

514. Wallace P, Bezjian Wallace L, Tamura S, Prochnio K, Morgan K, Hemler D. Effectiveness of ultrasound-guided platelet-rich plasma injections in relieving sacroiliac joint dysfunction. *Am J Phys Med Rehabil* 2020; 99:689-693.

515. Saunders J, Cusi M, Hackett L, Van der Wall H. A comparison of ultrasound guided PRP injection and prolotherapy for mechanical dysfunction of the sacroiliac joint. *J Prolother* 2018; 10:e992-e999.

516. Williams C, Jerome M, Fausel C, Dodson E, Stemper I, Centeno C. Regenerative injection treatments utilizing platelet products and prolotherapy for cervical spine pain: A functional spinal unit approach. *Cureus* 2021; 13:e18608.

517. U.S. Food and Drug Administration. Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2025. Accessed 9/20/2025. [www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2025?utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2025?utm_medium=email&utm_source=govdelivery)

518. World Health Organization. Guidelines on procedures and data requirements for changes to approved biotherapeutic products, Annex 3, TRS No 1011. Technical Document. January 1, 2018. Accessed 8/6/2025. [www.who.int/publications/m/item/approved-biotherapeutics-a3-trs-no-1011](http://www.who.int/publications/m/item/approved-biotherapeutics-a3-trs-no-1011)

519. World Health Organization. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology, Annex 4, TRS No 987. Technical Document. June 18, 2014. Accessed 8/6/2025.

520. H.R. 34 – 21st Century Cures Act. P.L. 114-255. December 13, 2016.

521. Honbo ES, Mattfeld R, Khadavi M, Podesta L. Clinical Rationale and Rehabilitation Guidelines for Post Biologic Therapy. *Phys Med Rehabil Clin N Am* 2023; 34:239-263.

522. Podesta L, Crow S, Volkner D, et al. Treatment of elbow partial ulnar collateral ligament tears with platelet rich plasma. *Am J Sports Med* 2013; 41:1689-1694.

523. Centeno CJ, Al-Sayegh H, Freeman MD, Smith J, Murrell WD, Bubnov R. A multicenter analysis of adverse events among two thousand, three hundred and seventy-two adult patients undergoing adult autologous stem cell therapy for orthopedic conditions. *Int Orthop* 2016; 40:1755-1765.

524. Arita A, Tobita M. Adverse events related

to platelet-rich plasma therapy and future issues to be resolved. *Regen Ther* 2024; 26:496-501.

525. Jerome MA, Lutz C, Lutz GE. Risks of intradiscal orthobiologic injections: A review of the literature and case series presentation. *Int J Spine Surg* 2021; 15:26-39.

526. Khadavi M, Pourcho A, Podesta L. Protocols and techniques for orthobiologic procedures. *Phys Med Rehabil Clin N Am* 2023; 34:105-115.

527. Narouze S, Benzon HT, Provenzano D, et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. *Reg Anesth Pain Med* 2018; 43:225-262.

528. Breivik H, Bang U, Jalonen J, Vigfússon G, Alahuhta S, Lagerkranser M. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. *Acta Anaesthesiol Scand* 2010; 54:16-41.

529. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM; European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: Recommendations of the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2010; 27:999-1015.

530. Vandermeulen E. Regional anaesthesia and anticoagulation. *Best Pract Res Clin*

*Anaesthesiol* 2010; 24:121-131.

531. Horlocker TT, Wedel DJ, Rowlingson JC et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). *Reg Anesth Pain Med* 2010; 35:64-101.

532. Ramsook RR, Danesh H. Timing of platelet rich plasma injections during antithrombotic therapy. *Pain Physician* 2016; 19:E1055-E1061.

533. Ling L, Camilleri ET, Hellelidie T, et al. Effect of heparin on the biological properties and molecular signature of human mesenchymal stem cells. *Gene* 2016; 576:292-303.

534. Sutherland FW, Perry TE, Yu Y, et al. From stem cells to viable autologous semilunar heart valve. *Circulation* 2005; 111:2783-2791.

535. Schipplinger G, Prüller F, Divjak M, et al. Autologous platelet-rich plasma preparations. *Orthop J Sport Med* 2015; 3:232596711558889.

536. Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. *Sci World J* 2012; 2012:1-14.

537. Best JG, Cardus B, Klijn CJM, et al. Antithrombotic dilemmas in stroke medicine: New data, unsolved challenges. *J Neurol Neurosurg Psychiatry* 2022; 93:939-951.

538. Mehta SR, Bainey KR, Cantor WJ, et al; members of the Secondary Panel. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. *Can J Cardiol* 2018; 34:224-233.

539. Moster M, Bolliger D. Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update. *Curr Anesth Rep* 2022; 12:286-296.

540. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: An American College of Chest Physicians Clinical Practice Guideline. *Chest* 2022; 162:e207-e243.

541. Douketis JD, Lip GYH. Perioperative management of patients receiving anticoagulants. *UpToDate* 2023. Accessed 9/20/2025. [www.uptodate.com/contents/perioperative-management-of-patients-receiving-anticoagulants/print](http://www.uptodate.com/contents/perioperative-management-of-patients-receiving-anticoagulants/print)

542. Slabiak T. *Stem cell-based therapies and FDA regulations*. Regulatory Focus, November 2012.

543. D'Souza RS, Her YF, Hussain N, Karri J, et al. Evidence-based clinical practice guidelines on regenerative medicine treatment for chronic pain: A consensus report from a multispecialty working group. *J Pain Res* 2024; 17:2951-3001.

544. Navani A, Li G, Chrystal J. Platelet rich plasma in musculoskeletal pathology: A necessary rescue or a lost cause? *Pain Physician* 2017; 20:E345-E356.

545. Noback PC, Donnelley CA, Yeatts NC, et al. Utilization of orthobiologics by sports medicine physicians: A survey-based study. *J Am Acad Orthop Surg Glob Res Rev* 2021; 5:e20.00185.

546. Shapiro SA, Master Z, Arthurs JR, Mautner K. Tiered approach to considering orthobiologics for patients with musculoskeletal conditions. *Br J Sports Med* 2023; 57:179-180.



Appendix Table 1. *Sources of risk of bias and Cochrane Review collaboration.*

Bias Domain	Source of Bias	Possible Answers	
Selection	(1) Was the method of randomization adequate?	A random (unpredictable) assignment sequence. Examples of adequate methods are coin toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing of balls of different colors, drawing of ballots with the study group labels from a dark bag, computer-generated random sequence, preordered sealed envelopes, sequentially-ordered vials, telephone call to a central office, and preordered list of treatment assignments.  Examples of inadequate methods are: alternation, birth date, social insurance/security number, date in which they are invited to participate in the study, and hospital registration number.	Yes/No/Unsure
Selection	(2) Was the treatment allocation concealed?	Assignment generated by an independent person not responsible for determining the eligibility of the patients. This person has no information about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the patient.	Yes/No/Unsure
Performance	(3) Was the patient blinded to the intervention?	Index and control groups are indistinguishable for the patients or if the success of blinding was tested among the patients and it was successful.	Yes/No/Unsure
Performance	(4) Was the care provider blinded to the intervention?	Index and control groups are indistinguishable for the care providers or if the success of blinding was tested among the care providers and it was successful.	Yes/No/Unsure
Detection	(5) Was the outcome assessor blinded to the intervention?	Adequacy of blinding should be assessed for each primary outcome separately. This item should be scored "yes" if the success of blinding was tested among the outcome assessors and it was successful or: <ul style="list-style-type: none"> <li>for patient-reported outcomes in which the patient is the outcome assessor (e.g., pain, disability): the blinding procedure is adequate for outcome assessors if participant blinding is scored "yes"</li> <li>for outcome criteria assessed during scheduled visit and that supposes a contact between participants and outcome assessors (e.g., clinical examination): the blinding procedure is adequate if patients are blinded, and the treatment or adverse effects of the treatment cannot be noticed during clinical examination</li> <li>for outcome criteria that do not suppose a contact with participants (e.g., radiography, magnetic resonance imaging): the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed when assessing the main outcome</li> <li>for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between patients and care providers (e.g., cointerventions, hospitalization length, treatment failure), in which the care provider is the outcome assessor: the blinding procedure is adequate for outcome assessors if item "4" (caregivers) is scored "yes"</li> <li>for outcome criteria that are assessed from data of the medical forms: the blinding procedure is adequate if the treatment or adverse effects of the treatment cannot be noticed on the extracted data</li> </ul>	Yes/No/Unsure
Attrition	(6) Was the drop-out rate described and acceptable?	The number of participants who were included in the study but did not complete the observation period or were not included in the analysis must be described and reasons given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term follow-up and 30% for long-term follow-up and does not lead to substantial bias a "yes" is scored (N.B. these percentages are arbitrary, not supported by literature).	Yes/No/Unsure
Attrition	(7) Were all randomized participants analyzed in the group to which they were allocated?	All randomized patients are reported/analyzed in the group they were allocated to by randomization for the most important moments of effect measurement (minus missing values) irrespective of noncompliance and cointerventions.	Yes/No/Unsure
Reporting	(8) Are reports of the study free of suggestion of selective outcome reporting?	All the results from all prespecified outcomes have been adequately reported in the published report of the trial. This information is either obtained by comparing the protocol and the report, or in the absence of the protocol, assessing that the published report includes enough information to make this judgment.	Yes/No/Unsure
Selection	(9) Were the groups similar at baseline regarding the most important prognostic indicators?	Groups have to be similar at baseline regarding demographic factors, duration and severity of complaints, percentage of patients with neurological symptoms, and value of main outcome measure(s).	Yes/No/Unsure

Appendix Table 1 cont. *Sources of risk of bias and Cochrane Review collaboration.*

Bias Domain	Source of Bias	Possible Answers
Performance	(10) Were cointerventions avoided or similar?	If there were no cointerventions or they were similar between the index and control groups. Yes/No/Unsure
Performance	(11) Was the compliance acceptable in all groups?	The reviewer determines if the compliance with the interventions is acceptable, based on the reported intensity, duration, number and frequency of sessions for both the index intervention and control intervention(s). For example, physiotherapy treatment is usually administered for several sessions; therefore it is necessary to assess how many sessions each patient attended. For single-session interventions (e.g., surgery), this item is irrelevant. Yes/No/Unsure
Detection	(12) Was the timing of the outcome assessment similar in all groups?	Timing of outcome assessment should be identical for all intervention groups and for all primary outcome measures. Yes/No/Unsure
Other	(13) Are other sources of potential bias unlikely?	Other types of biases. For example: <ul style="list-style-type: none"> <li>When the outcome measures were not valid. There should be evidence from a previous or present scientific study that the primary outcome can be considered valid in the context of the present.</li> <li>Industry-sponsored trials. The conflict of interest (COI) statement should explicitly state that the researchers have had full possession of the trial process from planning to reporting without funders with potential COI having any possibility to interfere in the process. If, for example, the statistical analyses have been done by a funder with a potential COI, usually “unsure” is scored.</li> </ul> Yes/No/Unsure

Adapted and Modified from: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. *Spine (Phila Pa 1976)* 2015; 40:1660-1673 (77).

Appendix Table 2. *Item checklist for assessment of randomized controlled trials of interventional pain management techniques utilizing IPM-QRB.*

		Scoring
I.	TRIAL DESIGN AND GUIDANCE REPORTING	
1.	CONSORT or SPIRIT	
	Trial designed and reported without any guidance	0
	Trial designed and reported utilizing minimum criteria other than CONSORT or SPIRIT criteria or trial was conducted prior to 2005	1
	Trial implies it was based on CONSORT or SPIRIT without clear description with moderately significant criteria for randomized trials or the trial was conducted before 2005	2
	Explicit use of CONSORT or SPIRIT with identification of criteria or trial conducted with high level reporting and criteria or conducted before 2005	3
II.	DESIGN FACTORS	
2.	Type and Design of Trial	
	Poorly designed control group (quasi selection, convenient sampling)	0
	Proper active-control or sham procedure with injection of active agent	2
	Proper placebo control (no active solutions into active structures)	3
3.	Setting/Physician	
	General setting with no specialty affiliation and general physician	0
	Specialty of anesthesia/PMR/neurology/radiology/ortho, etc.	1
	Interventional pain management with interventional pain management physician	2
4.	Imaging	
	Blind procedures	0
	Ultrasound	1
	CT	2
	Fluoro	3
5.	Sample Size	
	Less than 50 participants in the study without appropriate sample size determination	0
	Sample size calculation with less than 25 patients in each group	1
	Appropriate sample size calculation with at least 25 patients in each group	2
	Appropriate sample size calculation with 50 patients in each group	3
6.	Statistical Methodology	
	None or inappropriate	0
	Appropriate	1
III.	PATIENT FACTORS	
7.	Inclusiveness of Population	
7a.	For epidural procedures:	
	Poorly identified mixed population	0
	Clearly identified mixed population	1
	Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal stenosis or post surgery syndrome)	2
7b.	For facet or sacroiliac joint interventions:	
	No diagnostic blocks	0
	Selection with single diagnostic blocks	1
	Selection with placebo or dual diagnostic blocks	2
8.	Duration of Pain	
	Less than 3 months	0
	3 to 6 months	1

Appendix Table 2 cont. *Item checklist for assessment of randomized controlled trials of interventional pain management techniques utilizing IPM-QRB.*

		<b>Scoring</b>
	> 6 months	2
9.	Previous Treatments	
	Conservative management including drug therapy, exercise therapy, physical therapy, etc.	
	Were not utilized	0
	Were utilized sporadically in some patients	1
	Were utilized in all patients	2
10.	Duration of Follow-up with Appropriate Interventions	
	Less than 3 months or 12 weeks for epidural, facet joint or sacroiliac joint procedures, etc. and 6 months for intradiscal procedures and implantables	0
	3 to 6 months for intradiscal injections, epidural, facet joint or sacroiliac joint procedures, etc., or 1 year for intradiscal procedures or implantables	1
	6 months to 12 months for intradiscal injections, epidurals, facet joint or sacroiliac joint procedures, etc., and 2 years or longer for intradiscal procedures and implantables	2
	18 months or longer for intradiscal injections, epidurals, facet joint or sacroiliac joint procedures, etc., or 5 years or longer for intradiscal procedures and implantables	3
IV.	OUTCOMES	
11.	Outcomes Assessment Criteria for Significant Improvement	
	No descriptions of outcomes OR < 20% change in pain rating or functional status	0
	Pain rating with a decrease of 2 or more points or more than 20% reduction OR functional status improvement of more than 20%	1
	Pain rating with decrease of $\geq 2$ points AND $\geq 20\%$ change or functional status improvement of $\geq 20\%$	2
	Pain rating with a decrease of 3 or more points or more than 50% reduction OR functional status improvement with a 50% or 40% reduction in disability score	3
	Significant improvement with pain and function $\geq 50\%$ or 3 points and 40% reduction in disability scores	4
12.	Analysis of all Randomized Participants in the Groups	
	Not performed	0
	Performed without intent-to-treat analysis without inclusion of all randomized participants	1
	All participants included with or without intent-to-treat analysis	2
13.	Description of Drop Out Rate	
	No description of dropouts, despite reporting of incomplete data or $\geq 20\%$ withdrawal	0
	Less than 20% withdrawal in one year in any group	1
	Less than 30% withdrawal at 2 years in any group	2
14.	Similarity of Groups at Baseline for Important Prognostic Indicators	
	Groups dissimilar with significant influence on outcomes with or without appropriate randomization and allocation	0
	Groups dissimilar without influence on outcomes despite appropriate randomization and allocation	1
	Groups similar with appropriate randomization and allocation	2
15.	Role of Co-Interventions	
	Co-interventions were provided but were not similar in the majority of participants	0
	No co-interventions or similar co-interventions were provided in the majority of the participants	1
V.	RANDOMIZATION	
16.	Method of Randomization	
	Quasi randomized or poorly randomized or not described	0

Appendix Table 2 cont. *Item checklist for assessment of randomized controlled trials of interventional pain management techniques utilizing IPM-QRB.*

		Scoring
	Adequate randomization (coin toss, drawing of balls of different colors, drawing of ballots)	1
	High quality randomization (Computer generated random sequence, pre-ordered sealed envelopes, sequentially ordered vials, telephone call, pre-ordered list of treatment assignments, etc.)	2
VI.	ALLOCATION CONCEALMENT	
17.	Concealed Treatment Allocation	
	Poor concealment of allocation (open enrollment) or inadequate description of concealment	0
	Concealment of allocation with borderline or good description of the process with probability of failure of concealment	1
	High quality concealment with strict controls (independent assignment without influence on the assignment sequence)	2
VII.	BLINDING	
18.	Patient Blinding	
	Patients not blinded	0
	Patients blinded adequately	1
19.	Care Provider Blinding	
	Care provider not blinded	0
	Care provider blinded adequately	1
20.	Outcome Assessor Blinding	
	Outcome assessor not blinded or was able to identify the groups	0
	Performed by a blinded independent assessor with inability to identify the assignment-based provider intervention (i.e., subcutaneous injection, intramuscular distant injection, difference in preparation or equipment use, numbness and weakness, etc.)	1
VIII.	CONFLICTS OF INTEREST	
21.	Funding and Sponsorship	
	Trial included industry employees	-3
	Industry employees involved; high levels of funding with remunerations by industry or an organization funded with conflicts	-3
	Industry or organizational funding with reimbursement of expenses with some involvement	0
	Industry or organization funding of expenses without involvement	1
	Funding by internal resources only with supporting entity unrelated to industry	2
	Governmental funding without conflict such as NIH, NHS, AHRQ	3
22.	Conflicts of Interest	
	None disclosed with potential implied conflict	0
	Marginally disclosed with potential conflict	1
	Well disclosed with minor conflicts	2
	Well disclosed with no conflicts	3
	Hidden conflicts with poor disclosure	-1
	Misleading disclosure with conflicts	-2
	Major impact related to conflicts	-3
	TOTAL	48

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. *Pain Physician* 2014; 17:E263-E290 (78).

Appendix Table 3. *Bias domains included in the ROBINS-E tool, with a summary of the issues addressed for cohort studies.*

Bias domain	Issues Addressed	Possible Answers
Bias due to confounding	<p>Whether:</p> <ul style="list-style-type: none"> <li>all important confounding factors were controlled for using appropriate methods;</li> <li>the confounding factors were measured validly and reliably by the variables available; and</li> <li>variables after the start of the exposure window (and that could have been affected by the exposure) were inappropriately controlled for.</li> </ul>	Yes/No/Unsure
Bias arising from measurement of the exposure	<p>Whether:</p> <ul style="list-style-type: none"> <li>the measure of exposure used in the study well characterizes the exposure metric of interest;</li> <li>there was likely to be error in, or misclassification of, the exposure measurements in the study;</li> <li>there was differential measurement (or misclassification) error; and</li> <li>non-differential measurement (or misclassification) error would have biased the effect estimate.</li> </ul>	Yes/No/Unsure
Bias in selection of participants into the study	<p>Whether:</p> <ul style="list-style-type: none"> <li>start of follow-up and start of the exposure window were the same;</li> <li>selection of participants into the study (or into the analysis) was based on participant characteristics observed after the start of the exposure window;</li> <li>(if applicable) these characteristics were influenced by exposure (or a cause of exposure) and influenced by outcome (or a cause of the outcome); and</li> <li>(if applicable) adjustment techniques were used to correct for the presence of selection biases.</li> </ul>	Yes/No/Unsure
Bias due to post-exposure interventions	<p>Whether:</p> <ul style="list-style-type: none"> <li>there were post-exposure interventions influenced by prior exposure; and</li> <li>(if applicable) the analysis corrected for the effect of these post-exposure interventions.</li> </ul>	Yes/No/Unsure
Bias due to missing data	<p>Whether:</p> <ul style="list-style-type: none"> <li>complete data on exposure status, the outcome, and confounders were available for all or nearly all participants;</li> <li>(for complete case analyses) omission from the analysis is likely to be related to the true value of the outcome and predictors of missingness were included in the analysis model; and</li> <li>(for analyses with imputed data) imputation was performed appropriately.</li> </ul>	Yes/No/Unsure
Bias in measurement of the outcome	<p>Whether:</p> <ul style="list-style-type: none"> <li>measurement or ascertainment of the outcome is likely to have differed between exposure groups or levels of exposure;</li> <li>outcome assessors were aware of study participants' exposure history; and</li> <li>(if applicable) assessment of the outcome were likely to have been influenced by knowledge of participants' exposure history.</li> </ul>	Yes/No/Unsure
Bias in selection of the reported result	<p>Whether:</p> <ul style="list-style-type: none"> <li>the numerical result being assessed is likely to have been selected, on the basis of the results, from multiple exposure measurements within the outcome domain;</li> <li>the numerical result being assessed is likely to have been selected, on the basis of the results, from multiple outcome measurements within the outcome domain;</li> <li>the numerical result being assessed is likely to have been selected, on the basis of the results, from multiple analyses of the data; and</li> <li>the numerical result being assessed is likely to have been selected, on the basis of the results, from multiple subgroups of a larger cohort.</li> </ul>	Yes/No/Unsure

Source: Higgins JPT, Morgan RL, Rooney AA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). *Environ Int.* 2024 Apr;186:108602 (79).

Appendix Table 4. *Item checklist for assessment of nonrandomized or observational studies of interventional pain management techniques utilizing IPM-QRBNR.*

		Scoring
I.	STUDY DESIGN AND GUIDANCE REPORTING	
1.	STROBE or TREND Guidance	
	Case Report/Case Series	0
	Study designed without any guidance	1
	Study designed with minimal criteria and reporting with or without guidance	2
	Study designed with moderately significant criteria or implies it was based on STROBE or TREND without clear description or the study was conducted before 2011 or similar criteria utilized with study conducted before 2011	3
	Designed with high level criteria or explicitly uses STROBE or TREND with identification of criteria or conducted prior to 2011	4
II.	DESIGN FACTORS	
2.	Study Design and Type	
	Case report or series (uncontrolled – longitudinal)	0
	Retrospective cohort or cross-sectional study	1
	Prospective cohort case-control study	2
	Prospective case control study	3
	Prospective, controlled, nonrandomized	4
3.	Setting/Physician	
	General setting with no specialty affiliation and general physician	0
	Specialty of anesthesia/PMR/neurology, etc.	1
	Interventional pain management with interventional pain management physician	2
4.	Imaging	
	Blind procedures	0
	Ultrasound	1
	CT	2
	Fluoro	3
5.	Sample Size	
	Less than 100 participants without appropriate sample size determination	0
	At least 100 participants in the study without appropriate sample size determination	1
	Sample size calculation with less than 50 patients in each group	2
	Appropriate sample size calculation with at least 50 patients in each group	3
	Appropriate sample size calculation with 100 patients in each group	4
6.	Statistical Methodology	
	None	0
	Some statistics	1
	Appropriate	2
III.	PATIENT FACTORS	
7.	Inclusiveness of Population	
7a.	For epidural procedures:	
	Poorly identified mixed population	1
	Poorly identified mixed population with large sample ( $\geq 200$ )	2
	Clearly identified mixed population	3
	Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal stenosis or post surgery syndrome)	4
7b.	For facet or sacroiliac joint interventions:	

Appendix Table 4 cont. *Item checklist for assessment of nonrandomized or observational studies of interventional pain management techniques utilizing IPM-QRBNR.*

		Scoring
	No specific selection criteria	1
	No diagnostic blocks based on clinical symptomatology	2
	Selection with single diagnostic blocks	3
	Selection with placebo or dual diagnostic blocks	4
8.	Duration of Pain	
	Less than 3 months	0
	3 to 6 months	1
	> 6 months	2
9.	Previous Treatments	
	Conservative management including drug therapy, exercise therapy, physical therapy, etc.	
	Were not utilized	0
	Were utilized sporadically in some patients	1
	Were utilized in all patients	2
10.	Duration of Follow-up with Appropriate Interventions	
	Less than 3 months or 12 weeks for epidural, facet joint or sacroiliac joint procedures, etc. and 6 months for intradiscal procedures and implantables	1
	3 to 6 months for intradiscal injections, epidural, facet joint or sacroiliac joint procedures, etc., or 1 year for intradiscal procedures or implantables	2
	6 months to 12 months for intradiscal injections, epidurals, facet joint or sacroiliac joint procedures, etc., and 2 years or longer for intradiscal procedures and implantables	3
	18 months or longer for intradiscal injections, epidurals, facet joint or sacroiliac joint procedures, etc., or 5 years or longer for intradiscal procedures and implantables	4
IV.	OUTCOMES	
11.	Outcomes Assessment Criteria for Significant Improvement	
	No descriptions of outcomes OR < 20% change in pain rating or functional status	0
	Pain rating with a decrease of 2 or more points or more than 20% reduction OR functional status improvement of more than 20%	1
	Pain rating with decrease of $\geq 2$ points AND $\geq 20\%$ change or functional status improvement of $\geq 20\%$	2
	Pain rating with a decrease of 3 or more points or more than 50% reduction OR functional status improvement with a 50% or 40% reduction in disability score	3
	Significant improvement with pain and function $\geq 50\%$ or 3 points and 40% reduction in disability scores	4
12.	Description of Drop Out Rate	
	No description despite reporting of incomplete data or more than 30% withdrawal	0
	Less than 30% withdrawal in one year in any group	1
	Less than 40% withdrawal at 2 years in any group	2
13.	Similarity of Groups at Baseline for Important Prognostic Indicators	
	No groups or groups dissimilar with significant influence on outcomes	0
	Groups dissimilar without significant influence on outcomes	1
	Groups similar	2
14.	Role of Co-Interventions	
	Dissimilar co-interventions or similar co-interventions in some of the participants	1

Appendix Table 4 cont. *Item checklist for assessment of nonrandomized or observational studies of interventional pain management techniques utilizing IPM-QRBNR.*

		Scoring
	No co-interventions or similar co-interventions in majority of the participants	2
V. ASSIGNMENT		
15. Method of Assignment of Participants		
Case report/case series or selective assignment based on outcomes or retrospective evaluation based on clinical criteria		1
Prospective study with inclusion without specific criteria		2
Retrospective method with inclusion of all participants or random selection of retrospective data		3
Prospective, well-defined assignment of methodology and inclusion criteria (quasi randomization, matching, stratification, etc.)		4
VI. CONFLICTS OF INTEREST		
16. Funding and Sponsorship		
Trial included industry employees with or without proper disclosure		-3
Industry employees involved; high levels of funding with remunerations by industry or an organization funded with conflicts		-3
Industry or organizational funding with reimbursement of expenses with some involvement or no information available		0
Industry or organization funding of expenses without involvement		1
Funding by internal resources only		2
Governmental funding without conflict such as NIH, NHS, AHRQ		3
TOTAL MAXIMUM		48

Source: Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of non-randomized studies of interventional techniques. *Pain Physician* 2014; 17:E291-E317 (80).